april 07 us compendium

THE PRIVATE COMPENDIUM

: explanatory notes Page 2 : corporations

BIOTECH COMPANIES April 2007

page I

US BIOTECH

We do not make a market in any of the corporations named in this document. 2

2 A note on "fast track": - can be requested at any time (even before IND), requires theoretical improvement over marketed products, must demonstrate the disease is serious, and development program also; - consequences : - eligibility for priority review

- with hence rolling filing - and accelerated approval and possible softer endpoints.

TMC Development, The "US biotech" companies

- 2 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS A

AGILENT TECHNOLOGIES (A) was Hewlett Packard Aug 22/01 : slashes 4000 jobs

Also patient monitoring, ultrasound imaging, mass spec.

ABBI K Abraxis Biosciences, was American Pharmaceutical Partners ( APPX) IPO filed Oct 3/01 (CIBC) Merged (Nov 28/05) w/American Bioscience, to become "Abraxis Bioscience". Abraxane copromoted w/AZN (April 27/06). Sales 2006 $ 150m ABBI to copromote AZN analgesic & anesthetic line (April 06) Feb 15/06 : plant problems

- Injectable non branded generics (especially anti K and ABs) 70% of sales

- ABI 007, Abraxane, Taxol microencapsulated in human albumin. Ph III in metaststic breast N = 460, 260 mg/m2 versus Taxol 175, doubles response rate. No cremaphor.. Filed March 04 for 2nd line. Feb 25/05 Miami Breast Conf 2nd line > Taxol , signif; 1st line NS Approved 2nd line Jan 7/05 SABCS Dec 18/06, ph II 1st line mBC, N = 300, interim. A 100 mg/Kg/M2 qw vs Taxotere q3w. ORR 58%/36%. Data ASCO June 07. But A label is 260 mg q3w. and trial largely in RUSSIA. Ph III to init 1H07 Sept 7/06 ODAC votes 13/1 against extension to "adjuvant" because no trial done EU filing end 06 ? NOPE G-CSF FROM Biocon (India) July 20/07 for US & EU (approved in India)

ASCO partnered w/AZN

ABLX IPO ABLX

ABLYNX NV(Ghent) pricing early Nov 07 JP Morgab, KBC

ALX 0081 nanobodies that bind Willebrand; ACS, ph I, positive interim July 2/07. Ph II to init 2008 - vs TNF w/WYE - target in ALzheimer - SEpt 9/07 deal w/ B. Ingelheim

Practically no other willebrand competitor except Archemix, also in advanced ph I ACS

ABPI IPO K AB

ACCENTIA filed Feb 14/05 (ABPI) Robert Baird Jefferies Broadview

- SinuNase : amphotericin B solution , for sinusitis, IND for ph III to be filed ( PR Feb 17/05) - Biovaxid , ph III, NHL, Keyhole limpet hemocyanin + GM-CSF + autologous lymphoma derived vaccine

ACAD ACADIA (ACAD) IPO (R. Stephens) filed dec 21 June 2/04 to merge w/Virologic

Genomics based drug discovery drugs for Park, schizo, neuropathic pain : - ACP 103 ph II akathisia - ACP 104 ph II schizo, desmethylclozapine (neutropenia ??)? iiB INIT June 26/07

ACAM ACAMBIS (ACM/LSE; ACAM Nasdaq) SEE EUROBIOTECH. May 17/07 Adv Com Vaccines OK ACEL K ALFACELL Onconase (ranpirnase), mesothelioma, ph IIIb, +

doxorubicine vs Doxo alone

ACHN ACHILLION - Elvucitabine, NRTI, ph II, long half life - ACH 806, ph 1 Hep C, lic to GILD. Terminater Feb 9/07


- 3 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ACOR ACORDA (ACOR) - Zanaflex, mkt

- Fampridine SR,4opyridine (pesticide) ph III MS fatigue (K channels), Feb 07 seeks EU partner. 2nd ph III to init May 22/07 - spinal cord injury, precl

ACLA ACLARA (ACLA) (infringement issue w/Caliper)

-Lab on a chip (microfluidics) : OASIS -SNP typing : GeneMate→→→→→→→→→→→→→→

Packard BioScience →PEB

ACTI K ACTIVE BIOTECH (Sweden) 886624; SE; ACTI-B CEO: Sven Andreasson Aug 01 : vaccine business (SBL) sold to Powderject

-Laquinimod, ph II, oral immunomodulator, lic to TEVA -ANYARA : - ABR 214936 fusion prot. F(ab) anti 5T4 (oncofoetal Ac

RCC) with ??, ph II - ABR 217620 F(ab) anti 5T4 fused to ???

Amer Acad Neurol April 28 May 5 2007 5T4 gene therapy competition Sanofi + ??

ACTC C Advanced Cell Technology ( ACTC) h stem cell technology

ACTV ActivBiotics, IPO filed Aug 06 Rifalazil, oral antibacterial, ph III, PAD ACU K ACUSPHERE (ACU) AI 850 Taxol without cremophor, K, Ph I/II ADLR

ADOLOR (ADLR) trades since nov 15/00 May 04 : class action suits

analgesics & opioids -ADL 10-0101 injectable κ opioid agonist, ph II, efficacy ++ on poison ivy itch, ph II pancreatic pain -ADL 82698 alvimopan/Entereg (piperidine derivative),oral (inconvenient post op)mu antag ,phIII postsurgical ileus delayed : too many hysterectomies/colectomies & slipped again from June to 4Q02;enrol compl 1st ph III dec 5/02, data April 2/03; N = 450, endpoint recovery GI function: signif at 6 mg not 12!3 2nd III N + 510 (no simple hysterectomy), OK at 6 & 12 (but less). 3rd III (Jan 13 04), N = 450, only 22% hyst., 6 signif, 12 NS. Feb 23/04 fast track. Filing "June 28 04". May 7/04 file pharmacotox for post op ileus. PDUFA extended to July 25/05; July 25/05 approvable Feb 8/06 topline data improves 20h. May 31/06 FDA resumes review; FDA action YE : Nov 6/06 "approvable" again : CV risks. . III init July 01 opioid bowel dysfunction ($5/pill) data Nov 11/02, N = 168 bowel movement within 8 hours p = 0.001 (but cramps, nausea, vomiting, diarrhea). 3 ph III init summer 05 : sept 06 : 3 failures !! -ADL 2-1294 (imodium !), ph II, topical analgesic; w/GSK Puerto Rico

Many κ agons :GSK,MRK,PFE,AVE April 2/01∏ return to ph I (poor knowledge of MTD) Lic to GSK April 15/02 ($ 270m, 50m upfront), lic from Roberts who had it from LLY - more effective at 6mg than 12 - µ antag like Naloxone or Naltrexone : issues w/memory Competition : oral methylnatrexone (PGNX) GSK discont on DB failure (dec 24/01)

ADLS Advanced LifeSciences (ADLS) IPO filed April 05 (Unterberg) Traded Aug 5/05

Cethromycin (acq from ABT 2004), ketolide from ABT (already had 6 ph III). Ph III CAP N = 522, non inf to clarythro (June 21/07)

part. w/BMY


- 4 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ADNX IPO

K

ADNEXUS filed Aug 22/07 (Lehman); withdrawn. Acq by BMY Sept 27/07

Adnectins (pseudo antibodies) Angiocept, anti VEGF, ph I

ADPX ADERIS ( ADPX) was Discovery Therapeutics. IPO filed Jan 15/02 (UBSW)

Ritigotine CDS, transderm. DA agon, Park, ph III w

AEGN AEROGEN (AEGN) ∗DEVICES based on proprietary aerosol generator (for liquid or powder with calibrated aperture plates : - AeroDose : hand held breath activated - Home portable nebulizer - Ventilator nebulizer ∗PEOPLE : Jane Shaw was CEO af ALZA from 70 to 94 June 7/02 : 30% staff cut

- Tobi (AeroDose), ph I - Insulin (AeroDose) one ph I trial completed ph II initiated in type II (dec 14/00) - Albuterol (AeroDose), phII - Ipratropium (AeroDose), ph I - Home nebulizer, 510k cleared, launch 1H/01 -Ventilator nebulizer , 510k cleared, launch 1H01

w/Pathogenesis. Chiron terminates Dec 5/01 -w/Becton Dickinson (which is developing patient adjustable container);Aug 24/01 sues BD for failure to perform; sttled Oct 2/01 -no contract for insulin yet

Patents : 5 Headcount : 103

Manufacturing : outsourced except aperture plates

AEZS K AETERNA (AEL/TSE, AEZS) owns 48 % of Atrium (TSX) csmetics, profitable

- Impavido (Miltefosine), MKT, leishmaniosis - Cetrorelix (LHRH antag), IVF, MKT, w/Serono, endometriosis ph II Solvay, BPH ph III ti init 2H06. Regained May 8/07 - Ozarelix, 4th generation LHRH antag, ph HRPC - Neovastat (AE941) extract from cartilage, oral antiangiogenesis, renal K, ph III ( data 2007) endpoint placebo 8m survival/verum 12m ( but mean spontaneous is 11 m, and w/IFN 15m). Ph III NSCLC interrupted Feb 18/06 (slow enrol). Interim efficacy to come. Terminated - Perifosine, anti AKT, oral, ph II, NSCLC, BC, ASCO 06 - D 63153 (SPI 153) w/ Spectrum for US, LHRH antag Ph II

ASCO 02 For EU : Ferrer, Medac GmbH

AFFX AFFYMETRIX (AFFX) Annual EPO sales June 05 (IMS) 13B; 9 in US (3 in dialysis, 6 in onco & predial).

GENE CHIPS ( 53% of sales, instruments 23%)

THE FUNDAMENTAL MICROARRAY PATENTS ARE PROPERTY OF OXFORD GENE TECHNOLOGY LTD

GLX (14.5%∏13.4%) HGS Boehringer Ingelheim Aventis


- 5 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS BY UK HIGH COURT RULING APRIL7, 00, BUT AFFX IS

RULED TO HAVE A LICENSE (NOV 1). SETTLEMENT MARCH 26/01 May 7/03 : to market SARS resequencing array.

BMY Incyte MRK PFE ROCHE (P450 gene chip) SGP WLA AHP

AFFY AFFYMAX traded Dec 15/06

- Hematide, 50 aa pegylated peptide, ph II, EPO like,IV/SC, once a month, to develop & commercialize w/Takeda. July 16/07 4 ph III init Oct 12/07 vs EPOs in renal failure (2 dial, 2 predial). Filing 2010 - all others very early

AGEN V K

ANTIGENICS (AGEN) June 13/02 : shelf filing Aug 21 : acq Aquila : Adjuvants Apr 24/01 :acq ARNX $60m(July 01) Ags for vaccines→SBH,BMY,AVE, provides QS 21 adjuvant to ELN for Alzheimer vaccine. 4 severe cerebral inflam. (Jan 18/02). Window ? Secondary (UBSW) priced Jan 11/02, nets $ 56m July 02 CEO Garo Armen becomes Chairman of Elan

-K Oncophage vaccine (heat shock prot 96 + autoK cells) kidney K,ph II→III (N=300), , fast track granted, enrol to end mid 02. Interim data 4Q03; 2nd RCC ph III starting 1H05. Data 1H06 : March 25/06 : failure …..colorectal ph I/II …..melanoma pivotal started May 2/02, fast track (Feb 5/02), partial hold (better characterization) Sept 3/03, cleared Nov 24/03. Fails, but stage IVa fare better. Final data ……ph II initiated in sarcoma (oct 17) - AG 858 Heat shock protein 70, phII CML w/ Gleevec, N = 120, init April 9/03 -AG 702 : rHu Heat shock protein + synthetic HSV2 peptide Herpes vaccine, ph I (Nov 01) -QS 21 in antimalaria (GSK) & anti HIV (VaxGen) ∗Aronex products : -Atragen (liposomal trenitoin for APL),ph III, FDA turns down (jan8/01) -Niotran (antifungal),ph III -Annamycin (anti MDR anthracyclin),ph II - Aroplatin, liposomal Pt analogue, ph II

AACR & ASCO 02 Orphan drug status, May 30/02 - Clin Canc Res Aug 15/03 : more than 50% of 29 pts had signic immunol response in CRC

AGGX K AngioGenex antiangiogenesis, K, Id genes (interfere with transcription factors)


- 6 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS AGIX AtheroGenics (AGIX)

Secondary planned Jan 21/03 $ 43m. Morgan Stanley, Lehman, Lazard

-AGI 1067,oral, blocks V-CAM prod→restenosis, ph II→ Oct 4/02 meets endpoint post angioplasty stenosis. Another ph II (echographic total plaque volume endpoint) interim Sept 27/04 reduced 3.8% (signif), Ph III init Jan 14/03. N = 4000, follow up 18m, in pts w/coronary dis._ Endpoint : various vascular outcomes (MI, Stroke, etc), against placebo. Jan 10/01/07 CEO at H&Q . - AGIX-4207(dithicarbamate represses VCAM-1gene expression), oral ph II, RA; IV phI. Terminated Oct 13/04 - AGI 1096, oral, prevention transplant reject

SGPreturns rights Oct 5/01, Amer Heart (Nov 11-14) CART study Lic to AZN Dec 22/05 $ 1B Deal. AZN says "low probability of success". Data March 07 ACC. Terminated April 07 w/Fujisawa

AGNT ARGONAUT TECHNOLOGIES (AGNT) High speed parallel synthesis

AHYS AHYS, was ATHERSYS (ATHX) IPO filed 10/13 (CS) withdrawn april 17/01

Functional genomics MEDX, ELN

AIMM AUTOIMMUNE (AIMM) working with Teva on Copaxone, and RA only 1 staff member left AKC ACCESS Pharmaceuticals * Vit B12 as oral transporter for drugs

ALKS

ALKERMES (ALKS) POLYMERS & PROCESSES for DRUG DELIVERY : ™ SC/IM slow release - Prolease : big molecules - Medisorb : small molecules ™ CEREBRAL : Cereport ™RESPIRATORY, "AIR" for local or systemic delivery of dry powders. Aug 26/02 : staff ¬ 23%

PROLEASE : - Nutropin Depot (HGH), MKT, injected every 2-4 weeks

instead of every day. -EPO, ph II - rFSH ph I MEDISORB : - Risperdal(Respiradol) , approved in more than 50 countries, once every 2 weeks IM, NDA filed Sept 3/01.Data presented May 2/01 (int soc schiz) & Int Soc Psy 20/5/02 - Naltrexone (once a month)Vivitrex Vivitrol, for alcoholism, ph III init April 02, filed April 3/05; June 23/05 lic to CEPH. FDA OK April 14/06 - Exendin, diabetes, ph I CEREPORT carboplatin for brain cancer - ph III discont in 04/99 - ph II on going in children

DNA for US, Schwarz for Europe term 06/01 JNJ discont (june 00), won't compete with

NESP/AMGN w/Serono w/JNJ (10% royalties) Hopes FDA OK Sept 02. PDUFA Aug 02. Sales could be $ 3B in 06. Extrapyramidal sds. July1st Non Approvable letter (hyperprolactinemia → K in rodents) Approved Aug 9/02 Germany & UK. Response to FDA April 30/03Compet : Zyprexa depot to enter ph III w/Amylin w/Alza


- 7 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS

Acquiring RELIANT (since March 21/02), 750 reps, stock deal about $ 1B

(could they do a sort of King/Altace/Hope job with Lescol???) Aug 15/02 : terminated because off Risperdal

AIR : - Insulin (short & the only long acting); first ph II. w/LLY, 3rd ph III init April 26/06 - HGH, ph I -MAb to RSV (Numax), pre -Albuterol slow release (Albulast), ph II -3 small resp.molecules, pre, 1 in ph I RELIANT -Lescol (fluvastatin) from Novartis (for US) $ 228m in

2001 -Dynacirc (isradipine, Ca blocker) $ 32m/01 - Axid (Nitazidine, H2 antag), off patent April 02 - MIV 606 (from Medivir), ph II, shingles (was returned by

ABT in 96 (< acyclovir)

w/LLY who discont the Dura/ELN project that could not adapt to long acting(April 2/01) w/LLY w/MEDI a major has an option w/GSK

ALLP ALLIANCE (ALLP) Aug 30/02 staff¬ 40% CEO J. Roth Underwriter : Roth capital Management

perfluorocarbone derivatives oxygen carriers : -Oxygent, ph III:blood substitute. Ph III in general surgery shows (april 9/01)signif reduct in blood units needed (comparative, but not DB!!) -Liquivent, ph III: ARDS. Mortality (May 23/01) 19%, placebo 15%∏halted

→Baxter, Nycomed high frequency of stroke;CV surgery trial halted jan9/01 (CEO says linked to rapid blood harvesting ?) Acq Molecular Biosystems (Optison, ultrasound contrast agent)

ALNY K ALNYLAM (ALNY) RNA interference is a natural process for gene silencing Claim to have predominant IP position Sept 7/05 Novartis acq 20%, & $ 750m deal. March 27/06 : deal w/Inex (IEX/CND) for liposome delivery July 9/07 Roche $ 1B deal (excludes virology, infection, C-V, auto-immunity, CNS)

siRNA : - ARMD (anti VEGF w/MRK clinicals 2H05), term Sept 20/07 -Park (α synuclein targeted w/Medtronic pump), -Apo B, - Huntington, pre, w/Medtronic (July 30/07) - CF (target genes involved in CFTR folding, demonstrated rescue of deltaF 508) - ANTI TNF α nasal w/Nastech - RSV clinic Dec 7/05 US, Dec 19 EU, intranasal, more potent than Mab in animals (outside of NOV deal). IND filed Nov 1/05, init Dec 19/05. Intrasal ph I OK April

Other siRNA firms Combimatrix (CLMX), Cytrx (CYTR), SIRna Therapy (RNAI), Benitec (Austral), Nastech, Silence (was SR Pharma Plc & acquired Atugen), Acuity ICAAC 2005; Arrow Ltd has small molecule anti RSV A-60444, ph II, lic to Novartis June 30/05


- 8 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Sept 8/07 mi RNA JV w/ISIS (JV called Regulus) : - mir 122 Hep C, res - many others : K, etc

30/06 (N = 100), inhaled ph I to init 2H06: Oct 11/06. Ph II in adults experimentally infected init June 26/07 vs placebo. Data YE (Nov 1/07 : delayed to 1Q 08), N = 90 - ALN-FLU.01 Influenza : May 25/05 - H5N1 Novartis partnership Feb 21/06 $ 700m - miRNAOct 23 06 efficacy of miRNA in mice : antagomir that silences microRNAs (could be applied to K) ALN-PCS01 Dec 13/06 IND for SYSTEMIC to be filed anti PCSK9 (proprotein convertase subtilisin/kexin type 9) lowers LDL cholesterol, also expressed in liver, intestine, kidney, cortical neurons. W/Lipidoid nanoparticle technol from MIT - siRNA for PML (due to Tysabri), w/BIIB) - ALN-VSP01, anti VEGF & kinesin spindle protein, could be delivered systemically to liver w/Inex liposomes . IND 2H07 (Nov 1/07 : delayed 1Q08) - siRNA for Hemorrhagic fevers, Aug 9/07, $ 38M grant - si RNA for obesity w/ Southwestern, Sept 7/07

ALT ALTEON (ALT)

-ALT 711,pimagedine, alagebrium, cardiovasc aging,ph IIb since March 04 (SPECTRA) on syst BP :improves vascular elasticity. July 18/03 failure.. On hold June 10/05 -Ressuscitating fluid, pre : HemoMax

on hold Feb 25/05 rat carcino

ALTH K

ALLOS THERAP (ALTH) March 5/04 files shelf $ 75m May 29/03 : staff ↘ 30% - 30 min IV infusion -5 times a week for 2 weeks -pts receive 02 nasal canula 30 min prior Rx, during & 1h after Dec 17/01 : Steve Hoffman (sold 12% of his shares in 02)becomes Chairman, Mike Hart President & CEO US : 170,000 cases brain meta/year; price per ptn/year : $ 10,000 ($ 500 per dose, 10 doses for brain, 32 for lung) April 25/02 : $ 15m PIPE with Perseus Soros fund (Dennis Purcell). Nov 02 have

- RSR 13( efaproxiral, efaproxin),phIII,brain metastases.Open, contr. random. Enrol. compl. (N=538 6 m follow-up, will file based on 35% (all they need is signif diff.)increase in median survival time)& in lung/breast subgroup. Nov 8/00:FDA fast track designation. Manuf. by Hovione (Portugal, FDA inspected, make Mevacor)fill & finish was Acorn, will be Baxter; enrol compl. Aug 7/02. Interim May 30/02 (after 204 deaths) OK by independent Com.(may30/02). April 24/03 : global survival + 17%, NS but breast N = 115 + 101%, p = 0.006 (8.67 m > 4.57) Rolling fiiling complete Dec 4/03. Feb 3/04 accepted w/Priority review.. Approval June 4 ??, ODAC May 3/04 : NO (16/to 1), but Donna Przepiorka votes yes. Feb 12/04 w/Nat Breast K Coalition new ph III ENRICH, rand, open, N = 360. Primary endpoint survival (powered for 50% diff). Interims at 94 & 188 deaths. 1st interim 2H05 (March 05 50 of planned ww centers open). Total enrol. 2 years : 3Q06; 2nd interim mid 2007 (at 282

by allosteric increase of PO2/50 by 10 mm Hg, improves radiotherapy™ph II survival increase from 4.1 m to 6.4 m, +56%,p=0.027 Competition : Xcytrin (PCYC) photodynamic therap. (whose ph III fails Dec 13/01), Nimorazole → ASTRO, Nov 6/01 : 43 % 2 years survival Top line results 2Q03 if 402 deaths in intent to treat group & 308 in breast/lung. Feb 13/03 CEO says MRI analyses longer than expected.. FDA June 2/04 : approvable June 4/04 EMEA filing; Oct 2/05 withdrawn → ASCO 02 (2 year survival rate: 35%) → ESTRO 02 : Sept 19/02 : median survival 20.6m (hist compar. 14m, → + 47%)


- 9 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS 12.5 %. If no partner & $ 200 m sales in 2005 ( 20000pts) net income $ 25m (US Bancorp Sept 26 : $ 29m) In June 02 JNJ invest arm sold shares → SEC 13G Feb 4/03 (DJ press release) March 05 : $ 50m PIPE (W. Pincus)

deaths). June 19/07 FAILS NSCLC :ph II, N = 52, 83 % of responders w/paclitaxel & carboplat (ASCO/01). FDA meeting agreed on SPA (special protocol assessment) w/ sequential chemo/Rx rather than simult →ph III,some enrol.1H03; N = 600 (Europe), interim & will calculate if need to increase Screening suspended, partner seeked.Nov 10/06 ph II ASTRO, median survival 20.6m (matched RTOG group 13.3m) Glioblastoma :ph II;pivotal III /or NSCLC RSR 13+ BCNU™glioma, ph I/II (jan 17/01) Cervix K ph I/II w/cisplat & Rx init Aug 15/02 modest side effect : 8% of pts have creatinine ∨ - BGP 15,oral chemotherapy protectant, lic from N-Gene( commercial arm of Hungarian Innov. Technol, invested in by Soros fund), March 13/02. Ph 1 to start 2H03 (with platin). Suspended May 29/03 - PDX pralatrexate (antifolate), ph II, lic from MSKCC Jan 8/03. Maintained in NHL & solid K w/Taxotere

Aug 12/03 : World Conf Lung Cancer. Median survival 20.6m (best historical : 17m). Aug 3/04 : Orphan drug status for Brain breast metas

A LTU K ALTUS (ALTU) spin off from Vertex. Pancreatic enzyme mkt ww 2006 $ 750m HGH mkt 2004 2.2 B July 3/07 FDA revokes orphan drug status, because ALTU 135 can also be used in AIDS with malabsorption

- ALTU 135, 2 ph III init May 07 efficacy top line 2Q08, safety & filing 2009, CF N= 150, microbially derived crystallized pancreatic enzymes, capsules & liquid, only 1 pill/meal, supported by CF foundation. June 11/07 EU rights reacq from Dr Falk Pharma - ALTU 238, ph II, long acting HGH thanks to crystallization (no polymer or fusion), lic to DNA Dec 20/06. DNA has to opt in for ex-US. Nutropin patent expires 2008 - ALTU 237, pre, oral oxalate degrading enzyme, not absorbed. IND filed June 19/07. Ph I init Aug 14/07 - ALTU 236 for PKU, pre

Competitors (Creon Solvay, Ultrase Axcan (but refiled Aug 1/07), Pancrease McNeil) have to "renew" their older NDAs for April 2008. Eurand is new but porcine.

ALXA ALEXZA AZ-001, aerosol of prochlorperazine ph II, March 07 very good data in migraine pain

ALXN M

ALEXION (ALXN) Anti-complement monoclonals, humanized PG deal revamped Dec 12/01 : ALXN invests more in Dev & Mkt, &nd gets 50% of profits.

- Soliris 5 G1(Hu)eculizumab (anti C5). 1 → R.A.,ph II,12w data as good as Remicade membranous nephritis,ph II, fails endpoint Nov/02, also Asthma Parox. noct. hemoglobinuria, ph III (SPA) initiated Nov 04, N = 75X2. Enrol compl 1st trial Triumph

To be manuf by Lonza PNH endpoints Hb stabilization & reduced transfusions (p < 0.05). Prior papers show signif stabilization or increase of Hb, and very clear


- 10 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - Manuf by Lonza Nov 8/05 : have set up Alexion Europe for eculizumab. EMEA filing 2H06 US cases : 5 to 10,000 MStanley gives price 200 to 300,000 $/y, and 3,000 pts on drug (Feb 07) NEXT RISK : doesn't C5 protect against bacterial infection ?

(DB N = 87) April 12/05. Tmt end Jan 4/06 (see JAMA April 6/05). Data Jan 26/06 : transfusion rate drops to 0 vs 10 (p< 10 – 7 ) Hb stabilized 49% vs 0% p < 10 – 7 ;2nd trial Shepherd (open N = 95) enrol compl Sept 21/05 Data June 12/06 : safe , all primary (reduct intravasc hemol, but transfusions not disclosed)& secondary endpoints signif, filing US sept 20/06, EU Sept 26 (accelerated procedure 150 d granted); March 16/ 07 : FDA approves (black box meningo). EU OK June 07. 2Q07 $ 9.8M MDS : explor study June 18/06 - 5 G1. 1-SC (Hu single chain) pexelizumab →CABG, ph III: FAILS Nov 25/05 →MI.ph II: results jan 23/01: death & MI :41% at d30;ph IIIw/PTCA (COMMA) init dec 01 (for 12-18m): PRIMOCABG (w/CABG) ph III fully enrol Feb 24/03. N = 3000, results Aug 4/03 prelim data mixed. Full data AHA (Nov 03) narrowly misses endpoint, but very + in subset with 2 or more risk factors. PRIMOCABG 2, with 2 or more risk factors, N = 4250. Enrol compl. Aug 12/05, results 4Q05 April 3/07 PG terminates Xenotransplatation : res

reduced transfusions. ASH 05 : 2 papers : remarkable efficacy Lic from SCA (Enzon) Lic to PG AHA Nov 18/02; ph II, N = 814, infarct size not ¬ but 90 days mortality ¬ 70% p = 0.014 Sept 26/00: acq. Prolifaron the Scripps Mab res. Corp, with Phage Display patents Competitor NEUROGEN has a C5a receptor antag ph II RA

AMGN M K

AMGEN (AMGN) Aug 15/07 plan to reduce staff 2,600 What if erythroblastopenias & EPO K worsening gain momentum ? March 7/07 black box warning Hb >12 EU( 35% of sales), EPO patent expires Dec 04 (US exclusivity until 2012. Nov 6/00 : Elanex releases data on long term stability of its EPO (sold to Baxter Oct 01, MKT in central Europe). Also EPO from GMX (GeneMedix LSE who sells GMCSF in China) partn w/Skyepharma. Jan 22/01 : Infimed has a SR EPO in pre (&

-Epogen : $ 1.759 B/99;1.960/2000;2.1/01(+ Eprex $ 3.4B). 2002 $ 2260; FY 03 : 2.4B. 1Q04 590, 2Q 633, 3Q 681, 4Q 697, FY 04 2.6, 1Q05 583 , 2Q 647, 3Q 599 , FY 05 2.5B; 1Q06 604, 2Q 613, 3Q 633, 4QUS 661, 1Q07 625, 2Q 07 624; Nov 20/01 AFSSAPS : 40 erythroblastopenias w/Eprex (JNJ), 10 Neorecormon, 10 Epogen. EU patent : 2004 AMGN has US rights for dialysis, JNJ for US oncology & both ww. -NESP/Aranesp darbepoetin SC/IV (once a week hyperglycosylated Epo)→filed FDA/CPMP, 4Q99→CPMP OK march 12 01,FDA delays (april30/01).Approved Sept 18/01for dialysis. US onc OK July 19/02; EU OK Aug 28/02. Abs on package insert. Sales 4Q01 : $ 37m, 2002 : 416;FY 03 : 1.5B (35% in EU), 1Q04 542, 2Q 617, 3Q 608, 4Q 704; FY 04 2.5B, 1Q05 723, 2Q837, 3Q 840, FY 05 3.3B; 1Q06 893, 2Q 1.1 B, 3Q 1.067, 4Q 1.106, 1Q07 1.02 (US 654), 2Q 949

AMGN prevails (jan 22/01) on TKTX in US litigation ditto April 11/01 in UK Oct 18/03 Lancet paper on decreased survival of H & N w/Neorecormon. Roche to start ph III CERA : pegylated " continuous epo receptor agonist)

In Germany Fresenius distributes (Jan 22/02) NESP : $ 860every 1 or 2 or 3 w for 12-18w Aug 7/04 EU appoves Q3W/cancer & Q4W for predialysis CERA PDUFA Feb 20/07


- 11 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS part w/Novartis). Oct 07 : HOSPIRA Retard CERA & Neose Roche (NeoRecormon) is approved since Oct 01 (EU) for 1/week in dialysis. Feb 13/03 : Dragon Pharm. (CND) ships EPO to Itaca Labs (Brazil) Teva/Sicor G-CSF approved Lithuania 2003? Will file Mexico 2004. Dec 13/01 : to acq IMNX $ 16B (AHP will reduce to 8%); Feb 7/02 : FTC extends review period. OK July 17/02 Also generics from Stada, BioGenerix (RatioPharm), BioPartners (Merck AG + LG Korea who also hasHGH, G, GM & IFN α, Pliva, Novartis Austria. May 8/02 : AMGN acq EU rights to Neupogen from Roche Neulasta generic from BioGenerix AG, ph I, Nov 7/07 Sept 14/04 : FDA (after CHMP) refuses Omnitrope (Novartis generic of HGH) June 5/07 acq Ilypsa. Ph II Renagel like drug : ILY 101. June 6/07 acq Alantos $ 300 m : DPP inhib diabetes ph II.

Epo franchise 02 $ 2676 (JNJ Eprex 3.03, Procrit 1.23) -Neupogen : $ 1.256 B→1.220/2000;1.3/01;3Q02:332m, 4Q02 : 310. FY 03 1.266, 1Q04 269, 2Q 295, 3Q 608, 4Q 309, FY 04 1.2B, 1Q05 294, 2Q 312, 3Q 305, FY 05 1.2B; 1Q06 288 2Q 312, 3Q 308 4Q 373, 1Q07 299 -Neulasta SD-01 Peg(Shearwater/INHL) Once a week., BLA filed March 01. FDA OK Jan 31/02,EU Aug 28/02 sales 2Q02 Neupo + Neulasta + 39%. Neulasta 3Q02 : 142m, FY 03 1.3B, 1Q04 395, 2Q 426, 3Q 450, 4Q 469, FY 04 1.7B, 1Q05 501 2Q 587, 3Q 577, FY 05 2.3 B; 1Q06 608 (US 497) 2Q 567, 3Q 690 4Q 711, 1Q07 719 -IL1-ra, Kineret/Anakinra (was the Synergen sepsis drug)→ R.A., filed FDA/CPMP 4Q99(6 months efficacy/500 pts, & signif reduct joint destruction), less efficacy than Enbrel or Remicade (need for daily shots, could address their failure, painful inject?., high dosage (price ?),™new data(1300 pts safety) filed April 23/01. FDA adv panel Aug 16 OK 6/2. OK Nov 14 in pts who failed DMARD. Sales 4Q01 $ 12m; EO OK March 14/02 FY 05 : $ 77m, FY 06 60 - sTNF type I receptor pegylated inhib (PEGsTNF-RI) ph II. - Kepivance / Palifermin KGF mucositis filed June 23/04 (BMT), very signif : Grade IV goes from 62% pts to 20% ( N = 212) FDA OK Dec 16/04. EMEA OK Oct 28/05 FY 05 26 - AMG 073 Sensipar, Mimpara cinecalcet, oral calcimimetic, 1st ph III init Dec 01 : April 23/03 signif metab endpoints, 2 more running. Reduces PTH in renal failure, but pain, emesis, URTI : competition for Renagel.Filing Sept 9/03. Approval March 8/04 Price $ 5,400/y. EU (Mimpara) OK July 31/04. 2004 26 m. 1Q05 : 13.7, 2Q05 : 16.8, 3Q 51, FY 05 147; 1Q06 61 2Q 79, 3Q 83 4Q 98, 1Q07 105, 2Q 108 - AMG 655, fully human Mab, TRAIl receptor 2 agonist - AMG 162, IgG2, denosumab, fully Hu anti RANKfrom

Neupogen : $ 2000/10 days Neulasta : $ 2360 equivalent period Early 05 Centres for Medicare & Medicaid Services will publish average sales prices forAranesp, Neulasta & Neupogen IV 3 days befor and 3 days after chemoablation for PBSC To be covered by Medicare in 2005 see NPSP Amer soc nephrol Nov12/ 03 Amer soc bone metab res Sept 22/03


- 12 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ABGX (receptor activator of NF kappa B) ligand, inhibits osteoclasts, Ph II, 1/6m sc = Fosamax QW; 2 ph III init Aug 10/04.. Filing Q3/07Launch 08/09, July 20/05 enrol compl 10,000; data 2H06 : probl of rebound osteoporosis (2Q press release) that biphosphonates do not have K : phases III prostate and breast metas - GDNF (from Synergen), Park, ph II halted Feb 10/05 inefficacity + cerebellar toxicity in animals. -BVT 3498 ph II diab, inhib 11β OH steroid dehydro, Biovitrum. - AMG 706, phII, oral mixed kinase inhibitor (VEGF 1,2 & 3, PDGF, Kit, RET) : Imatinib resistant GIST, NSCLC, CRC. GALL BLADDER TOX: To init vs Avastin 1st line NSCLC 4Q06 : delayed. ASCO 07 thyroid ph II not impressive, will not pursue this indic. NSCLC Ib Sept 07 w/carbo Taxol w/ or wo Vectibix - AMG 714 HuMax IL15 ph II, RA lic from GenMab (July 1/03), ACR Oct 04 - AMG 531 : peptibody (Fc peptide fusion protein) that stimulates TPO receptor, ph III for ITP, to file 2007 - ALS 2-0426, diabetes, DPP IV inhib, ph II from Alantos (in France, Seevier)

AMGN AVIDIA acq Sept 30/06, $ 290m + $ 90m milestones

Protein structures that bind more than 1 site, like Mabs. Manuf in e.coli (B. Mannheim) Anti IL6, ph 1

DEALS

AMGN M

IMMUNEX (IMNX) Aug 11 : secondary that decreases AHP from 55% to 41% Manuf Capacity issues for Enbrel!!!, Rhode Island approved Dec 26/02. B.I.essential RISK : Remicade could take their patients but it is IV (but 1 a month), & Enbrel subcut (BIW or QIW, QIW for RA), Humira twice a month subcut Merger declared July 17/02

-Enbrel/etanercept (sTNFr, Fc CH1 + CH2 + hinge fused to p 75 portion of TNFr : active on α & β ),FDA OK 98,CPMP OK 12/99→RA→ Also Enbrel ph IIICHF discont March 23/01, subgroup analysis ready in June 01 ??? PSO : ph III jan 17/03 50% PASI 12w ; PSO arthritis BLA filed July 17/01, approved Jan 17/02 FDA & Dec 17/02 EU. PSO dermatol filed July 8/03, OK May 3/04 oct 3/00 : CPMP posts warning on cytopenias OCT 11/00: warning on demyelinating disorders -Novantrone→MS, FDA OK (but cytotoxic!) -Nuvance,inhalable sIL4r→asthma, ph II(but infect.?no )

by AHP, selling its shares ($367m→653/00; 762/01; 802/02 (Remicade 1200/02; Humira 1Q03 $ 26m, 2Q 57 YE forecast 250).FY 03 1.3B, 1Q04 397; 2Q 440, 3Q 496, 4Q 567, FY 04 1.9B, 1Q05 592, 2Q 639, 3Q 668, FY 05 2.6 B; 1Q06 658 2Q 724, 3Q 705 4Q 792, 1Q07 730, 2Q 823 FDA approv.early use in RA (June 7/00) - Ankylosing spondylitis (350000 US pts) : Adv Com + June 24/03. Approved July 25/03 - EULAR June 03 50 mg QW = 25 BIW → AASLD Nov 02 : ph II DB, Hep C : Ifn α/Rebetol alone 28%, + Enbrel 58% viral + ALT normalisation, p = 0.04


- 13 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -ABX-EGF→K, phII, fh - Avrend (CD 40 L), ph II, kidney K (w/DNA) - Mobista (Flt 3 ligand), K, ph II;ex-vivo dendritic cells x 20; tumor bulk¬. - Trail/Apo2L, K, pre - Anti IL15 from GenMab, II, RA (Roche has CRB 15 precl) - HuMax from GenMab, Lymphoma, pre,

FEV1>placebo (signif); 2 ph II w/β- :no efficacy, but steroid sparing ongoing w/ABGX (competition : OSI, AZN) w/CAT : fh MAbs

AMGN

TULARIK (TLRK) IPO Dec 99 Nov 18/02 : Jack Anthony VP Bus Dev (from Cell Therapeutics) Founded by guys from DNA Hepatocellular K : 1M (US 20 000)cases per year, no approved therapy, 6m survival 50%, 2 years : 5%. Mostly post Hep C PharmaVision owns 24.7% MEDX acq. 0.2% (Jan 02) Oct 02 : recruit clin VP from Roche, & regulatory VP Shelf priced at $ 25.7m Oct 18/02 May 21/03 : w/AMGN acq 21.3% ($ 35m) + 125 m committed funding. Could buy more over 3 years. After shelf AMGN : 10.8% March 29/04 : being acq by AMGN $ 1.3B Completed Aug 16/04

- T 64 ,lometrexol(antifolate), ph II,NSCLC, H&N,

melanoma, breast, lic from LLY. Term June 02 -T67, ph II irreversible tubulin binder(taxol is not), &

resistant to MDR,& enters brain (neuropathy at high dose),

ph II hepatocellular K 2 studies at 165mg/m2 , First line completed, 2nd line also. Meet FDA Aug 26/02 OK for ph III at 250 mg/m2 ( supported by PK 12 patients to start). Ph I/II wDoxo

ph II in Glioma, breast, NSCLC, colorectal at 330 mg/m2

-T 607, like 67, but does not cross BBB,ph II HCC, Ovary, gastric, oesophageal.

NHL halted - Geldanamycin, res, inhibits IKK (inducible kappa kinase) -T 611 : oral anti CMV, phII. Term June 02 -Antibacterials/antifungals : research - Anti Xa oral, w/LLY, ph I ∏ milestone Nov 12/02 research -obesity (Knoll) : term Sept 01 -cholesterol (Sumitomo) : term Jan 01 - GPCR targets w/Sankyo June 02 - T 131, PPAR γ agonist ( like Avandia, witout heart

side-effects ) , Diab II ph II UK Dec 2/02 - T 487, phII, antiCXCR3, PSO, RA

Partnerships on regul of gene expression : Roche(antiinflam), , Taisho, Yamanouchi, JNJ, JT (PPAR) 11 presentations at ASCO 02 1st line 9 PR, 38% stabil N = 750/survival (& interim)/ IV every week compared to Doxo 60 mg/M2 every 3w,started March 25/03. Could end 2H04, filing 1H05 ????, sales 1H06 (faster if fast track : granted Oct 22/03) FeRx had a ph II/III


- 14 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS w/MEDX : Mabs to 3 oncogenes from TLRK

AMGN M

ABGENIX (ABGX),CEGE owns 10.5 % Dec 14/05 : AMGN to acq $ 2.2B cash. Compl April 3/06 Fully human monoclonals Oct 30/02 : staff¬ 15% (N=450) but +4% in 3Q/02 (XenoMouse,acq. from J.T.) XenoMouse +SLAM∏XenoMax Was spun-off by CEGE in 96 Nov 00 acq ImmGenics (SLAM) Thanks to SLAM , no need to use Hybridomas : can manuf. in CHO. Feb6/01: lic to Celltech SLAM(selective lymphocyte Ab method) -Jan 30/01 : manuf agreement w/LONZA (exclusive access to part of Slough site) Fremont pilot plant will be ready (for 100kg/year)4Q02 ∏ customers ????? At present manuf in hybridoma but will make economic decision on hybridoma or CHO. May 24/01 granted US patent "Human MAbs to EGFR" -Scott Green to go from CEO to Chairman mid 02, Withy (COO becomes CEO) -Feb 26/02 : $ 200 m convertibles issued - Feb 27/02 : SEC filing of ownership of declining shares in CRGN & IMGN. A charge is recorded : $72 m for first 9m/02. Resteering might be AMGN's influence : the anti EGFR mkt could be the most important K mkt in 5 years Aug 26/04 : CEO resigns NOV 05 : increase in shorts Competition Genmab HuMax fully human anti EGFR, ph I/II H & N ASCO 05 VECTIBIX : $ 8,000/month

-ABX CBL,m antiCD147 →GVHD, ph III ABX RB2,fhu antiCD147∏GVHD,pre -ABX IL8 IV/IM →PSO,IV (every 3w;subcut in dev) phII DB. PASI 75:50% or better (Lancet remicade paper) →RA, ph I/IIֱ∏ph II term. Jan 4/02. No ADR but poor efficacy ∏ COPD, ph II (results 1Q03), IL8 responsible for excess leucocyte extravasation ∏ melanoma, ph II (Jan 3/02) w/dacarbazine, data 4Q03 : time to progression

-ABX EGF panitumumab Vectibix IV/2.5mg/kg/qw, 2w or 3w(anti EGFR, IgG2, but IgG3 very linked to C’) isotype → no C'(this is bad for Rituxan, ASH02 n° 2256),5 times more affinity than IMCL C225 (see GenMab data) -renalK,phI→phII(april18/01) IL2/IFN failures Accrual complete year end, endpoints tumor shrinking,T. to prgr.,survival, PhI ASCO 01. N=28, 9w. trial, rashes at high doses, no allergy. EORTC nov 12/02 N = 88; 1/1.5/2/2.5 mg/kg. Acne in 70/91/95/100%. Consistent kinetics. At 2mg/kg blood levels > IC90 of xenograft model - NSCLC w/taxol-carbo, ph II (Aug 1/01) data ASCO 04 : N = 19, ORR 25%, 2/3rd line, Part II N = 175 ongoing . Sept 07 w carbo Taxol +/-706 -Colorectal refract mono N = 100 ph II (Dec 29/01) data 1H03 response & TTP (will disclose interim of 40 first if ORR < 10%). Feb 20/03 interim OK ! ASCO 04, N = 148, 2/3rd line, 10% ORR. ESMO 04, 1st part open ph II, 1st line CRCm w/Saltz, N = 19, PFS 8.2m ASCO 05 ph II N = 95 CRC, Prostate, RCC, NSCLC, pancreas, esophagus, gastric, same efficacy & safety q1, 2 or 3w 1st line CRC ph III init April 2005 - Colorectal combo (+ campto 5FU) - Prostate ph II Feb 24/04 fails internal threshold Aug 06 : H & N delayed -Anti MUC18 : melanoma ph I since Feb 03 - AMGN 162 fully Hu anti RANK ligand , 5% royalties, init July 10/01, ph I osteoporosis, ph II metastasis - ABX-PTH, ABX 10241, ph I, for dialysis & PTH cancer, IV, good data ASBMR Oct 04 - anti CTLA4 ticilimumab w/PFE, ph II, CP 675,206, melanoma - anti IGF-1R/AKT, w/PFE -Anti CD28 (w/Diabetogen, CND)∏Diabetes I, res - Anti properdin f hu, pre, lic from Gliatech Nov 2/01

→SangStat, term Feb 18/03 →SangStat

→ Amer Acad dermat : march 15/01:significant++

→ AADFeb 02(1 abstract,N= 94, 3mg/6/0, DB, PASI ∨ P=0.02, no rebound)) & Soc Inv

Derm May 18/02: PASI 75/15 weeks reached by 3% placebo, 2% 200mg, 6% 300mg

JV (restructure?)IMNX/AMGN (resp for ph III) :competition:OSI,IMCL,AZN(Iressa ph III),MDRX,PFE (CI 1035,TK inhib,phII), ICR 62(phI, MAb),YM Biosciences (TheraCIM,MAb,phI), GSK. → ASCO 02 : N = 88,8 weeks, 58% have minor response or stable;( IFN/IL combi gives 18%)ORR 3 PR, 2 minor R; TTP & survival available when?. "very encouraging, not quite enough a signal to go to phase III"says chief med officer. my comment 8 w stabilization is not unusual in RCC → EORTC Nov 03 NSCLC 1st line ongoing ph II, rand, data 2H05) → colorectal MonoASCO 03 : 10% PR, 55%SD (will enrol 150). FDA SPA: Jan 20/04 init 3rd line oxaliplat refractory; Mono, N = 300, 6m enrol, 6 m to measure ORR. BLA Filed March 31/06; FDA OK 3rd LINE Sept 28/06. AACR : OS NS, PFS = Erbitux. Also EU trial ( data 4Q05; endpoint PFS, vs BSC which is usually 8 w; ABGX at ASCO 05 had 13 w in N = 148). Enrol. full March 18/05. EU Data Nov 3/ 05 N = 463, 46% decrease in T progression rate (p < 10 -9 : time to disease progr or death 96d vs 60 (bsc). Precise PFS ? (Erbitux = 6w). Also ECCO Nov 3/05 1st line CRC ph II, N = 24, ORR 33%, PFS


- 15 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - Smallpox MAb w/US army : Sept01

10.9m. 1 eyelid edema, some CV tox.; Avastin has PFS 9m & ORR 17% PACCE : Panitu Advanced CRC evaluation, 1st line, oxali or irino +/- panitu, N = 1000, init April 30/05, interim 2H06 (some data YE : increased side-effects, terminated March 24/07 signif lower PFS & OS). SALES 4Q06 : 39, 1Q07 51, 2Q 45 EMEA : NO May 25/07 Sept 23/07 OK but only in non KRAS mutations

AMLN AMYLIN (AMLN) Class action suit for false statements (Aug 9/01) Jan 13/03 : shelf for $ 141.7 m (Goldman, Morgan Stanley, Lehman), sold by jan 17

-Pramlintide(Symlin,amylin analog, synergistic to insulin), diabetes, ph III failure→ filed dec 7/00; ADV COM JULY 26/01: rejected (severe hypoglycemia & not GCP).Approvable in assoc w/insulin Oct 12/01 require more tests, to be filed 1H03.! CPMP filing May 31/01, withdrawn Oct 24/02. Dose rising trial underway (June 02), full enrol (N = 300). Feb 03 . Refiled June 16/03. Dec 17/03 approvable letter asks for sensitivity to hypoglycaemia. Data submitted Sept 20/ 04., PDUFA March 20/05 OK March 17/05. Sales 06 $ 43.8m, 2Q07 15.2. Oct 1/07 "non approvable" for assoc w basal insulin Symlin in Obesity, ph II -Exendin/Exenatide, Byetta (GLPr agon) SC BID / AC2993 (39 aa peptide) →diabetes,phII, HbA1c¬ & fructosamine¬ (ADA june23/01); ph III init Dec 10/01. Results 1Q03; 2nd ph III in type II init Jan 02, 3rd ph III init 1Q02 w/Metformin. All ph III data (N= 1600) filing June 30 04 PDUFA April 30/05.April 29 approved in combi, approvable alone. EMEA OK Sept 21/06.. Sales 06 $ 430m, 2Q02 152, 3Q07 177 Oct 16/07 FDA reviews 30 cases of pancreatitis Long acting (LAR) init. ph II mid 03, Aug 05 : ph II data qw OK (filing 2H09 Plant issue) - AC162352, injectable gut hormone (L cells, enteroendocrine cell lineage)) PYY3-36, ph I Obesity; post prandial release by gut L cells of GLP & PYY (36 aa ).

JNJ discont. amylin is a natural hormone from pancreas that contributes to postprandial glucose lowering ⇑inject. long action w/ALKS : ph I -once a month FDA asked for "additional clin data to identify a patient population and method of use where there is no increased risk of hypoglycemia lic to LLY (Sept 20/02), value $ 325 m, upfront 80 + stock 30 + 80% dev costs Aug 7/03 partial results of 1st ph III OK, Npv 11 2nd ph III OK, Nov 25 3rd ph III efficacy BUT hypoglycemias Nastech has inhaleable

AMO IPO AMSTERDAM MOLECULAR (EuroNext) Priced June 20/07

AAV gene therapy - AMT 011 : lipoproteine lipase gene for hyperlipoproteinelia, ph II/III, to file 1 Q/08 - AMT 020 acute intermittent porphyria, pre


- 16 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - AMT 030 : hyperoxaluria ; res - AAV-ILGF for liver cirrhosis

AMRI ALBANY MOL. RES (AMRI) contract chemistry research -royalties for Allegra (SEPR ?) from AVE -res agreement w/CBST (Aug 20/01)

AMRN AMARIN (AMRN) 30,000 US patients Myasthenia : 15,000 cases in US (incidence)

- Miraxion ( eicosapentaenoic acid) active in subsets ( < 45 CAG repeats) of Huntington). 2 ph III (SPA Sept 12/05). US init Sept 21/05, both fully enrolled. April 24/07 FAILS - EN 101, acq with Ester Neurosciences, NOT a siRNA, but oral antisense to mRNA of immunogenic variant of A-Cholinesterase, ph Ib & IIa in Myasthenia not bad

ANDS ANADYS (ANDS) - ANA 975, oral prodrug of isatoribine, small molecule TLR 7 agonist, ph I; ph I b for H205 in HCV. "intense immune stimulation in animals" June 27/06 : trial halted - ANA 380, ph II, Hep B, w/LG Korea - agonists of TLR 7, 8 & 9

JUne 2/05 part. w.Novartis $ 570m

ANPI ANGIOTECH PHARM. (ANPI) -paclitaxel coated stent, phIII A. Heart Nov ?? ™Boston Scientific, Cook

ANSV ANESIVA, was until June 06 CORGENTECH (CGTK) traded since Feb 12/04 To merge w/AlgoRx, who has ALGRX 3268 ph III Powderject lidocaine.: failure March 27/06 Dec 31/06 Cash & equiv $ 80m Total Knee per year US 470,000

transcription factor decoys - CGT003, adifoligide, oligo transfected to vein grafts by pressure; E2F decoy : blocks E2F transcription factor, responsible for proliferation of smooth muscles that block arterial by-pass; ph II CABG at 12m, 33 % reduct of 75% blockage ph III, N = 2400, CABG data 1Q05 (endpoint signif reduct of graft stenosis > 75%) March 30/05 Failure ph III, N = 1400, PAD, data 2H 04 meeting end March w/FDA to discuss regulatory pathways. Enrol compl Sept 03. Dec 6/04 failure, endpoint graft clinical failure /amputation, but (Feb 3/05) secondary endpoint of arterial flow significantly improved - NFKB decoy, eczema, ph I/II to init 1H/05; pre Crohn (congr mucosal immunol, Boston, June 27/05) - HIF decoy : pre - 4975 : Capsaicin PEG, sensitive nerve terminal killer, ph II already very signif,end 06, 1 single injection : - Total knee replacement, N = 50 , vs placebo : pain d 14 p = 0.007 - Bunionectomy N = 21, vs placebo, p = 0.03 - End stage OA knee, 6 w , p = 0.03 - Moderate OA knee, N = 55, open, - Elbow tendinitis, N = 22, vs placebo, at 4 weeks p = 0.026 - Interdigital neuroma, N = 58, at 4 weeks p = 0.018

Capsaicin competition : NGSX FDA requests (meeting Jan 7/07) : - safety data base 1,500 pts to init 1H07 : --- arthroscopic shoulder ph II, N = 50 --- Hip replacement ph II, N = 50 ---Knee replacement higher dose ph II N = 50 To init 2H/07 : --- Knee replacement ph III,N = 450 --- Knee OA ph II, N = 200


- 17 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS . FDA meeting Jan 07 requires ph II OA knee init 1H07 & arthroscopic shoulder. Ph III knee replacement 2H07 - ZINGO lidocaine spray files Nov 27/07 pediatrics (N = 1100) reduct in pain signif. PDUFA Sept 22/07; FDA OK pediatrics Aug 17/07 ph III adults init March 27, data YE 07

ANX K ADVENTRX (ANX). IPO pulled May 22/06 April 28/06 merges with SD Pharmaceuticals (emulsion formulation of vinorelbine, only needs bioequivalence)

- CoFactor (active metabolite of Leucovorin, 5-10 methylene tetrahydrofolate) ph III init Nov 06 in BC (5FU/CoF vs Xeloda) & 1st line CRC (+Avastin 5FU vs Avastin/5FU/LV) endpoint PFS init June 06, ph II suggests better than LeucovorinCRC, 1st line Avastin/5FU + Leucovorin or Cofactor (SpA), endpoint PFS. Oct 1/07 trial IIb CRC 1st line CoF + 5FU vs leucovorin + 5FU = signif worse side efects w VoF. - ANX 513 paclitaxel emulsion - ANX 514 docetaxel emulsion

ASCO 06?

AOLS C AEOLUS (AOLS) was INCARA (INCR) change July 16/04 many links to Interneuron

-liver precursor cell technol (patent issued 03/00) ?? -SOD programme 10150, ALS ph II - OP 2000, ultra LMWH™ulcerative colitis,phII/III

nearly delisted acquired Renaissance (hepatic cell therapy) w/ELN

APBI A P BIOTECH (APBI), filed oct 3 w/MSDW Floating delayed (March 27/01) Nycomed Amersham has 45%, PHA has 45%. Pulled April 23/02

"Amersham Pharmacia Biotech" A leading provider of biotech systems, products & services

APHT V K

APHTON (APHT) 4Q04 moves to Philadelphia May 2/02 : recruit CMO Pat Mooney, their Thomas Weisel analyst. APHT is responsible for dev cost, then receives royalties. April 1/03 APHT says will not restructure Aventis deal, and refuses to comment. Aug 26/04 : files CND monotherapy , then Austral, CH in refractory pancreas.; NDA filing if Feb 05 data OK

Peptide vaccines tagged to diphteria toxin : Gastrimmune (antigastrin)G17DT, Insegia →K, -gastric 2 ph II(+5FU + cisplat) enrol compl Jan 24/02, Feb 5/04 data from 1st line + 5FU cisplat median survival 8.9m.-pancreas stage 2, 3 or 4, ph III 1st line w/gemcitabine(phase II survival ↗)DB N n= 383 v/Gemzar , data 15 Feb 05 Failure on survival ( & 2nd v/placebo available Oct 30 03 : median survival 151d & placebo 83, p = 0.03 in stages II/III & III but not in stages individually). ASCO 05 failure - colorectal ph II - also trial for GERD

Aventis, 30 first gastric pts presented Feb 8/02 : ORR 50%, no side effects due to immunogen. ASCO 02 ORR 53%, but only 1/36 CR. June 12/02 : reports on N=58, ORR 48.3%. modif letter of intent Dec 23/02 (royalty ↘, but R/D paid for). Feb 21/03 Fast track for gastric July 18/03 : claims will file in US monotherapy for pancreas Feb 5 Aventis Press Conf does not mention amongst 15 onco products !!!....and AVE will file Taxotere in gastric K 2H04 (first line ph III N = 463, +


- 18 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Dec 15/04 to acq Igeneon (Austria), compl/ March 25/05 SASY terminated Nov 10/05

-Gonadimmune (anti LHRH) pharmacine→K,prostate II→PSA¬ (Aug 00) - IGN 101 vaccine (Ag is murine Mab tu Hu colon K cells) that "mimics" EpCAM epitopes (epithelial cell adhesion molecule), ph III NSCLC, N = 760 (600 enrolled Dec 04). Compl. end 07. Ph II CRC - IGN 311 Mab anti Lewis Y (comes from PDLI, SGEN has some)

cisplat + 5FU, 1st line, chemo alone median survival 8.5m, Taxotere + CT 10.2 m, signif) Sept 20/04 Gastrimmune partnered w/Xoma GSK Serono licensed in an anti Ep CAM monoclonal adecatumumab (Dec 7/04)

ARAY IPO ACCURAY traded Feb 8/07

Robotic radiosurgery

ARDC ARDEA RDEA 119 : MEK inhib, oral, precl : K, inflam ARDM

ARADIGM (ARDM) ∗DEVICE : The AERx platform is a hand-held electronic inhaler device platform that : - guides the patient to breathe and automatically delivers when respiration is adequate, - allows dose adjustment in increments (of 1 insulin unit). The device lasts 3-5 years; with disposable LIQUID drug capsules it forms a Razor/Razorblade approach ∗PEOPLE : CEO R. Thompson is in diabetes since 20 years; he founded JNJ's LifeScan ( GlucoMeter). ∗PIPE completed Aug 23/01 : $14.6m

- Hu r Insulin (15% royalties + fees & bonus=25%) liquid is more stable and cheaper than powder; bioavailability 18% (INHL : 10 %); phase II studies ongoing, some published; Ph III init Sept 3/02 (300 pts/2Y, to end 2H04, filing 05). FDA requires this + 700/6m + 500/1Y Early jan01 : carcino concern in rats (was only rumor) Delays post prandial reduction : trial to stop. March 7/06 Novo restarts !! July 06 transfer of patents to NN. Data 2009. - Pulmozyme, ph II; delivery in 2 min rather than in 15-30 - ARD 3100 :Inhaled Ciprofloxacin ph II 2007 - ARD 1500 : Inhaled Remodulin, trials - Inhaled Morphine : on dec 15/00 ARDM took over clinical trials due to GSK slowness (merger…). Agreement persists. on jan 16/01 ARDM sells $5m shares to GSK, to finance IIb (but ??) - Respiratory gene therapy , PRE, w/GeneRx Alphagene (α 1AT) & Coxagen (for pulm Hypert.) - 2 biotech drugs - classical respiratory / Beta 2, steroids, antichol : asthma, BPCO) w / Cydex, Sept 7/07

w/Novo Nordisk (building new plant April 01); increases stake to 23% (Oct 01)

Competition : LLY/ALKS, NKTR, Mannkind Events : milestone for initiation of ph III (1H02) ADA June 01:smokers have∨absorption EASD Sept 01 : safety in asthmatics ADA JUNE 02 : IIb : FEV1 OK, DL/CO ? w/ DNA,discont jan 7 for commercial reasons by DNA who intends to enter another agreement w/GSK


Manufacturing : filling of blisters and adding disposable nozzles


- 19 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ARIA

K ARIAD (ARIA) patent on NFKB modulation Sarcome incidence : soft tissue : 8,000/year US bone : 900/year US Sarcoma 5 year survival : - stage 3 : 56% - stage 4 : very few ph II sarcoma CTOS Connective tissue oncology society Competition for sarcoma : - ARQ 197, to init ph II soft tissue sarcoma - CTIC Brostacillin to init ph II

Aventis terminated Src for osteoporosis AP 22594, small molecule EPO mimetic, Pre, IND 1Q03? AP 1903 + T lymphocytes transfected with fas & binder of AP 1902 (when AP 1903 is injected, fas dimerization : apoptosis), GVHD, ph II Aug 15/01:PNAS paper Src inhib for osteoporosis - AP 24534, Bcr-Abl kinase inhib (also active on T3151 mutant), to file IND Q4 07. Sprycel (dasatinib BMY approved June 06, Morgan S. 2010 : $ 700M) and nilotinib (Novartis) are inactive. Only Ceflatonin (CXSP,to file 2008) is. AP 23484 blocks VEGF activated pathways AP 23573 ( deforolimus) w / MRK mTOR antagonist, ph II, K, ASCO 05 "striking benefit" ASCO 06 very exciting in sarcomas (bone & soft tissue) N = 212, ph II open, doubles PFS ( 17m vs 9 m) compared to EORTC data base. April 6/07 FDA meeting on ph III, endpoint to be (Sept 10/07)PFS, OS depends on type of translocation complexity of caryotype). Enrol to init sept 07 (N = 650). Metastatic soft tissue and bone sarcoma, after favorable 1st or 2nd line therapy, vs placebo, powered to detect 33% increase in PFS. Init Sept 24/07; data 4Q09 (WYE Temsirolimus approved RCC Sept 07). ASCO 07 ph II endometrial meta, good. Other ph II : HRPC, leukemia/lymphoma, NSCLC

Mike Gilman, CSO, left for Biogen July 12/07 ($ 652) w/MRK. "many trials to be initiated". Torisel (WYE) approved May 30/07 RCC . Trials in NSCLC & Prostate. Cowen forecast $ 25/07, 75/08, 375/12. RAD 001 (Novartis in Ph III) ARIA clever trial design

ARNA ARENA PHARMACEUTICALS (ARNA) Plan to screen the 800 GPCR of the human genome

-T 82 : Achol enhancer, Alzheimer, ph I,may terminate - G protein coupled receptors: insulin secretion, blood pressure, obesity, hippocampal memory, asthma. - ADP 356 obesity, ph II, N = 352, 28d, efficacy p < 0.001but headaches & nausea; 5HT2C agonist (like GSK/Biovitrum who stopped), ph III init Sept 06 : N = 3000

Fujisawa, LLY (term Nov 14/02), Taisho Competition : Meridia (Knoll), Xenical (Roche), Acomplia (SASY)

ARPN ARPIDA (SWX) - Iclaprim, diaminopyrimidine. 2 ph III, 1st finished; SSTI, IV vs linezolid. 2nd ph III : non inf. To file end 07. Hosp acq pneumonia : ph II Oral form ph I - Arpida 709 , inhaled , ph I strong lung biodistribution AR 2474, pre (March 8/07), > topical mupirocin (was GSK, pyocyanic acid derivative) MRSA. ICAAC Sept 07, ph III MRSA eradication 84.7% vs 85.3% linezolid.


- 20 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ARQL K ARQULE (ARQL)

Summer 03 acq Cyclis ($ 25 m) for Activated Checkpoint Therapy platform (ACTP) Staff ↘ 31% Dec 11/02

Combinatorial chemistry - P 38 Map kinase inhibitors - ARQ 501, ph II, K, reactivates "checkpoints": activation of E2F-1. April 2/04 lic to Roche upfront $ 15 m, total 276 Pancreas ph II ORR 16% w/Gemzar vs 8% Gemzar alone Leiomyosarcome 17.5% ORR alone. But side effect hemolytic anemia - ARQ 171 ph I, E2F1 pathway- ARQ 761 precl - ARQ 197, oral c-Met receptor TK inhib, ph I, lic to Kyowa-Hakko for Asia. ASCO 07 nice ph I ORR 60%, better than AMG 102. Ph II will be soft tissue sarcoma, gastric, breast; also ph II in MIT (microphtalmia transcription factor ) tumors, and pancreas K

AHP, JNJ, Bayer, PHA, PFE

ARRY K ARRAY BIOPHARMA (ARRY) Traded since nov 17/00 mMelanoma PFS 1.9m w/Temozolamide, vs 1.5 spontaneous, p = 0.012 OS DTIC 6m, Temozol + Thallium 13m Deal w/CELG Sept 24/07 $ 40 M upfront, total up to 1B

- ARRY 886 oral MEK inhib, RAS pathway (mitogen activated extracellular signal regulated kinase kinase) lic to AZN (AZD 6244) , ph I; Dec 18/03, upfront $ 10m. Ph II melanoma N = 182, 1st line, vs Temodar, init Sept 06. Primary PFS/OS/ORR, secondary in patients w/BRAF mutations NSCLC phII vs Alimta 2nd/3rd line CRC ph II vs Xeloda 2nd/3rd line Pancreas ph II 2nd line vs Xeloda - ARRY 704 selective oral MEK(RAS) inhibitor, ph I init April 07, w/AZN (AZN 8330) - ARRY 162 ph I for RA , oral anti MEK - ARRY 797 oral p38 MAP kinase inhib. RA. Ph II - ARRY 520, Kinesin spindle protein inhib, ph I init May 3/07 - ARRY 380 oral ErbB2 inhib. IND filed Aug 3/07 for ph I Herceptin resistant breast (competitor Tykerb) - ARRY 543 dual Her2 / EGFR inhib, ph II, Breast, prostate, NSCLC, ovary, colon. Data end 07

MRK, ICOS, LLY, IMNX, TRMS, DNA Data ASCO 08 More at AZN R/D day Dec 7/07 could present at AACR Oct 22/07 or San Antonio Dec 12/07

ARWR ARROWHEAD RESEARCH Corp (ARWR) research funding company, in exchange for exclusive key investor of Calando*


- 21 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS rights

ARYX IPO ARYx filed August 31/07 (MS)

Esterase destroyed drugs rather than by cytochromes - ATI 7505, ph II, cisapride like - ATI 5923, ph II oral anticoag - ATI 2042, oral for atrial fibrillation

ASM M K

(ASM/LSE)

- Theragyn(Pentumomab), murine *Y MAb anti PEM (polymorphic epithelial mucin : HMF G1): -ovary K ph III (one single intra-abdominal shot, after surg. + CT), seems to considerably lengthen survival (there was a short interupt. of trial) -gastric K, ph II - Therex (humaniz HMFG1) : breast K, phI/ II - Therafab : F(ab)2 of HMFG1; IV, phI: NSCLC - AngioMab : radiofragment of BC1 (that binds to fibronectin),pilot study in Glioblastoma - Thioplatin, K, pre - ASA 404, DMXAA (dimethylxanthenone acetic acid), lic to Novartis, upstream to P38 MAP kinase, vascular disrupting agent induces cytokines via NFKB : ASCO 05 QT & visual issues NSCLC (all cytologies) ph II, 1st line rand w/carbo taxol ASCO 06 OS 14m vs 8.8 (HR 0.73); 2nd ph II data March 8/07 : ORR 50%; Int Lung K conf 07 OS 14.7 m ORR 37.9% Ovary, rand 2nd line, ORR 27% vs 24% Prostate (ASCO prostate Feb 07) + taxotere : improved PSA response rate. ASCO 07 ditto. Oct 15/07 improves ORR but TTP only marginally improved April 19/07 lic to Novartis $ 890, ph III to init 2008 -Enzyme that liberates cyanide in K cell (res) - AS 1409 fusion protein IL12 & antibody to tumor blood vessels

lic to ABT (amended Jan 5/02 : ASM to pay dev. costs), lic from ICRF ….all papers carry same name ⇑results mid 02, filing 2H02. June 6/01 : FDA requests additional patients∏ filing not before 2004∏2005. Completion 2H04 (trial will finish when total 116 deaths across both groups). other vascular disrupting agents : Oxigene CA4P, AVE8062, Myriad Azixa, Nereus, MediciNova MN-029 / Angiogene Pharmaceuticals Ltd, ABT751 " 1st vascular disrupting agent in late stage dev" Novartis Bus day Sept 12/07

ASPV ASPREVA (ASPV) priced March 4/05 Pac. Growth, ML

Cellcept (mycophenolate) from Roche for LED ph III, K vs cyclofosfamide, myasthenia (ongoing, 136 sites, to end late 06), Lupus ph III vs ciclophosphamide : not superior (June 27/07). Patent expiry 2009

ASTM V C

AASTROM (ASTM) working with leading German dendritic cell centers (German subsidiary Zellera AG)

Replicell kits for auto bone marrow & osteoblasts : -Dendritic cells DC 1(for use as anti K vaccines) product in trials Germany & US, could commercialize Germany -osteoporosis ph I/II init oct 31

May 15/01 : key patent issued on "cassette" approach for growing human cells


- 22 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - jaw bone fracture, ph I/II - repair of diaphyseal fractures, report March 22/06 ph I/II; 12 m follow up 90% very satisfactory (Oct 20/07) - TRC (tissue repair cells) for hip osteonecrosis, ph II, March 23/06. Ph III to init summer 07, N = 120 (20 sites), open, carrier alone or w/cells; follow up 2 years; Oct 4/07 German Soc Stel Cell Therapy : 4 osteonecrosis patients with good results : no hip replacement, back to work ! - April 30/07 init ph II critical limb ischemia PAD

ATIS C ADVA. TIS. SCI (ATIS) Medtronic has 7.7%

Dermagraft (from foreskins), MKT(UK) ;non-approvable by FDA in 98, refiled aug 25/00⇑ diab foot ulcer approved Oct 01

Smith & Nephew (Nov 2/02 sale of Dermagraft to S & N completed)

ATL ACTELION (ATL Zn.S), 936767

SEE EUROBIOTECH

ATLC ATLANTIC VENTURES (ATLC.OB) -synthetic analgesic cannabis -ABI 001, myasthenia, pre,w/GZTC - aerosol antisense to RSV

ATRX

ATRIX LABS (ATRX) Aug 10/00 technol lic to PFE Secondary filed July 25/01 June 14/04 QLT merging w/Atrix

drug delivery systems -Atridox,periodontal dis., MKT -Atrigel:sustained release (1 month) Leuprolide SC,phIII, filed March 27/01. OK Jan 24/02. Eligard 6 months duration - Atrigel 3 months in ph III (filed Sept 26/01) - Atrisone (dapsone),ph III, acne, lic to Fujisawa

™ less painful than IM,(competition: TAP, AZN, AZA) lic to SASY for N.Amer.& MediGene for EU w/HGSI (Aug 20/01) sustained release protein

AVAN V AVANT (AVAN) Oct 01 : lic vaccine to DynPort

-TP-10,C' inhib, sCR1 soluble Complement receptor 1 (cardiac surgery CABG ), ph II. Fails. Feb 02, but important benefit in males . Feb 04 trial init in 300 women, full enrol 1H05, data 3Q05 - TP 20 sialyl Lewis form of TP 10 -CETi-1,vaccine for atheroma,phII, to ↗ HDL chol ph II -RSV vaccine,phII→AVE - Anthrax, plague vaccine : pre -Rotavirus vaccine,phII (Rotarix)→SBH/GSK; MKT - oral cholera vaccine : ph II

Novartis terminated transplantation deal

AVGN

AVIGEN (AVGN) BAYER risk

- AAV/IX, ph I/II -challenges to keep in mind : -genes might be more immunogenic than proteins

-upscaling production. -IM route limited by N of injection sites & post- translational

BAYER →facility scheduled June 19/01 : AVGN abandons IM route for AAV/IX


- 23 - printed : 03/07/10 (d/m/y) 08:07


Oct 25/02 : staff ¬ 28% April 4/05 stopping all AAV Key : Katharine High (Penn)

saturation Mark Kay's center had been temporarily halted - Intrahepatic art.started Aug 16/01, but the issue of hepatic carcinogenicity of AAV in mice is debated (2 publications Sept 5/01). Halted because vector in semen. Restarted Feb 4/02. N = 6 (ASH 02 : circulating levels). Terminated June 04 - Park : AVI 201, gene delivery to striatum of AADC (converts brain levodopa to dopamine), init Dec 16/04 LIC TO GENZYME - Pain : AV-411, AV 333, IIa, PDE inhib - Spasticity : AV 650 Tolperisone (MKT in EU, Mydocalm, Hungary, has a history of anaphylaxis) lic from Sanochemia Jan 17/06. US ph II to init 1Q07 - AV 513 : algal fucoidan for hemophilia

(pre) because of Abs. AVGN will go into hepatic delivery. June 1/04 Coagulin B Phase I terminated

AVII M K V

AVI BIOPHARMA (AVII), was Antivirals Inc Pipe May 2/03 : $ 15m Sept 29/05 "exon skipping pre-RNA interference technology (ESPRIT)

-Avicine is a hCG vaccine for K –pancreas, phIII™™alone equal to Gemzar, assoc. improves results

-colorectal,ph III since Jan 01 -Neugene,antisense to c-myc for restenosis,phII, lic to Medtronic (May 23/01), terminated, lic to Cook March 13/06 - Antisense to XIAP genes (that block apoptosis), pre (see Aegera ) - AVI 4126, antisense to c-myc, ph I/II,polycystic kidney disease; in rats oral OK Jan 23/03 - AVI 4557, w/midazolam (BZD hypnotic) to modify Cyt450, also decreases Taxol catab - AVI 4451 antisense to androgen receptor, prostate K, pre(Nov 17/03) - Neugene anti P 450, ph I -Antisense to TGF β™stem cell multiplication (feb 7/01) -TAG6,telomere inhib :RES - antisense to SARS coronavirus, pre - AVI 4020 ph I/II, West Nile; croses BBB. - antisense to H5N1, pre in-vitro good Jan 20/06 - AVI 4658 ESPRIT (Exon skipping pre-RNA interference interference techno logy) ph I to init 1Q 07 (UK) with morpholinioligos for Duchenne

Abgenix (human MAb to hCG), Preclinicals. to initiate. Neugene partnership w/EXEL ™Avicine partnered with SUPG for pancreas

AVNR M AVANIR (was LIDAK), (AVN) -Docosanol cream (Abreva)™herpes HSV1, FDA GSK, Yamanouchi


- 24 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Spinoff : Xenerex, fully Hu MAb (Hu lymphocytes to SCID mice), but patent also assigned to IDEC (acq from IDEC feb 01)

OK:june 26/02 -AVP 923 oral (Neurodex, Zenvia, dextromorphan!+ quinidine),ph II/III→ emotional control , signif 5june 22/02 on pseudo bulbar sd of ALS. Ditto Nov 20/02 (ALS sympo Melbourne),30/06 approvable. MS ph II/III init Nov 02 on PB sd. Rolling filing PB init Dec 04, also trial in neuropathic pain. Completed summer 05. FDA delays PDUFA to 1H/06. New data Dec 16/05. Oct 06 "approvable", new trial needed. AVP-28555, MIF inhibitor for inflammation, pre, w/Novartis - AVP 893 : inhibits IgE synthesis, pre, decreases IL4 & 5 in BAL of mice (AVP 13358)

May 01 : 3 cancer Ags provided by EOS

AVNC ADVANCIS (AVNC) IPO Lehman, Pacific Growth) Aug 4/03 Nov 19/04 : staff reduct. 18%

Oral pulsatile delivery of ABs : tablets of multiple pellets types, 3 in ph I/II, once a day - Augmentin Pulsys lic to GSK, ph III to init 2005, Term Oct 19/04 - Ampicillin Pulsys ph III to init Oct 05 : once daily for 7 days vs peni 4 each day/10d. June 16/05 fails

AVRX K AVALON pharma (AVRX) IPO May 3/05, Legg Mason

AVN 944 oral inhib inosine monophosphate dehydrogenase (lic from VRTX Feb 05) . hem/onc, ph I Res : - MYC inhibs, - Betacatenin inhibs, - Aurora kinase inhibs

IMP is a precursor of GTP which inhibits caspase II dependent apoptosis. Competition for 944 : Cellcept

AVXT V C K

AVAX (AVXT) Aug 24/00 : acq Genopoietic SA Feb 01 : CEO leaves April 23/01:2 VPs resign Dec 23/02 : C00 resigns

-autocell therap for melanoma,M-VAX,phII→phIII to last 5 years…March 23/01 : on hold by FDA ( some non sterile batches), hold confirmed Sept 25/01;warning Nov 9/01. Launch ( by Pro-Vaccine AG), produv=ced by Genopoietic, CH Oct 05 July 14/05 french trial peritoneal metastases - NSCLC stage I/II adjuvant vaccine, init Jan 06 -HSV/TK for heart transplatation immunosuppression - Gene therapy for SCID X1

Interim data (nov 13) : 2 year survival of 60% of 37 first patients. But AACR March 01 not at all conclusive.

AXO M K

AltaRex (TSE: AXO), acq by VIRexx in 2004

-OvaRex, anti CA 125, m, ovary K, II/III, but from ascites rolling BLA filing 2H01 ???.. Diff. results US & CND, but combi signif (Jan 31/02). Lic to UTHR

Production discussions ongoing w : Lonza, Genesis Pharma (Greece), Medison (Israel) Lic to UTHR for US (April 22/02)

AXPH AXYS (AXPH) -Combinatorial chemistry™™™™™ ™PHA, AVE, Daichi


- 25 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS From Sequana/Arris merger (1997) Equity in DPII (IPO 7/7) brings AXPH cash for 5 years acq by Celera (June 13/01)

-drugs : -tryptase inhib. for IBD, ph II -tryptase inhib for asthma, inhaled, pre™™ -Cathepsin inhib for osteoporosis, pre™™™™

™Bayer Discont (May 24) ™MRK

AXYX AXONYX (AXYX) - Phenserine, Alzheimer, ph II AChE inhib, M+ & inhibits product β amyloid (PNAS June 14/01) - Peptide against amyloid , Alzheimer, w/Serono,pre - Peptide against prions, w/Serono, pre

AZN CAT M

Cambridge Antibody Technol. (CAT/LSE) Nasdaq : CATG SEE EUROBIOTECH

to be acq by AZN (May 15/06) $ 1.3B

AZN M V K

MEDIMMUNE (MEDI) FOR SALE April 12/07 > 12B Synagis : $ 3500/infant (?) Dec 17/02 panel FluMist: - safe & effective ages 5-49 - 50 to 64 ; safe 10/8, effective 4/14 Barbara Fischer (Pres Nat Vaccine Info Ctr) : NO, danger of injecting live virus. Approved June 17/03 : 5 – 17 : 2 doses 18 – 49 : 1 dose launch Sept 03. Wye sales 4Q03 $ 15m ? Copromotion w/WYE, 50% revenues to each (but COGS high); 1Q04 : $ 31, 9m 04 : $ 33 New CEO was with MRK vaccines, and Merieux Aug 31/05 reacq EU Synagis starting June 06 AVIRON (AVIR) Acq compl Jan 17/02 MKT issues : -US flu vaccine mkt is $ 200m (35% AHP, 35% CLL/Medeva, 20% generic, 10% Aventis). But Aventis ww sells €200 m of flu vaccine, and is

-Synagis (palivizumab)→RSV MAb hz :$293/99m→427/00; 516/01; 672/02; 849/03; 1Q04 : 422, 2Q 56, 3Q 61, 1st 9m 2005 $ 624 (US 526); FY 05 1.1B, 1Q06 463; FY 06 1.1B manuf essentially by B. Ingelheim. Cong Heart (30000 births/y US, 50% for Synagis)ph III ∏ AAP Oct 18/02. DB N = 1287, 4 years ∏ 47% less RSV hospitalizations. Will file US/EU -Cytogam(anti CMV) :$30m/99,36.5/00, 2Q04 : 8 -Respigam→RSV polyclonal :$4m -Ethyol :$75m, 2003 : $ 100m -Medi 507,siplizumab, IV/sc( hz anti CD2)→GVHD, ph II;PSO ph II→ph III delayed (induces Abs !!), precl +in TCL xenomice -Medi 501,2 &3(anti HPV16/18 vaccine), ph I & II™™ (FDA Nov 28/01 on surrogate endpoints) -Abegrin Vitaxin(hz MAb to alpha/nu/beta3 integrin, CRC Asco 03 Melanoma ph II, prostate ph II; PSO & RA ph II term Aug 30/04. AACR 06 good ph II m. Melanoma, ph III to init YE 06. Decision to stop Vitaxin + dacarbazine < dacarbazine alone - 2nd generation Vitaxin, ph I/II, K -Numax, motavizumab,respiratory MAb to RSV; 2 formulations, 1st ph III enrolled, 2nd starting (Nov 2/ 04 Fully enrol N = 6600 Dec 9/05. Filing delay (Feb 07) -E. coli vaccine for UTI,ph II, stop Oct 02 (poor efficacy) - MEDI 491, B19 parvovirus vaccine, ph I - Anti IL9→asthma,pre lic from Genaera (april 01) being improved by

AMEV w/Vasgene (Sept 05), pre, Mab to Eph B4 and Mab to its ligand Ephrin

B4 ligand, cancer. w/Burnham Institute res on peptides targeting EphA & EphB subfamilies

of tyrosine kinases -FluMist, live attenuated nasal vaccine : ph III, had manuf. probl. w/Medeva ; CLL vaccine unit acq by Powderject sept 8, AVIR leases facility and is manning production and building a new facility. Has to be kept in freezer prior to administration Not so easy to use : one shot from syringe in each nostril

ABT (ROW) June 03 : A. Acad Pediatr. tightens rules →w/GSK Cervarix. Ph III init 1Q04 (Baculo difficult to scale up). MRK (Gardasil)in ph III (BLA filed Dec 05) also active on HPV 6 & 11 (men). MEDI has 4 patents on HPV VLPs (some also sublic to MRK). CSL (Austr)has adjuvant lic to MRK. Adv Com May 21/06 + collab w/ Ixsys (now AMEV) collab w/ Ixsys (now AMEV) →Alkermes & AMEV -WYE (who already sells Pasteur/Merieux type


- 26 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS looking at US. -Tamiflu : sirup and prevention since nov 00. Sales 00 $ 81m, E/01 : $170m Price issues : -Standard shots are $10, FluMist $46 (CHIR has increased Fluvirin post Powderject acq. Was $ 2 !). Feb 04 : will rebate 50% Regulatory issues : -FDA site inspection ? -Recombination with other viral genes -Risk in immunocompromised patients - Asthma ? - Use of assoc. vaccines ?

- LiquidFluMist,CAIV-T, ph III init Oct 21/04, does not need freezer, to file 2Q06. Filed 3Q06. PDUFA Feb 07. Approved Jan 8/07 -Parainfluenzae III : ph II -EBV : ph II (with GSK) -CMV : phI - Dec 15/05 lic from Biota oral anti RSV - MEDI 545 (w/Medarex), fully Hu Mab anti INF alpha. Lupus, Ph I init 1Q06. Ph I init March 24/07 - IPI 504, w/Infinity, ph I, HSP 90 inhib

vaccine), increased stake in April 02: 50/50 JV. Jan 04 WYE analyzing head to head; could terminate. April 27/04 terminates. -BLA filed oct 31/00,accepted for review dec 29/00, Adv Com : July 27/01 Efficacy OK(13/2 in adult, 8/7 in pediatric & ado), safety 9/6 against. Could be 1 year delay. Sept 5/01 FDA requests clarification on clinical & manufacturing. Berna/AVE in Switzerland is having safety issues (facial palsy) after "Nasalflu". Possible approval 3Q02. AVIR files its response to FDA's "full response letter" Jan 8/02. → July 02 CRL w/68 questions, 24 manuf, 44 clinical (& asthma). Answers provided Aug 27/02. FDA can respond within 2 or 6 months. PDUFA Feb 27/03 , Jan 31/03 CRL w/5 questions labelling, PMS, assays) Feb 7/03 response provided.

BAVN Bavarian Nordic MVA-BN Her 2, Breast K vaccine, ph I/II init Jan 07 BCRX K BioCryst (BCRX)

July 12/02 staff ¬ 43% PIPE Feb 17/04 Orbimed $ 21.4m Feb 16/06 funding from Kleiner Perkins "Pandemic & Biodefense fund". June 15/06 Peramivir lic to Green Cross (Korea)

- BCX 1812 : Peramivir (RWJ-270201)→Flu, oral neuramidinase inhib, ph III initiated feb 8/00 in ROW, Jan 3/02 in US. Enrol could finish March 02. once a day, also has IV formulation. Active on more subtypes than competitors. June 25/02 failure of ph III. Poor bioavailability, but excellent efficacy (and on H5N1). New IND (IV/IM) filed Nov 29/05. Fast track Jan 17/06. IM init 2H 06, IV vs Tamiflu ph II init hosp Aug 07 March 12/07 partn w/ SCOLR Pharma (Amex DDD) for oral sustained release June 18/07 positive data IM : bioavailability & safety. Sept 20/07 results from 313 patients IM NS : median time to alleviation of symptoms 11.9h with 150 mg , 21h w/ 300. NS vs placebo. Earlier ph I used 40 mm needle, switched to user friendly 2.6 mm. 101 parients had adequate IM (judged on CPK) : improvement of 64.8h at 300, 44.6h at 150; Tamiflu trials improve by 1.3 days - BCX 1777 Fodosine, IV & oral, purine nucleoside phosphorylase inhib for T cell lymphoma, ph II, not myelosuppressive, partnered MundiPharma/Purdue/NAPP, Feb 3/06. Pivotals to init 3Q06. March 27/07 IV, T cell ALL IIa : not as effective as at ASH. Also particulates in solution. Wants to go oral for CTCL

JNJ⇑dec 26 JNJ stops trials in US, continues in Europe. Deal terminated (april 30/01)because of insuff. activity, not safety Sept 05 BioDefense Committee requests stockpiling. HHS says "not enough funds". Jan 4/06 HHS : $ 102 m ICAAC Sept 06 : ph I IV/IM very effective levels induces unbalance of nucleotide triphosphate pool, producing apoptosis of high mitotic index cells ASH, ASCO ?


- 27 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS BCX 4208 purine nucleoside phosphorylase inhib. for acute graft rejection, ph I, lic to Roche Nov 30/05.($ 560m). PSO init July 07 - BCX 4678, Hep C, to init ph I

BDAL Bruker Daltonics (BDAL) Mass spec to identify contaminants

BHRT IPO BioHeart filed Feb 14/07

Myocell, autologous muscle cells for heart failure, ph II but competitor Myosix has poor results

BIIB M K

BIOGEN IDEC ( BIIB) FOR SALE Oct 15/07 Avonex patent expires 2011 ???? (Bgen only has lic. to patents of dates unclear, Taniguchi, Roche. Berlex has the McKormick patents last issued 98, lic to Serono & court case w/Bgen settled $ 55m Feb 03)) Serono files sBLA Oct 8/01 ,FDA OK March 8/02. 25% of Avonex sales are ex-US : CHAMPS shows efficacy in early MS. CPMP OK, filed US April 16/02 : launches 2 stage trial : - stage I : evaluate pts having received 15/21 months of Avonex 1/w or Rebif 3/w - stage II then go on following each group for 3 years on clinic and MRI Antibodies : Avonex 5%, Rebif 24% ?? PFE w/Serono will boost Rebif from Oct 02 onwards. PFE commiting 450 reps (17000 untapped general neurologists). Manuf : N. Carolina 6x15000 l fermentors to be certified for Amevive & Antegren May 25/04 : FDA filing MS, PDUFA 25 Nov 04, OK Nov 23/04 Crohn filed EU Sept 28/04, later in US June 4/04 EMEA filing MS Sales 04 (1 month) $ 3.1m Feb 28/05 : 2 pts w/Progressive

Avonex(β1a,CHO,IM,once a w. no skin ulcerations, 2 year study)$ 621m/99(+ 55%) Orphan drug protection against Serono expires May 2003. <Betaseron (A. Acad Neurol May 6-11/01), Serono (but 6months,DB not feasible : different aspects) ditto w/Rebif( subcut,00 : $254) May 8/01 March 14/03 FDA warning on depression & liver March 4/04 : potential product issues (new liquid formulation prefilled syringe) pain, pH 4.8, competition 7.. -Amevive (alefacept), LFA3/IgG fusion prot (anti-CD45RO+;binds to LT's CD2 preventing interaction w/APC's LFA3)→PSO,IV/IM (deep frozen) ph III:PASI 75:14%IV,21%IM,(LT¬!),filed (2 pivotals w/different formulations)FDA/EU Aug 6/01; launch 1Q03? Feb 20/03 : CPMP says NO Once a w 12 w course (IM or IV) costs 7 to 10000 CD4 must be monitored weelky & used to adjust. Forecast 115/03, 230/04. LAUNCH. Sales 1Q03 : $ 4m, reimbursement ??, 2Q03 : 7m, 3Q 12, 4Q 17; FY 40. 1Q04 : 13; 2Q12, 3Q8, 3Q 10, FY 04 43. Sept 9/05 : plans to divest. FY 05 48 : selling to Astellas April 4/06, $ 60m -Adentri, Adenos. ant., natriuretic→CHF,phII,(I.V)STOP Tysabri / Antegren /Natalizumab(Hz MAbantiα4β7 ,α4β1/VLA4), IV, once a month $ 23,500/m - MS, POSITIVE MS data Jan 22/01(ph II, DB) presented Sept 14/01,once a month IV/6m (12m follow): new MRI lesions -88% (p<0.0001 to placebo), relapse rates reduced 66% p= 0.03. But prior 1 m trial relapses>placebo. New ph II, N = 213: Jan 3/03 : MRI � 93%, relapses 13, placebo 27. - Crohn POSITIVE ph II May 23/01(ph II,DB); 2nd ph II Jan 3/03 on remissions 6mg/kg NS, 3 mg/kg signif. Ph III Enact I (850 enrolled), Enact II also

→sales 00 : $ 765 M;01 : 971.6 (+28%),3Q02 $ 262 ww (+ 5%) of which 186 US (+2%), Rebif ww $ 139m (+ 46%) & US 18. 4Q 02 Rebif ww 172 (US 34.7); Avonex 256 (US 184). FY 02 BGEN 1034 ( + 7%, w price ↗), Rebif 549 (+ 77%). 1Q03 274 (US 189, ROW 85), Rebif 175 ww (US 40), 2Q03 286 (US 196) Rebif 199 (US 43), 3Q298 (US 204)4Q 310 (Rebif US 55). FY 03 1.2B (Rebif 850); 1Q04 355 (US 240) (Rebif US 63, ww 259) 2Q 347 (US 227, Rebif US 69.6 & ww 257)3Q 346 (US 224, Rebif US 77 & ww 186). FY 04 1.4B, 2Q05 382; FY05 1.5B, 1Q06 393, 3Q06 445, FY 06 1.7 B, 2Q07 462, 3Q07 455 48w Evidence (Rebif/Avonex): % pts relapse free, weeks:

0 → 24 24→ 48* 0 → 48 Rebif 75 82 62 Avonex 63 83 52

* for the subset exacerbation free at 24 weeks Could infringe DNA patent A. Acad Derm (Feb 22-27/02) : IM. 21% pts reach PASI 75. 10% have T < 250 (risk of TB, fungal, CMV etc & Lymphoma) Adv Com : May 23/02 OK 8/2. CRL June 14/02 requests clarif & info "on data filed". Labeling includes weekly T cell count. Resubmission filed end Aug 02; Class 2 answer Feb/March 03 (concerns on PMS & T cell counting or overall lymphos ?). FDA OK Feb 1/03 CV Therapeutics w/ELN; 2 Ph III in MS init. Dec 18/01. US +/- Avonex (Sentinel N = 1200 fully enrol YE 02 to be rand YE 03 to Avonex + placebo or + Antegren), interim at 1Y: June 03→ early04 to look at both trials(MRI + flares). EU /Placebo (Affirm N = 942), full enrol end 02, follow up 2 years.. Sentinel shows Antegren + Avonex better than Avonex alone on relapse rate (p < 0.001) Nov 8/04 : 1 year data Affirm clin. relapse reduced


- 28 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Multifocal leukoencephalopathy. JC virus destroys myelin sheaths Pulled March 1/05. BLA refiled Sept 27/05. Adv Com March 7/06 : OK, CHMP April 28/06 OK April 28/06 approved EU June 5/06 approved FDA (monotherapy & restricted). Sales 2Q06 5m, FY 06 : 38m, 2Q07 72 (46.8 in US by Elan, 23.3 by BIIB in EU), 3Q07 93

- Feb 04 : RA starts - CDP 323 from UCB (Oct 3/06) oral alpha 4 integrin inhib. Ph I

66%. 2 year disability available Feb 16/05 : risk of disability vs placebo reduced 42% April 17/03 : weird letters in NEJM on Antegren DATA CROHN : ENACT I (endpoint 70 pt reduct score) missed July 24/03. ENACT II (maintenance) signif Feb 04 (but relevance ? : rerandomize success pts of Enact I to Antegren once a m/12m versus Placebo : 44% maintain remission , & placebo 26%)


- 29 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS BIIB M

IDEC see BIIB NHL 56000 new cases/year US. 5 year survival 52% For Rituxan ($ 16,000/year) : -Competition : IMMU/AMGN Lymphocide, ph III - GSK patent litigation :2 suits filed against DNA. Sept 11/01 files suit against CRXA & GSK IDPH, will contract out its MAb manufacturing capacity IDPH has 32 reps (+ DNA onco 105) Zevalin kit :$ 17 to 28 000 : Medicare reimburses from Oct 1/ 02, $ 21,911 30% of Rituxan pts become refractory opportunity for Zevalin/Bexxar (and need to not deteriorate bone marrow, so as to use 3rd line CT) Also Lymphocide. April 25/02 : raises $ 675 through sale of convertibles Nov 29/02 President & COO files to sell 300000 shares over 12m (has 1.5m)

-Rituxan/MabThera (chim. antiCD20)→NHL→→→→ (ASCO 01 : good data for maintenance therapy) Aug 31/05 Filed for TNF refractory RA, PDUFA late Feb/early March 06 (Orencia PDUFA DEc 31/05). OK Feb 28/06 ASCO 03 : 21 presentations, 6 on CLL Not effective on RCC (# 688) - Panaclar fumaric acid ester (BG12) for Psoriasis, Fumapharm AG acq June 06, oral BG12 active in MS (ph II), ph III init Jan 07 -Zevalin, ibritumomab, Y tagged mur. anti CD20,BLA filed nov 1/00 ;priority review,FDA letter May 3/01: °CLINICAL ph III : N= 113 (DB) + 57 _no additional trials necessary before approval _need to analyze incidence of infection, and interaction w/G-CSF _precede Y-Zevalin with Indium-Zevalin for imaging 'could show nearby vital organs ' will require a double kit ! ' phase IV requested in patients already treated with murine Ab, at risk of HAMA. °CMC (chemistry, manuf, controls) _NDA for Yttrium to cross reference with DMF _Y suppliers & filling partner to be inspected BLA refiled July 9/01: ODAC Sept 11/01: recom. for Rituxan resistant pts, & discussion on accelerated approval approach. Jan 7/02 (Catalytica manuf issues ??), Compl. Rev. Letter Jan 08/02. OK Feb 20/02. CPMP filed Jan 01, OK Sept 23/03 (Schering AG). US launch March 27/02; 1Q03 : 5.7, 3Q 03 4.4, FY 03 : 20; 1Q04 4.8; 3Q 5, 4Q 8, FY 04 23 -IDEC 152(hz antiCD23)inhibits production of IgE→asthma, ph I AAAAI → March 03 ?, anti K synergy w/Rituxan, -IDEC 114,(galiximab, hz anti CD 80,B7-1) →PSO, phII term. Sept 5/02; ph I/II in NHL, associated to Rituxan good data June 14/05 Int Conf Malignat Lymphoma Lugano, Jan 29/07 ph III init -IDEC 131(hz anti CD 40 L)→ITP, MS,PSO,Crohn, ph II, on hold (June 02) leg thrombus in 1Crohn patient (N=200)but BGEN had halted in 99 its anti CD40L because of thrombosis. -IDEC 151 (hz anti CD4)→RA, ph II (returned by GSK early 2000) - HMN 214 lic from N. Shiniaku, oral stilbene prodrug, ph I, K - anti LTBR Mab , pre (lymphotoxin B receptor) from BGEN (Feb 03) - anti CRIPTO Mab (cell surface signaling prot, from BGEN ( Feb 03) - IFN β gene for glioblastoma - June 03 : new Hz anti CD20 w/DNA, res W/PDLI : daclizumab, volociximab, fontalizumab

US sales booked by DNA, Roche sales in EU (R = 10%). Revenues are shared profit, reimbursements, bulk sales, royalties.1Q02 $ 80m (34% US sales), 1Q03 111 (IDPH books 34% of US sales) EU 2001 Roche MabThera $ 146m, 2002 E $ 450m ASH02 : maintenance → event free survival 23 m with, 12 without; ASCO 04 PFS 4 years 58%/34% → Amer Coll Rheum N = 122 (final results N = 161 "later")Oct 29/02: ACR70 + MTX : 23%, alone 13% (= Enbrel, Remicade). Best dose not known yet EULAR June 18/03 : ACR 20/50/70 @ 6m = Enbrel. EULAR 04 ditto; ph III REFLEX initiated for "refractory to anti-TNF" Nov 2/04 positive top line IIb. April 6/05 > placebo ACR 20 w 24, only injected d 0 & d 15. EULAR June 05 ph IIb OK. ACR Nov 05 ACR20/50/70 > placebo; 2nd cycle (Date ??) N = 78, data unclear. But very good in Lupus BMY Orencia approved Dec 27/05 > 50% pts grade 3 neutro or thrombopenia lic to Seikagaku (Europe + Asia) lic to Mitsubishi (Asia) lic to Eisai (Europe & Asia)


- 30 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS BIIB

Jan 4 /07 Acq Syntonix (40 m + 80). Specialist of FcRn (protects and transports across epithelium), already partnered w/Serono & BI (inhaled peptides)

-June 01: partnership w/NsGene (subs of NeuroSearch) for Neublastin in neurodegener. dis -sept : jv w/Eos : anti K compounds - VLA-1 inhib, pre, asthma, lic to MRK (1997) - IC747 LFA 1 oral inhib w/ICOS, ph I. Term June 6/03 - Hep B vaccine lic to GSK, sublic to MRK - IFN α lic to SGP - Humicade, ph III, Crohn, w/CLL (April 25/02), fails, could be active in subgroups - 3 early stage anti K lic to IDPH (Feb 1/03) - anti K partnersip with Sunesis - BAFF-R/Fc of IgG fusion protein, pre, that inhibits overstimulation of B cells by BAFF (B activating factor of TNF family = BLys) on BAFF-R3, RA, w/DNA - IFN beta Adeno gene therapy hepatic metas : pre - Oral Fumarate, PSO, Ph II - CNF 1010 (from Conforma, acq May 3/06), ph I init 2004, geldanamycin derivative, HSP 90 inhib - CNF 2024, oral HSP 90 inhib, ph I init 2006 (from Cabrellis) - Lumiliximab (Idec 152) : anti CD 23, CLL ph I/II ASH 06, also anti IgE - FIX Fc : F IX fused to FcRn (neonatal) to protect against degradation, precl., from Syntonix - Galiximab, anti CD 80, w/Rituxan, ph III, N = 700 - Lixivaptan (lic from Cardiokine, who got from WYE) ADH receptor oal antag, ph III to init 2H07

w/Morphosys (dec 00) :MAbs to EST proteins w/ABGX (June 13/01)

BIME BIOMUNE SYSTEMS (BIME) neutraceuticals BIO BioInvent AB (Sweden) BI-204, Mab anti-oxidized LDL, lic to DNA Jan 16/07,

pre, DEAL, for coronary, $ 175m. In association w/statins prevents plaque build-up in animals - BI 402 Mab anti factor VIII, ph I

BIORY BIORA AB (BIORY) Emdogain (periodontal surgery), MKT BIOS BioMedicines ( BIOS)

IPO filed nov 3/00 -UBSW. Trading April 3

BLSI BOSTON LIFE SCIENCES (BLSI) - Cethrin: r Protein spinal section, lic from BioAxone Jan 4/07, Ph I/II -Therafectin : failed -Altropane (imaging for Park), ph III -Troponin→K, antiangiogenesis, ph I 3Q01


- 31 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -Inosine for optic nerve regeneration, Res (June 14)

BLT BENITEC (ASX : BLT) dsDNA - Jan 06 : HIV IND, engineered stem cells w/lent delayed, init City of Hope June 07 - April 18/06 : halve work force

BLUD IMMUCOR (BLUD) Blood Typing disappointing 1H sales→reorg. Settlement w/Becton Dickinson

BMR K Bradmer Pharmaceuticals (TSX) Glioblastoma median OS - surgery + RT 53w - Surg + RT + temo : 64w - Ph II + Neuradiab 86.7w - Recurrent 16-24w

Neuradiab (developed at DUKE): anti Tenascin (expressed by 99% GBMs, not in b rain) Mab + *I, ph III to init glioblastoma, N = 760 (enrol 24mm). Interim 2010

Senetek has a siRNA to Tenascin for GBM

BMRN BIOMARIN (BMRN) June 03 : $ 125 m convertibles 30.6% owned by Glyko Biomedical Ltd (Toronto). Feb 7/02 : acqires Glyko GMP plant April 21/04 acq Ascent Pediatrics (sells Orapred for children) , will sell Aryplase & Phenoptin New CEO since Nov 00: Fred Price, who was at AMBI Aug 14/04 Fred Price resigns May 12/05 JJ Bienaimé CEO Role of Orbimed ++ TKTX has a license tu US patent on the enzyme, but was rejected by EPO Jan 7/03 files for secondary $ 63.3 (UBS, CIBC, SGC) Oct 10/01 : acq IBEX and its Heparinase (already failed a phase III). Dev terminated Sept 22/03 PKU mkt 50,000 pts ww, 40% can respond to Phenoptin, i.e. 6000 pts in US; price $ 20000/Y MPS VI mkt 1,100 pts ww, 250 identified

-iduronidase (Aldurazyme, in CHO) for Hurler(MPS I, bone, brain, liver,spleen, heart), ph III BLA rolling filing init 04/02 (completed July 29/02, accepted for filing Sept 16/02), CPMP filed 03/02. . Estimate "3400 "available" patients(in rare cases early BMT has allowed retention of intelligence) According to Pr J.Muenzer (U.N.Carolina) enzyme will not cross BBB, but "holds a lot of promises for the future : a lot of chidren could have improved quality of life"He also says the purity is OK, and that enzyme could be associated to BMT. Dg is easy by dosage of enzyme, and a lot of heterogeneity exists. He knows of 500 severe cases in the US. -r Hu arylsulfatase B / Aryplase/ Naglazyme , Galsulfase, 4 h infusion qW for MPS VI (Maroteaux Lamy sd., 1/200 000 births, 1,100 pts in developed world), ph I/II (6pts, 24 weeks). Completed July 25/01. Sept 6/01 : positive results. Ph III data June 3/04, N = 39, DB, 12 min walk p = 0.025, age 5-29, filed Nov 29/04 (endpoint 12 min walking distance) 48 w data March 05 improvement ditto PDUFA MAY 31. Approved June 1/05, post mkt trial to init in less 1 year olds w/skeletal dysplasia. CHMP OK Sept 15/05, EU OK Jan 31/06 - for MPS 4 (Morquio A) ? - PKU : - Phenoptin KUVAN (tetrahydrobiopterin, sapropterin, oral) Nov 20/03 manuf agreement w/Merck KGaA.. Feb 23/04 ph I (good responders phe Ala down > 30%); lic to Daïchi for Japan Nov 04. Ph II init Dec 26/04. Ph III init April 7/05, N = 100 (pts who reduced PHE levels in Ph II),

50/50JV Genzyme; manuf. issues seem solved, s 2nd ph III enrol is completed march 4/01w 45 pts to end Aug 01(1st trial + with 10 pts). Clinical endpoints : exercise tolerance, lung function. 2 year data May 15-19 (Int Congr Hum Gen):liver size ¬24%,spleen¬82%,urine carbohydrates¬72%. Phase III on HS pts (clinical endpoints only : 6 min walk, FEV1). Data unblinded Nov 1st 01. Press release Nov 2: 6 min p = 0.066). June 02/03 shoulder range of motion NS Jan 15/03 Adv Com OK (but 1 tracheostomy for allergy). Jan 28 CRL w/PMS (allergy monitoring), manuf inspection; launched Feb 21/03 : CPMP OK Lic to Serono for ex USMay 16/05; $ 257m Lic to Daichi for Japan Nov 04


- 32 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS filing 1H06. Data March 16/06 p < 0.0001. Open extension confirms (Dec 19/06). Filed May 24/07 - Phenylase subcut PAL (phenyl alanine ammonia lyase), pre, will pegylate - 6R-BH4 (active ingredient of Phenoptin). Fails in HBP, Feb 20/07

Lic to Serono May 16/05

BMTI BIOMIMETIC PDGF/ Ca Phosphate device mkt for orthodontics, trials in orthopedics. Dec 13/06 US 20 ankle fusions (14 PDGF, 6 autografto) results similar Jan 25/06 (Sweden) wrist fractures , N = 19, bone healing at 6 w 100 of treated, 56 % others, but all similar at 24 weeks Pivotals US/EU to begin

Keep in mind BMP with Medtronic success & Biogen/Strtker failure.

BNC BIONICHE (TSX : BNC.CN) - Cystistat (hyaluronic acid) for cystitis, lavage, MKT - MCC (Mycobacterial cell wall complex, Mycobacterium phlei), bladder K, ph III

BNPI IPO K

BIONUMERIK (BNPI) IPO filed march 6/01 (MSDW), then June 9/04 UBS

-BNP 7787 Tavocept, ph II, for neurotox of platinum (w/Asta), ph III in Japan - BNP 1350 , camptothecin like, ph II

BPUR BIOPURE (BPUR) Equity line SG (June 01) Class action suits

Hemopure ,ph III; bovine blood for humans, BLA to be filed 2H01. In dogs HbO2 dissociation problem, vasoconstriction.. Aug 28/01 : transfusion sparing effect (signif, March 20/02, anesthesia sympo). BLA filed Aug 2/02. response July 03 requesting more data

Approved South Africa April 01 May 01 : Chief medical officer quits : renal safety ??

BREL BIORELIANCE (BREL) Was Microbiological Associates

Preclinical manuf & testing. - To test Acambis smallpox vaccine (& fill & finish)

BSLN BASILEA (SWX) - Ceftobiprole, w/JNJ, to file 2007. Clear cut data (no mixture of MRSA and not, or of ABS), on non inferiority, clin cure rate MRSA 91% vs 86%, 2nd ph III SSTI ok non infer. Filing May 17/ 07, fast track, approval YE 07 ?. EU filing June 18/07 IDSA Oct 9/07 Diabetic foot infections 86.2% success vs Vanco + Ceftazidime 81.8% - Isavuconazole : to start ph III - Alitretinoin : hand dermatitis, filing 07

BSMD K BIOSPHERES (BSMD) Embolotherapy (MKT) for tumors (meningioma, uterine myoma), vascular malformations.


- 33 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS BSTE M BioSite (BSTE)

Leader in POC mkt(using phage display) March 27/07 : bid by Beckman $ 1.55 B

- IVDg : troponin, natriuretic peptide, CK June 00 w/Medarex on TransPhage technol (TPT) Jan 01 LLY/MDX/BSTE alliance w/LSBC to generate targets for proteomic biochips March 02 : TPT w/AMGN Also alliances : MOR, Diadexus, Corixa

BTA BIOTA (ASX : BTA) May 01 : acq Numax (US)

- Relenza GSK - BTA 188 : antirhinovirus

BTH M BIOTIE (Finland : BTH1V) - Nalmefene, alcoholism, ph III - VAP-1 Mab (vapaliximab), ch ph I failed, Hz & Hu in R/D - recombinant oral heparin, Sanofi terminated

BTRN M C

BIOTRANSPLANT (BTRN) to acq Eligix

Chimeric xenotransplant systems (also for pancreas) -Patent on PERV (porcine endogenous retrovirus ) free swine -XenoMune system based on anti CD2 (MEDI 507 & BTI322), to allow xenotransplantation -licensor of Medi 507→GVHD to MEDI

NVS decreases support to create JV (Immerge BioTherapeutics, 67%NVS, 23%BTRN) who will own PERV patent & XenoMune

BTX BIOTIME (BTX) Hextend (starch plasma expander), MKT

ABT

BVEX K BioVex*, IPO filed June 20/06 Oncovex, oncolytic virus (which also stimulates K cells to secrete GM-CSF), ph II melanoma (N = 50), ph II H & N N = 16 + RT + CT

CALP CALIPER TECHNOL (CALP) The Lab on a Chip company IPO Dec 99 oct 31 : wins lawsuit against Aclara

CALY CALYPTE BIOMEDICAL (CALY) urine HIV,gono & chlamydia tests 8/24 : approv. In China CARN CARRINGTON (CARN) Nutrition & skin care CBMX COMBIMATRIX (CBMX)

Acadia has majority ownership IPO filed (SSB) nov 22

Semi-conductor based array processor

CBST AB

CUBIST (CBST) Dec 4/01 MRK & PFE decline partnership CAP 1 : ceftriaxone 87%/Cidexine 79%, better data in US, poor response in Russia 500 mg vial $ 134

-Daptomycin/Cidecin/Cubicin (lipopeptide w ristocetin nucleus acq from LLY, manuf by Dobfar/Italy;new facility June 18/01): ph III (muscle tox serious at 25mg/kg), IV very active on VAN resistant strains. Lic to Gilead for EU (jan 01) July 27/00 FDA requests additional Ph III,completed July 16/01

Aug 24/04 : FDA warning on misleading ad "active on MRSA" Competition : oritavancin (LLY) ph III, licensed out (high protein binding) to ITMN., and see THRX


- 34 - printed : 03/07/10 (d/m/y) 08:07


Sept 10/02 GILD discont partnership EU

July 9/02 : first US case of VR staph, treated with Bactrim !!!!. But CBST makes noise. Manuf site in Italy approved by FDA : pre-approval inspection completed June 19/03 Oct 3/03 : Cubicin lic to CHIR (Novartis) for ex US, EU filing Dec 2/04, approved Jan 06. Sept 6/07 approved EU right side endocarditis staph strep

phIII efficacy (4mg/kg)on skin & soft tissue infect (march 14/01), and April 01: equivalent to Vanco(16% of comparators) or Oxacillin(84% of comparators). 2 CAP(DB/Ceftriaxone, enrol. compl.Sept 6/01, Jan 17/02 failure (efficacy 83%/85%), 2nd trial suspended. UTI ph II initated 3Q/00 : not < cipro For "suspected VRE", DB/Zyvox;6mg/kg, US army, data 2H03 ?????? Init endocarditis (animals need 25-40 mg/kg)trial Sept 5/ 02 : pts w/endocarditis & Staph bacteremia alone; open label, comp 6mg/kg to Nafcillin or Vanco. Enrol will end when 200 endocard. pts are enroled. Several interims ? Aug 4/04 Safety Board recommends continuation. Nov 9/04 enrol compl. N > 230 of which 37% MRSA, bacteriemias (51%) & right endocarditis (23%) . Data June 28/ 05 : non inferiority to comparators, muscular side effects. sNDA filed for bacteremia w/endocarditis staph Sept 26/05 <PDUFA March 24/06. March 27 "approvable" (label ?). May 29/06 FDA OK for Staph bloodstream infections & right sided endocarditis Feb 22/05 : all enrolled have completed tmt. data mid 05 -Oral formulation init w/Emisphere (nov 6/00) - CAB 175 IV cephalosporin, ph I terminated Feb 04 (tox) - Oral ceftriaxone (Rocephin like) lic in Nov 27 from U. of Utah (in GRAS carrier), ph I was to start 4Q01. Could start 1H04 ! (go/no go bioavailability : halted April 29/04 -Bacterial tRNA synthase inhib -Bacterial tRNA synthase inhib -Bacterial tRNA synthase inhib - 2 molecules lic (res) to MRK

2nd ph III (US) at IDSA (Oct 28/01) : SSTI, equal to Vanco / oxacilline. Patients had free access to Aztreonam Was to file mid 02 for SSTI/CAP/VRE March 7/02 : FDA says could file NDA for SSTI. Filing Dec 23/02(pack also has UTI & some data from VRE bacteremia). Approval was to be simultaneous to release of VRE & endocarditis data, or 2004. Priority review status PDUFA June 20/03. Adv Com ( CBST says FDA said no need). June 19/03 : delayed 3 m to Sept 30/03 Approved Sept 12/03 "for the tmt of SSTI by susceptible G+ at 4 mg/Kg/d (7-14d)". Sales 03 $ 2m, Jan + Feb 3.3m. 1Q04 : 6.3, 2Q 13.3, 3Q 18, 4Q 21, 1Q05 , FY 05 114, 2Q06 45.7 , FY 06 190, 2Q07 69.5, 3Q 76.3 → IDSA (Sept 30-Oct 3/04) : positive abstracts in bacteremia/endocarditis & osteomyelitis (but very "observational") ICAAC Oct 30/04 2 cases of resistance presented by independent clinicians PFE terminated in 97 BMYterminated MRKongoing June 27/01 partn w/Syrrx on bacterial targets

CEGE M V

CELL GENESYS (CEGE) March 04 : $ 53m follow on (acq Somatix in 97)

GVAX allo (irradiated cells transfected w/Gcsf : - GVAX allo (2 K cell lines) HRPC ph II, N = 34, median survival 26.2 m. (taxotere = 18.9m); 2nd ph II (ASCO prostate Feb 06) median OS > 29.1m, N = 22. April 3/07 OS is now 35m

PSA rate of rise goes down (→ASCO 02: dose dependent trend to survival).1st Ph III init 3Q04. 1 trial comp to Taxotere /survival, 2nd trial init July 05 + taxotere /Taxotere alone on OS. 1st trial to compl. enrol. 3Q06.


- 35 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS K

owns 10.5 % of ABGX Ceregene : 60% owned spinoff (jan 11/00) for gene therapy Jan 02 : $ 60m asset backed debt financing has lic to TKTI & AVE the Gene activation patents +++

Also ph III w/ipilimumab (Medarex/BMY) : PSA reduct > 50% - GVAX allo pancreas ph II. Data Nov 17/05 EORTC : N = 60, IIb mainly, extensive resection, then vaccine. 2 year survival 76% (historical 40 – 50%) - CML ph II, init Dec 012, ongoing w/auto BMT , data ASH 05, Dec 12 (enhances GVTumor). 5/19 have complete disappearance of bcr-abl GVAX auto : - GVAX Adeno auto NSCLC ph I/II. N=26, 12%CR, 27% PR; w/JT(Feb 18/04 response is proportional to dose of GM-CSF) - GVAX patients irradiated K cells + "bystander GVAX": --NSCLC ph I/II N+40 init June 01 w/JT, ongoing --myeloma ph I/II, ongoing -Lentiviral GT→VIII, pre, Term Jan 03 -GT with Endostatin/Angiostatin, RES -GT with VEGF&FGF, RES -GT IX primates/AAV™no Abs - CG 7870 (engineered Adeno), phI/II, IV & intraprostatic, oncolytic, K. Also combi Taxane. - CG 7860, intratumoral, pre - CG 0070 recurrent bladder K, Ph I/II, w/Novartis

→ w/JT (term Oct 02) -Entremed -Collateral Therap lic to Novartis lic to Novartis

CELG C K

CELGENE (CELG) July 3/00:merger w/Signal Oct 9/01 : Drug Royalty Corp acquires $ 4.9 m royalty interest ECOG has a ph III fully accrued Thalomid + IFN Nov 14/02 acq Anthrogenesis (umbilical cord blood banking) $ 45m May 27/03 rumor that AMGN could acq.

-thalidomide (Thalomid, patent 2018) for myeloma, ph II (delays annonced April 01); TT2 (Total Therapy 2 trial) w/pharmacogenomics, N= 600, first 120 pts to be unblinded. Filing was to be end 01/1H02. → 2Y delay FDA wants "survival"for "refractory" & t. to progr. for early stage MM, filed Dec 03, Oct 26/04 "approvable" but wait for data ECOG E1A 100 ; Nov 15 05 : again "approvable". CPMP filed April 02. Annual price per patient $ 10 000. Sales 01 : $ 82m, TTM dec 02 : 140, 2003 : $ 224m, 1Q04 69, 2Q 74.6, 2Q07 117.7 MKT in Leprosy, sNDA filed for MM end 03. Appovale letter 3Q04? could reply 1H05 renal K (NO PR, ASCO 01), ph II w/IL2. Ph III to start colorectal w/Xeloda-Roche & irinothecan-PHA, melanoma, glioma, June 30/04 HRPC + taxotere : median

-lic. from Entremed; & to Pharmion & Penn for EU -FDA warning letter for off-label ASCO 03 : 19 presentations RCC signif ORR w/IL2 ∏ ASCO 02, results 1Q03


- 36 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MDS : 300,000 ww 10 to 20,000 new cases/year US, 20 to 30% are 5Q deleted MM ww 74000 new/y; prevalence ww 200000; deaths 60000/y Price Revlimid : $ 4,500/month, retail 6,400 Competition : - Pharmion Vidaza azacitidine(approved 04) - MGI/Supergen Dacogen (decitabine), approvable

survival 28.9 m, ph open, N = 75.; ASH 04 ph III myeloma + dexa : > response rate. - Revimid/Revlimid / lenalidomide, CC-5013 (thalidomid analog, with less ?? neuropathy), ph III myeloma w/Dexa; endpoint TTP, 2nd 3rd & 4th line N = 705 (354 US, 009 + 351ex US 010), March 7/05 TTP (BLADE) p < 0.0015, melanoma & CHF (anti-TNF) danger++. April 28/04 melanoma halted by Data monitoring com. Filed April 8/05 in 5q MDS (ph II). N E J MED Feb 9/05 ph I/II of 20/43 pts EPO refractory achieved transfusion independence & complete cytogenetic response. Rand ph III ongoing in EU placebo/5mg/10mg. Aug 05 CHMP filing for MDS MM filed Jan 06, PDUFA June 30/06 :OK Myeloma July 3/06, - EU OK MM 2nd line March 24/07, Commission OK June 19 Actimid : Jan 8/03 ph II init Refractory prostate -D-Methylphenidate(Focalin), NDA filed dec 27/00, approvable Aug 22/01(FDA OK Nov 15/01); Ritalin LA approvable Oct 1/01 -Serms from Signal, w/Novartis : 8490 to enter ph II 2H02, K, another for osteoporosis - SPC/CDC 839 w/Serono, oral anti TNF (IKK, inducible κ kinase for NFκB) inhibitor, pre - CC 401, JNK (c jun N terminal kinase) inhibitor, ph I (oct 02) for inflammation. - CC 10004, PSO, oral, ph II - CD 1088, ph I/II, Crohn - CC 8490, ph I/II, glioma - Jan 21/03, w/Cytogen on Ubiquitin ligases (anti kinase) - Placenta derived stem cells

009 (US) : TTP 60.1w/ 20.7 p < 0.0015, ORR 51.3%/22.9% p < 0.001, CR 19.1%/3.8%; OS p< 0.0001 010 (EU) TTP 53.4/20.6, ORR 47.6%/18.4% < 0.001, CR 9.1%/ 1.2%; OS p< 0.03 "Rick Pazdur wants it" To file 4Q 05 ? Adv Com Sept 14 OK for approval in transfusion dependent 5q deleted (10/5). But 13/2 "the data does not provide a basis for a recommended dose". On Oct 3 PDUFA delayed from Oct 7 to Jan 7/05 Approved on ph II N = 148 Dec 28/05, 1Q06 $ 32m, 3Q 101, 2Q07 108.9

CEPH K

CEPHALON (CEPH) June 03 : $ 600m convertibles Dec 3/01 : acq Lafon ($450m). This will not increase Provigil sales in France! Feb 5/02 : accounting practices

-Provigil (sch IV/DEA)→Narcolepsy : $ 25/99;72/00m ;150/01,196/02; 290/03 (+ 40%) FY 06 727. Generics : 2003 → 2006 ? (orphan until 06, but sNDA filed Dec 23/02 for "daytime sleepiness"panel split Sept 25/03PDUFA Oct/20 03; OK Oct 22/03; sNDAs filed by Teva, Mylan, Ranbaxy, Barr) trial fails in ADHD july 31/01→ stock ¬ 40%, Aug 11/06 FDA rejects ADHD

Jan 15/02 : FDA letter on "false or misleading promotion".


- 37 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS questioned (by Sterling Financials): SASY & Lafon deals Feb 12/03 : $ 161m takeover bid for SIRTex ( 13.5% premium) :Y* spheres ( 2003 sales $ 10 to 12 m , very undeveloped, only used in 3 UK hospitals for Europe) Aug 21/03 : takeover bid for CIMA, rejected, Sept 2/03, counterbid by AAII, finally completed Aug 04 Jan 05 acq Trisenox from CTIC May 13/05 : to acq Salmedix for Treanda (bendamustine) for NHL, ph II :*; mkt in Germany Dec 6/05 acq Zeneus Ltd ($ 360m), mkt Myoset (liposomal doxo), Targretin, Abelcet)

- Nuvigil (armodafinil) filed April 4/05 - Gabitril (acq USfromABT, & EU from SASY) MKT, 1Q03 12.7m (+ 25%) 2Q 14.6. FY 06 58; Feb 25/05 black box seizures -Actiq (oral transmucosal fentanyl),MKT($15m/00,51/01, 2003 forecasts 214, 1Q03 46.2m ,+ 139%) 2Q 52.7 (+85%) ; FY 06 572; acq Anesta July 00 - Vivitrex (alcohol dependence) from ALKS. Approvable Dec 29/05 -CEP-1347→PARK, ph II;Alzheimer .SAP (stress activated protein kinase=JNK=c-JUN N terminal kinase) inhibitor. Protects neurons & neurofibrils. Term May 12/05-CEP-701(trk tyr kinase inhib)→Prostate K, pancreas, ph II, precl also in pancreas w/Gemcitabine, CML ph II. But Xenova failed in this field, and anti EGFR (OSIP/Roche; AZN, ABGX/IMNX) and Herceptin (DNA) are close. In vitro corrects FLT 3 mutations in AML (Johns Hopkins June 3/02) - CEP 7055, ph I, K, antiangiogenesis (VEGF kinase inhib)- Oravescent fentanyl ph III OK May 5/05 - Treanda (bendamustine) filed for CLL Sept 20/07, ph III nHL : ORR 75%, 2nd line, Oct 24/07

lic from Kyowa Hakko, dev w/Lundbeck lic from Kyowa Hakko, dev w/TAP & Schwarz .

CEPH CIMA LABS (CIMA) acq by CEPH (Aug 04)

-coating for pills (e.g. Zomig/AZN) - oral soluble technologies, fast acting : Remerin (mirtazepine, antidepressant) solTab, MKT, w/Organon Nulev (Hyosciamine), MKT, w/Schwarz, Irr Bowel sd

CEPO Ceptor (OTC BB: CEPO) Myodur, for Duchenne, filing IND (YE 05). Duchenne has up-regulation of Calpain. Lepdur associates a leupeptin analogue (calpain inhib) and a carnitine carrier molecule

CERS C

CERUS (CERS) -products for antisepsy of blood transfusion ("Intercept") ∗for platelets (amotosalen, activated by UV, cross links nucleic acids of pathogens) EU approved, US under review∗for blood ph II with S-303 ?, activated by pH when RBC are introduced into set. -Stem cell transplants - vaccines : listeria delivery platform. Ag : Eph A2 (w/MEDI)

BAXTER (owns 16.5%) w/Kirin


- 38 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS CGEN

COMPUGEN (CGEN) Israeli company

Bioinformatics and algorithms +++ -Software for EST databases (LEADS) with error and alternate splicing detection -Software (Z3) for 2D proteomic gels -LabOnWeb.com -discovery with LEADS of CXCL 16, novel HIV receptor on LTs, Oct 5 - leading the Consortium on MAPK

⇑PFE(WLA), HGSI, ABT Bayer, MediGene, Genox, GENE, AMGN, AVE

CGPI COLLAGENEX (CGPI) -doxycyclin for dentists, MKT -coprom. Vioxx to dentists CGRB.OB

K COUGAR ( merged April 8/06 with public shell)

- CB 1089, Seocalcitol, calcitriol analogue, prostate K, ph II - CB 7630 (17 α OHlase 17-20 lyase inhibitor), prostate K, ph I - CB 3304, Noscapine, microtubule inhib, ph I

CGXP CERAGENIX (CGXP) Tmt for cracked skin CLGY CELLEGY (CLGY) -consumer skin care :anal fissure ointment (Anagesic,

nitroglycerin ointment) Dec 23/04, FDA : NO -transdermal delivery : testosterone phIII to start

NDA withdrawn April 29/02 : headaches in 50% pats.

CNCT CONNETICS (CNCT) acquiring Soltec (Australia), drug delivery company Becoming a specialty dermatology company ?

-r hu Relaxin→scleroderma, ph III ⇑failure oct 9/00 - Luxiq (bethametasone foam) since 99 - Minoxidil foam (like Rogaine), in clin. - Velac gel (clindamycin + tretinoin) lic from Yamanouchi (May 16/02) - Soriatane (retinoic acid) for PSO lic from Roche Feb 23/04.

BLA filing 2001 ???;part w/Flamel (jan/01)

COLY V K

COLEY ( COLY) Acq by PFE Nov 16/07 $ 164m I.P ??? -research on human cells in Dusseldorf Private placement $ 35m, Aug 25/03 IPO filed (COLY) April 20/05 (ML, JP Morgan), traded Aug 10/05 $ 106 m Unterberg : positive echoes at ASCO 07

CpG company - w/GSK : Engerix + CpG ph I/II : much higher & faster response - w/GSK Nov 7/02 : K vaccines with GSK genes (MAGE III) , also $ 72m; Milestone Oct 25/07 - w/AVE : CpG 7279 antiallergy : enhancing Th1 response to allergens rebalances the immune response away from IgE - potentiate Rituxan : increses expression of CD20 receptors on B cells - CpGs alone up-regulate cell surface Ags & increase CTL proliferation. - CpG 7909 S. Cut. Promune (to TLR9), ph I April 29/02, RCC (N= 3-6) then 24 w ph II on 12 pts. Melanoma stage IV ph I/II monotherapy init June 13/02. Ph II NSCLC N =

Competition on TLR : Vaxinnate ∗part of $ 72 m deal , upfront $ 8m, for Inf dis Jan 21/03 : "on track to enter clinicals" 7909 partnered w/ PFE March 24/05, total $ 455, JUNE 20/07 PFE terminates. Oct 30 PFE


- 39 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS 75, "to improve the outcome of 1st line taxane/Pt; enrol compl May 13/04, interim data ASCO 04.. Feb 3/05 1st line improves RECIST more than CT alone ORR 37%/19%. Active in adeno & squamous cell. Nov 28/05: 2 ph III init stage 1st line IIIb/IV w/current standard of care CT(taxol carbo or gemzar cisplat) vs Standard of care alone; N = 800 x2, sites opened by PFE; Enrol compl May 5/07, Data YE 2007; filing 1Q08. Endpoint OS +20% (standard tmt OS 8m). June 20/07 PFE terminates Ph II w Avastin/ <carbo taxol 1st line NSCLC, ph II 2nd line w Alimta/Tarceva Ph II melanoma w/ anti CTLA4, init 1Q07 Also CTCL - Actilon CpG 10101 ph I CTCL (40 pts, 40 nls), Hep C ph II term. Jan 23/07 - CpG 10103 immunostimulant for inf dis & vaccines : VaxImmune lic to Chiron Dec 26/03, lic to MRK April 12/07 - Inhaled TLR9 agonist against BioTerrorism (NIAID grant $ 5.8m Oct 22/03)

repartners for 2nd generation; ph II 7909 ongoing w/Tarceva refractory NSCLC, & ticilimumab (anti CTLA4, tramelizumab, IgG2) melanoma

COR CORTEX (COR) Ampakines hypothalamic AMPA agonists : - CX 516⇑mild cognitive impairment ph IIb init April 3/02. Feb 17/04 NS - CX 516 for ADHD w/Shire, ph II - CX 717, ph I, Alzheimer init 2Q04 (1mg/Kg), on hold April 3/06 animal data competition LLY 451 395 ph II - ORG 24448 w/ Organon schizophrenia/autis:/depression

Servier (oct 16/01).N= 160, for 12m

CORT CORCEPT (CORT) IPO filed Dec 27/01 (CIBC)

C-1073, antidepressant, ph III (it is RU 486 !!!!!!!!!!) fails Aug 25/06

CPHD CEPHEID (CPHD) - Biological warfare agents detection : will start selling suitcase sized dg machine in 03, already available to military. -Microfluidic genotyping -PCR kit for CEA in lymph node biopsy (AATS,May 01)

CPRX IPO CATALYST traded Nov 9/06

CPP 109 based on Vigabatrin (Sanofi) gamma vinyl gaba inhibitor of GABA transaminase, eliminates feeling of pleasure associated w DA enhancing drugs. 2 trials in Mexico. DB to init in US. But retina ??

CRA K CELERA (CRA) "to become the definitive source of genomic and related PEB


- 40 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS June 13/01 : acq AXYS (Arris + Sequana)

medical & agricultural information" DRUG DEV : - CRA 024781, cancer, pre, histone deacetylase inhib - Cathepsin S, w/Aventis - Cathepsin K, odanacatib w/MRK (MRK 0822) SEpt 18/07 ASBMR, 12 m ph II data excellent, ph III init Oct 1/07, 1 a week - Factor VII a inhib - Tryptase asthma program.

-AAAS, Feb 18/00 : drosophila genome, -HUMAN GENE MAP :Science feb 16/01

CRGN M K

CURAGEN (CRGN) Nov 7/02 staff ¬ 25% June 19/03 : staff ↘ 20%

Genomics database (GeneScape portal) issued convertibles on Jan 20/00; James Vincent resigned from board on Jan 19 - CG 53135, FGF 20 Velafermin, for mucositis & IBD, ph I, active on epithelial AND mesenchymal layers ( # AMGN, HGSI). Dec 13/05 ph II mucositis fails; énd ph II fails Oct 11/07 - PXD101belinostat lic from TopoTarget A/S, June 4/04, HDAC inhib, ph II Myeloma - CR 011 fully Hu Mab conjugate, antiglycoprot NBB, melanoma, ph I/II - CR 014 anti TIM1, ovary, RCC - CR 002, anti PDGF, lupus nephritis

GLX DNA DuPont/Pioneer BGEN CORR Roche Abgenix(MAbs to 24 CRGN targets) Bayer +++ Mitsubichi (Nov 5/02) schizophrenia targets

CRIS M K

CURIS (CRIS) CEO : changed Sept 01, Doros Platika becomes chairman BMP competition is GI(AHP)/Sofamor Danek merged w/Medtronic; for spinal fusion. Feb 15/02 : work force cut.

-BMP-OP1,phIII, w/Stryker & Biogen (accepted for filing by FDA in July 99):Feb 1 CPMP/OK(after autograft failure),FDA negative jan 30/01(not >autograft for pseudarthrosis)! Approved Oct/01 "when autograft not feasible". -single chain Mabs patents (Creative Biomolecules) - autologous cartilage (Chondrogel) for vesicoureteral reflux and stress incontinence, ph III term Feb 15/02 - PPY peptide (diabetes, obesity) lic to Amylin Dec 7/02 ($ 15 m deal) -BGEN returned hedgehog prot to Ontogeny July 10/00∏July18/01 JVw/Elan for drugs that stimulate Hedgehog pathway.Returned - Topical antag of Hedgehog pathway w/DNA, ph I/II

merger of Ontogeny , Reprogenesis and Creative Biomolecules (July 31/00) Dec 2/02 : BMP 7 active IV on stroke rats after 24h, Feb 03, lic to JNJ (upfront 3.5, milestones >35) The AHP /GI BMP-2ACS rejected by FDA for long bone fracture but Adv panel OK spinal fusion (Jan 10/02 June 11/03 lic Hedgehog, with CUR-61414 (basal cell K) to DNA. $ 240m deal, upfront 8.5 (Cash 5, equity 3.5, & 2m/year/2 years, then milestones. Jan 25/06 partial failure. Also w/ WYE e . July 12/06. Systemic IND filed Oct 5/06 for ph I


- 41 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS CRL Charles River Labs (CRL) Leading provider of animal research models since 50 years

CRME CARDIOME (CRME) RSD 1235 ion channel inhib, atrial fibrillation, IV ph III OK, oral ph II

CRTQ CORTECH (CRTQ) Seeking acquirer

-Bradycor : failed in TBI -elastase inhibitors : halted

All activity halted

CRTX

M CRITICAL THERAPEUTICS (CRTX) (analysts Matt Geller, Pi CEO from SEPR, GSK, ABT (made zileuton) COO from SEPR CMO from GSK Res from MLNM

- ZYFLO (zileuton), 5 lipox inhibitor, acq from ABT (not detailed since 97) New manu (sNDA filed April 2/05) could launch end 05 ( in Singulair failures). Open label IIIb init March 15/05 in pts who had benefited from Zyflo. Also orphan drug trial in Mastocytosis. manufacturer found June 28/05. FDA OK Sept 29/05 4 times a day, can increase ALAT - Retard being prepared - Preclin : inflammation - CTI 101 Halted (March 15/06) - Fully human Mab anti-HMGB1 for inflammation associated tissue damage, pre (w/MEDI)

AAAAI Mar(ch 18 – 22/05 ATS May 20 – 25/05 Competition : LT receptor antagonists : Singulair once a day; MRK $ 2.6 B 2004 (rare Churg & Strauss), Accolate AZN $ 0.1 B

CRXL CRUCELL revenues 2005 37.5 m € 2006 : 140 m € 1Q07 : 32 m €

- PER.C6 : human cell line, licensed to most biotech & pharma companies. The Mabs JNJ was supposed to produce since 2001 seem to have vanished. - STAR : a technology to enhance yield of CHO X 4, being tested by DNA & MEDX, but the produced proteins would probably need novel clinical trials…. - Berna vaccines : - On the mkt : hep B, Hep A, influenza, typhoid _ Being developed : the usual - Recombinant proteins being developed : Factor V Leiden for thrombophilia : Bof - Plasma extracted : alpha 1 proteinase inhib lic from Bayer, but being developed by others as recombinant & as AAV.

CRXX IPO

CombinatoRx (CRXX) filed Jan 19/05 Pacific Growth Traded Nov 9/05

Synergistic applications of approved drugs (NTMD model)Steroid "amplifiers" : CRx 150 amoxapine + dipyridamole, failed June 06 periodontitis CRx 139 : prednisolone ( 2.7 mg) + SSRI (Paxil GSK), ph II RA to be presented in Spring 07 (w MTX vs MTX alone : it will sow that Paxil alleviates symptoms !!! CRx 102 prednisolone + dipyridamole, to init in knee OA CRx 119 prednisolone + amoxapine; for periodontitis. April 10/06 misses endpoint (CRP)


- 42 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS CRx 170 budesonide/nortriptyline, April 18 positive data lung function Cancer : - CRX 026 Chlorpromazine/Pentamidine, ph I ASCO 2005 harmless

CTEC CHOLESTECH (CTEC) -electronic analyzer from 1 drop of blood - P.O.C. diagnostic screening

CTI Chemokine Therapeutics (TSE/CTI) CHKT OTCBB IPO Canaccord

- CTCE 9908 ph II, antag of SDF1 (stromal cell derived factor 1) that binds competitively to receptors (CXCR4 ) on K cells, inducing metastasis - CTCE 0214, regained April 18/06 from PPDI, peptide agonist of CXCR4, increases WBC, ph Ib

CTIC K CELL THERAPEUTICS (CTIC) Chairman : Max Link Has subsidiary (Pangenex) specialized in knockout. Jan 5/04 acq NovusPharma stock exchange $ 236m, w/Pixantrone ph III for NHL Feb 04 : Europe hiring PharmaMar sales personnel June 10/05 reduces workforce by 130

-Lysofilline -Trisenox (As trioxyde, NDA approv. 09/00 & EU 2002 for PML 2nd line, sales 01 : $ 6m!!!, 02 : $ 12m , 03 : $ 24, 04 : $ 26.4 m ; trials in myeloma. ASCO 03 June 10/05 sold to CEPH $ 170m - Xyotax PG (r polyglutamate)-TXL (paclitaxel derivative) phIII ovary since July 02, Feb 03 data on I/II ovary : bof, ph III NSCLC init Oct 02 N = 840, 2nd line, data 2H05, rand, survival, comp to Taxol. Nov 20/03 dose reduced. STELLAR II vs Taxotere 2nd line NSCLC data April 05Stellar III 1st line, N = 400, to reach 311 deaths (June 04 : 400), endpoint 30% survival improvement, data March 7/ 05 only non inferiority, w/carbo, comp to Taxol; Stellar IV ditto alone 1st line vs Vino or Gemzar in poor performance status, N = 477, enrol compl Mat 04, data mid Feb 05 Delayed Stellar III & IV better in women (Aug 05) To file 2H06 → 1H07 (June 1/06) competition Abraxane APPX American Pharmaceutical partners : nanoparticles cremophor free paclitaxel (was ABI 007) NDA filed March 8/04. Good Data at San Antonio03 - Dec 6/05 init PIONEER 1. NSCLC, late stage, 1st line, poor status, female only N = 600 - PG Interferon

→3 deaths published march w/QT↗ (march 9/01and posted on FDA web site). EU approval March 12/02 → lic to Chugai (Asia) ASCO 02 ++ → ph II AACR, Nov 02 → ASCO 03 : ph II alone in adv NSCLC 7% PR → ASCO 04 2nd line ASCO 06 Sept 10/06 Xyotax lic ww to Novartis


- 43 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - CT-2106 : polyglutamate camptothecin, ph I to start in CRC & SCLC - Inhibitors of LPAAT β for K (AACR, Nov 02) - Zevalin, acq Aug 15 fromBIIB - Brostacillin (acq w/SMI July 25 07, SMI founded by Dan Von Hoff) minor groove binder. Targets pts w/mismatch repair deficiencies, high glutathione, t (12:16). EORTC ph II in 108 1st line sarcomas vs dexa. Could be enough for filing

CTIC NOVUSPHARMA, Nuevo Mercato,NOV.MI traded since nov 6 President : Erich Platzer, who played a key role in the discovery of Neupogen Established in 98 by a management spin-off from B.Mannheim/Roche Oncology

-BBR 2778,Pixantrone, anthracenedione (near mitoxantrone), devoid of cardiotox (?), ph III w/Rituxan compared to Rituxan alone NHL, init April 5/02, N = 800, EU/US CR rates & TTP. Ph III to init N = 320, double refractory NHL, endpoint response, TTP, survival. Enrol will take 12 m. To be complete mid 05 - BBR 3464, triplatinum, not nephrotoxic, phII⇑NSCLC (halted), ovary & gastric disappoint Oct 01 - BBR 3438, ph I, mitoxantrone derivative™gastric K - BBR 3576, ph I, mitoxantrone derivative. -Oral antiangiogenic,pre, w/Prolifix (UK,private)

…but cardiosafety evaluation is LVEF & not diastolic ASH 04

CTRX CoTHERIX (was Exhale) CTRX IPO filed March 15/04 (CIBC) Secondary Feb 10/05 $ 35.6 to be acq by Actelion $ 420 m Nov 20/06, compl Jan 9/07

- Ventavis (iloprost) nasal, PHT, lic from Schering AG; EMEA OK Sept 03, FDA OK Jan 3/05, Orphan drug. 2Q05 4.1m. New device ? 1Q06 : $ 14.5m - CTX-100 inhaled hyaluronic acid, emphysema, ph I/II, not on web site anymore - Fasudil, lic from Asaki , rho kinase inhib for PHT

CURN CURON MEDICAL (CURN) electron tipped catheter to treat GERD CVBT IPO CardioVascular Biotherapeutics (CVBT)

filed Sept 27/04 traded March 15/05

FGF for intracardiac injection, ph I/II

CVM K CEL-SCI (CVM) Multikine (mixture of many natural cytokines, peritumoral injectionp, ph II

CVTX

CV THERAPEUTICS (CVTX) June 14/03 PIPE $ 100m convertibles + 100m credit line Acqua Wellington aug 9/00 : $ 120m equity financing line from Acqua Wellington June 7/01 : $ 100m secondary Dec 01 : $131m secondary

-Ranolazine Ranexa( lic. from Syntex/Roche;patents issued 95-99), antianginal (pFOX inhib switches heart metab from lip to gluc, acts on mitochondria);++ treadmill test, ph III,→NDA filed Dec 30/02 (using SR formulation). Why so late ?? → bioequiv Marisa (old Roche supplies) Carisa ( 2 diff contract manufacturers)

→AHA : nov 14/00, MARISA(n=200) improves treadmill , p<0.0001) A.Coll. Card (March 18/01) confirms and extends to pts with also CHF (p<0.001). Association trial (CARISA) last tmt completed Aug 8 01, results 4Q01. (Nov 14 AHA , but not all data,


- 44 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS CAVEATS : - Profitability in 2003/4 depends on 510 - MKT costs could be underestimated - CHF for Ranolazine could be a mistake - QT issue in CARISA, & many pts from east Europe JAN 13-14/03 FDA workshop on QT. New guidelines 5-10 ms OK, 10-20 : concerns (problem is SD, not mean) R. seems lic in France to P. Fabre Oct 26/05 CHMP filing withdrawn

Is Innovex (Quintiles) the right mkt partner ? Targeting 8000 cardiologists, only 75 reps : July 10/03 reacquires rights Also CHF ph II, data was to be4Q01 : DANGER : α-β- Positives : remarkable study of QT . Corrects electric anomalies linked to quinidine or cisapride. Due to late Na channel blockade effect. Feb 03 more data : 3 pts on high dose had QT > 500 ( 2 also on placebo). 24 h IV, N = 24 → some syncopes. -Adentri(adenosine A1r antag) natriuretic for CHF, ph II, halted,BGEN will continue with backup (pre) -CVT 510(ad.A1r antag), IVantiarrythmic, ph II→phIII, needs additional trials -CVT 3146 (ad.A2r agon for cardiac perfusion imaging),phIIw /Fujisawa 20% royalties, "pharmacological stress agent" used to be for coronary imaging, ph III to start 2003 -Tangier disease gene (lic from Incyte)…to find a pill to increase HDL ( Aceon, perindopril Servier, ACE inhib, comarketed w/Solvay, PDUFA extended to Sept 10/05)

compares 750 mg bid w/1000 mg bid & placebo). N= 823, treadmill improvement 24 sec (p=0;012). QT↗(<10 sec but signif). Time to 1 mm ST denivellation p=0.10 → ACC : March 30/03 : 1 presentation in diabetes → AHA Nov 17-19/02 Carisa subgroup analysis

Drug Max QT Change from baseline Placebo 425 ms - 2.2 +/- 0.9 750 426 2.3 +/- 1.08 1000 428 5.6 +/- 0.9

( Ranexa is 3 to 9 ms) FDA panel Sept 15-16/03, cancelled Aug 3/03 "more time needed to prepare adequately for the panel". Queries from FDA on Tox (see etomoxir), Stats, metab. Aug 10/03 : class action suit. PDUFA Oct 30/03? Could be "approvable letter " in Oct and/or Adv Com in Dec, or PDUFA redelayed 90 days. Nov 2/03 App. letter requests another trial (bothered by unclear dose ranging, constant QT elongation, also rat testicular tox. Adv Com Dec 9 does not vote. CVTX may be able to complete enrol. in 2005. SPA OK ( ERICA )June 3/04 on N = 500 refractory to amlodipine (1000 mg x 2 + amlodipine/6w; endpoint angina frequency per week 2.8 verum vs 3.2, but SAE 21% vs 6% , April 18/05 p = 0.028 2nd SPA : "Merlin" trial for acute coronary sd non ST elevated (data end 06 → spring 07 July 27/05 amended NDA filed, PDUFA Jan 27/06 Approved Jan 30/06. Labeling restricted to failure of other drugs, & must be combi (Ca-, β -). Launch 03/06 sales 2Q : $ 1.2 m.

CXSP K CHEMGENEX (CXSP, CXS/ASX) in EU : Stragen (Fr) Merck AG on the Board (Elmar Schnee)

- Ceflatonin (homoharringtonine), CML ph II/III, MDS ph II, AML Ph I. June 12/07 active on T3151 - Quinamed (amonafide) needs genotyping to avoid side effects, K prostate ph II, ovary breast colon ph I

Interim YE 07, filing 2008

CYAN CYANOTECH (CYAN) -nutritional supplements from algae


- 45 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -GFP

CYCC

V C K

XCYTE (XCYT) IPO filed (SGC) dec 26/00, withdrawn Dec 4/01, then refilled. Trading March 17/06 merging with Cyclacel. Completed end March 06

Autocell therapy to stimulate T cells ex-vivo : K, HIV ph II NHL & MM, ASCO 05 : NS, CLL terminated, will refocus on HIV (May 16/05)

CYCC K CYCLACEL Ltd -Seliciclib, oral CYC202, CDK inhib, purine analogue, inhib of cdk 2 cyclin E, cdk 7 cyclin H, cdk 9 cyclin T. Active on mantle cell cell lines (chromosomal translocation t(11, 14') (q13,q 32), NSCLC, Ph II, 3rd line, ph IIb vs BSC init June 06; also nasopharyngeal K (EBV), ph I/II - Sapacitabine (analog of gemcitabine) , CYC 682, DNA polymerase inhib, K, ph I; ASCO 07 - CYC-116, oral aurora kinase A, B & VEGFR2 inhib, K,IND filed Dec13/ 06. Ph I init June 30/07

CYGN CYGNUS (CYGN) Aug 7/01 FDA approval of large manufacturing site

Glucowatch, FDA adv com(dec 6/99) but labeling cond ⇑sales starting in UK; March 22/01 FDA approval.

sold their drug delivery bus to JNJ , to concentrate on Glucowatch ™seeking partners

CYPB CYPRESS (CYPB) CEO : Jay Krantzler (McKinsey 85-89)

-Platelet extracts MKT: back to phase II, blood from Dutch Red Cross (heat inactivated) -Prosorba columns for RA : sold to Fresenius - Milnacipran (NA reuptake inhib) from BioMerieux P Fabre for fibromyalgia : fails Sept 29/05; Jan 5/04 partnered w/Forest lab, 2nd ph III init Jan 06. Topline + May 23/07 - Mirtazapine (from Organon) with another agent for sleep apnea ph II

CYPH CYTOCLONAL THERAP. (CYPH) -Technol. to produce Taxol from a fungus -Library of antisense to 8000 human genes ???

BMY

CYTC CYTYC (CYTC) Acquiring DIGE (Feb 20/02), Term July

Semi automated PAP test : ThinPrep PAP test.

CYTK K Cytokinetics (CYTK), IPO filed Jan 28/04 (G. Sachs, Pac Growth) traded April 29/04

- SB 715 992 ispinesib, Inhibitor of KSB (Kinesin spindle protein) ph II : ovary, NSCLC ph II refractory not good Sept 28/05 GSK will not move to next stage (April 1/06); ph II 1st line ongoing, breast 2/3rd line 3PR/30.; ovary;

w/GSK San Antonio 05 : 2nd line mBC, N = 32, 50% grade IV


- 46 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ASCO 06 CRC ph II NS. Oct 2/06 ph II H & N fails. Nov 8/06 GSK amends ( not termination, but CYTK to assume all dev costs). ASCO 07 RCC not good. More poor data June 30/07 - SB 7432 921, ph I, NHL, MM - GSK 923295 pre, selected by GSK Dec 13/05, CENP (centromere associated protein E) inhibitor. Aug 15/07 ph I initiated. - CK 1827452, cardiac myosin activator, ph I. IV (to become oral). Heart failure Soc Spt 18 – 21/05. Oral init Aug 20/06. Jan 3/07 collab w/AMGN $ 750M; ph II init April 12/07

neutropenia, 1 PR

CYTO M CYTOGEN (CYTO) -Dg imaging *Indium MAb -Proteomics through Axcell subsidiary, WW interaction mapping; on tyrosine kinases & serine threonine kinases

-Quadramet(Samarium)→pain metastases, MKT -Oncoscint colorectal: MKT -Oncoscint ovary : MKT -Prostascint : MKT

Schering AG (Berlex) rights regained June 16/03 by CYTO JV w/PGNX : The PSMA Development Company. Term April 25/06

CYTR

CYTRx (CYTR) Jan 9/07 creation of RXi Pharmaceuticals owned 85% by CYTR

-Flocor (was RheothRx), ph III. Lic to SynthRx for sickle cell disease -TranzFect technology lic to MRK, used for HIV vaccine, successful in Rhesus (April 2/01) - siRNA lic from U. Mass Med School (obesity, cancer, diabetes, ALS) - Arimoclomol (HSP 70 co-inducer), ALS, ph II init Sept 05. Could activate a molecular chaperone. Active on SOD mutant mouse w/spinal & cortical lesions. IIb to be init 4Q07, will last 18m, 400mg TID, oral

ALS more than 20 drugs in trials

CYTX C

CYTORI therapeutics CYTX, (was XMPA , Frankfurt) San Diego company JV with Olympus CorporationTokyo Nov 4/05

Specialized in Stem Cells from auto adipose tissue : device to purify them : CELUTION approved can isolate and concentrate cells in 1 hour. Uses uncultured non phenotyped.. Efficacy ++ in pigs for heart attacks. Ph Iheart chronic ischemia init Jan 07, data 2008; ph I/II heart attack to init 2H07 Plans : spinal disc repair

Adipose tissue : see also Stem Cell Sciences plc

DBLT DOUBLE TWIST (DBLT) was Pangea IPO filed 9/6 (LB),withdrawn march 10/01

Genomics portal


- 47 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS DCGN DECODE GENETICS (DCGN)

Icelandic company Roche has 14% March 02 : acq of MediChem (highthroughput) Staff¬ 35% Sept 30/02

Population genomics -late onset Alzheimer gene - schizophrenia gene (oct 20) - PAD gene (nov 14) - gene for stroke -Nov 3/00 : initiates large scale STR (short tandem repeat) genotyping - w/PHA pharmacogenomics of heart disease - pharmacogenomics of response to steroids in asthma : 10 000 genes explored, only 20 correlate with drug response - DG 031, inhib of FLAP (5 lipox activating protein) that leads to LTB4. Ph III init May 4/06 to reduce incidence MI & stroke

Roche Roche w/Medarex & GenMab

DDD SCOLR Pharma oral retard formularions, and enhanced bioavailability

Trials w/ Ondansetron, Raloxifene Parnerships with : - Wyeth (Dec 05) for Ibuprofen, term. March 07 - Perrigo (PRGO), world's largest manufacturer of store-brand OTCs - w/ BCRX for oral peramivir (March 9/07)

DDDP K 3 Dimensional Pharmaceuticals(DDDP) MEDI owns 5.9% Jan 16/03 : to merge w/JNJ

-Highthroughput + Combinatorials -Products : °Oral thrombin inhibitor(3DP4815), ph I→→→→ °Inhibs for K (RES) : -of ανβ3,MDM 2, MMP, VEGF

DuPont, B.Inge.,AVEn BMY →lic to JNJ (Centocor) jan 2/01

DDXS M DIADEXUS (DDXS) formed in 97 by SBH (21%) & Incyte (20%) IPO (LB) filed nov 21/00, pulled 12/12/02

Use of genomic data for dg. and MAbs

DGEN DELTAGEN (DGEN) -Functional genomics -Gene target validation in mammalian cells - Advanced knockout systems

MRK PFE ROCHE SGP GLX

DIGE DIGENE (DIGE) Being acq by CYTC (Feb 20/02), Term July ½

- The only FDA approved test for HPV - > PAP smear alone for detection of cervical K (June 19/01)

Roche

DIL DIADIC (DIL) DMI DepoMed (DMI) Drug delivery to reduce gastric intolerance (GR = gastric

retention) - Metformin GR ph III lic to Biovail (May 30/02)

JNJ


- 48 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - Ciprofloxacin GR ph II

DNA K M

GENENTECH (DNA) """Roche decreases stake 65→58.9% March 9/00""" Rituxan per ptn/y : $ 15, 000. 700 000 potential WW pts; 50 000 new cases/y US, 5 year survival 50% The largest mammalian fermentation facility ww : ++ for future of Rituxan ∗Will manuf Enbrel for IMNX 1Q04 H is indicated 1st line w/Taxol or 2nd line alone in Breast st IV . Tanox : July 10/01 : Complete response letter requiring Labeling only adult allergic asthma Sept 30/04, Nature : mutation explains Herceptin good results in NSCLC Xolair approved June 20/03, NVA & DNA to copromote in US, sales force 250, sales start July 10/03 Raptiva $ 17,800/y. Adv Com Sept 9/03 unanimous on risk/benefit, 9/2 on efficacy. FDA says PASI 75 : 18 -37% (4 trials), 50% relapses; 2nd course 31% efficacy in pts who had efficacy w/1st course. Thrombopenia, infections.

-Rituxan (since 97)anti CD20, IV, weekly: $279 m/99→$424/00,$ 819/01 (+ 84%).1Q02 235 (+40%) 2Q02 : 274 (+46%), 3Q02 293.9 (+38%),4Q02 347, 2002 : $ 1. 162B;1Q03 341of which 31 ex US sales to Roche (+38%, price +5.8% March 7) 2Q : 363 3Q 372( 18 ex US), 4Q 413, FY 03 1,489, 1Q04 401; 2Q 424.7, 3Q 438, 4Q 448 ; 1Q05 441 (US), 2Q05 US 450, 3Q US 452;FY 05 US 1.8B (ww 2.4B);1Q06 US 477 2Q 536, 3Q 509 4Q 560, 1Q07 535, 2Q 582; 3Q 572; RA ph IIIinit 04 for "refractory to anti-TNF" -Activase : $236m→$205/00 (competition JNJ Retaplase $110m. TNKase (Metalyse/Tenecteplase)Launch US feb 01, EU march 01. All Lytics 01 $ 197 (- 4%) w/B Ingelheim; 2002 : $ 180 m, 03 : 185, 1Q04 46; 1Q05 54, 1Q06 59 -HGH : $221 m→$228/00 (competition LLY, N.Nordisk)- All HGH 01 : $ 250 m (+ 10%); 2002 : 297; 1Q05 92, 1Q06 87, 2Q 94 Nutropin depot approved (Schwarz/Europe Term.06/01), term 06/04. ALTU 238 HGH lic from Altus, qw, SC, Dec 06 -Herceptin (trastuzumab): $ 188 m/99→$275/00, $346/01 (wholesaler fill, + 25%), 2002 : $ 385 m; 1Q03 93.7,+8%, 2Q 109, 3Q 108, 4Q 114, 2003 : 427, 1Q04 113.5, 3Q 126, 4Q 126;FY04 479 1Q05 129 (US)/14 row, 2QUS 152, 3Q 215;4Q 250; FY 05 747; 1Q06 290 2Q 320, 3Q 302, 4Q 322, 1Q07 311, 2Q 329 may 5/00 : "Dear Dr letter :potentiates cardiotox of anthracyclines and taxol :15 deaths.Nov 8/01 alert at "Chemotherapy foundation sympo". Jan 29/01 a trial stop. ph III + CT : 10000 pts, 800 centers : ongoing To file 07 1st line meta w/ Taxotere FDA - Trastuzumab DM1, ph I, w/Immunogen, Feb 1/06 -Pulmozyme : $ 111 m→$122/00, 2002 : 138, 2003 : 167; 1Q04 43; 1Q06 49, 2Q07 55 -Xolair (omalizumab) ,hz anti IgE filed June 5/00 . S cut. (1 or 2/month) FDA/CPMP;Novartis/Tanox. $ 7000- 10000/y. 3Q since Jul 10 : $ 6.8, FY03 25.3; 1Q04 30, 2Q

ASH01 : GELA(8 cycles) results mkt (beware of ECOG(4 cycles) N = 630 accrued at ASH 02(192 abstracts), 2nd part of ECOG MAINTENANCE (4 infusions every 6 months). Data 2004. 193 abstracts at ASH 02 Alkermes April 27 & ASCO 05 : interim of 2 ph III, 1st line, adjuvant, "early stage BC". Adria/cyclo/Taxol +/- Herceptin : 52% decrease in recurrence = trial stopped. Filed Feb 16/06, FDA action mid-April ? Aug 15 extended to Nov 17 Nov 16/06 OK w/ doxo cyclo taxol EMEA OK May 22/06, early stage patrients Her 2+ following surgery and standard chemotherapy Competitor Tykerb, filed Sept 18/06 & EU Oct 9 additional platelet data filed march 01(???). Compl Resp Letter from FDA July 10/01. Trials ongoing .


- 49 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Roche option to mkt Avastin in Europe : exercised July 8/03 . Filed EU Dec 5/03, CHMP OK Oct 21/04, EU OK Jan 14/05 "in combination with 5FU/FA or FOLFIRI"UK launch March 10/05 Manu in S. Francisco, will be Vacaville (1H04) & Spain ( RCC : Onyx/Bayer & PFESutent approved )

43.7, 3Q 54, 4Q 61, 1Q05 69, 2Q05 80.4, 3Q 81.6, 4Q 93, FY 05 320, 4Q06 117, 1Q07 111, 2Q 120 Manuf :first Vacaville (then NVS) DNA + NOV to coprom In US, Nov alone outside Oct 27/05 CHMP approved -Raptiva Xanelim/efalizumab, hz anti CD 11a ( LFA-1 is CD11a/CD18)→PSO, weekly, subcut, phIII (May 01: PASI 75improvement>placebo). Peak PASI 75 : 38% (Enbrel 56%, ciclosporine 70%,Remicade 84%). Rebound issues. New ph III w/DNA material (Sept 17/02) > placebo, N = 556, data at A. A. Derm March 21/26-03 Sales 03 (20 days) $ 1.4m; 1Q04 $ 6m, 2Q 13.4, 3Q 18, 4Q 19;1Q05 24, 2Q05 21.3 , 3Q 20.0, 4Q 20.4, FY 05 79 2Q 22; 1Q06, 3Q 23, 2Q07 27 21 March 21/04 ph II PSO arthritis NS, -hz anti VEGF A (bevacizumab, Avastin) IV every 2 W + CT→ Colorectal : 2 trials 1st line stage 4 (+ IFL vs IFL alone) 1st = 900 (100 on FU/A) enrolled 2Q02 : survival hazard ratio 20.3m > 15.6, 2nd 200 is 24 m survival. Side effect HBP. Filed Sept 29/03, PDUFA March 29/04 if priority review: accepted Dec 1st 03. 2nd line & adjuvant ongoing. Dec 1/03 ph II +/- 5FU, 1st line, survival NS, but progression free survival signif ECOG 3200 : Folfox+/- Avastin (Nov 29/04), 2nd line 12.5m/10.7 (but Avastin alone 2nd line < Folfox alone). Feb 26/04 approved 1st line metastatic CRC w/5FU based therapy 2nd line CRC filed Dec 18/ 05. PDUFA June 20/06 : approved June 20 NSCLC (w/Xeloda) only Adeno, ph III; ECOG 4599 1st line, N = 878, init July 01,Taxol/Carbo +/- Avastin. endpoint modified March 8/04. 1st line data 4Q05, or ECOG June 05 : March 15/05 interim survival 12.5m/10.2m (dosing twice CRC).sBLA filed April 12/06 in combi w/Pt based therapy for 1st line non-squamous, PDUFA Oct 11/06 OK. EU

Refiled Dec 19/02. Advis Com May 15/03 (K X 4 !!!); PDUFA June 19/03 But high dose & COGS high. NVS to file CPMP 1H04 Jan 17/06 peanut trial stopped (unsafe test) -Xoma, Serono Oct 5/01 : filing delayed until summer 02 (FDA requests human kinetics → not comparable). Also comparability of manuf methods (XOMA/DNA). Delayed again April 02 (different glycosylation). Filed Dec 26/02 → FDA adv com Sept 9/03 PDUFA Oct 27 FDA OK Oct 27/03 Beware of Sugen/Pharmacia SU 5416 (anti VEGFR2, ph III failed Feb 02 in colorectal because of tox) - ECOG 3200 ph III : Avastin/Folfox 2nd line CRC, N = 590. - Roche ph III N = 1600, 1st line, comparing Avastin/Folfox & Avastin/Oxali/Xeloda $ 46,000 per tmt course 1Q04 (6w) $ 38m, 2Q 133, 3Q 183, 4Q 200; 1Q05 214 (US 203), 2Q05 US 246, 3Q US 325.2 (50% in CRC), 4Q 359, FY 05 1.1 B, 1Q06 398, 2Q 423, 3Q 435, 4Q 490, 1Q07 533, 2Q 564; 3Q 597 Aug 4/04 Dear Dr Letter thromboembolism x 2 May 23/06 AVANT trial to resume, early stage →efficacy(ASCO/00), but 6% fatal bleeding NSCL Asco 03 : Tarceva + Avastin NSCLC


- 50 - printed : 03/07/10 (d/m/y) 08:07


OK Aug 25/07 ph II NSCLC, 2nd line, N = 120 ASCO 06, 6 m survival A/T 78%, A/CT 77%, CT alone 62%. 2nd ph III w/cisplat/Gemzar ASCO 07 : low dose same efficacy as high, more safety ! SCLC : ph II w/RTx + CT N = 29 terminated after 2 traceal fistulas ph II renal K interim (Oct 25/01)→ endpoint reached, enrol. stopped until strategy decided. Ph III 1st line init Oct 03, CALGB 90206 will evaluate TTP, + IFN, +/- Avastin, fully enrol. July 05; N = 700 . Same study by Roche (AVOREN) interim Dec 11/06 PFS signif improved 10 mg/Kg. See ASCO 07 : DNA trial PFS 10.2m vs placebo 5.4 (but Sutent alone 11.8 m vs 6.2) ECCO Nov 05 : data Avastin/Tarceva : bof ? ph III : refractory breast K w/Xeloda, enrol compl N = 462 ,3Q01, data 14/9/02 (tough endpoint TTP↗>50%) → misses TTP, ORR signif, 12 m survival NS. 1st line breast stages III/IV, HER- or Herceptin treated, Taxol +/- Avastin ECOG 2100, ph II/III, N = 722, enrol compl Feb 05.Data April 15/05 doubling of PFS (11m vs 6m), 52% reduction in risk of disease progression or death, compared to Taxol alone, SABCS Dec 05 survival 28.4 m vs 25.2, Filed May 25/06 for 1st line, PDUFA Nov 22/06. DELAY FDA requests independent review of scans, will take until mid 07, then 6 m to approval YE 07. Feb 23/07 CHMP OK for mBC. Aug 25/07 refiles to FDA w/Taxol 1st line (E 2100), ODAC Dec 5/07 NO; PDUFA Feb 25/08 Pancreas : 1st line CALGB 80303, N = 602, Gemzar +/- Avastin, June ²27/06 NS AVITA trial + Tarceva + Gemzar, DB, init July 05, last enrol YE 06 -rFab Hz/VEGF2 (Lucentis, ranibizumab), binds to all 5 isoforms of VEGF A (SmithBarney, May June 05, Yaron Weber) intraocular, ARMD, ph I/II promising (Oct 02), good data Aug 03, 2 ph III ongoing. Filed Jan 2/06, PDUFA June 30/06 : OK; 3Q06 163, 4Q 217, 1Q07 311, 2Q 209 - Tarceva : OSI/Roche : 774, oral anti

ASCO 02 phII: TTP↗ (147d / 41d), no survival diff But 13% neurosensory (taxol 6%), Taxol not approved 1st line Breast, Taxol alone TTP 2.9m, Gemzar Taxol TTP 5.2m → competition Visudyne (IV) Lic ex US to Novartis Lucentis competition : late stage Cand5 (Acuity), Sirna 027 (RNAI/MRK)


- 51 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS EGFR,K,phII∏ASCO 01: H&N PR 6%; NSCLC 24%). July 25/01 : ph III NSCLC + carboplat + paclitaxel (N=330)→ASCO 02; pancreas w/gemcitabine (N=750). - 2C4, pertuzumab, Omnitarg: Hz Mab, interacts w/Her 2-EGFR heterodimerization/trafficking/signalling → ASCO 03 phI, ASCO 04 : "pulled", ASCO 05 ovary (CA 125 drop in 15% pts), breast "limited activity", HRPC (no PSA response) Ovary ph II complete 4Q03 (to reinitiate w/Gemzar end 04). Breast (enrol compl 3Q04; Jan 7/07 fails ??), NSCLC (enrol compl Nov 04), HRPC ph II enrol compl 3Q04. Go/No go 2005 ASCO 07 Pertuzumab + Herceptin not bad, envisage ph III for 1st line - Anti tissue factor (for coronary) IND filed 1Q03, discont for CV Oct 8/03

Phase II/III : - 2nd generation anti CD20 - ALTU 238 retard HGH - anti CD40 w/Seattle Genetics - HAE1 2nd generation anti IgE

Phase I - ABT 263, oral anti Bcl-2, ph I - ABT-869, anti TK-VEGFR, ph I - 3rd generation anti CD20 - anti IFN alpha (like MEDI 545) - apo2L/TRAIL - apomab - BR3-Fc - MEK inhib - Met Mab from Exel (XL 518) - PARP inhib - Systemic Hedgehog Antagonist

DNA M

TANOX (TNOX) Plans $ 400 m plant in Taiwan to manufactute MAbs (Sept 13/01) June 18/02 : Approved in Australia

- E 25 : hu anti IgE MAb for allergic asthma & rhinitis, BLA filed June 5/00;add. data to be filed march 01; adv Com April 25-26 canceled,new data filed;CRL July 01 CPMP was to give opinion 2Q01(but Mut Recog with Germany as reference???). CPMP withdrawn, resub 1H04, accepted Oct 27/05 Could be dangerous if parasitosis. Also thrombopenia

Novartis/DNA 10% R ATS May 24/01 : signif steroid sparing effect


- 52 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Could sell $ 10,000/Year Nov 10/06 acq by DNA $ 0.9 B

?⇑ enrolment halt sept 22/00(lifted nov) - TNX 650 Mab anti IL13, NHL, ph I - TNX 234, pre, dry ARMD

DNDN K V C

DENDREON (DNDN) June 14/03 PIPE $ 26.7m They rearrange the Ags by changing position of epitopes & adding a cassette visible to dendritic cells Major agreement w/Gambro US to use their clinics for cell collection CEO : Chris Henney, cofounder of IMNX. Nov 02 chairman. Gold CEO Feb 26/03 : acq CVAS ($ 73m stock), completed July 30/03 Follow on Jan 27/04 : $ 130m Gleason < 7 = 75% of late stage prostate K ALIVE AT 36 MONTHS

Gleason Provenge Placebo <6 40.9% 28.6% 7 32.1% 11.1% 8 40.0% 12.5% >7 27.3% 0%

Jan23/06, rolling BLA to init mid year Provenge in advanced stages

Proprietary Ags from Prostate acid phosphatase tagged to autologous patient's dendritic cells obtained by apheresis, and reinjected ;5 centres in US, 1 in Japan: -Provenge, Sipuleucel-T (3 infusions in 6 w), PSA ( prostatic acid phosphatase) vaccine(+GM-CSF) →HRPC. 1st, ph III DB 9901 N =127, enrol complete Sept 01 , but failures cross over open to Provenge; results on PSA not bad but not remarkable;. 1st ph III interim Jan 11/02 : time to progression not improved, New anal Aug 12/02 subgroup Gleason <7signif better data. Ditto ASCO Feb 05

provenge placebo p survival 25.9 21.4 0.01 survival G < 7 28.4 22 0.0046 TTP G < 7 0.06 % G < 6 26.8 15.6 % G > 8 39% 44%

- 2nd ph III D 9902B will enroll N = 225 in 12-14m, Gleason < 7;. SPA (special protocol assessment OK June 11/03); Feb 22/05 will open this trial to all Gleason scores (data end 07 - D 9902 A N = 98 HRPC, ITT "encouraging ? survival trend", TTP NS for "all" and for "Gleason < 7". ). July 20/05 : anal of 3 year data NS, but better than placebo. Signif if combined w/D9901 Also ph III in andr dependent : data ASCO Feb 05 PSA doubling time signif increase BLA filed for HRPC Nov 15/06. PDUFAZ May 15/07, ODAC March 07 : safety reasonable (all), substabtial evidence of efficacy (13/4). Also strokes 3.9% vs 2.6%; ongoing new ph III data 2010, PDUFA MAY 15/07 -Mylovenge→myeloma, ph II™ 60% of pts have strong decrease in Ig BLA filing 1Q 03; new ph II w/Thalomid (start Nov 5/01) June 12/02 signif TTP in pts who have immune response, especially IgG pts, but ASCO 02 abstract less good - APC 8024 : breast, ovary & colorectal K, I, ant her2/neu vaccine - acq 2 Ags (CEA & MN for kidney/colon K) from Bayer Sept 26/01 - anti HLA DR patent issued July 10/02 - Trp-p8 gene, overexpressed in K , lic to DNA Aug14/02

Kirin (discont Provenge Nov 14/03), JNJ ASCO 01 ph II (11/12 pts stable 4 months) ASCO 02 Gleason : histol score. 5-7 well differentiated, 8-10 poor differentiation. Feb 23/03, Int Prostate k SYMPO / & CASE W:LONG SURVIVAL Sept 18/02 : <release for Prostate K conf : TTP improved, but NS (p = 0.06) Nov 03 (Prostate K Foundation) Provenge median survival 26.3 m/placebo 19.3 Jan 12/04 : Gleason < 7 : 30.7m/22.3 placebo, p=0.001 Oct 29/04 : 3 year follow up of ph III HRPC (or 36m?), N = 127 (?), survival benefit in ALL pts better than placebo) Not the same population as Taxotere :

Taxotere Mitoxantrone p survival 18.9 16.5 0.0094

issue w/FDA : 2 unapproved therapies orphan drug status granted April 25/02 ECCO Nov 05 3 year data OS 19m vs 15.7 (log rank 0.3; Cox 0.002) Rolling filing init (Clin, Pharmacol) Aug 24/06 for mHRPC, essentially 9901. Completed Nov 13/06


- 53 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - ARF (alternative reading frame) : abnormal peptides produced by K cells used as immunogens : 100% success in mice (April 24/03)

DNDN CORVAS (CVAS) rNIF manufactured by LONZA July 24/02 staff ↘ 40% Acq by DNDN $ 73m Feb 26/03 in stock

-rNIF(neutrophil inhibitory factor from canine hookworm)UK279276, t1/2 7d. anti CD11bI→stroke, ph IIb (N=1000) EU enrol ended Oct 01 (>100 centres), follow up Jan 02. Results mid 02 : April 25/02 failure (more data in June∏ no effect -rNAP nematode anticoagulant protein (anti VII), ph II→DVT,reduces risk 50% versus LMWH (hist)venography. July 01 end of ph II FDA ∏delays. To initiate trials in unstable angina. -oral anticoagulant, anti Xa, PRE - Hep C viral protease inhib compounds, pre⇑⇑⇑ - serine protease inhibs for K , RES, w/ABGX & DYAX

PFE terminates June 17/02 Feb 5/04 lic to Nuvelo ⇑ lic to SGP ∏lic to SGP

DORB DOR Pharmaceuticals, was ENDOREX ( DOR)

- Orbec, Oral beclomethasone tmt of intestinal GvHD, fails primary endpoint ph III ( time to treatment failure) Jan 4/05, but secondary (survival) is OK.To file 4Q05. ODAC May 9/07 : NO; FDA Oct 20/07 approvable -OraSomes : oral liposome delivery proteins/peptides -Oral & transmucosal drug delivery for vaccines -Oral HGH, w/Novo Nordisk, pre -Oral Insulin,pre - Biodefense vaccines (ricin, botulinum)

JV w/Elan

DOVP DOV pharmaceuticals ( DOVP) Ipo filed (Lehman) Jan 29/02, completed April 02 ($ 65m)

- Indiplon, NBI 34060, insomnia, ph III, lic to NBIX ( 3.5% royalty) - Ociplanon, ph II, anxiety, w/ELN - Bicifadine, pain, ph II, w/ELN (bunionectomy), ph III fails April 25/06 - DOV 216303, depression ph I - diltiazem formulation w/Biovail - triple reuptake inhibitor


- 54 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS DPII DISCOVERY PARTNERS INTERNAT.

(DPII), was Irori Summer 06 : to be absorbed (reverse merger) by Infinity (INF will own 69%) CRA is becoming largest shareholder ( Axys has 30%)

Highthroughput screning and services -July 01 Part w/Maxia (partner of JNJ) who has nuclear receptor targets for diabetes II

-Customers : ABT, AMGN, AZN,BI,Bayer, BMY,JNJ, PHA,SGP,GSK,Takeda,AVE - Microcide

DRRX DURECT (DRRX) - exclusive licence for certain uses of Duros - deliver opioids for chronic pain -market a catheter for delivery to inner ear - IFN α for hep C sutained release

spin-off (17%) from Alza lic to BioPartners (Switzerland)

DSCO

DISCOVERY LABS (DSCO) Neonatalogy "Specialty" pharma Shelf March 30/04 : $ 24m June 20/03 PIPE 27.5 m Feb 18/05 PIPE (SGCowen), closing Feb 24 price of other surfactants $ 750 to 1500 per infant Animal derived surfactant sales : $ 200m but large unmet need Adult trials w Exosurf (lipid) and SP-C protein have failed Dec 28/05 acq manuf in NJ ($ 16m) PDUFA April 5/06 Adult ARDS data 1Q06 May 6/08 work force – 34%

-Tyloxapol : COPD, ph II -Surfaxin DTPC + sinopultide lucinactant (21 aa peptide KL4 modeled from human SP-B protein) humanized surfactant →neonatal ARDS, ph III (against Curasurf (Mkt leader EU pig lung from Dey LP)& Survanta ABT Bovine/Beractant), enrol delay from May to Oct 03 (Feb 21/03), East Europe, S. America. Pivotal v/Exosurf (GSK only lipid, synthetic) or Survanta (ABT bovine, US Mkt leader). Ph II to init. neonat. resp failure (aerosol/CPAP) Ph II to init BP dysplasia. data Oct 11/06 death 57.8% vs 65.9% →adult ARDS ph II, endpoint survival or off-respirator at d 28, with segmental lung lavage; Dec 7/04N = 78, mortality 13.8%/20%; but failure of Altana & Exosurf (purely lipid), $ 2B mkt →meconium aspiration ph III -DSC-103S,vit D analogue™osteoporosis, ph I

3 m delay in manuf Dec 23/02 (Akorn) Sumitomo, Taisho US w/Quintiles (regained for warrants Nov 5/04), EU w/Esteve30% royalty (Spain) June 03 : at least equiv to Curasurf. Feb 19/04 FDA puts on "Continuous marketing application Pilot 2 Program for ARDS" div of Pulm & Allergy drugs NDA filed April 14/ 04 (PDUFA Feb 13/05), filed EU Oct 6 04. Feb 1/05 delay due to manuf compliance. Re-inspection. Launch 1Q06? . Feb 14/05 Approvable letter "highly correctable manufacturing issues". Aug 15/05 FDA requests more manuf clarifications, response for Oct 05. Approval hoped for April 06. April 5/06 "approvable" more specifications needed on active ingredient). Manuf delay April 25/06 until 2007. June 8/06 EU filing pulled. Meets FDA 4Q06, to refile Sept/Oct 07 Nov 25/03 RDS related death at D 14 Surfaxin 4.7%, Exosurf 9.6% (p = 0.001), Survanta ABT 10.5% ( p = 0.001). N = 1294 .Against Curasurf mortality d 28 11.8%/16.1% Dec 13/04 pooled data to Survanta & Curasurf p < 0.05

DUSA DUSA (DUSA) Competition : -ALA : Medac (Germany), ESC (Israel), Photocure (Norway)filing EU -PDT : QLT, Miravant, PCYC, Scotia.

-Levulan (ALA, no product patent protection) : ™Kerastick for actinic keratosis, Mkt (3Q00) * bladder K , ph I/II * restenosis, ph I/II

Schering AG. Reimbursement issues. Term June 12/02


- 55 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - BLU U : non laser light source

DVAX V K

DYNAVAX (DVAX) files (B of A)for IPO dec 7/00, withdraws April 01. Raises $ 35m series D April 02 Refiles Oct 24/03 (Bear Stearns, Deutsche) Feb 19/04 raises $ 45m (half of pricing) March 28/06, acq Rhein AG (Ag manufacturer)

- Tolamba AIC( Amb a 1, ragweed Ag), ph II/III init Jan/Feb ,04, N = 462, fully enrolled May 19/04 (Quintiles). Primary endpoint : change in nasal symptoms. purified allergen linked to nucleotides (ISS : immunostimulatory sequences), for desensitization. Fails Jan 8/06 - Inhaled ISS for asthma, ph I AAAAI March 9/03, ph II ongoing - Hep B prophylaxis Heplisav, ph II/III (ph III planned ex US), Ag from Berna. June 14/05 > GSK Engerix in elderlies. Ph III init June 23/05; 400 seronegative adults aged 40 – 70, in SE Asia, vs Engerix. 2nd ph III to initiate EU & CND for younger population.. To file 2H08 - ISS for K : ph II NHL w/Rituxan, N = 30, data end 06 - Vaccines for HIV (W/Aventis) - mCRC 2nd line w/ Campto erbitux, ph I init Dec 5/06

→ Stallergenes lic ww to UCB, returned March 19/05 Sept7/06 $ 136m precl deal w/AZN to move into clinic within 3 years for asthma COPD DEAL : 10m upfront, 17 m research funding and pmrecl milestones. Rest through regulatory milestones, then royalties and could copromote. →Triangle

DVSA DIVERSA (DVSA) Enzyme discovery libraries for Chem, Agro, Pharm lic to IntraBiotics(released from obligations July2/01 DYAX

M

Dyax (DYAX) Also chromatography business part w/ABGX part w/XTL jan 22/01 Staff ¬ Sept 11/02 Patients ww 22,000 Price for Pharming $ 4,000/attack, 7 attacks per year

A key MAb company. Also have drugs in development : --Reltran(EPI-HNE-4),neutrophil elastase inhib (r prot in aerosol) ∏COPD,CF; phII --DX 88,r kallicrein inhib(IV, working on SC)→inflam; phII; JV w/GENZ, hereditary angioedema (EDEMA I & II, data "positive" 2Q04 but N = 48 and randomization 5/1) but Bayer Trasylol did not work.Edema II open label ongoing . "met FDA year end to discuss possible registration pathways based on ph II". Edema III (N =72)SC init Dec 8/05,1st part DB (compl Nov 20/06), then open Approval 2007 ? May 16/06 dose ranging issue delays > 2007. Data April 12/07 OK. Edema IV requested by FDA, to init 2Q07, approval YE 08 ? DX 88 also in CABG (Ecallantide), further only if partner. Nov 6/07 : Bayer terminates Trasylol --antiK f Hu MAbs acq with Target Quest : -scFv anti p21 Ras, pre

.Hold the Ladner patent for phage display (CAT & Morphosys could be dependent) and for scF (CLL could be dependent). More than 50 licensees .alliance w/Bracco. w/DebioPharm - competition : Extractive Esterasine ( Cinryze) Baxter C1E inhib Sanquin in EU (MKT), LEV in US (ph III init 1Q05 for tmt filed July 31/ 07, Nov 05 for prevention to conclude 2H07) -Jerini AG (public since Nov 1/05, Icatibant (decapeptide) antibradykinine, manuf by Bachem (March 18/04), rights acq Nov 7/05 for US by KOS (acq by ABT $ 3.3 B Nov 6/06 ); IV & SC (April 5/04), ph III init Sept 8/04 in US (FAST I fails sept 20/06) & Europe (FAST II OK Sept 20/06), Orphan status. Filed US Oct 8/07 -Pharming Hu.r C1E inhib.in EU rand DB placebo ph III ongoing, , good data Madrid March 15/05. Compassionate ongoing EU. Feb 3/06 Paul Royalties $ 30m for small share of royalties. -ZLB Behring ph III Berinert


- 56 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -F ab anti MUC-1, pre - anti MUC-1 immunocytokine(IL2 conj),pre - phage display peptide for purif. of VIII lic to AHP (May 22/01),also one for HGSI's BLyS - DX 890 depelestat, ph II, Cystic F. & ARDS, rInhibitor of neutrophil elastase (w/Debiopharm).

EBIO

EPOCH BIOSCIENCES (EBIO), Was MicroProbe

Gene modifying oligos (enhance binding to minor groove)

PEB,Aug 18/00, for Taq kits

EBSI EMERGENT (was BioPort) IPO filed Aug 16/06

Anthrax vaccine, FDA approved

ECX K EPIGENOMICS AG (ECX Frankfurt) diagostics for K based on DNA methylation EMBX EMBREX (EMBX) AUTOMATED POULTRY VACCINATION 80% of US MKT EMIS EMISPHERE (EMIS)

This oral delivery is essential : the risk of respiratory side-effects should obviously be much less than with the respiratory route. But for the time being only polysaccharides and peptides have shown bioavailability June 02 : staff reduction 30%

-Heparin liquid: phIII initiated with Quintiles..First ph 3 enrol compl 4Q01 (N=2200), 2nd to start then.Failure May 15/02 : < Lovenox - Heparin solid, ph I -Calcitonin (salmon) : phI successful. Partner Novartis exercised (Feb 00) its licensing option, ph II. -Insulin : was tested in rat model, then PHA terminated. Ph I good data (Sept 7/01); March 5/03 potential partner drops -PTH oral with LLY, but on hold before clinicals. -HGH with LLY. Tested in primates.Ph I init Aug 02 -Oral vaccines are also being developed. -Oral Axokine for Diabetes II→→→→→→→→→→→→ - Oral Daptomycin, pre™™

DuPont for Heparin & LMWH (July 30/00) discont by EMIS (May 2/01) Competition: buccal spray (Generex/LLY), other oral (Nobex/GSK) Regeneron w/CBST

ENCY ENCYSIVE (ENCY) was TEXAS BIOTECH (TXBI) March 21/02 : new CEO from JNJ June 2/06 CHMP OK FDA June 15/07 Approvable

-Novastan (argatroban) ,anticoagulant. FDA approved for HIT june 30/00, filed dec 24/01 for PTCA(approvable letter July 21/01) -Sitaxsentan Thelin,oral, once a day, phII/III, PHT & CHF ph II PHT seems also active in stage II PHT 12 w random 100/300/Placebo. Primary endpoint VO2 reached at 300. 6 min walk distance improved at 300 & 100. PHT halted July 24/02 : Transam ↗& clotting issues… will meet FDA. Feb 14/05 ph III STRIDE II vs/ Tracleer BID vs placebo, N = 246. 100 mg > placebo (p = 0.03) on 6 min walk distance. Filing April 05 : filed May 24/05. PDUFA March 24/06. March 27 : "approvable". June 15 accepted Compl response for review : action July 24 : July 25 : 2nd "approvable". Refiled Nov 5/06 PDUFA JUne 15/07

w/ GSK SASY was for Europe, but terminated in 99 -June 7/01 : 50/50 JV W/Icos endothelin antag. Feb 3/03 TXBI to regain, done April 23/03 -july 11/01 : lic to SGP of oral VLA4 antag, Res ATS May 05 BUT : inhibits warfarin catab, Tracleer increases it


- 57 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - TBC 3711, March 23/06 2nd generation Thelin on hold

ENMD K ENTREMED (ENMD) Aug 8/02 staff¬ 25% Pipe Nov 4/03 : Rodman Dec 28/05 acq Miikana Largest shareholder : CELG

-Endostatin prot : ph I (bad comments Boston Globe, May 12/00), 24/26 tumors increase in 4 months (ASCO/01). New ph I/II init July 01 - ENMD 0996 : FGF 2 vaccine -Angiostatin prot : ph I/II - Panzem, oral, 2Methoxyestradiol, K, myeloma, ph II; inhibits HIF (Hypoxia inducible factor & triggers apoptosis (upregulation of DR5 (death receptor 5), & disrupts microtubules; scheduling key to efficacy. - TFPI peptide fragments, pre, lic to Affymax (Oct 24/04), trying to increase bioavailability w/Elan FROM MIIKANA / - MKC-1 (from Roche) oral cell cycle inhib to init ph II refractory mBC 1Q06, then NSCLC - MKC-1693 aurora kinase A inhib, pre - MKC-1704 HDAC inhib

-

ENVG ENVIROGEN (ENVG) Remediation ENZ

V ENZO BIOCHEM (ENZ) -antisense GT→Aids : ph I

-EHT899, oral™hep B, ph II - oral 14 aa peptide (from HLA B27) for uveitis, ph I June 10/05 - oral Ag for Crohn, ph I (Israel) -sales of reagents for genomics & sequencing

-good data CD4 still express after 8 months -good ph I data (oct 31) AASLD & ph II (oct 12/01) OK

ENZN M

ENZON (ENZN) The one stop shop for pegylation due to relationship w/INHL & Shearwater -May 23/01 : new CEO (A. Higgins), former President of ABT pharmaceutical division. -Complex litigation SGP/ENZN/ROCHE/Shearwater (who nevertheless has "manufacturing role" in ENZN PEG!);SETTLED (Aug 13/01, will share royalties) -May 22/01, INHL acq Shearwater, key PEG competitor of ENZN

-PegIntron (12kD)™Chronic hep C, E.U. approved May 30/00; filed FDA Dec 23/99→approval jan 22/01 PEGIntron +Rebetron alone NDA filed feb 6/01(priority rev. March 23/01)∏approved Aug 8/01,launch Oct 4/01 PEG-Rebetron EU approved March 27/01 Dig Dis Week (May 01): PEG Rebetron improves Hep C in 35% IFN non responders. Synergy w/Lamivudine in Hep B (May 02) ASCO 01 Efficacy of PEG IFNs not > to IFN in K, but melanoma ph III ongoing Jan 14/ 02 : SGP capacity for IFN plateauing. Seems overcome (Feb ½)

SGP( royalty 7.5%) EASL(May 01)™HCV efficacy=Pegasys : -Roche Pegasys (40kD) filed FDA May 23/00(but questions May 27/01∏filed Pegasys bioequivalence April 15/02. Oct 17/02 Pegasys approved US Hep C; priority review granted for combi with Copegus, Adv com OK on combi Nov 14/02, FDA OK Nov 4/02. EU Pegasys approval March21/02 & Copegus (Ribavirin like) Sept 18/02. See my ENZN file for Rebetron


- 58 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Aug 21/01 : first year of profitability INF α generics : Retard SkyePharma & GeneMedix ( GMX/LSE, SGX) which sells GMCSF in China, could be approved 2007, Sicor (SCRI) is selling in East Europe. Feb 18/03 US IFN α manuf patent issued to Roche ( → 2019) Feb 20/03 : to merge w/NPSP. Term June 03Profitability delayed to 2006/7

- PEG secretin for cystic fibrosis IV, without PAG in ph II (Pharmagen UK) - Abelcet (US) acq w/sales force (60) & facilities from ELN Oct 2/02 ($ 370m), 2002 sales E $ 80 m. in Europe, but US small - Prothecan (Peg camptothecin)ph I∏phII (July 25/01), NSCLC, pancreas, gastric - Peg-Paclitaxel (Taxol), ph I, without Cremophor. Term Jan 3/03 - CDP 870 pegylation Molecules from SCA ventures (wholly owned subs)™ - scFv s - PEG scFv s, w/Micromet AG (April 12/02) has linker & fusion patents - rhMBL (mannan binding lectin) from NatImmune A/S for infection in deficient patients - anti – survivin oligo, pre, lic from Santaris, July 27/06 - HIF antag for K, IND filed Jan 7/07

lic to Alexion(phII), CEGE, CAT, BMY, LLY,MOR, Baxter, Aventis, Seattle Genetics

EPCT IPO Epicept (EPCT), filed Jan 10/05 Wachovia, traded, acq MAXIM

Lidocaine patches

EPCT K

Maxim Pharmaceuticals (MAXM) to become Epicept (EPCT) Aug 11/00 : Roche collab for Pegasys + Maxamine hepC & K April 13/04 FDA permits recovering costs for compassionate use w/IL2 "most critically ill melanoma", while ph III is completed (N = 230, enrolled Sept 03, NDA filing 1Q05. Sept 20/05 fails to meet survival endpoint. Filing withdrawn Oct 18/04 : halves staff Sept 6/05 : to be acq by Epicept ($ 136m)

-Maxamine/Ceplene (histamine HCl2), increases expression of CD86 (CTL trigger) (AACR, March 01) -with IL2→phIII,melanoma,filed July 19, sept 8, priority review granted Dec 13/00 ODAC negative because of biometric imbalance in 305 pts DB™class action suit. Jan 20/01 : non-approvable letter from FDA, they are not content with 1 single study,new ph III ongoing, results end 01/1Q02. 4th ph III init Jan 02,enrol + follow up 3y EASL (april 20/01), 72 weeks data for hep C, but only historical comparison, no impact on stock -AML, ph III, completed (oct 9/00) : N = 320 +IL2. Only

enrolled pts in CR. Controlled versus no tmt, 18 months, TT relapse > no tmt, p = 0.026 (they should have received maintenance tmt)

2007 : seeking EU approval remission maintenance AML -with Ribavirin+Roferon™hep C, �hi good @AASLD -oct 13/00 : precl . activity on sarcoma - TIP 47 : IGF II receptor binding protein, precl - Lidopain SP ph IIIEU trial data 2Q06

ASCO/00 : IL2 alone™187 days survival + Maxamine™355 days survival. Oct 01 : 24 m

follow up : p = 0.003

June 14/03 : improved QOL in meta melanoma

Say (Sept 22/03) will file CPMP melanoma Nov 03

Nov 10/03 files EMEA data refused in US in 01 (2

year survival 18.2%/IL2 alone 2.7%). To withdraw.

AML : ASH 04


- 59 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS EPIX EPIX (EPIX)

-Current MRI contrast mkt $ 400m (Schering 50% w/Magnevist, Nycomed 30%) -Potential mkt : Xray angiography mkt : 2m pts/Year. MRI is less invasive. Aug 06 : merger w/ PREDIX

MS 325 : MRI vascular enhancer (moiety binds to albumin),ph III;enrollment by end 01; submission 2-3QO2 delayed until 1Q03 to include broader peripheral indications ACC March 02 : 1 of 4 ph III compares MRI w/ & wo/325 to angiography. w/325 ; 88% "accuracy", but p?, and "indication on tmt course" 84%. From PREDIX : - GPCR w/GSK Jan 4/07 (upfront 30m, up to 1.2B). Alzheimer - S1P1 modulators w/AMGN

-Agreements with potential competition : Mallinckrodt will manufacture, Schering will distribute (and EPIX has rights to SCH 555C and Gadinex 17 that Schering developed for vascular imaging) - license of 2 patents to Bracco (Sept 01), upfront $10M

EPTO EPITOPE (EPTO) Oral screening tests for HIV & Nicotine sells to insurance companies merged w/STC⇑OraSure

ERGO ERGO SCIENCE (ERGO) oct 16/00 : 3 Board members resign March 24/01 : delisted

Bromocriptine failure in diabetes

ESPR ESPERION THERAPEUTICS (ESPR) CEO (Roger Newton) codiscovered Lipitor at WLA PIPE (July 26/01) Dec 22/03, PFE to acq for $ 1.3B

Products licensed from PHA, Inex, etc -The concept : statins lower LDL (bad cholesterol). ESPR seeks drugs to increase HDL (good cholesterol). -The molecules : for the time being more like cholesterol scavengers : -rApoA-1 Milano (lic from PHA)™phI. -proApoA-1, ph I, IV -LUV, ph II, IV:large unilamellar vesicles (empty liposomes) : results 4Q01 -RLT (reverse Lipid Transport)22 aa peptide :pre -ESP-A :small molecule HDL elevating agent,Res.

→could be IP issue w/Cidars Sinai Med Ctr (LA) who use AAV Apo A1-Milano →patent from Region Wallone expires in 2008

ETRX ESSENTIAL THERAPEUTICS (ETRX) was MICROCIDE (MCDE) Top management experts in ABs from SGP, PHA, Acq. Athexis* ( Aug 01) that was involved in Zithromax discovery

-Cephalosporin, ph I , injectable - oral cephalo, pre - Efflux pump inhibitors for bacterial & fungal resistance,

pre, potentiate Quinolones & Azithro. - Rhinovirus protease inhibitor - MARstem , small molecule peptide analog, bone marrow

stimulator, phI/II.

JNJ Daichi ICAAC 01 : 19 abstracts

EURX IPO EURAND (Italy, Holland) Drug delivery Many partnerships


- 60 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS founded 1969, traded May 17/07

- Zentase, EUR 1008, porcine derived pancreatic enzymes, 2 ph III completed. Rolling filing init June 12/07.

Competition see ALTU

EVC EVOLUTEC Plc (EVC / AIM) - r EV 576, C5 inhibitor, pre - r EV 131, ph II antihistaminic - r EV 131 ph II, cataract surgery

EVSC ENDOVASC (OTC BB : EVSC) and its fully owned subsidiary Angiogenix

Liprostin (liposome PGE1) successful ph II in PAOD, ph III for 05

EXAS Exact sciences (EXAS) IPO filed oct 27 (ML) trading since jan 31/01 Will outsource manufacturing. Can sell under "home brew" reg" Strong IP situation

Genomic detection of colonic K in stools (detection of microsatellite deletions caused by mutations in genes of mismatch repair, and loss of heterozygoty), more sensitive than occult blood or sigmoidoscopy, less invasive than colonoscopy PreGen 26 : available in US since June 1/01; full launch Dec 01 by LabCorp; lic to LabCorp June 27/02

Trials at Mayo Clinic and Johns Hopkins, will initiate blinded multicentre trial (5300 pts) 4Q01 11 abstracts at DDD (May 19-22/02= CEO Myriad says "excellent test, but positive later than Myriad's Colaris, which detects predisposition to colon cancer" Good papers : J n. can. inst June/01,NEJM Jan 3/02, but success rate of detection only 57%)

EXEG EXEGENICS (EXEG) Drug discovery: - OASIS : patented software to design antisense - research on mycothiol depletion to fight resistant TB

EXEL K

EXELIXIS (EXEL) Chairman St Papadopoulos Sept 4/07 major collab w/Dow Agro June 14/03 : shelf 10m shares ($ 75m) Sept 8/00, acq AGTO Nov 20/01, acq Genomica Oct 29/02 w/GSK upfront $ 30m, stock 14m (premium x 2), dev funding $ 90m on 6 years, loan facility $ 85 m, milestones $ 220-350 : collab to dev theraps in vascular, inflame & oncol using Exel drug candidates (XL 784, 647, 999, 844, 9820, 2880, 6309, 2942) RISK : GSK returns May 23/01 : partn. w/PDLI: targets for MAbs

-Functional genomics - Antisense partnership w/AVII (April 01) -Drug for Alzheimer : pre (lic to PHA) -Insecticide($ 10 B mkt) Discont April 3/05 - XL 119, becatecarin topoisomerase II inhib, DEAE analogue of Rebeccamycin(from BMY) , bile duct K ph II, data Feb 03 Paris Conf on K , N = 20, maybe safe & effective. Enters ph III June 23/04 versus 5FU for 3 years, SPA, survival w/interims 05/06.. Not for GSK. Lic to Helsinn (Ch) June 10/05 - XL 784,ph I,oral, targets cell surface Adam10 metalloprotease involved with growth factors, to be developed in renal & cardiac failure. Ph II in diabetic proteinuria -XL 647.ph II,inhibitor of EGFR/Her2neu/VEGFR2/EphB4 (Ephrin B4, highly expressed in Breast cancer), ,Aug 06 ph II NSCLC 1st line, adeno with activating mutation or Asean init. July 26/07 GSK opts out. EXEL says data was OK (could be worried w/Tykerb approved March 07). Interim ph II Seoul Sept 5/07 Int Assoc Lung Cancer : N = 30, ORR 60%, QT

BMY ( from 2001, Dec 18/03 extended $ 100m), PHA. for Ser/Thr kinases in PTEN & Caterin pathways → ASCO 03 : Bil K first line, N = 30 survival 8.8 m, double of historical ! Bile duct K incidence US + EU 15 to 20 000/Y. Orphan Drug March 15/04 ASCO 04


- 61 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS elongation 81% - XL 999, multiple Receptor TKs inhibitor., ph II, suspended Nov 2/06 : cardiac; but not bad NSCLC & AML : ASCO 07 - XL 9820 anti cKIT - XL 844 anti check point kinases I - XL 880, ph II gastric, H & N, RCC, anti Met & VEGF R2 TK. Eval for GSK from Sept 14/07, then 90 days to Dec 14, precl active BC, CRC, NSCLC, GBM - XL 228 IND filed Aug 3/06, Kinase inhib of ILGFR, Src, Abl - XL 418, pre, anti AKT - XL 518, anti MEK RAS pathway, IND filed Dec 20/06, lic to DNA Dec 22/06 - XL 281, ph I, anti RAF kinase - XL 281, ph I, anti RAF kinase - XL 147, anti PI3K, IND filed March 16/07 - LXR (liver X receptor) agonist, precl, lowers cholesterol, w/BMY (Dec 6/05) - FXR (farnesoid X receptor, nuclear hormone receptor) drug w/WYE Dec 22/05 - XL012, oral JAK2 inhib, IND filed May 24/07

XL 518 : other MEK inhibs ARRY 438162, ph I, PFE PD-325901, ph II; Ardea Biosciences

FHRX First Horizon Pharma (FHRX) A "Specialty Pharma company" with 14 marketed drugs. Acquired on April 14 from WLA : -Ponstel (NSAID), but how will they manufacture it -Cognex : the Alzheimer drug nobody uses since Aricept (PFE)

FLML FLAMEL (FLML) See EUROBIOTECH FMVR FERMAVIR (FMVR OB) CF 1743, shingles, development candidate

owns patents for compounds varicella-zoster, CMV

FOLD IPO Amicus Therapeutics * CEO Crowley's 2 children have Pompe. He founded Novazyme files for IPo May 17/06 (AMTX), withdrawn summer 06 Priced May 31/07

Treatment of protein mis folding of chaperone with oral small molecules (deoxynojirimycin derivatives) - AT 1001,Amigal, migalastat, ph II init Sept 8/05, Orphan status, Fabry. Enrol compl March 07, digestive tox - AT 2101 (Plicera, isofagomine)Gaucher, ph II init March 07 (might only be for pts with high residual activity), data 4Q07 - Pompe AT 2220 ph II init Dec 14/06, to file end 07 (?)

Fabry good data 42nd annual sympo study inborn errors of metab. Paris. Sept 5/05 Other misfolding firms : FoldRx, Reata Pharmaceuticals


- 62 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS FVRL IPO

K

FAVRILLE (FVRL) filed April 04, traded Feb 2/04

- Favid : biopsy, identify unique idiotype gene, manufacture patient specific recombinant protein conj. to Keyhole limpet hemocyanin (KLH) to vaccinate with associating GM-CSF; NHL, ph III since July 04, enrol compl Jan 06. Interim Nov 13/06 : failure

ASCO/ASH 06 ?

GCOR GENENCOR INTER (GCOR) Partn. w/Dow Corning : "Silicon Biotechnology". J.J. Bienaimé CEO Nov 02

-Biomaterials -Genetically modified enzymes - VP 22 technol acq from Phogen (Aug 01)

PG

GEN K GENMAB (Copenhagen) Nasdaq GNMSF MEDX 20%; sell 5.1% on Feb 16/07 (now have 11%). Same day Goldman Sachs sold 2.6 M shares Serono 6.7%

Fully human Mabs - MDX-CD 4, HuMax CD4, Zanolimumab RA, phIII initiated 02. Ph I/II T cell lymphoma ASH 06; Ph III CTCL w/Serono. Returned Aug 1/07 HuMax-CD4™PSO, ph II, now (2006) seems reserved for non cutaneous T cell lymphoma (very rare). June 30/07 Serono returns - anti IL15, pre, PSO w/IMNX/AMGN anti IL15, ph I/II, RA w/IMNX/AMGN, Sept4/02 26% reach ACR 70 (Enbrel : 15%) anti IL15, pre, NHL w/IMNX/AMGN now AMGN has put it back (AMG 714) into preclinicals - Anti EGFR, Zalutumumab (ch, IgG1), claim activity at 0.125 mg/QW. Ph III init Sept 14/06, N = 273, 2nd line H & N vs BSC. Primary endpoint survival (Erbitux only had ORR, nope : since Oct 2/07 OSapproved). 1st line H & N ph III Sept 07, to potentiate RT - Hu CD 20 ofatumumab. Dec 19/06 lic to GSK (2.1 B upfront 102), depletes B cells more than Rituxan Efficacy independent of levels of expression of CD 20 (so they say). Strong action on C', Sept 7/07

ph III CLL refractory init May 06 ph III NHL init July 10 06, N = 162, refractory to

rituxan, endpoint ORR Cheson criteria (clinical, lymph nodes, BM)

RA ph II (side-effects, see CIAO Med). Ph III in MTX refractory, & in TNF refractory, to init 1H08 EU

- MDX 018, ph I/II glioblastoma init Sept 13/07. IgG1 anti IL8. Will also go to COPD


- 63 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS GENR M GENAERA (GENR)

was MAGAININ (MAGN) Aug 11/02 staff ¬ 35%

-Squalamine(antiangiogen.)→NSCLK w carboplat & Taxol, ph II N = 90, good data nov 16/01. Jan 28/03 enrol halted at N = 40 to economize. Will analyze at mid year for response, ph I/II ARMD. Terminated Jan 4/07 -anti IL 9→asthma, PRE - Produlestan (also aminosterol),obesity, pre - Lomucin MSI-1995,oral, blocks respiratory mucus overproduction, ph II. Good data Oct 03.

ASCO 03 NSCLC N = 45, ORR 23% Genentech(May 2),returned dec 18∏w/MEDI (april22/01)


- 64 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS GENZ A

K

Genzyme General (GENZ) Fabrazyme. ADV COM Sept 26/02. IgE or not ?? → POSTPONED→ Jan14/03 “ near normalization of renal capillary endoth is likely to predict clinically meaningful effect”. Ph IV (18m) required on “prolongation to time to deterioration or death”. Genz disagrees on design, wants blinded but not placebo.

PDUFA April 23/03, approved April 23 (ph III DB N = 58). ORPHAN If ph IV (to complete Jan 04 not +, could be removed !) Prices : - ceredase : 150-175 000/y - Fabrazyme : 180 000 - Aldurazyme : 175 000

Patients : Gaucher : 1/10 000 ashkenases

(3200 pts treated ww) Hurler : 1/100 000 all

Fabry : 1/40 000 caucasians Pompe :eastern world : 1/40 000

COGS Myozyme 20 000/200 000 Sept 22/03 : 11% of CAT w/Myosix (France) ph II, myoblast transplantation (Ph Menasche)

- Ceredase/Cerezyme recomb (imiglucerase) US patents 2010/2013 : $ 479m/99; 537/00→ Gaucher 570/01, 619/02; 03 guidance 655; 1Q03 167.2/2Q 184.7, 3Q 189, 4Q 198; 1Q04 203; 2Q 209.4, 3Q 208.4, 4Q 219, FY 04 839, 1Q05 226, 2Q 236, 3Q 238.3, FY 05 932; 1Q06 239, 2Q 254, 3Q 252, 4Q 262, FY 06 1B, 2Q07 283, 3Q 286 Thyrogen :3Q03 : 11.4 m; FY 03 : 43; 2Q04 16.3, 3Q 15.4, 4Q 18, FY 04 63, FY05 78; 1Q06 23, FY 06 94, 1Q07 264, 1Q07 28.2, 3Q 26.8 - Fabry (Pain ?)Fabrazyme agalsidase β (CHO) BLA filed june 26 (TKTX june 19!),CPMP OK March 28/01, w/slightly better labelling for Replagal (TKTX),EU approval Aug 01 priority review granted (⇑dec 26/00 FDA requests additional data ,given April 19 /01 and initiation of ph IV on clinicals renal, heart, CNS, N = 82),sold in France (was ATU).1mg/kg Infusion 180 min. >95% clearance of GL3. Pain improvement same as placebo. $ 6 m/01, $ 26 m/02. 1Q03 11.8/2Q 15.4, 3Q 21.5 (6.5 in US), 4Q 32; 1Q04 38.1 (US 15.8), 2Q 49.6, 3Q 58 (US 21.9), 4Q 64, FY 04 209 1Q05 70, 2Q 74, 3Q 79.1, FY05 305; 1Q06 81, 2Q 89, 3Q 93, FY 359, 1Q07 101, 2Q 104.3; 3Q 105 - Hurler MPS1(intelligence ?), Aldurazyme w/Biomarin,PhIII;enrollment completed march 4/01. CHO. 2Q03 : $ 1.1 m, 3Q 3.4, 4Q 6.7; FY 11.5; 1Q04 7.3, 2Q 9.2, 3Q 10.3, 4Q 16, FY 43, 1Q05 16, 2Q 19, 3Q 20.1FY 05 76.2; 1Q06 21, 2Q 23.5 3Q 25, FY 06 96.8, 1Q07 28.8, 2Q 29.1 - Hectorol : 1Q06 19, 2Q 22.4, 3Q 25.5, FY 06 93, 1Q07 28, 2Q 27.3; 3Q 30.3 -AT III , w/GTC Biotherapeutics (mainly EU mkt $ 250m?) filed EU Jan 26/04 - Myozyme(CHO from Synpacdiscont April 17/02, will use in-house product) :phIII started april 2/01, ph II efficacy data on heart size (oct 5/00, in 3 pts)+++ Myozyme α glucosidase for Pompe, 2 studies init 1Q/2Q03. Enrol compl 2H03. Filing ASAP. To start observational study (n = 60), then placebo controlled. Also special access programs. Filed Dec20/ 04 EU CHMP OK Jan 27/06. filed US July 29 05 PDUFA JAN30/06 delay 3 m. 3Q06 20.4, ,FY 06 59, 1Q07 37.9, 2Q 46.7; 3Q 53.6 -CAT 192 human Mab (anti TGF β) for scleroderma , ph I/II NS (Feb 9/04), gender issue.

Patents : process 2010, composition 2013 TKTX to file IND for generic (early 04) sept 8/01 ph III efficacy p < 0.001, GENZ sues TKTX Genz says Replagal & Fabrazyme are "very structurally similar and funtionally equivalent" Are there IgE Abs to Fabrazyme?? Trial against Replagal in Holland (not by Genz) → see BMRN (50/50 JV),Rolling BLA compl Jul 29/02. CPMP filed March 2/02. 2 new ph III to init. PDUFA Jan 28/03→ CRL answered, FDA to act < April 30. OK April 30/03, shipped May 15/03. EU OK June 11/03. FDA & EU want 100pt posr mkt trial Launched Scand, Deutsc, UK, F. EMEA filing Jan 26/04 JV w/Pharming, entirely GENZ (Aug 26/01)

Competition from Novazyme*; acq Aug 7/01!!($ 137m)

Aug 07 Myozyme manuf issues


- 65 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS May 4/05 acq Bone Care BCII ($ 600m), doxercalciferol IV/Oral (Hectorol) sales around $ 75 m/y. Aphios has a non toxic vit D for cancer prostate. Sept 28/05 collab w/RenaMed renal epithelial cells in hollow-fiber cartridge

GELTEX PRODUCTS -Renagel (sevelamer, polyallylamine) : $20/99→ 55/00; →177/01(due to inventories).2Q02 : $ 39.5 (-4.4%) 2002 : 156; 2003 guidance 240. 1Q03 58.8, 2Q 66, 3Q 75.5, 4Q 82; 1Q04 83.5; 2Q 87.6; 3Q 93.3, 4Q 99; FY 04 364 1Q05 99, 2Q 101 , 3Q 106.9, FY05 417; 1Q06 119, 2Q 126.6 3Q 134.7, 1Q07 137.4; 3Q 154 . Open label ("treat to goal")ph IV, N=202, less aortic calcif. (EDTA June 26/01 then ASN Nov 01 : coronary calcif score lowered, but groups not comparable on initial figures). New large trial initiated but concluded 0ct 12/01 cause results so good!!??. New trial again, mid 03. Many agreements with dialysis clinics (Gambro Feb 4/02). Metabolic acidosis (ASN, Oct 01). Also sold in EU– GENZ 29 155 : MS, ph I -Cholestagel/Welchol(cholestyramine-like) : NDA approved May 30/00 -Clost. diff. Tolevamer: ph III DB Vanco, ph III init April 2/05. Fails July 07 - DX 88 antikallikrein (JV w/DYAX), Ph II, HAE..Discont.

FDA (Sept 14/01) : misleading promotion Pr Fournier (oct 01) : really effective doses are 12 x400/d & give digestive issues. Calcifications are linked to too much vitamin D and not Calcium salts, and to vascular causes. AMGNs calcimimetic could be interesting. April 18/03 Problems w Renagel/Phosphate trial, extended to 2005. -lic to Sankyo/Parke Davis

GENZ M

Genzyme Molecular Oncology (GZMO) Very large in-house Ag discovery program

-Melanoma vaccine(Ad MelanA/Mart1+gp100 : ph I/II -aaATIII (antiangiogenesis),shape modified : PRE -p53 gene therapy : ph II, lic to SGP

ASCO 03 (retinal issues : hypopigmentation ?)


- 66 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS V -Breast, renal & melanoma : patnt specific vaccine

Kcell/Dendritic electrofusion,phI/II (Donald Kufe licensor) : breast ph I OK ASH 01, RCC init 2003 DIAGNOSTICS GENE THERAPY w/Aplied Genetic Technologies Corp (May 05) AAV - Alpha 1 AT ph I - Pompe, pre ? - Lebers's congenital amaurosis, pre ?

ASCO 02 w/Purdue to manufacture MAbs w/Kirin (Nov 01, ditto)

GENZ GENZYME BIOSURGERY (GZBX) merger of Biomatrix,Genzyme Biosurgery & G.Tissue repair Feb 8/05 acq Verigen AG (MACE : matrix induced chondrocyte implantation) on sale in EU & Australia since 1998.

-Carticel : annual around $ 20m (not on EU mkt) -Seprafilm, Sepracoat 3Q03 : 12, FY 04 61.6, FY05 68, FY 06 85, 1Q07 23; 3Q 26.4 -AdHIFα (hypoxia inducible factor : turns on VEGF expression) gene therapy for myocardial neoangiogenesis, phI A.H.A. Nov 03 limb survival rate 67% (expected rate 50 to 65%), BOF! From Biomatrix : -Synvisc™O.A. knee in US & hip in EU (ph III in US) ,MKT in US by WYE (all rights regained Nov 5/04 upfront $ 121m), to reach $ 270m in 03 (for Genz : 90/02; 2Q03 : 29.6, 3Q 29.8, 4Q 26m; 1Q04 22.4, 2Q 27.5, 3Q 24.6, 4Q 15; FY 04 88.3, 1Q05 44 2Q 59, 3Q 57.5, FY 05 219: 1Q06 53, FY 06 234, 1Q07 54

s competition Supartz (Smith& nephew), Hyalgan (Fournier Sanofi), Arthrease JNJ (filed) , Ostenil (TRB Chemedica UK, bacterial fermentation), Durolane (bacterial, 1 single injection for OA, from Q-Med Sweden), ph III Anika

GENZ M

SANGSTAT (SANG) New strategy announced on oct 16/00 : efforts much more on Thymoglobulin than on Gengraf $ 15M in PIPE (June 22/01) Dec 29/01, files for $ 100m secondary July 30/02 : Novartis seeking court order to have ABT withdraw Gengraf

-SangCya, MKT, oral solution bioequivalent to Neoral , withdrawn (bioavailability¬ w/apple juice). Settlement W/NOV does not concern capsules. -Gengraf (neoral capsules )FDA approved may 16, sales by ABT disappointing (<$50m/Y), generic (Eon) price pressures. For Europe, MCA application was to be withdrawn & replaced by new formulation mid-01. Sales 2002 $ 37m -THYMOGLOBULIN(rabbit) : mkt, $ 60m/01; 80/02, 2Q03 : 15.4 US + (EU + ROW = 9) 4Q 03 25; 1Q04 25, 2Q 25.3 (w/Lympho) 3Q 28.3. 4Q 30, FY 04 109, 1Q05 27, 2Q 33.6, 3Q 32.4 , FY 05 128; 1Q06 33 , FY 06 150; 1Q07 39Head to head Simulect (NOV) data March 15/02 :

⇑ discont N° 1 generic (16%MKT share, $29m/01, EON has

11%) ABT


- 67 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Aug 4 03, being acq by GENZ, Aug 13/04 $ 600m Partner w/THP (Therapeutic Human Polyclonals). Rabbitt polyclonals. Are they human or humanized (CDR grafting) ?claim to have transgenic rabbit w/human polyclonals. But Hematech (acq by Kirin July 25/05) has very good technique in cows (chromatin transfer, also used by genetic Savings for cloned cats) knock-out Ig genes in calves fibroblasts, knock in human genes (with HAC human artificial chromosomes vectors). Other Hu polyclonal see Nabi. See also AVIDIA, with avimers, proteins with multiple binding sites

stopped as efficacy x2.5, but open. -ABX-CBL(m anti CD 147), ph IIIGVHD, lic from ABGX ; TERM FEB 17/03 -ABX-RB2(f hu anti CD 147), pre, from ABGX -RDP-58 : small oral (not absorbed) peptide TNF synth.

inhib (& inhib IL12 & γ IFN), ph II ulcerative colitis April 9/03 > placebo; ph II Crohn (Oct 01) April 9/03 < placebo. Also ph II in EU. CT induced diarrhea kept by GENZ

July 12/01 part w/Synt:em for 2nd generation RDP 58 Lic to PG April 1/04 $ 10m upfront

GENZ M

ILEX ONCOLOGY (ILXO) Deficiencies in Campath file noted by FDA; response filed June 27/00→ODAC dec 14/00 : OK by 14/1, the negative vote from FDA biometrics. This is an open trial in 93 pts (PR 31%, CR 2%), with high rate of side-effects & drug related deaths. Acq by GENZ Dec 22/04 Competition : - Cytarabine (araC, cytosine arabinoside), neuro hemato tox, 25% CR pediatric AML - Fludarabine (Fludara Schering), 13% CR, annual sales € 150m - Cladribine (Leustatin, chlorodeoxyadenosine), JNJ, only ind in Hairy Cell. Limited activity in AML (ASCO 03) Clofarabine & Cladribine have mitochondrial tox - Nelarabine (Novartis), ph III : 50% CR in ALL ( ASH 03) - ARRANON (GSK) approved Oct 04

-Campath(hz antiCD52), alemtuzumab IV inf TIW→CLL,BLA filed fast track Dec 99(but June adv comcancelled) , EU(03/01)OK for "use in exceptional circumstances", FDA ditto May 7/01 .(sales 01 around $ 30 m; 02 : 44m; 2Q03 : 28.3; 3Q 16.1, 4Q 18.4, FY 03 71.7, 1Q04 21.1, 2Q04 17.2, FY 06 42.7; 1Q07 18 Ph III N = 284 CLL 1st line vs chlorambucil. Enrolled June 23/04 - ILX 651, ph I, tubulin active pentapeptide analog of Dolostatin (anti K from sea hare), ph II melanoma init Oct 8/03 (19 sites); HRPC init June 17/04, NSCLC - NMR 3, oral anti VEGF - Clofarex IV , Clolar (clofarabine CAFdA chloro-arabino-fluoro deoxyadenosine), , from Southern Res Inst., lic ww to Bioenvision (EU & NASDAQ BIVN) who lic US to ILXO. ph II, AML. April 2/03 : EU Orphan Drug designation. Oct 23/03 init rolling filing for refractory pediatric ALL/AMLfinalized April 1/ 04, then delayed to add cases up to 84 (CR in AML still 0) .,Pivotal ph II of 40 ALL, 30 AML; ORR ALL 31% (10CR), AML 26% ( 0 CR) But 50% of responders in ALL & AML were NOT refractory. Ph II AML "older

lic to Schering AG (Berlex), JV w/LeukoSite (acq by MLNM), lic ww to Schering Feb 5/03. March 13/03 ILXO gets all non K rights →MS ph II against Rebif (5 days/y) init Jan 03( rand, open, on "disability", N = 240, fully enrolled April 22/04.. Suspended Sept 05 3 cases ITP. 1st ph III vs Rebif Sept 21/07 Nov 9/05 ODAC to check commitments ASCO 2004 & AACR March clofarabine 3 ph II posters ASCO 2003 (28% ORR, N = 39, open label) ASH 02 : active (MD Anderson) in multirelapsed ALL (17) & AML (8) children : 5CR & 3 PR→Ph II update at ASCO 04 : N = 40 ALL (10% ORR), 29 AML (1 CR). Active in failures of fludarabine or cladribine Lic to Serono & Ivax for MS (oral): Mylinax See BIVN ODAC Dec 1/04 (9/6 OK ALL, 14/1 NO AML), PDUFA Dec 30/04 50 to 60% febrile neutropenia


- 68 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS adults" N = 25, May 20/04 : 9/14 pts with drug alone have CR. US launch May 14/05. FY 05 : 12.4, FY 06 17.3; 1Q07 4 -Eflornithine(ornit.decarb.inhib)→bladderK,phIII, fails Jan 15/04 -ILX-295501→NSCLC, ph II

Median overall survival ALL 8w, AML 14w FDA OK 3rd line pediatric ALL Dec 28/04 (VION is going into ph III for refractory AML)

GENZ K BIOENVISION (BIVN, was BIV) Secondary $ 60m Feb 3/05 to launch Clolar in EU June 07 : being acq by GENZ, acq Oct 21/07

- Clofarex EVOLTRA clofarabine for Europe (see ILXO for US) has ww rights from Southern Res Instit., Filed EU Aug 21/04. Pivotal ph II init EU AML, Aug 10/04. Aug 05 responded to questions : EMEA action Oct 05. Oct 13 EMEA wants more safety data. Feb 23/06 OK 3rd line pediatric ALL. EU OK May 31/06. AML ph II non rand filed 2007, questions end May ? US Clolar sales 3Q06 4m AML adult data pts unsuitable for intensive CT ORR 67%, Europ Hemat Assoc June 6/05 Clofarabine gel PSO ph I - Modrenal (trilostane) approved UK refractory breast K, ph II prostate init Sept 20/04 - Gossypol (from cotton plant), ph I, prostate, bladder - Oligon, anti-infective catheter (Ag, Pt, C impregnated), FDA approved.

GENZ AOM ANORMED (AOM/TSE & AMEX) Aug 31 06, GENZ bids $ 380m Sept 26 06 MLNM bids $ 515 m Oct 18/06 GENZ OK 580 Good SAB offering closes Dec 8/05 Licensor of Fosrenol to Shire April 18/06 : Onyx VP CMO elected to Board June 06 : why did they spend $ 7 m to change the Board GENZ (Aug 1/07) estimates peak sales at $ 400M)

- AMD 3100 Mozobil Plerixafor ,small molecule inhibitor of binding of SDF 1 (stromal derived Factor 1) to CXCR4. Potentiates release of CD 34. Ph II w/G-CSF signif, ASH 2004, ph III w/GSF vs GSF alone enrol end 06. Top line data 2Q06 MM, NHL. Filing 2Q07 to 2H07 (Oct 23/06). Aug 2/07 ph III in MM & NHL doubling of HSC collected - AMD 3100 Mozobil IND for heart attack filed April 3/05 - AMD 070, ph II, HIV, small molecule anti CXCR4 chemokine receptor, HIV - CCR5 HIV entry inhib, precl - CXCR4 inhib, precl

- CXCR2 : Grosß (Growth regulated oncogene). Very

active mobilizer of stem cells (even CD34-), precl, but also

IL8 activator

11 abstracts ASH 05 (Dec 10 – 13) Phase II data ASH 04 : > 6M stem cells/Kg of patient weight in 2 or fewer aphereses : 70% vs 20% COMPETITION : PGG from Biothera, ph I/II


- 69 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS GERN

C K

GERON (GERN) 30 % cut in workforce (June 25/02) CEO Thomas Okarma In K cells Telomerase is abnormally active, and maintains lengths of telomere even after cell division, allowing cell to proliferate indefinitely

-Telomerase inhibition GRN 163 L (13 mer oligo)→K treatmt ph I - (w/RZYM) GRN 163 thiophosphoramidate oligo to inhibit telomerase, binds to its RNA component, CLL, ph II init 07/05 - TVAX ph I/IImeta prostate; w/dendritic cells (Merix inc.) pulsed with mRNA that codes for hTERT (protein component of telomerase) antitelomerase vaccine, w/MRK (July 18/05) - Oncolytic virus (w/CEGE) E2F/hTERT, pre -Pluripotent stem cell differentiation→skin, brain, bone, heart, liver,etc.(lic from Wisconsin univ, who is disappointed Nov 01). Might not elicit immune rejection - Derivation of new hESC lines hESC give hematopoietic cells (June 05)., also for spinal cord injuries (to file IND end 07, cardiomyocytes, pancreatic islet cells, osteoblasts, chondrocytes

-PHA(discont jan 23), Kyowa Hakko -thanks to NUCLEAR TRANSFER technique acq 99 with Rosslin Bio-Med (the firm that cloned Dolly)

GGEN GALAGEN (GGEN) Neutraceuticals from bovine colostrum


- 70 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS GILD

GILEAD (GILD) Pure growth story Became profitable 2Q02 Poor pipeline Dec 2/02 : to merge w/Triangle (valued at $ 364m). Compl. Jan 23/03 Dec 15/02 : offering of $ 300 m, 5 year convertibles April 12/06 GILD invests $ 25m in CORUS, July 20/06 : to acquire Corus, inhaled antibiotics

-Ambisome : $ 129m/99;141/00;167/01; 185/02, 1Q03 41.1 2Q 51.2 3Q 49, 4Q 54.5, 1Q04 52, 3Q 49.8; 4Q 44.4; 1Q05 54.2, 2Q 56.2., 3Q 54.7; 1Q06 54 less nephrotoxic than Abelcet(ELN), approved for package insert. 91% of EU mkt, 41% of US mkt -Daunoxome < $ 5m -Vistide cidofovir (→CMV):<$5m; very high doses mice pox ! -Tamiflu FDA OK 4/99; CPMP rejects (end May 00) refiled 27/2/01;OK 21/3/02 prevention FDA OK nov 20 Children syrup FDA OK Dec 17/00. Manuf issue at Roche (Jan 02). June 24/05 seeks to get back from Roche Aztreonam-lysine ph III inhalation SIGNIF (Dec 20/06); 2nd ph III OK May 30/07, to file 4Q 2007 - P-680 epithelial Na channel inhibitor, precl, CF -Adefovir→Aids; FDA adv Com : no(renal tox 60-500 mg/d) -Adefovir/ Hepsera Hep B : ph III fully enrolled (lasts 2 years),endpoint liver histol.EASL (april01)reduct viral load (p<0.001)in lamivudine resistant pts. 1st ph III signif v/placebo, no kidney tox 10mg/d (June 22/01). Efficacy in e+ & e- But rebounds. IQ03 5.8, 3Q 16.4, 4Q 15.8,1Q04 18.9, 3Q 29.7, 4Q 34.2; 1Q05 43, 2Q 45.8, 3Q 46.9, 4Q 51.2; 1Q07 71; 3Q 79.3. May 07 loosing MKT to BMY (Baraclude, entecavir), GSK (Epivir), Epicept (Tyzeka) GLX sponsors trial in pts failing Lamivudine -Daptomycin lic from CBST for EU ph III : returned Sept 10/02 -Tenofovir, NRTI (Viread,PMPA),one pill once a day (Zerit is 2 a day), RTI→AIDS, no renal tox.. Sales 01$13m1Q02$27m, 2Q02 $ 44.7m,3Q $ 68.9.FY 225, 1Q03 107; 2Q 167, 3Q 59, 4Q 177; FY 566 (40% in EU, where retail price will drop), 1Q04 193 (internat 77), 2Q 197 (US 109), 3Q193.9 (US 108.5), 4Q 198.8; 1Q05 197.8, 3Q 189.4, 4Q 182.4; 1Q06 192, 3Q 170, 4Q 159, 2Q07 155; 3Q 149 Int Congr AIDS (July 0, 2Q 209.1 (US 88.4)2) equiv to BMY Zerit in triple assoc. (w 3TC & Sustiva) June 7/07 phase III + in Hep B - TRUVADA : Viread + Emtriva , QD combi, to compete w/ Combivir (BID) (Zidovudine + Lamivudine). Ph III init Aug 11/03. Filed US/EU March 12/ 04. FDA OK AUG 3/04, sales 3Q 18.2 (inventory stocking) 4Q 43; 1Q05 91.2 , 2Q05 123, 3Q 162.4 , 4Q 191.1 (US 149); 1Q06 249, 3Q 06 308, 4Q 337 ,1Q07 345cannibalizing Viread & Emtriva (Dec 04) 2Q07 385 (EU 199).; 3Q 409.1 EU approval Feb 22/05, launch 1Q06 Ital, Fr, Spain, Germ. ATRIPLA package truvad + Sustiva.JV w/BMY Dec 20/04 (coformulation mises bioequivalence). Aug 10/05 initializing bilayer, to file 2006. Triple formulation bioequivalent (Jan 9/06). NDA filed April 27/06, OK July 12/06, 3Q 06 68.4, 4Q 137; 1Q07 190, 2Q 212; 3Q 241 - GS 7340 prodrug of Tenofovir, ph I, term Oct 22/04

GS 9005 protease inhib ph I/II term Oct 22/04

acquired Nexstar ™w/PHA Tamiflu sales by Roche (10%royalty 1Q04 $ 27 1Q05 17, 3Q07 77.4) Relenza (GLX) is mkt for Tmt in US & EU(GLX files sept 18/00, but"will not proceed" nov 30/00) Tamiflu is leader in US Filed FDA March 21/02 & CPMP March 26/02 6 m priority review requested Early access programs init in France (07/01) & US (04/02) ADV com Aug 6/02 all +; Approved Sept 20/02. CPMP could OK mid 03 AIDS congress Glascow Nov 02 Adv Panel Oct 3/01: mitigated OK (restricted or not to resistant pts ??). FDA OK no restrictions Oct 27/01. EU OK Feb 02, Feb 03 CPMP extends indications March 29/02 : FDA warns on false claims safety : cases of lactic acidosis. Ditto Aug 03 contrary to worries, GSK Epivir/Ziagen : BOF ! compar. trial Combivir : non inferior (Aug 04), ICAAC Oct 30/04 > to Combivir on viral load (p = 0.038) Integrase inhib competition : MK 518 ph III (to file 2007), Tibotec, JNJ (protease + NNRTI), Panacos ("maturation inhibitor)


- 71 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - LB 84451, from LG Life Sciences (Korea), caspase

inhibitor, for hepatic & pulmonary fibrosis, ph II

GILD TRIANGLE PHARM (VIRS) Workforce cut 35% (Aug 7/01) Shelf filed Sept 23/02 Merger (Dec 5/02) w/Gilead compl Jan 16/03 : $ 464 m deal. First cash tender $ 6 for all outstanding VIRS stock (price $ 4.5). Interim financing $ 50 m with convertible notes.

-Coactinon(emivirine, NNRTI),ph III,but FDA has required additional trials,TERM Jan 20/02 -Emtriva Coviracil(emtricitabine,NRTI) 1 a day, Ph III was delayed (liver tox, Efficacy> Zerit (July 31/02) but ABT terminates..Filing Sept 5/02, CPMP Jan 9/03. AIDS, Hep B ph III.PDUFA July 3/03 Approved July 2/03; CPMP OK July 25/03. Sales 4Q03 $4m, 1Q04 12, 2Q 16.5, 3Q 16; 1Q05 12.4, 2Q05 : 12.1, 3Q 11.7, 4Q 11.2; 1Q06 10; 3Q07 6.5 -DAPD(NRTI), ph I/II - Amdoxovir NRTI, ph II, AIDS. Term Jan 28/04 - Clevudine, nucleoside, ph II, hep B

MYOG Myogen (MYOG) IPO raises $ 70m European subs (only Perfan) sold Feb 3/06 to Wulfing GmBH Oct 2/06 to be acq by GILD (Traceer sales 1H06 : $ 339m) : $ 2.5B Price $ 3,940/month (like Tracleer)

-ENOXIMONE PDE III inhib,( like Milrinone) - IV in EU, MKT, Perfan - Oral, 4 ph III (other trials since 20 years increase death) Emote : weaning of Milrinone; completed Feb 9/04, March 28/04 miss endpoint Essential endpoints TT 1st CV hospitalization, 6 min walk I & II (US, EU) hospital use, compl Y May 04, June 27/05 : all endpoints fail. Drug abandoned. Empower : tolerability of β-; Feb 18 : "enrolling slowly" ? - Ambrisentan , LETAIRIS, oral ph II for PAH, ATS May 23/04 : signif 6 min. 2 Ph III (186 x 2)ongoing. Feb 4/05 : 6 m delay in enrolment for ARIES I (USenrol compl Nov 10/05, data mid 06), ARIES II in Europe on schedule (enrol compl end June 05). Prelim data 6 m after end enrol. Top line data EU dec 12/05 : 6 min walk 60m>placebo (Thelin only 30m), no hepatotox, no interference w/warfarin), top line Aries I April 10/06 12 w 6 min walking test signif, but time to clinical worsening NS.. Filing Dec 18 2006. Could obtain priority review, to be decided before Feb 18 (could then launch YE 07): yes Feb 18. Approved June 15/07; 3Q07 6M, $ 177 forecasted for 2008, strong switching from Tracleer

competition PAH : ENCY, Actelion, UTHR, ICOS/LLY, PFE (Rovitia), Flolan, Cotherix Selective & once a day : Thelin & Ambrisentan Bosentan & Thelin interact with warfarin; Myogen claims Ambrisentan NO interaction w/ warfarin Tracleer increases catab of Warfarin, Thelin inhibits it ENCY (Thelin) to file April 05 May 20/05 init trial in 36 pts who discontinue Tracleer or Thelin because of transaminases, Feb 13/06 correction of PAH and normalization of transaminases March 7/06 lic to GSK ex US (& MYOG will mkt Flolan in US, but ww rights to GSK), filed 1Q07 EMEA ARIES II data ATS (May 23/06) : T to clinical worsening signif


- 72 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - Histone deacetylase inhib to block myocyte hypertrophy, w/Novartis, Res - Darusentan : hypertension, ph II, oral, ( lic from ABt, who had flushing & edema). Positive data in last line hypertension mid-August 05. Ph III init June 5/06

GLGC GENE LOGIC (GLGC) A gene expression database (GeneExpress) company, knowing which genes are expressed in which tissues, and when. Uses Affymetrix chips to create universal database of gene expression profiles

PG, JT,Akzo Nobel, AHP Aventis, SBHMRK SGP,UCB Fujisawa

GLGS GlycoGenesys (GLGS), was SafeScience CGS-100, targets galectin-3, ph I/II, K, lic from Karmanos & Wayne

GLIA M GLIATECH (GLIA) Delisted Jan 14/01 Merger terminated by GLFD (aug 28) Being audited by National Assoc. of Security Dealers Files for banckrupcy May 10/02

Adcon (surgical anti-adhesion gel):$27m/99, but CSF leakage! -Perceptin (anti H3)→alzheimer, ph II -AntiProperdin f hu MAb→coronary, stroke (remarkable molecule but nobody seems to realize),pre

Aug 23 : FDA finds disturbing protocol violations Could be relaunched outside US JNJ discont, now ADHD ph II Lic to ABGX ( Nov 2/01)

GLPG Galapagos (GLPG AIM, Euronext) JV Tibotec Crucell

Adenoviral screening technology -Osteoarthritis, discovery , June 7/6 € 144 m deal (access fes € 4m milestones 140)

GNBT GENEREX (GNBT) Oralin, oral insulin spray, ph I/II, w/LLY from 2000 to 2003. Ph III to init 2H07

GNLB GENELABS (GNLB) Oct 24/07 w/JNJ for RA $ 1B = 12 targets, of which kinase GT418

-GL 701/ Prestara (DHEA)lic to Watson→SLE, 2 ph III (1st reduct in steroid use; 2nd improvement of bone density N = 381 but only 37 with complete density measures). Adv Com April 19/01 : no answer!!June 27/01 : not approvable. Sept 2/02 CRL : approval contingent on addition of new ph III on bone density. Failure Oct 5/04 Jan 16/06 will init new ph III in LE -GL 331 (Etoposide like), ph II ???? - Hepatitis E vaccine, w/GSK, Ph II

Genomic activity : positional cloning on long arm of 5 :genes for IL13, 4, 5, 3 & GM-CSF

GNMX GENOMETRIX ( GNMX) IPO filed 3/15 (LB/CHQ) withdrawn feb 28/01

Throughput genomic services


- 73 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS GNOM GENOMICA (GNOM)

To be acq by EXEL

"Discovery Manager" : annotated genomic data base

GNSC GENAISSANCE PHARM (GNSC) Aug 7/02 : staff¬ 20% -J. Drews is Chairman -1700 patent applications on haplotypes Creating new markets : -the non responders : using haplotype prediction in a pilot trial they went from 8% respondrs to 44% -the adverse effect type responders

-Have proprietary haplotype markers for over 600 genes -Have already correlated response to Ventoline with specific markers. April 25/01 : init of Mednostics trials : - pts are haplotyped for 50 genes, & randomly allocated to Lipitor, Zocor, Pravachol or Baycol. Correlation w/safety-efficacy. Results 1Q02. Enrol compl July 01 - JAN 16/02 : init of trial on Mevacor - preparing trials in asthma, diabetes, schizophrenia, obesity, long QT sd. ALSO : drug development program to market a generic + haplotyping kit - for clozapine - for a statin, ph II: Partn. w/BGEN genotyping for Amevive -

-Haplotypes are groups of SNPs easier to correlate with drug response than SNPs. -Part w/Telik : compounds active on haplotypes of E2 receptors. w/JNJ : nov 28/00; w PFE Oct 9/01; w/AZN; wBGEN (Feb ½)

GNSL GENOMIC SOLUTIONS (GNSL) IPO May 5

Genomics toolbox MRK, CAT Perkin Elmer

GNT GENTIUM (GNT) 1,200 allo BMT in France 2005, 6,000 EU, 12,000 ww

- Sulfated fucans - Defibrotide. Weak fibrinolyticfrom porcine mucus. Venous occlusive disease in BMT. THerapeutic ph III init June 06 , Nov 5/07 65/80 enrolled, primary changed w/FDA from survival 100 d to bilirub < 2 mg/dl; data 1H08, large prophylactic ph II ongoing in Europe. "Bone marrow transplantation" May 14/07 paper Royal Marsden, 58 patients with allo: no VOD after 100 days ( litterature 20 to 30%!). June 07 positive data in MM. July 07 Int Soc Hemost : enhances plasmin activity

GNTA K

GENTA (GNTA) Bcl Competition : Gemin X Biotechnologies Inc. May 13/04 slashes employees 50% April 12/04 files shelf $ 150m Aventis partner (April 29/02)$ 477 : 135m initial & near term payments (of which 75 equity if a milestone is reached), 40 dev fees, 10 convertible debt, 10 lic fee, 280 cash, 65 convertible notes based on

-G 3139 : Genasense –oblimersen -antisense to Bcl2→K, , ph II, many centers, tested with DTIC, Taxol, Taxotere,Rituxan,Camptosar, Fludara. Ph III stage III/IV, 1st line, open, random: melanoma initiated March 9/00 (enrol compl 750 Jan 03),myeloma feb 01( 200 enrol compl 4Q02), CLL march 01 (enrol to compl end 1Q03). AML ph II; NSCLC init w/taxotere Nov 5/01, prostate :ph II. SCLC (Feb 02 w/carboplat + etop) same at AACR Nov 02 : 82% ORR, NHL (Feb 18/02)

FDA (Aug 7) : orphan drug design., fast track. Rolling filing was to start 1H/02). Delay(May 16/02)Init Sept 03, completed Dec 8. FDA accepts + priority Feb 6/04. Action before June 8 ,Adv Com MAY 3 : 13/3 NO. May 13/04 GNTA withdraws Gnta will NOT supplement the application with complete 12 m survival data, unless requested. By April 8 will supply 8 m safety data


- 74 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS milestones. March 17/02 advance credit line $ 40m Royalty 25% US, 18% EU Terminated Nov 8/04 PIPE $ 28 M (Nov 28/01) June 11/02 : $ 5m stock repurchase Manuf : Avecia Sept 10/03 Melanoma stage III & IV - all pts survival 9.1m/7.9 NS - 480 first 10.1/8.1 p = 0.035 - RECIST on all : + 11.7%, p = 0.019 Sept 06 (JCO) vs dacarbazine N = 771, ph III, ORR 13.5% vs 7.5% PFS 2.6m vs 1.6 m May 10/05 Aventis terminates Sept 19/05 CLL better ORR than placebo, but twice as many deaths

w/Rituxan. Myeloma : + thalomid + dexa init Sept 24/02 Myeloma + Velcade CML + Gleevec, init Oct 2/02 Breast w/Taxotere + doxo RCC, ph II, + α IFN Pancreatic K, ph I/II w/Gemzar Colorectal ph II w/Eloxatin+ 5FU NSCLC w/Vinorelbine (GSK) + precl at AACR April 03 Solid T ph II w/carboplat + paclitaxel AACR April 05 + Iressa xenograft NSCLC interesting - new antisense lic from Atugen AG (jan 01) - Ganite : Gallium nitrate, NHL & K hypercal, ph I/II, sNDA for K hypercalcemia filed April 1/03. 1Q04 : 0.4m. Promotion stopped May 10/04

→ ASH 01( but results of myeloma IIb 1H02) for CLL (severe IL8 side effects) & AML (w/Mylotarg). AACR (Oct 29/01) → ASH 02 CLL (fast track JUne 30/03) ASCO 03 : w/Campath (alemtuzumab) potentiates HRPC w/Taxotere ph II, N = 29, will start ph II EORTC CLL July 05 rolling NDA init. 2nd line w/Fludarabine + Cyclo, completed Dec 29/05. PDUFA Oct 28/06 ; ODAC Sept 6/06 7/3 against, endpoints complete or nodular (C but with persistent lymphoid nodes in BM) 17% vs 7% (p = O.O25). But ORR 41% vs 45%, and Toxicity. July 05 letter of intent EU filing 1st line melanoma w/Dacarbazine, filed Jan 3/06. Ph III melanoma Paris Cancer Congress Jan 06. Dec 15/06 CLL "not approvable". Competition : Bcl2 inhibs, Geminx Biotech, Abbott, Santaris, Ascenta

GNVC K C

GenVec (GNVC) traded since dec 12/00 April 16/03 to merge w/Diacrin, completed Aug 22/03 TNFerade could sell at $ 25,000 (2007) __________________________________

GENE THERAPY - Ad VEGF(BioBypass), ph II, coronary & PAD, AHA Nov 02 , ph II, N = 71, signif on ST, IIb init March 1/05 (EU, Israel) w/Cordis (JNJ). PAD term Jan 03. - Ad TNF w Rxinducible promoter (TNFerade) : intratumoral ph I (Nov/01 ASTRO) + Rx : 2/7 CR, 2/7/PR,pancreas ph I Ph IIb QW/5w then Gemzar Tarceva, rand Pancreas 1st line N=150 init Aug 14/02 (+Rx + 5FU), enlarged March 16/06 to N = 330, endpoint % patients with 12m survival. Dec 19/06 interim on 51 pats : at 12m 70.5% vs 28%. Oesophageal PACT ph II/III init Nov 14/02. Maintenance with Gemzar/Tarceva Ph II ASCO 04 : median survival dose dependent > 340 days; -rectal ph II - melanoma ph II - Soft tissue sarcoma :EORTC/NCI/AACR Nov 19-22/02, N = 14 w/Rxtherapy, ph I/II, interim on 7 : 2CR, 3PR

→WLA/PFE (discon jan 02); Jan 04 : JNJ ASCO May 02 N=22, CR 5, PR 7 All K ASCO May 03 pancreas N = 20, ORR = 85% ASCO Jan 24/04 GI sympo "promising efficacy" Nice pictures. CA-19-9 is suppressed by 70%.. DDW May 17/04, N = 37, good data Sept 1/04 data in Clin Cancer Res. N = 13, 2 CR, 9 PR AACR Oct 3/04 good data esophageal Oct 7/04 : on hold FDA (clots in esophagus K), hold released Feb 11/05 for pancreas, for all May 25/05 ASCO 03 : sarcoma N = 14, ORR = 85%


- 75 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS DIACRIN (DCRN) Merged (April 18/03) w/GNVC, compl Aug 22/03

- Ad PEDF (pigment epithelial derived factor), ph I init Nov 26/02. Data Amer Acad Opht Nov 03 +/- - Adeno vector for SARS vaccine (April 25/03) - Adeno vector & MATH1 gene for deafness ______________________________________________ -porcin neurons, stroke,phI : on hold -NeuroCell, Park, ph II (w/Genzyme)extended to 18 months (sept 15) to maximise efficacy data∏march 18/01: results unclear -Hepatocytes for hepatic failure ,ph I -AutoTransplant of muscle cells to heart,phI. 3 year follow up OK March 05 ACC. To be divested (Oct 18/05) Dec 29/05 sold to Mytogen

GPCB K GPC Biotherapeutics AG (GPCB) May 06 : data monitoring board recommends interim anal of OS June 25/07 lic to Yakult (inventor of irinotecan) for Japan, $ 10 m upfront

- Satraplatin ph III, 2nd line oral HRPC N = 912 endpoint TTP (from Spectrum), + Pred vs Pred alone (Taxotere was approved 1st line). Rolling NDA (CMC) init Dec 05 (was planned for 2H06). Full enrol. Dec 5/05. Interim delayed from <end 03 to end 04/06. Final results 3Q06. Roll. filing init July 12/06. Sept 24/06 PFS 11 w, p < 0.00001. Completed Feb 16/07. Asco prostate 07 11.1 w vs 9.7 (median), but at 12 m 16% satra had not progressed vs 7% control. Free expanded accessFeb 21/07. Adv Com July 24/07, PDUFA Aug 15/07. ASCO 07 : OS not yet; is Pred the right comparator ??? ODAC July 24 : NO. OS required. July 30 filing pulled. Init w/Taxotere ph I Dec 05, ph II w Taxol in NSCLC, & w/ tarceva - 1D09C3, ph I, anti MHC class II (HLA-DR) fully human (ASH 2004)

in 1st line TTP (N = 50) 5.2m/2.5m; OS 14.9/11.9 Satraplanin lic to Pharmion for EU (Dec 05) 2nd line median OS w/Taxane 10.7 m (ASCO Prostate 2005)

GPRO GenProbe (GPRO) Key customer : Chiron (47% 2004 revenue)

Nuclear acid probes (hybridization) : - HIV, HCV, West Nile, Chlamydia, Gonorrhea, TB

Competitors : PCR (Roche, Becton Dickinson) Their use of amplification depends on license from Vysis acq 2001 by ABT

GSK ID Biomedical (IDBE) acquired Shire vaccine business Sept 7/05 to be acq by GSK $ 1.4B

- FluInsure : non living intanasal vaccine. Clinical efficacy (July 20/04) - Fluviral, marketed in CND since 1975 - Fluviral 2nd version : CND trial vs Vaxigrip completed Jan 05 US trial to initiate end Jan 05, vs Fluzone (Aventis) IM

GSK PRAECIS (PRCS) PDUFA AUG 27/03, OK Dec 1/03

-Abarelix/Plenaxis,prostate K, ph III,LHRH antag; Lupron/TAP & Zoladex/AZN are agonists. June 12/01 :

Amgen (discont Sept 20/01), SASI ASCO 00 : only �hi� data ASCO /01:only marginal differences w/Agonists


- 76 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS for "pain relief in pts who are not viable candidates for treatment with LHRH agonists, and refuse castration". Launch Jan 04. 1Q04 : $ 0.4m Dec 21/06 being acq by GSK

rejected by FDA; meeting Sept 10/01→to investigate allergies & testosterone resurge after 3 months. Will resubmit end 02 : refiles Feb 26/03. Will file CPMP Endometriosis ph II/III. Promotion suspended May 20/05 - Latranal, back pain, ph II. Terminated. -Apan for Alzheimer, Ph I - PPI 2458, ph I, Inhib of methionine aminopeptidase 2.

April 28/04 lic to Schering AG

GSK M V K

CORIXA (CRXA) June 9/03 PIPE offering $ 30m convertibles $ 75m March 19/02 : breast K genes for dg lic to JNJ (BRCA sales $ 5M by MYGN), CVSN sells Her 2FISH. CEO : Steve Gillis Very high expenditures: $150m/Y (Had 510 employees, PDLI has only 60) : March 20/01 10 % staff cut. May 28/02 down to 375 $75m line of credit from BNY (Dec 5/01) Aug 13/02 : $ 45m PIPE BEXXAR : use of this or that RAIT for NHL will depend on variable radioresistance of pts, synergy or not with ABMT, possibility of lower dose of MAb with *I, size of tumor mass (*Y, with high energy, might be preferred for large tumor mass, and *I for more disseminated masses). Competition Zevalin (IDPH), also *Y Lymphocyde (anti CD22,ph I/II) IMMU/AMGN,& *I Oncolym (ph II/III) PPHM/Schering AG CRXA owns US patents to Rx Mabs to CD 20 ASH 01 : 13 papers for Bexxar & 13 for Zevalin. Very prestigious authors for both. For B. more than 800 pts !, &76 first line ++. For Z issues of *Rx contaminat. of gut (Indium insufficient to detect) ∗ risk for family (feces), heart, testes. Bexxar manuf : B.I (like Synagis). , then in US R* labeling/ fill & finish by MDS Nordion , in EU Amersham. - Clinical benefit in Rituxan refractory 10/3 - ORR is likely to predict clinical, benefit in Rituxan Refractory 13/13. June 30/03 Bexxar approved for Rituxan refractory, sales init Aug 1/03

- Ribi 529 lic to AHP (Oct 30/01) -Melacine(lys.from 2 hu cell lines)→melanoma,phIII improves survival in women with αIFN.. SWOG ph III (oct 30/00):dis. free surv. signif improved (p<0.005), in HLA-A2 and C3 pts (60% of pts). -her2/Neu vaccine in PLGA microspheres→K, ph I→→ -MPL genital herpes ph III MPL Egerix B to be filed - TB vaccine, pre -MUC 1 peptide vaccine : pancreatic K, ph I -PVAC(mycobact bov. Ag)→PSO, ph II;feb 15/01 p=0.08, but end point too strict;march 12/01 SR Pharma reports + ph II in atopic dermatitis.PhIII∏3Q01.Peak PASI 75 : 50%. New US ph III init June 6/02 -High capacity for providing Ags - Proteins that act as Ags, and could protect against acne (April 5/01), genome deciphering contracted out to Genset -Anergen products :Anergix RA,ph I/II (w/Organon) -COULTER PRODUCTS -Bexxar(radio-I m anti CD 20 MAb) tositumomab→NHL 2 phase III (N = 60 + 273, ASCO 01) Jul 26/01: + CHOP trial with GSK March 19/01 FDA asks for hematol. recovery data in low grade, thyroid safety & comparison of manufacturers(CLTR,Lonza,BI). Chem/Pharm filed Aug 9/01,completed Sept 7/01 SWOG is running first line BEXXAR April 2/02 survey 1000 Hem/onc : most promising new agent May 23/02: GSK press release says launch 02/03 JCO Aug 15/02 : Bexxar & Zevalin equivalent Enrolling (Feb 03) SWOG Rituxan + CHOP vs Bexxar + CHOP Feb 24/03 : European orphan Drug Designation → patent protection 10 more years ASCO 03 5 presentations. # 2316, N = 250 follow-up median duration

will get Ribi's royalties for new Engerix (from 2002) May 24/02 lic to MEDX of toxins for MAbs -from Ribi acquisition part : SGP Approved CND (feb 16/01) FDA (Nov 01) wants 2nd ph III : meeting on Feb 27/02 : OK for Melacine V nothing in A2 & C3. Nov 03 discont in US. →GSK (reneg Jan 30/03) CRXA pays Dev, but JV possible →GSK → GSK lic from SR Pharma (UK) w/Medicis (CND/USA), Zenyaki Kogyo for Japan Trials in Brazil∏ Nov 6/02 PASI 50 p = 0.053; 75 NS Trial init in N Zealand Nov 7/02 →to ABGX(21/03/00), MEDX(June 7/00),Purdue sept 26/00 Anergix Myasthenia lic WW to Beaufour (Jan 02) Oct 29/01 : Amersham for EU +++++; to file cPMP 2H03 (acq by GE Oct 10/03) BLA refiled sept 18/00; GSK,USpartner (50/50 profit sharing), strong patents (Versus/Idec); oct 5/00 :priority review granted -April25/00 : CLTR regains rights outside US NO NEED FOR INDIUM IMAGING March 12/02 : CRL March 25 CRXA informs FDA intent to amend BLA,should be May 15:diff of opinion CRXA requests dispute resolution by ODAC (FDA to respond in 45 d). Safety does not seem issue. CRXA will provide info on "level of durable response" once request is accepted. Request accepted June 27/02(and withdrawn Dec 2/02. → files Oct 02 for "low grade NHL that does not respond or progress following Rituxan"; ODAC Dec 17-18/02 FDA confirms (Dec 2/02) that "this constitutes


- 77 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Sept 22/03 recruit Head of Sales Chris Rivera (who was in charge of Renagel) Dec 14/04 Bexxar lic to GSK May 2/05 being acq by GSK

complete response (30.4%) : 58.1m. Some pts now treated 9.5 years. -prodrug of doxorubicin, Pre - INF α receptor antag : res Nov 10/03 : concentrating on TLR4 agon & antag.

substantiated new info addressing prior concerns"; these data include durability of response. PDUFA May 2/03→ Aug 1/03 (no new trials required) -April 3/00 : MEDX for fully Hu MAbs -May 21/01 : agreement w/Biovation (Merck KGaA) for deimmunization -March 02 w/Synt:em for vaccines

GTCB M GTC Biotherapeutics ( GTCB), was Genzyme Transgenics (GZTC) May 15/01 CEO leaves, Geraghty takes over interim, now Geoffrey Cox Secondary Jan 24/05 Other transgenic : Merrimack

-AT III,ATryn, filing end 00 delayed to 2002 !, filed CPMP March 04, March 16/05 : more questions. GTW will respond by JUly 8, Sept 15/05 time line for CHMP response delayed from Oct 05 to Feb 06, June 06 CHMP OK for cong def in surgery; 2nd ph III for FDA (N = 17) init April 6/05. Sept 6/07 FDA grants fast track. Nov 1/06 lic to Leo for ROW (except Japan). Leo also in DIC. Aug 6/07 ph II init by Leo in sepsis DIC, N = 200, results 2H08 -Transgenic Remicade, PRE -Transg Hu anti TNF alpha→RA, pre -Transg MAb (must be anti C'), pre - Trans Hu Albumin as stabilizer (w/Fresenius) - anti CD 137, K, pre, agonistic, stimulates immune response - MM-093 (w/ Merrimack) : r hu AFP, immunomodulator, ph II, RA, PSO - Transgenic anti-CD 20, w/LFB

second ph III bleeding issue, discont Feb7/01 Centocor (JNJ )extended to 2nd MAb BASF/KNOLL™CAT/ABT/ELN Alexion

GTOP GENITOPE (GTOP) IPO filed Aug 7/03 (WR Hambrechst + Punk Ziegel). Traded

MyVax, NHL, ph III (auto + allo vaccine + GM CSF + keyhole limpet hemocyanin) July 31/06 misses endpoint

GVEC GENETIC VECTORS (GVEC) tests to identify DNA & RNA impurities

HALO Halozyme Therapeutics (was HTI), traded on Nasdaq since May 10/07

- Chemophase (recombinant hyaluronidase rHu PH20) to enhance chemotherapy delivery, w/ Mitomycine, superficial bladder K, Ph I/II init April 25/06 - r Hu PH20 associated w/ 13 Roche targets (monoclonals ?), Dec 6/06; lic to Baxter Feb 14/07 for 2 molecules - rHu Hyaluronidase (Hylenex, Enhanze) : FDA OK Dec 05, launch 2Q07 - July 10/07 good data w/Humira (ABT) - Sept 10/07 new deal w/ Baxter subcut extractive immunoglobulin


- 78 - printed : 03/07/10 (d/m/y) 08:07


HBIO Harvard Bioscience (HBIO) Exists since 1901!!!! trading since dec 7/00

Enabling tools for drug discovery. 10 000 products, 60 countries, 1 000 page catalog.

HEB HEMISPHEREX (HEB) Ampligen NDA filed Oct 11/07 for chronic fatigue sd; binds to TLR3

HEPH HOLLIS-EDEN (HEPH) Bioterrorism drugs to protect against radiation

HGSI M K

HUMAN GENOME SCIENCES (HGSI) March 25/04 lay off 20% Interest income 01($77m)> revenues ($12m) * on june 30/01 HGSI regaineds all rights on GSK genomic agreement Strong GMP manufacturing capacity, including for MAbs

Genomics :-patent applications for medical uses of more than 7400 genes .→→→→→→→→

-collab with Compugen on cSNPs ("collection of SNP expressed genes")→→→

.-SB435495 (pyrimidone)lowers Lp-PLA2(Paf acetyl hydrolase), enters clinicals -feb 22/01), enters ph III in 04 - SB462795 (cathepsin K inhib) osteoporosis, phI

Proteins : -KGF 2 (repifermin)→venous ulcers, mucositis, ,ph II : Dec

10/01 : no efficacy in ulcerative colitis. -MPIF (myeloid progenit inhib fact)mirostipen,ph II -inhib of CCR 5 receptor (metchemokine beta3), blocks allergic reactions.

- BLyS protein : ph I, for "common variable immunodeficiency disease" - Albumin fusion products (technol acq from Principia/Aventis), like PEG, but antigenicity ??? (but no issues in the 1st 50 pts) -new Interferon (Albuferon)⇑Hep C,phI init March 01;

Nov 4/02 : safe, longer T1/2; ph II AASLD Nov 05 can be given

SBH/GSK*,MRK,SGP,SASY Merck KGaG, Takeda "to achieve the first chromosomal map of expressed human genes" GSK(10% royalties + 20% copromotion right ∏ 30% profit), named by JP Garnier 480848 in Feb 03 R/D GSK Interim anal. (Sept 24,03) leads to drop venous. ph II ongoing in mucositis, fails Feb 3/04 SGP (oct 9/00)

All pts make Abs, but not neutralizing Higher discont rate than Pegasys


- 79 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -owns 10% of Transgene - Off balance sheet lease financing will have to be recognized as liability $ 500m in 03 - Convertible debt 2007 - Not profitable until 2010 ww SLE 300,000 (Morgan Stanley)

every 2 w, but 4w inferior, Pegasys is every w. Partner 06 ?? yes June 6/06 Novartis. June 7/07 ph IIb not better than Pegays (more side effects). PH III init 1Q07

- Albutropin, ph I, HGH - Albuleukin (IL2) ph I, Jan 8/02 -also PTH, INFβ , G-CSF (albugranin), EPO (albupoietin),

GLP (resistant to dipeptidase : Albugon GSK 716155) lic to GSK Oct 27/04, IND filed Jan 10/06, ph I to init 06

MONOCLONALS (phage display) →→→→→→→→ -Lymphostat (belimumab): Fully hu anti BLys (B Lymphocyte stimul):

I, for RA (where this prot is overproduced), SLE ph I,+ April 21/03, ph II init Sept 26/03, decreases anti DNA. RA ph II N = 283 signif April 6/05. Oct 6/05 SLE data : only active(clinically) in pts with anti DNA (75%).

Eular June 07 good ph II SLE 1st Ph III LE w/GSK init Feb 12/07, 2nd init May 30/07,

both ph III only sero +. Enrol 1 year . 2 X 810 pts (ser+) vs placebo, endpoint SELENA 12 m. On MKT 2009 , now (feb 07) filing 2010….

ACR Nov 06 in seropositive primary efficacy endpoint 46% ptts w 52, 56% w 76

- LymphoRad : *I anti Blys, pre, NHL, myeloma ph I - HGS-ETR1, anti DR4 (death receptor 4) TRAIL, mapatumumab

IV(TNF related apoptosis inducing ligand)R1 Agonistic Mab from CAT , K, synergistic topotecan, ph II CRC enrol compl Feb 22/05, NHL compl March 3/05, OK June 13/05. GSK opts OK Aug 05

- TRAILR2, I -VEGF2 Mab, K, pre - CCR5 Mab, AIDS,ph I (init March 05), acq from ABGX -C2A Mab, asthma, pre - ABthrax, Ph I, 100% survival in animals; May 04 : back burner GENE THERAPY→→→→→→→→→→ -VEGF 2 →PAD & coronary ischemia , ph I/II (on hold, 1

death)→→→→ (Jeff Isner died )

EASL Vienna April 26-30/06 12w data AASLD Nov 02 : works in INF α resistance Partn w/Atrix for protein delivery (Aug 01) Alliance with CAT, DYAX, MEDX, ABGX GSK opts OK July 05 SLE fast track April 21/03, 0.25 or 10 mg/kg every 4 weeks Trail is used as a drug by AMGN/IMNX, but does not work due to decoy receptorsFor Japan Trailr1→ Takeda, 2 → Kirin CRC ECCO 05 ph II CRC SD 30%, NHL ASH 05 : clinical response in 3/40 pts !! Competitor ZGEN JV With Vascular Genetics, now Autus (HGSI has 10%) Hep C : see Idenix !!

HMSL HEMOSOL (TSE/HML;HMSL/Nasdaq) June 7/02 : cuts 35 % of work force April 7/03 staff total lay off

Hemolink (purified Hb from outdated bank blood) ph III, filed in UK feb 01 July 01 : files answers to queries of Health CND. Decision end 01→ March 21/02 : refusal Aug 14/01 : FDA requires modif ph III protocol; March 28/02 FDA allows ph II. Delays in trials enrollment (CABG). March 13/03 enrol suspended.

™Dompe (south & east Europe)


- 80 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS HNAB K HANA Biosciences (HBX) - Zensana Ondansetron oral spray, filed July 06,launch 07;

GSK threat lawsuit. March 24/07 filing withdrawn (manuf). Aug 1/07 lic to Par - Talotrexin, Talvesta, antifolate, ph II NSCLC (2nd line), N = 120 , ALL ph I/II; discont March 24/07; could come back (Aug 1/07) - IPdR, ph I, digestive K - Marqibo (sphingosomal VCR) from Inex (March 17/06). dec 04 ODAC : NO; new ph III ALL to init YE 07, SPA refused (March 24/07). Aug 2/07 ph II 2nd line ALL - Sphingosomal vinorelbine (ditto) phase II NSCLC - Sphingosomal topotecan (ditto), pre - Vit K3 percut lic in Oct 16/06 for anti EGFR eruptions

HYBD HYCOR BIOMEDICAL (HYBD) kits for urinalysis & allergy testing

HYSQ HYSEQ (HYSQ) Chairman : G. Rathmann Nov 11/02, merging w/Variagenics July 26/01 : 20% reduct ow work force

-Genetic testing with proprietary arrays -Genomic databases : cardiovasc, metabolic→→→→ -Downstream proteins : -IL1Hy1,pre, IL1Hy2,res:antiinflammation -DDF (CD39 L2) antithrombotic,pre - Alfimeprase, thrombolytic, lic from AMGN

CHIR, AHP, Kirin

IART INTEGRA (IART), Soros owns 15%

-products for neurosurgeons - artificial skin (NaOH treated bovine collagen): MKT™

™JNJ

IBPI

IntraBiotics ( IBPI) April 11/01 : Deutsche Bank suspends coverage Ernest Mario, CEO since April 25/02 (was CEO of Alza). Steps aside Feb 03, becomes Chairman, invests Staff ¬ 70% Oct 14/02 Being Terminated : June 21/05

-Ramoplanin (oral AB),ph III, suppresses intestinal VRE ; trial in BMT to prevent febrile neutropenia events. Was to be completed 1Q01,NDA filing delayed (march 12/01) at least 1 year: only 104 of planned 900 pts enrolled. But ph II had efficacy in 90 % of pts⇑⇑⇑⇑ -Protegrins (peptides) : aerosol CF, ph I Iseganan mouth wash(mucositis) ph III dispensing error by CRO! FDA ™ fast track (jan 01) April 26/01 : end point missed. Oct 4/01 : ph II + p<0.01;Nov 7/01:new phIII in BMT (fully enrolled June 6/02, N=509) ; NS 27/9/02 Feb 10/03 could launch ph II/III in prevention of ventilator associated pneumonia, N = 900 X 2, 1st initiated Sept 03, 450 enrolled May 5/04.. Fast track Sept 5/03. Feb 19/04 selected by FDA for Continuous Mkt Application Pilot 2 program (by anti-infectives division). 1st trial halted June 23 by Safety Com (more deaths)

Lic from Biosearch Italia (Nuevo Mercato), also developing it; manuf by Aventis May 31/01 : nearly discontinued OCT 10/01 : lic to GENE by Biosearch I. ASCO 01 : end point missed, but pain reduction in 19% of pts May 6/02 : Rxtherapy trial : failure -DVSA partnership modif (July 2/01)


- 81 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ICCC IMMUCELL (ICCC) Bovine health

ICLL INTERCELL (Vienna) July 2/07 Novartis rises equity stake from 6.1% to 16.2% for $ 270m (of which 170 licensing rights)

vaccines - HEP C therapeutic peptide vaccine (T cell response ?), ph II - Jap. Encephalitis, ph III, w/Novartis - TB, ph I

HEP C many groups w POC in chimps using adeno vaccines; Transgene MVA in ph I Jap encephalirtis competition Acambis

ICGN ICAGEN (ICGN) Feb 3/05

oral molecules to modulate ion channels (have cloned entire ion channel genome) - Aug 14/07 $ 1B deal w/ PFE on pain ICA 17043 senicapoc (W/JNJ) ph III init Feb 22/05 N = 300 ASSERT endpoint rate of crises : sickle cell disease (active on transgenic mice red cell dehydration). Ph II ASH 04 12 w change of Hb from baseline p < 0.001, Orphan Drug. On hold April 4/07. JNJ terminates June 23/07

ICN ICN (ICN) June 11/02 : Milan Panic retires June 20/02 acq Genetronics electroporat.

To spin off " Ribapharm" (IPO filed) : - Ribavirin (MKT by SGP) - Tiazole for CML, ph I/II - Adenazole, colon K, ph I

IDDS Innov. Drug Delivery Syst. (IDDS) IPO filed (JPM) Jan 2/02

Ketamine nasal ph II Morphine nasal ph II

IDEV INDEVUS (IDIC) was INTERNEURON -Redux -Pagoclone→panic/anxiety : ph III -Citicoline→stroke, ph III?? - Sanctura, Trospium (lic from Madaus), hyperactive bladder, ph III OK Sept 25/02. FDA OK Aug 04 - Valstar (valrubicin) bladder K. Approvable Aug 17/07

Suing AHP for non disclosure!And won !!h w/PFE, returned June 10/02

IDIX IDENIX, was NOVIRIO (IDIX) Oct 1/07 outs 1/3rd work force 57% Novartis Filed for IPO April 15/02 (Goldman Sachs).Withdrawn April 15/02. Refiled Dec 15/03 5M. Stanley, Bear Sterns) Chairman CEO JP Somadossi; major investors Nomura, MPM Boston. Has $ 52m in cash (BWT Dec 16/03).

Telbivudine (LdT) Sebivo / Tyzeka oral, once a day, hep B, ph III init May 03 (FDA OK Oct 06). EMEA approval April 30/07. Lic to Novartis Veltorcitabine (Val LdC), Hep B NM 283, Valopicitabine, nucleoside analog, Hep C, ph I/II, lic to Novartis (March 29/06) $ 525m. Nov 06 Valo + PegIFN : 4.2 log reduction !!). July 15/07 on hold : GI side effects - IDX 8999 NNRT hiv PH i:ii


- 82 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Refiled Dec 03. OK July 22/04

IDMI c K

EPIMMUNE (EPMN) was Cytel Sept 13 : CEO resigns E. Loria, from Biovector SA appointed March 15/05 : merger w/IDM, and be IDMI (IDM Pharma Inc) compl Aug 16/05

complex carbohydrates - HIV vaccine ph I/II; sold to Pharmex A/S Nov 28/05

IDMI M V C

IDM (Immuno-designed molecules)*, France Part. SASY (20 options) Jan 22/02 forthcoming IPO oct 23/00 : MEDX increases stake to 34% Have 10 cell processing centres (1 in Montreal) May 30/07 JL Romet Lemonne leaves

-The MAK (Macrophage activated killer ) is a simple device for autologous immunotherapy with MAK cells. These are monocytes activated by γinterferon in-vitro - BexidemVaccine therapy for bladder K, ph II/III - MEPACT / Junovan , ph III, osteosarcoma N = 800, 4 years, completed, to file 2006, IV, liposomal muramyl tripeptide phosphatidylethanolamine to target macrophages. NDA filed Oct 26/06 : 6 year probability of survival 77% vs 66%. ODAC May 9/07: NO 12/2; EU filed Nov 7/06. DFS is not > control. FDA Aug 27/07 NOT approvable dendritic cells derived from the patient's WBC, exposed to Ags, reinjected : - Uvidem IDDD3 (w/SASY) melanoma, ph II (+IL13). ASCO 07 N = 30, 1CR, 2PR, 6SD - Collidem, ph I/II CRC

ongoing ph III with MDX 210 (partnership w/MEDX) in ovary cancer; this is anti her2neu. agreement w/Epimmune Oct 14/02 Competition : ZIO 201 active metabolite ifosfamide, from Ziopharm Oncology

IDP K IDERA Dec 11/06 w/MRK $ 455m TLR 7/8/9 June 2005 Novartis $ 136 m TLR 9 asthma,

- IMO 2055 ph II, RCC, solid T Ph I w/Gemzar Carbo - IMO 2125 Hep C, pre

IDXX IDEXX (IDXX) Veterinary diagnostic kits

IEX K INEX (TSE/IEX) partnership w/ALNY Jan 9/07

- Onco TSE (liposomal VCR Marqibo) w/ELN, ph II/III NHL - TCS (transmembrane carrier system, liposomes) lic to GSK for Camptothecin

ODAC Dec 1/04 : NO

IGEN IGEN (IGEN) The key provider of electrochemoluminescence kits Roche dg, Organon teknica, Eisai, Bayer dg.

ILGN INTERLEUKIN GENETICS (ILGN) tests for susceptibility to disease : diabetes, cardiovascular, osteoporosis, being developed


- 83 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ILMN ILLUMINA (ILMN) Bead arrays for large scale analysis of gene variations, for

SNP genotyping

IMCL M V K

IMCLONE (IMCL) CEO was Sam Waksal Production facility in Sommerville completed end 01(3x10,000L) & 110,000 L in a few years. Approved July 02 Jan 2/02 : FDA refuses file : irinotecan refractoriness not documented, undeclared deaths. Also stock options ?? Feb 5/02 : BMY wants to renegotiate & that S & H Waksal should resign. March 7/02 : milestones reduced. Claim they will provide FDA with data from EU ph III. Filing 03 ? Launch 04? April 25/02 Merck delays CPMP filing until 1H03 (colorectal & H&N). May 17/02 : Merck will not enlarge EU colorectal trial for IMCL May 22/02 : BMY & IMCL to run 3 "big" trials June 12/02 : S. Waxsal arrested Feb 10/03 BMY & IMCL → limited access program March 6/03 receives $ 60m milestone from BMY (1 year anniversary) April 10/08 : 10K filing delayed. June 5/03 meeting w/FDA IMCL will refile. Fast track. Approval 2H03:1H04 ??? Aug 14/03 file FDA w/Irinotecan CRC (Merck trial). Panel Dec 16/17? Priority review granted Oct 13/03 (PDUFA Feb 13/04) OK Feb 12/03 & CPMP March 23/04 Approved CH Dec 1/03 for refractory CRC

-Cetuximab/Erbitux(C225, ch antiEGFr IGg1) IV QW →K, ph III, manuf by Lonza, Merck & IMCL pancreatic +gemzar : 12% PR (N=40) colorectal + irinotecan(PHA) :23% response in CT refractory patients.N=121, open, no control; CHMPOK March 23/04, ditto FDA Indicated w/Campto in metastatic if refractory or intolerant to Campto alone Oct 2/07 FDA OK for OS H & N + Rx +CT(taxol,cisplat) :21%response in CT refractory patients, 61 patients ph III ongoing ASCO 04 median survival 54m/ 28 m, N = 424 To file 2Q05, delayed to 4Q (April 13/05), June 05 independent private review OK. Aug 31/5 Filed, PDUFA March 2. OK March 2/06 H& N 1st & 2nd line Acneiform rash in 53 %pts correlates with efficacy (but links with IgG1 isotype→C') Priced at $ 10,000/Course, 4 courses/year Sales start Feb 24/04 by BMY + Merck. 1Q04 23.4 (39% royalty), 1st full quarter $ 71.4, 2Q 85.4, 3Q 114.6, 4Q 88, FY 04 260; 2Q05 97.8, FY 05 413, 2Q06 176, 3Q 174.6, FY 1.1 B ($ 652 in US), 2Q07 319ww (US 162) - CDP 791, from UCB Celltech. Aug 16/05. F di (ab) Mab to VEGFR-2 (KDR), ph II. Feb 5/07 IMCL opts out. ?? -cp1C11, IMC 11 21 B(antiKDR,VEGFr2)→K,ph I, ph II RCC init Aug 25/07. ?? -Mitumomab(BEC2) anti-idiotype→SCLC,ph III (not mentioned in 2Q earnings report).Ph II CRC fails Aug 29/07 -IMC 18 F1anti flk(a VEGF receptor)→ph I BC, CRC -gp75 vaccine→melanoma, RES -melanoma vaccine hTRPx3 (2 melanoma proteins + tyrosinase), pre - IGF-1R , ati ILGF, IMC – A12(IgG1), ph I, ASCO 07, ph II CRC init July 07, ph II prostate init Aug 28/07

Merck KGaA (8-12% royalty, coexclusive for Japan) N =330, enrol compl May 02) →ASCO 03 (but some control patients received Erbitux, & Feb 17/03 head of Pharma resigns). BMY (Sept 22/01) 39% royalty (or 60% profit ?) & up to $ 2B deal March 28/03 : Merck statement confirms has been reviewed by radiological committee H&N ASCO 02 : N = 120, cisplat+/- 255, no difference ASCO 03 : 10 posters, 1 oral BOND : ORR in CRC st IV 11% Erbitux alone, 23% Erbitux + Saltz. (I'd prefer> Saltz) July 7/03 Merck file EU, H & N CHMP OK Feb 23/06, EU OK April 3/06 Manuf site licensed FDA June 18/04 CRYSTAL : 1st line CRC w/Merck Folfiri +/- erbitux, open, rand, init May 04, N = 1000. Data Jan 11/07 : PFS signif sup; more at ASCO 07 (and OPUs w/Folfox) Sept 4/07 Merck files EU for 1st line Merck 1Q06 : € 74m Why did they invest in Valigen (May 00) ?? & in Advanced Cell Technology ?


- 84 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS IMGN M IMMUNOGEN (IMGN)

Aug 1/03 :deal w/AVE - anti CD 56 (MY-9-6 DM1), AML - anti IGF 1 receptor for solid k, anti AKT pathway ??

-C242DM1,humaniz.MAb anti mucin cantuzumab +Maytansinoid (mersantine) →colorectalK, phI/II - hu C 242 DM4 -hu901-DM1,maytan. MAb anti CD 56 →SCLC ph II, cervix , AML PRE→→. Ph I AACR Nov 06. 1CR in Merkel. ASH 06 Myeloma. - anti IGF 1R : K, Myeloma, AVE 1642 : in vitro very active on CD 45 – plasmocytes (the worst prognosis) - Trastuzumab DM1, ph I - anti CD44v6, maysantinoid, w/B/ Ingelheim, discont feb 9/05 (skin toxicity ph I)

GSK renegot. june 24/02, term Jan 24/03 ASCO 01 : CEA decreases in 5 pts and ↗ in 4 →may 8/02, partner. BBIOY ( returned July 03 by Vernalis), also GZTC -lic (May 9)maytansinoid technol for MAbs to DNA's Herceptin, TERM June 24/02 -sept 7/02 :partnership w/ ABGX -oct 2/00 :partnership MOR -march 6/01: w/MLNM. Term Jan 26/06 - march 29/01 :w/Raven for targets & Abs.

IMMC K IMMUNICON kit for circulating tumor cells : June 1/07 lic to BMY - approved 2004 for Breast (w/JNJ) - HRPC ongoing - CRC - w/PFe prediction of good responders to anti IGF1R Mab (CP 751,871)

competition Adnagen AG

IMMT IMMTECH INTERNAT (IMMT) -dicationic antiinfectives binding to DNA minor grove -CRP derivatives for K

IMMU K M

IMMUNOMEDICS (IMMU) 30 mn infusion versus 4h for Rituxan 30% of pts become refractory to Rituxan

- CEA scan : dg, MKT - CEA-cide, hMAb *I meta colorectal K, phII™ 85% disease free for 18 months, 58% ORR at 36m (Feb 288/02); naked Ab had quality of trial issue w/FDA -LymphoCide epratuzumab( hu antiCD-22)→NHL, ph III (since 9/00) w/Rituxan in Rituxan relapsed pts: good ORR Dec 9/05, RA ACR 04. Lupus ph III init June 2/05. Ph II OK on clinical score 1pril 24/06 Sjögren ph I/II (ACR 05). Lic to UCB, May 10/06. Sept 06 FDA on hold -*Y LymphoCide, ph I/II

new peptide linker for *I

ASCO 02 :Centre René Gauducheau (Nantes, Dr Kraeber-Bodere) →lic to AMGN (20% royalties) ASH 02 ph I/II, N = 114, active in follicular & large cell, median TTP 86.6 w. Monotherapy trial term (Jan 23/03). Nov 11/03 all terminated. All rights returned April 8/04

IMNR V

IMMUNE RESPONSE CORP (IMNR) Sept 10/02 staff ¬

-Remune (killed, env. depleted HIV) +CT,ph III∏end 02, positive ph II data announced April 23/01, but ph II endpoint missed in Spain (june 3/01). Good data in Thailand w/TMGUE.OB (June 15/01) Trinity Medical Group June 11/02 : to add CpG April 4/07 terminate HIV program

Agouron/Parke Davis(WLA/PFE)TERM July6/01 oct 31/00:legal issues on study publication


- 85 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS INCY INCYTE (INCY)

acq PROTEOME (dec 00) 30000 licenses to pharmaceutical industry!!!! Oct 30/01 cuts 400 jobs (out of 1100) to go into drug dev. w/DNA(Mabs to INCY proteome), MEDX (Mabs to INCY targets). Nov 02 Staff of 700 ¬ 37% .Nov 13/02 acq Maxia ( $ 28.3m) Early 2004 shuts down Genomics. Cuts 275 jobs

-LifeSeq Gold : key genomic data base for EST→→ -LifeExpress : adds RNA and Protein info→→ -SNP in-silico data base -LifeTools : bioinformatics software MAXIA : - MX 5064, pre, diab, w/JNJ - MX 6198, pre, diab, w/JNJ - Reverset, DFC, NRTI, Ph II. July 25/05 data : 1.4 log drop, Sept 28/05 FDA requires 2nd ph II. On hold April 3/06 hyperlipasemia - INCB 3284, CCR2 inhib for inflammation, ph I/II, lic to PFE (£ 40 + 560m) for RA, CV, but keeps MS - INCB 7839, sheddase inhib, ph II, K (sheddase activates EGFR) through ADAM.

DIADEXUS : JV with SBH. BMY,GLX,Nvrts,SGP,PFE,SBH,DNA,BGEN,MLNM. from Oxford Glycoscience proteomics data-base collab LLY, ABT COMPETITION CCR2 antags / MLNM (ph II), MRK (ph II), ChemoCentrix. Sheddases (the ADAM family) cleave CD23 receptor from B lymphocytes. ADAM 10 cleaves CD23, the IgE receptor. So long it stays in the receptor, the response is OK. But if it gets outside, severe allergy occurs.

INFI K INFINITY CSO Julian Adams CEO Steve Holzman merging w/DPII, summer 06

- IPI 504 Hsp 90, Ph I, Myeloma, Gist (good data AACR Prague 06), lic to MEDI/AZN - IPI 609 Hedgehog pathway, pre, w/AZN - anti Bcl 2 res, deal w/Novartis $ 400m March 7/06

Deal with MEDI Aug 25/06 $ 500m

INGN K INTROGEN (INGN) traded since oct 12/00 Aventis could have 23% transferred to spun off Gencell June 18/03 PIPE $ 11.5m

-ING201 (Advexin, Advexin),Ad p 53 gene therapy ™ H & N K, ph III,SPA, March 04 1st ph III init (endpoint survival), 2nd planned (endpoint TTP). NSCLC, ph II. ASCO 01 63% local response. prostate �hi bladder ph I breast : good data San Antonio 2004 H & N ph II -ING241,Ad mda 7 (melanoma differentiation associated gene),ph II, belongs to IL10/IL24 family (immunodepressant) -ING251, Ad PTEN, for glioma & colorectal, PRE - INGN 225 mNSCLC ph II to init IQ08. Patients own cells to stimulate anti-tumor immune response

Aventis returns rights (april 5/01) Adp53 patents uncertain w/Canji/SGP Swedish subs : Gendux Nov 1/06 : to file Advexin EMEA for Li-Fraumeni

INHX AB INHIBITEX (INHX) files for IPo March 4/04 (Piper, Lazard) trades July 04 in US 43000 very low weight neonates per

- Veronate IV (polyclonal Ab to fibronectin like elements of adhesion proteins, from human donors, manuf by NABI), ph II n = 512 completed Dec 03, signif reduct of Staph & Candida infections in very low weight newborns. Ph III init July 7/04(design agreed w/FDA). N = 2000

Data presented ISSSI (11th int sympo staph infections & staph ) Oct 24-27/04 Competitors : NABI vaccine, MEDI/GSK Mab BSYX-A110 (anti lipoteichoic acid), ph II (from


- 86 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS year, 50% develop infection followed by Lazard, Bear Stearns, UBS.

(18m). Endpoint prevention of staph infection in infants 500 to 1250g, nrand v/Placebo. Secondary : candidaFollow-up 70 days. Study to close end 05. Data 1H06 Jan 7/05 : enrolling very fast. FDA fast track (Sept 22/04). Nov 16/05 enrol compl; Nov 29/05 FDA says approval possible for "very low weight group" even if endpoint not met in 500 to 1250 g. Dec 5/05 : DMSB unanimously recommends continuation Rolling filing init Feb 14/06. Topline data April. April 6/06 : NS - Aurexis, ph II, Hz anti staph (MSCRAMM) MAb, manuf by Avid (subs of PPHM), to be manu by Lonza (Nov 12/04). N = 60, completed Jan 7/05. May 9/05 Top line positive

Biosynexus).

INKB M INKINE (INKP) -Thrombospondin derivatives for K : res -Fc receptor regulators : res - Colirest ,oral progesterone, ph III, Inflam. B. D.

INMX INFORMAX (INMX) BioInformatic software

INO K INOVIO (INO) was GENETRONICS (GEB) Oct 17/06 acq Poly Gly polymers for transfection from Valentis S4 filed March 14/01 Claim to have 190 patents (only 27 US issued on Delphion) Oct 29/01 : departure of COO, CFO & 20% of staff. June 10/02 $ 4.3m PP June 20/02 electroporation Bus sold to ICN: NO term Aug 20/02

→K,Bleomycin electroporation, ph II No new data since May 99 : 33 pts in US (H & N, published); 12 in France (not published); pancreatic cancer concept seems to have vanished. Reappears Pancreas Bleo ph I March 1/05 Canaccord mentions ph III H&N and melanoma could start in Q1/Q2/01 electroporation for GT - transluminal cath. for arterial disease w/CHIR & B. Ingel, Sept 13/05 - Prostate I/II init April 1/05 UK (Southampton) MEDPULSER electroporation for chemo (Bleo) or DNA ph III SCC H & N, and skin (sept 06 N = 150) ph I D genes : IL1 melanoma (Vical), IL12 (Lee Moffitt), MRK (Her 2, CEA).

JNJ termin. July 26/01 -communication at ICOOC (April 23/01)on H&N K, discussing but not presenting French trials (Seroussi, Boucicault) B.I. (June 21/01) JNJ australia, Boehringer Ingelheim Merck KGaA

INSM K INSMED (INSM) competitor Tercica Sept 24/02 staff ¬55%

-Somatokine( mecasermin rinfabate) subcut (ILGF + its binding prot), filed HGH resistant growth retardation March 10/05, PDUFA Jul 3/05 (Tercica filed Feb 28) diabetes, ph II (IGF alone DNA/CHIR : retinal lesions). Approved Dec 05 - for osteoporosis : ph II - for Steinert myotonia ph II init Jan 4/06

merged with Celtrix, discussions in France,JV w/ELAN


- 87 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -INS-1: (inositol derived)natural oral insulin sensitizer,ph II:failure (nov 27). June 01 ADA : good data. jan 8/02 : new analysis™better results,Sept11/02 termin. -rH IGFBP-3/AKT Herceptin resistant Breast K, May 10/04 , sequesters circulating ILGF, ph I, - INSM 18 , small molecule inhib AKT, ph I/II prostate (not on web site) ??

ASCO 06 ?

IOMI IOMAI Immunostimulant Ag sparing patch : - bird flu - traveler's diarrhea : good data (April 26/07) but ref probl on web site. Cholera toxin adjuvant ?. May 28/07 : trial shows vaccine made less efficient !!!

ISIS K

ISIS (ISIS) New functional genomics division

(GeneTrove)

Aug 22/01 : LLY has 9% Dec 14/01 : collab w/AMGN LLY agreement : upfront 25 cash + 75 equity + 100 loan repayable after 4 years; milestones $ 50m, royalties & supply agreement, dev costs refunded. Renegotiated June 5/03 on manuf & supplies. Sales forecasts of LY9 by analysts are quite low. March 3/04 $ 19.5 m BioWarfare contract. March 12/04 partnership w/Alnylam

Vitravene (antisense to CMV)→→MKT→→→→ -Hepasense, antisense to Hep C Isis 14803, ph II (micropump inf TIW/4w)→ -ISIS104838, IV/SC, anti TNFα, ph II RA init March 13/02; oral ph I bioavail 7%, Nov 02 (OraSense, JV w/ELN -ISIS 104838, topical, ph II, PSO -ISIS 2302 alicaforsen (anti ICAM 1), Crohn, ph IIIinitiated (enema) failure Dec 2/04; ph II ulcerative colitis (enema) N = 100 init April 1/03, success (Dec 2/04) vs placebo & vs mesalamine. PSO : ph II : failure (Feb 25/02) but topical promising - ISIS 301012, anti Apo B, ph II, w/ statins : lowers > 50% LDL chol, chol, TG , injectable - anti PCSK9 (proprotein convertase subtilisin kexin 9) lowers LDL, lic to BMY May 9/07 - ISIS 2503 anti h-ras, ph II, pancreas data Dec 19/02 N = 48 w/Gemzar, M survival > 6 m, breast & NSCLC enrol compl 4Q02 - ISIS 5132 anti C-raf kinase, ovary, �hi -113 715 (anti PTB1,negative modulator of insulin receptor signalling )for diabetes : ph II, lic to MRK 05/01 -ISIS3521 Affinitak (LY9),anti PKCα→NSCLC, phIII open label "blinded"+ carboplat + taxol (init oct 18/00), fast track granted nov 8. Full enrol N=616. Jan 17/02→ data March 17/03 survival 10m/9.7 NS. 2nd ph III N=1000 3 arms w/Gemzar + cisplat, carbo/taxol,

Ciba Vision Elan, rights returned Nov 6/02 →JV Elan to init. oral in 01:OraSense, init April/01 → returned Dec 26/02 w/LLY (Aug 22/01) ASCO 02: data on 600 pts (in LLY 4Q/01 report) : NO, only ph II. Oct 1/02 LLY loans $ 21m to build facility Dec 02, UBS says “not very effective”.


- 88 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS docetaxel init April 02; data 2H04?Ph II NHL - LY 2181308 (anti-survivin), ph I, lic to LLy May 6/04 - ISIS 345749, anti STAT-3 - LY 2275796 anti initiation factor-4E, ph I, Feb 1/06 - OGX 011 w/AVE & OncoGenex, anti Clusterin (survival gene/protein that increases when apoptosis is induced) - ATL 1102 w/Antisense Therapeutics (Austral) anti VLA 4 integrin, ph II, MS - anti SARS : pre -Genetrove w/CRA, ABT, JNJ, Aventis, LLY, CHIR, MRK, PFE, GSK

ISPH INSPIRE PHARMACEUT. (ISPH) Specialized in respiratory & eye mucosal hydration & clearance, by modulating P2Y receptors. These are linked to the mucosal G protein system. Have patented UTP derivatives : -INS 365→COPD, ph II,suspended April/01 to improve protocol; Nov 02 : discont -INS 365,ph II→dry eyes. Fails prelim anal of ph III. Restarted April 3/02, signif (June 18/02),Approvable, confirmatory underway. Feb 9/05 : failure, Dec 05 2nd "approvable" saying need to demonstrate ! -INS 32217 (denufosol)→CF, ph II - INS 37217 P2Y2 agonistintranasal ph I increases muco ciliary clearance (temporarily stopped (April 02) AUG 14/02 ph II perennial rhinitis p < 0.05, ditto URTI (on nasal drip).,ph III, N = 630, 28 days, DB, composite endpoint, data mid 03

DNA terminates June 20/01. Kissei terminates w/Allergan (has a competitor)& Santen

ISTA Ista Pharmaceuticals (ISTA) Oct 4/02 : could be delisted was "Advanced Corneal Systems" May 15/02: quaterly report warns on financing issues June 12/02 plans $ 30m offering

-Vitrase(hyaluronidase.)→vitreous hemorr (450 000/ Year., phIII;w/Allergan. Fails to reach endpoint of clearing hemorrhage (March 26/02). April 10/02 FDA OK for visual acuity as endpoint. Rolling filing clin end 3Q02, CMC (chemistry-manuf-control) end of 3Q, validation 1Q03. Cardinal Health will manufacture (July 9/02). Adv Com March 17/03 : no. April 7/03 "approvable letter" requests another trial.. OK May 6/04 as "ophthalmic spreading agent for other drugs". -Keratase→corneal opacifications

-Timolol, ph III - Bromfenac, topical NSAID, ph III - Caprogel, ph III, epsilon amino caproic acid

ISV INSITE VISION (ISV) Glaucoma research & drug delivery -Genotyping for TIGR (glaucoma)

-Ciba Vision -Bausch & Lomb


- 89 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - ISV 205, anti TIGR, ph II, returned by PHA (May 01) - ISV 401, azithromycin for bact conjunctivitis, ph III (endpoint bacterial + clin) - ISV 403, quinolone, lic to Bausch & Lomb

ITMN

INTERMUNE (ITMN) 85% of sales are off label in IPF, but declining April 03 "Patients fighting pulmonary fibrosis" sue ITMN for "suppressing" a life-saving drug (pirfenidone) to protect Actimmune mkt. Nov 10/04 Subpoena on promotion of Actimmune Pirfedinone would sell at 30 to 40,000 $/year; cases US/EU 200,000

-Actimmune : gamma interferon, MKT for chronic granulomatous dis.& ostopetrosis $13m/00;36/01; 105/02; 1Q03 38, 2Q 33. 2004 : $ 125m, 2005 $ 107 Phase III init w/BI for resistant TB (March 01) Interst. pulm. fibr. ph III DB N=330 completed Aug 28/02 : reduct in mortality NS (p = 0.08) except in subgroup mild to moderate (p = 0.0008) perhaps by reduced surinfection.Filing 4Q02? Fast track (Feb 02). Ph II Vienna was only N=18. Presented ATS May 05. Data 08. Terminated March 6/07 Cryptococcus meningitis, ph II Other ph III anti K, ovary, w/cytostatics : halted Feb 3/06 -Duramycin (Lantibiotic, 19 aa peptide, increases Cl transport) CF, ph I (Johns Hopkins) - Infergen, Hep C , MKT (00 : $ 14M), active in pts unresponsive to PEG IFN + riba (DDW 03), 50% of pts are non-responders; data 2007. Sold to Valeant Nov 29/05 $ 135m - PegInfergen, pre, w/INHL (Oct 9/02) - Amphotec (liposome amphotericine) comkt w/Alza, sold to Three Rivers (May 25/05) - Oritavancin (lic from LLY Sept 20/01), ph III SSTI (init Jan 01 to be completed end 02?) N = 570, ICAAC 01 = Vanco/cephalexin, but faster , ph II sepsis (was to be completed 1H02); high affinity for Albumin - Pirfenidone, P38 gamma inhibitor (lic in April 02 from Marnac), ph II, , May 12/03 > prednisone on SaO2 (p = 0.014) in pulmonary fibrosis ph III ( N = 580) init April 28/06 (25% hypersensitivity reactions ?). and ph III in Hermansky Pudlak to initiate 1H06. Blocks TNF receptors.. Data 09. March 20/07 135 pts added, & Tmt increased from 60 to 72 weeks. Endpoint FEV1. Nov 26/07 bought back from Marnac - ITMN 191 : NS3/4A protease inhib. Hep C. Lic to Roche

spinoff from Connetics → Eur Resp Soc Sept 15/02 → Amer Coll Chest Physicians Nov 3-7/02 Amer Thor Soc May 22/02 N=18. Press .release but not in abstracts on ++ 5 year survival ?? (weird trial) Jan 8/03 : follow-up survival NS. Init 2H03 a 2 year ph III in 600 mild to moderate IPFs. Topline 1Q08 w/Molichem (MLCM) acq by CZVD (Cortez Ltd) lic from AMGN (June 18/01) acq from Alza, Jan 01 NDA filing SSTI end 02 ? or 4Q03, then 1Q 04, and 2005 !!!!.I'm not sure about the protocol. Will be manuf by ABT. Oct ½ LLY exercises option to force ITMN to purchase reduct in royalty rate. Dec 27/05 lic to Targanta Marnac Inc had Pirfenidone in MS, ph II, now only neurofibromatosis

IVGN INVITROGEN (IVGN) Acquired "Research Genetics", costs

negatived 1Q earnings

sells 250 different cloning kits to more than 30 countries a low risk entry to the genomics playground (as LTEK & TECH less "genomic focused",and Promega and Stratagen private)


- 90 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Oct 02 : acq InforMax July 2/03 acq Molecular Probes ($ 325m) leader in fluorescent labels

July 9 :merger agreementw/LTEK

IVPH K INNOVIVE - tamibarotene : oral retinoic acid derivative, 3rd line APL (under SPA) init Aug 3/07, N = 50; endpoint 28 days CR - INNO 206, ph II, prodrug doxo, SCLC - INNO 406, ph II, dual bcr-abl/ Lyn kinase inhib (in vitro 50 times > imatinib)

APL is due to fusion between 15 & 17 involving retinoid alpha gene. Ist line ATRA, 2nd line Trisenox

IZP INFLAZYME (IZP/TSX) - LSAIDS (leucocyte selective antiinflammatory drugs) - IPL 512602, asthma, allergic rhinitis, ph I , Aventis will go into ph II

Aventis Feb 99 Aventis Nov 02 ( $ 90m deal)

JI4G JERINI (Frankfurt JI4G GR) Icatibant, see Dyax. To file end 07. Top line 3Q06

JNJ AB

PENINSULA (PPRX) CSFB, DEc 16/03, postponed March 04, refiled Jan 19/05, delayed Feb 10/05 : Acquired $ 245 m April 19/05 by JNJ

- Doripenem, S 4661ph III, injectable Carbapenem, HAP, VAP - PPI-0903, cephalosporine spun out to "Cerexa"

JNJ

SCIOS (SCIO) PP of $ 125 m convertibles July 29/02 Feb 10/03 : JNJ acq for $ 2.4B (30% premium on shares) cash

-Natrecor(ANF)I.V.→acute CHF,FDA turns down (but Adv com was 5+/3-;gives bradycardia). New ph III init. Oct 99,�hi�lmen jan 01; Adv Com May 25 /01:OK 10/0. FDA to decide by July 10 (�hi�lment issues, panel concerned by t1/2>nitrites). July 10 approvable letter ∏ manuf inspection compl. July 19/01, �hi�lment.. $ 380 per vial. FDA OK 8/14/01. Sales 2001 $14m, 2002E$56m, 1Q02 15.4m -w/Medtronics assoc.w/heart failure devices -Fiblast(rFGF)→stroke -Fblast→coronary→→→→→→→→→→→→ -SCIO 469,oral p38 kinase inhib(anti TNF,IL1 & COX2), ph II,RA.

lic to Bayer Bayer discont. GSK for EU (Jan 8/02),launch 1H04 -alone (a niche mkt is possible) 2 negative letters JAMA end July 02 AHP returns rights to Scios, who lic to CHIR (whose FGF is bovine) competition : other oral p38 inhibs GSK & JNJ

KAL K CALLISTO (KAL) - Atiprimod anti PI3K / Akt & Jnk / STAT3, multiple myeloma, carcinoid ph I/II - Annamycin ph II ALL - Degrasyn (from MD Anderson) Stat3 inhib (pre)

AACR April 07


- 91 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS KERX K KERYX Biopharmaceut. (KERX)

Jerusalem Aug 15/02 staff ¬ 45% Jan 9/04 acq Access Oncology Feb 13/04 PIPE init $ 32m

Regulators of signal transduction : - KRX 211, pre, Jak kinase inhibitor (w/Lynx) -KRX-101(sulodexide,mixture of heparins, oral) : diabetic nephropathy (reduct of proteinuria), ph II. To file for ph III - KRX 123, prostate K, ph III - KRX 0401 perifosine (in CND Aeterna/Zentaris): AKT inhibitor (also inhibits MAPK & JNK) oral. Ph II Breast, prostate, Melanoma, pancreas, sarcoma, H & N, NSCLC, Breast w/Herceptin, init May 11/05, ph II leukaemia init March 2/06. ASCO 06 ph I/II lung, breast; mono & combi CT/Rx - KRX 0402, inhibits DNA repair, ph II - KRX 0403 spindle poison, ph I/II. - Zerenex, ph III, iron based phosphate binder, oral - UCN-01 (7 hydroxystaurosporine), ph II, multikinase inhib lic from Kyowa Hakko, Oct 4/06

other AKT inhibs : Neogenesis, Amphora, Immunogen, ABGX/PFE, Insmed, Exelixis (PTEN path), P. Fabre (F 50035 lic to MRK), Greewich Therapeutics (& Vioquest : Tricirbine), Rexahn (RXHN). Astex (anti PKB, lic to AZN July 27/05)

KOOL C THERMOGENESIS (KOOL) agents for cell therapy

KOSN K KOSAN (KOSN) trading since oct 9/00 Dec 10/03 shelf SGCowen, CIBC, Adams Harkness - Drops secondary Aug 16/05 - Aug 15 : NCI amends protocols : EKG prior to treatment

-new polyketide ABs, oral, pre - Epothilone D (KOS 862), phIb w Gemzar init March 4/04, non MDR sensitive Taxol analogue patent issued April 10/01 to MSKCC, exclus lic to KOSN, lic to Roche (Sept 24/02, term Oct 07). Upfront $ 30m. $220m deal including milestones. Signif royalty. Ph II mono CRC, NSCLC. June 13/04 CRC halted (neurotox in pts who had had oxali).Nov 23/04 NSCLC halted Init alone in HRPC, ph II init Feb 14/05.. Oct 18/05 prostate halted, breast ongoing HER2+. Discont Feb 27/06. - KOS 1584, new Epothilone, w/Roche TERM Oct 07, ph II (R1645) - KOS-953, tanespimycin, 17 AAG allylaminogeldanamycin, which disrupts heat shock protein HSP 90 binding of many oncogen client proteins (BCR-ABL, cRAF1, ErbB2, AKT, CDK4, mutant p 53) & thus neutralizes them, ph II melanoma , monotherapy colon, then assoc w/Xeloda, ph I myeloma. June 15/05 : 3 EKG issues April 16/07 serial EKG on 85 pts OK; Assoc w/ Velcade Eur Hemat Assoc June 3/05; assoc w/ Herceptin Breast ph III MM 2nd line to init 1Q08; Sept 7/07 FDA OK on protocol 2nd line.

JNJ competitors : BMY (ph III, ASCO 06 ixabepilone, Breast ), Novartis (have another one, less toxic ??) Competition : IP 1504 (Infinity Pharmaceuticals ph I/II w/MEDI), highly soluble HSP 90 inhibitor, Conforma


- 92 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - KOS 1022, alvespimycin, HSP 90 inhib, ph I; Sept 10/07 clinical benefot in refractory Her+ breast. Preparing for 1st line alone & 2nd line w / taxol - KOS 1815, res, NEI (nuclear export inhibitor)

LCBM LIFECORE BIOMEDICAL (LCBM) -Titanium dental implants hydroxyapatite coated :MKt -Hyaluronic acid :MKT (production on hold)

LEXG LEXICON (LEXG) -Human GeneTrap database - Switching strategy to develop proprietary drug portfolio

The world's largest bank of knock-out mice:OmniBank -ABGX, BMY,AHP,TLRK,JNJ,BI

LGND

LIGAND (LGND) Nov 02 $ 135 m 5 year convertible offering ELN had 20% after conversion of convertibles (Dec 26/01). Selling all July 3/03 PIPE (April 17/02) $ 69m Complex debt situation (GSK, ELN, Glycomed) 4 products marketed Sept 29/04 class action suit on Avinza : sales 4Q03 due to overfilling of wholesalers

ONTAK denileukin diflitox (DAB 389-IL2 : CTCL, mkt since 1999. 2002 : $ 26.6m, 2003 : 34; 1Q04 7.3 RETINOID RECEPTOR ACTIVATORS (gels 2001:$2M) -Panretin gel→Kaposi, MKT,CPMP OK July 17 -Panretin oral→breastK, ph II/III -Targretin gel→CTCL, MKT, 2003 $ 4m, 1Q04 0.9 -Targretin oral (bexarotene)→CTCL,MKT 2001 $ 14.5M,

2003 : 10, 1Q04 : 3.5 (breastK, ph II NSCLC, good ph IIdata at ASCO, 2 ph III. 1st N = 600 IIIb/IV enrolled Aug 15/03. Front line + cisplat/vinorelbine (EU), carboplat/taxol US. Survival data -> 1Q05: failure March 28/05. 2nd line ongoing w/Gemzar, 3rd w/Carbo-Tarceva -Morphelan (Avinza):once a day morphine capsule,approvable, launched July 11/02 ($ 6.2m for 3Q, 1Q03 : 6.6m, 4Q 32; 1Q04 22.4) . 3.7% Mkt share sustained release opioids. Leaders Purdue's Oxycontin & non branded generics -LGD 1550→H & N K, ph II -collab. res. w/BMY : new antialdosterone

-collab. w/GSK on PPAR agon. Diabetes 501516 -collab. w/LLY on LY 519818, PPAR agon. diab II,ph III to init March 04 : no, delayed 2 years new FDA reg - collab w/WYE on TSE 424 basedoxifene (SERM), osteoporosis,phIII to file 2005 -collab w/TAP on SARMs, osteoporosis -collab w/PFE on Lasofoxifene, osteoporosis, ph III, NDA filed Sept 16/04

Royalties on Novartis's Simulect (from Seragen) Sept 8/06 All antiK drugs sold to Eisai w/ Elan; PDUFA March 23/02:OK March 20/02 For $ 100 m royalty reduced from 30% to 10% May 03 : w/ORGANON (650 reps!!). Jan 18/06 Organon terminates. Sept 06 sold to King $ 265 m


- 93 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -SB497115 w/GSK, oral small molecule thrombopietin mimic, ph I/II (Jan 03). Ph II init Feb 05 : data nov 30/05 2nd line ITP strong efficacy - LGD 4665, also for thrombopenia, to file IND 1H06

LIFC LIFECELL CORP (LIFC) Alloderm (from cadaver skin) : MKT

LIV Samaritan On message board : a scam

- AIDS anti –entry drug, ph III acq Metastatin, r uteroglobin, pre, anti metastatic

LJL BIOSYSTEMS (LJLB) Highthroughput screening To merge with Molecular Devices (MDCC) specialized in other highthroughput systems


- 94 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS LJPC LA JOLLA PHARMACEUTICALS (LJPC)

Avecia manufactures

- LJP 394 (Riquent) 4 twenty mer dsDNA epitopes conjugated to triethylene glycolanti-lupus nephropathy oligonucleotide, ph II/III,not promising new ph III ( N + 730) initiated sept 21/00, reinit 3Q06, to complete enrol. End 07. Interim March 7/07 : at 300 mg/w decreases anti-DNA (soluble complexes) …could be inducing an antibody switching like Coley).. - LJP 1082 (4 copies of 1st domain of β2 GP1 coupled to chemical moiety), I/II, thrombosis in antiphospholipid sd

Manuf by Avecia. ABT terminated Feb 19/03 primary endpoint missed (time to creat ↗ & proteinuria ↗) Follow on trial discont April 10/03., NDA filed Dec 03. Approvable letter Oct 15/04, more clinicals needed, could last 4 years.. Init Summer 04 : 100/300 mg , perhaps 600 & 1200, for 12m, DB.. March 15/05 FDA "unlikely" to grant accelerated approval.; March 31/06 files EMEA

LLY AMEV M K

APPLIED MOLECULAR EVOLUTION (AMEV) was IXSYS Royalties < 3% Nov 21/03 : to merge w/LLY (equiv to $ 400m). Acq completed Feb 12/04

Engineered monoclonals -anti ανβ3, phIIRA -anti CD 40 (anti graft rejection)→→→ - Numax (2nd generation inhaled Synagis), clin. to start 2H01……not yet (4Q02) → Q3/03 - Anti IL 9 being optimized for MEDI - AME 527, anti TNF, to file IND 4Q03 - AME 133, anti CD 20, to file IND 2004

with MEDI (MEDI 570) with BMY w/MEDI

LLY

ICOS (ICOS) acq Oct 17/06 by E. Lilly $ 2.1B Completed Jan 30/07

-IC 351/Cialis tadalafil(PDE5inhib)→MED, 24 hours, less effect on PDE6 than Viagra $ 1.5B 2001 (→less blue vision),NDA filed June 28/01, CPMP July 12/01 -LeukArrest(antiCD11/18)→stroke, ph III halted----- - - PAFase(rPafacylhydrolase),ac. pancreatitis,ph II/IIIsepsis ph III endpoint 28d mortality(enrol since April 01, up to 2500 pts,1st interim 2H02, end 2H05). Term Dec 02 -Sitaxsentan, oral endothelin antag, ph II/III,CHF & PHT( data STRIDE:. to relieve impaired exercise in PHT 3Q/02; terminated ?? - IC 485 (PDE4 inhib), ph I, COPD, ph II fails March 28/05 - RTX (from Afferon), ph II, local use vanilloid for overactive bladder. -IC 747, PSO, LFA1 antag oral, w/BGEN, ph II - 23F2G, hz anti CD11/CD18( LFA1; α Lβ2, MS, Ph II, ? - IC 14 (Mab to CD 14), sepsis, ph I

JV LLY (manuf issues launch delays: 2 plants need to be inspected, this began April 16/02), labeling not agreed on yet. PDUFA June 28/02:CRL April 29/02 on confirmatory clinical & pharmacol studies, & LLY GMP issues (confirmed June 28/02. Icos to file response 2H2003 (Jan 22/ 03 in UK). CPMP OK July 26/02, EPAR available Jan 10/03 testicular tox in animals w/Suntory →50/50 JV TXBT (now ENCY); A Heart Nov 02 ?? - Aug 14/01: partn w/Seattle Genetics for SGN15


- 95 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS LOR K Lorus Therapeutics LOR (CND)

LRP (AMEX) from merger between Lorus & Genesense Nov 2/05 : staff cut 35%

- GTI 2040 antisense to R2, ph II, refractory RCC N = 21, w/capecitabine, 21 d continuous infusion. Jan 12/04 > 50% SD; April 12/05 N = 33 ditto; AML orphan drug status; breast ph II April 18/06 decrease expression molecular target. Also ph II AML - GTI 2051, antisense to R1 component of ribonucleotide reductase, HRPC, ph I - GTI 2601, anti thioreduxine, pre, w/Sumitomo - Virulizin, ph III since Nov 2001 (N = 350), pancreatic cancer , immunostimulant (bovine bile extract), increases IL 17 E & IL 12. Data 2H05: OS 6.8m/6m. But subgroup anal is OK for ECOG 0/1 and "meta" rather than" advanced" Approved in Mexico for malignant melanoma.

ASCO 1st line + Gemzar vs Gemzar alone, then 2nd line for Gemzar failures (Virulizine + 5FU vs 5FU alone)

LPTN K Lpath Anti lipid Mabs - Sphingomab, anti sphingosine 1P, pre, antiangiogenic - Lpathomab, anti lysophosphatides, antimetastasis, Res

LSBC M Large Scale Biol. (LSBC) June 5/02 : cuts staff March 30/05 : cuts staff 1/3

-Hightroughput technologies, especially in Proteomics & functional genomics - Galactosidase α , Fabry, from plants, orphan status Jan 23/03 -Non-embryonic human stem cell research -MAb manufacture in plants(w:Prodigene allied to Epicyte) - vaccine for NHL ph I

-GMNI -BSTE, to generate Ab targets for protein biochips

LYNX LYNX THERAPEUTICS (LYNX) April 18/02 cuts staff 30% Aug 16/01 : collab. on SNPs of Diabetes IIw/GCI (Genomics Collaborative Inc, a tissue repository; private :Invesco,Soros)

Microbead techniques for analysing : -large DNA samples :MPSS Massive parallel signature

sequencing→→→→→→→→→→→→→ -SNPs : MegaType -Proteomics

Aventis, BASF,Hybrigenics SA, AZN March 22/01 : collab w/UroGene SA

MAPP IPO MAPP Pharmaceuticals priced Oct 5/07

aerosolized drugs for asthma & migraine

MATK K MARTEK BIOSCIENCES (MATK) Products from microalgae : -Long chain polyinsatutated fatty acids -GFP

ABT (April 00) : neutraceuticals


- 96 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MATX MATRIX (MATX)

Oct 10/01 : 40% layoffs Jan 5/02 : being acq by CHIR/ Novartis

-Intradose(cisplat+inject.gel)→H&NK,filed4Q00. ODAC Sept 10/01(improves quality of life): negative. FDA non approvable. -MPI 5020,radiopotentiator,phI/II --FMdC(DNA chain terminator)tezacitabine→K,ph II - Accusite (5 FU implant) ph III discont (96)basal cell K

July 31, H & N conf : did not show placebo data

MAXY MAXYGEN (MAXY) spun out of Affymax & GSK IPO dec 99 Simba Gill, President since May 00 Ernest Mario on Board (Aug 01) May 22/03 : IFN deal w/Roche $ 230m

Directed molecular evolution, thanks to : -DNA shuffling technology -Molecular breeding : vaccine deal w/Aventis Nov 6/01 -MaxyScan screening 35 product candidates, Maxy-Alpha, Hu αIFN 250000 x active, IND for 2006, lic to Roche, but have retained the right to develop novel IFN α product candidates specifically tailored for infectious diseases, oncology, inflammation, auto-immune diseases. Sept 23/07 Roche puts ON HOLD Maxy G-CSF ph I init Sept 06 : half life double of Neulasta; July 2/07 init IIa w/TAC γ IFN lic to ITMN (Sept 6/01) Maxy VII (w/Roche, Dec 05).March 14/07 - -Collab w/ALK-Abello (Holland) for allergy drug

Novo-Nordisk, AZN, Dupont/Pioneer, PFE (sept 14) Acq. Profund (DK) specialized in "Intelligent Protein Diversity" Board links with GLX & SBH sept 20/00 : lic prot. for MS to Lundbeck Collab w/Shearwater, the PEG group working w/Roche, competitors of ENZN (for INF ???)

MBI MICROLOGIX (MBI.TO) MBI 853 NL, prevention hosp acq. staph : suspended July 16/01

MBI 594 AN, Acne, ph II MBI 226 (cationic peptide)gel, catheter related infection,

ph III Lipopedtide program acq May 02

ICAAC 02 ?? July 9/02 lic to Fujisawa (20% royalty, low upfront)

MBRX Metabasis (MBRX) CS 917, ph II, diabetes, neoglucogenesis inhibitor, Sankyo halts ph II March 16/05

MCHM MACROCHEM CORP (MCHM) Transdermal/mucosal drug delivery : -Topiglan(alprostadil)→MED, ph III fails endpoint Sept

7/01 - EcoNail : antifungal nail lacquer, ph I

seeking partners


- 97 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MCLS MediChem LifeSciences (MCLS)

Inception 1987 traded since oct 26/00 Acq by DeCode (March 02)

-Medicinal chemistry/combinatorials -Partnership w/Elitra (premier provider of bacterial genomic targets) to develop novel antibiotics

PFE, PHA

MCU MEDICURE (MCU) Albert Friesen

MC-1 (what is it), ph II, OK (Dec 05) to improve CABG results, and angioplasty

Medicure International in Barbados

MDCO

The Medicines Co. (MDCO) Follow-on filed March 5/03 raises $ 85m (MS, CIBC) PIPE (May 01, R. Stephens) recruited reps from Cor & Centocor June 22/02 : shelf $ 32m T1/2 = 25 min : no need for protamin ! Risks/ victories : - CPMP (approval Sept 20/04) for PCI - New manuf process : approved by FDA May 27/03 (CHEAPER !) - 4Q 04 : data from CABG (600000/Year US, 1/3 off pump) . Filing 4Q04 -> Sept 05 ?? June 04 : FDA rejects label extension for HIT, because of CK, and bleed ? files sNDA PCI :answer 05) : OK Dec 1/05 June 15/05 label extension for "percutaneous intervention" and not only PCTA) July 2/07 reacq EU rights $ 45M Aug 7/07 ACC recommends Angiomax for unstable angina (NSTEMI) Plavix T½ > 8h (needs liver metab, CURE trial); Cangrelor : platelet aggreg is nL 15 min after infusion (T1/2 10 min)

- Angiomax (bivalirudin, lic from BGEN March 97, but royalties to climb 10 to 21%, chemically manuf by UCB).Pivotal trials compare to too much Heparin. Sales 01 : $14.2m; 2002 38.3; 1Q03 16.7, 2Q 18.8, 3Q 21.2, 4Q 28.9; 1Q04 31.3, 2Q 34.4, 3Q 37.3 (EU 3.3), FY 05 150.2, 1Q06 32.8, 2Q 53.3, 3Q 55.7; 4Q 60.2; 1Q07 66.6 FDA approved (dec 00) for unstable angina undergoing PTCA,+aspirin. CPMP rejected oct 99. Refiled Aug4/03. Approved June 24/04; being reviewed for NSTEMI (Sept 07) Ph IIIb/IV ongoing with Integrilin (Replace I),Plavix, ReoPro (Cachet), SK (Hero). REPLACE II (angioplasty) started mid 01, AHA Nov 02 1 m data; N = 6000. Angiomax +/- antiplatelet > historical heparin comparator. Nov 03 AHA 1 year data still good (especially in "elderly" or "at risk". Acute Coronary Sd : ACUITY ; Enrol compl Dec 5/05 (13,600), data ACC March 12/06 : RISK : see table. ACC March 07 50% less bleeding than in control group. sNDA 3Q07 filed Aug 7/07; PDUFA CABG Choose (in pts at risk of HITTS, heparin induced thrombopenia & thrombosis sd) & Evolution (150 on pump, 150 off pump) ongoing, open label. Evol.Off pump data Nov 04 : less blood loss than with Heparin (p = 0.03). Evol On pump Dec 29/04 : 95% success vs 91.8% w/heparin-protamin (success = 7 days post surgery w/ no death). Choose data 4Q 05, sNDA in 2005 March 5/04 publication of New Zealand trial N = 100, random, open label, off pump, same safety as heparin, better graft perfusion at 90 d. -CVT-05, bacterial vaginosis, ph II: failure March 26/02

Ferrer (partner for South Europe), and Nycomed Europ soc Cardiol : Sept 01:HERO2 (+SK)∏ missed endpoint Transcatheter : Sept 03 : 6 m data on Replace II : less 180 d mortality than Heparin + antii Gp (but NS) A. Heart Nov 03 A Coll Card April 03 : although costs $ 335 per intervention & heparin $ 10, overall cost savings & less deaths from bleeding. June 1st 03 price increase 8.9% ($ 365) TCT Sept 27/0ct 1-04 : synergy w/Plavix (especially as Plavix will be generic !); registry shows often used w/Cypher stent

outcome 30 days UFH or

LMWH + antiplat

Angiomax + antiplat

Angiomax alone

ischemia% 7.3 7.7 7.8 non inf p 0.007 0.01 bleeding 5.7 5.3 3.0 non inf p 0.001 0.001

Nov 8/04 PROTECT trial of Integrelin vs Angiomax : Integrelin does not meet primary endpoint of coronary flow reserve, but Integrelin improves "perfusion".


- 98 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ReoPro T1/2 12-24h. - Clevidipine/ clevelox from AZN , short acting Ca antag

for acute hypertension, ph III, on hold March 28/05 for atrial fibrillation. Filing accepted Sept 14/07, ECLIPSE trial presented Oct 15/07 - IV antiaggregant (Plavix receptor P2Y12) Cangrelor, from AZN, very short half life. 2 ph III init April 06 vs Plavix. To file 2008. (ReoPro is $ 280m/year)

ACC March 6 – 9 / 05, in favor of PCI and unstable angina, according to Hibernia, but less for CABG

MDVN MEDIVATION Sept 11/07 facility to sell $ 100 m shares

Dimebon (dimebolin) binds cholinesterase & NMDA receptor. Alzheimer ph II vs placebo. June 11/06 : 1 year data, better than Aricept. To init ph III in 2008. FDA might allow filing before. But trials in Russia. Ph I ongoing in US

K

MEDIGENE AG (NM 502090) Board : Winnacker, Afting, who were in HAG top management Aug 02 : cardiovasc is divested. To become an oncol company

Focusing on cardiovasc. & cancer, with gene therapy and classical pharmacology -Vaccine (in AAV)for melanoma, auto-cell therapy, GMP production by AVE/Genopoietic:ph I - Vaccine (in chimeric virus-like particles, VLP) anti HPV for cervical K : initiated in Germany. IP issues -Polyphenon : drug to treat HPV, 1st ph III completed -Etomoxir (inhib of carnitine palmitoyl transferase (switches from fatty ac. to glucose catab),phII⇑CHF - Working on a gene associated with CHF (DCMAG1, dilated cardiomyopathy…) - Leuprogel s-cut, prostate K from Atrix for Europe (April 5/01), filed in Germany (reference state) Dec 4/01, on MKT.

w/AVE w/Schering AG -Genomic alliances : Affymetrix (sept 26), Ciphergen (oct 19), Compugen (sept 13) Known tox : insulin resistance, intramyocellular lipid accumulation, hepatic & cardiac hypertrophy. Terminated June 13/02 - Acq.(jan 01)NeuroVir (US)⇑K Therapy vaccines from recombinant HSV: - G207, brain K, ph I/II (MSKCC) -NV1020, hepatic metastases of colorectal K, ph I/II, MSKCC.

MEDG IPO Medgenics (LSE) Traded Dec 4/07

BIOPUMPS Biopsy sub cut to get tissue; transfect w/gene in Adeno, reimplant :ph I/II EPO, planned HGF, hemophilia. BIT SENSORS ???

MEDX V

CELLDEX filed Sept 4/04) 70% owned by Medarex

- HCG-Vac (cancer vaccine), Ph I, CRC, pancreas, init May 04 - CDX 110 anti EGFRvIII peptide vaccine, glioblastoma

Has acq Lorentis Ltd (program on NOTCH, and Alteris Inc.


- 99 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ph I ( Brain tumor Ctr at Duke , MD Anderson) : TTP 315d vs 124 (historical) p < 0.007; OS 21m vs 12, ph II N = 23 enrol compl April 06

MEDX M K

MEDAREX (MEDX) The HuMAb-Mouse company (acq GenPharm in 1997) May 17/07 new CEO (from Chiron, until sale) Howard Pien owns 30% of GenMab acq. 34% of IDM (oct 24/00) cGMP manufacturing : Utrecht San Jose (CA) Annandale & Greenwich (NJ) Aug 15/02 : delaying manuf build-up Partnership w/PFE Sept 20/04

Fully human : -MDX-CD4,→RA, ph II -MDX 010, ipilimumab anti CTLA-4, IgG1, K prostate, also w/CEGE GVAX, RCC, ph I/II; ph III (SPA) init Sept 04. N = 750, melanoma refractory stages 3 & 4 (3 arms : alone, w/MDX 1379, 1379 alone). Endpoint : response rate. To end 1H 2006. 2nd ph IIImonotherapy, 2nd line, init April 1/06. enrol compl Jan 4/07 To file 4Q/07-1Q/08. 1st line init June 19/06, N = 500 +/- dacarbazine, endpoint PFS -Anti CD 137 (BMS-66513), ph I init Nov 15/05 - MDX 066 (anti toxin A) and MDX 1388 (anti B), Sept 6/06 init of ph II Clostridium difficile associated diarrhea. Single dose randomized vs placebo. N = 200. Data end 07/1Q08 -MDX44 f hu anti IL8 Fab, very high affinity, PSO, res (w/BSTE); but look at ABGX!! - Golimumab, CNTO 148 , anti TNF (successor of $ 3B Remicade) (once a month SC ! Humira is QW. To file end 08. 3-5 % royalty, w/JNJ; ACR 4Q07 - MDX IL15, ph I/II, RA - MDX 060 (antiCD30), lymphoma, ph II - MDX 070, anti PSMA, cross lic. w/MLNM - Ticilimumab (CP-675,206),anti CTLA4, IgG2, ph III, melanoma, w/PFE - CNTO-1275 anti IL12/IL 23, 3-5 % royalty JNJ, PSO - 19D12 : anti IGF-R Bispecific : -MDX-210 (anti her2/Neu & FcγRI) Ovary , ph III, Prostate, ph II ,PSA¬ -MDX-447 (anti EGFr)→K, ph I/II→→→→→→→→ -MDX-220 (anti TAG72)→K, ph I/II,colon&prostate Humanized : -MDX-33(anti FcgammaRI)→autoimmuni., ph II w/AVE -MDX-22, BM purge/AML, ph II Immunotoxin bound : ricin

patents cross-licensed w/ABGX ASCO 02 melanoma N=17, 2PR;prostate N=7,2 PSA¬ 010 partnered w BMY $ 530m Nov 9/04 Royalty 20% Competition PFE/AMGN/ABGX Ticilimumab IgG2(royalty 10%) Anti CTLA-4 side effects ? w/IMNX +activated Monocytes w/IDM: ph II ASCO:good data outside of cell therap : Scil AG w/Merck KGaG REGENERON : Targeted genomics EOS : high throughput research of Ag targets Kirin (transchromomouse)& crossbreed of both mice. MEDI : Numax -Epigen (Human carcinoma Ag), -OGS to develop Abs -LLY (nov 6), -GMNI, -Athersys, JNJ (Centocor), Corixa - BIOSITE : phage display, + LLY:Transphage -Novo Nordisk, -Novartis, -Aventis, -Seattle Genetics (feb 01) -Immusol (inverse genomics), feb/01


- 100 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -MDX-44, →PSO, ph I/II -MDX-RA→anti epith. regrowth post corneal surg. Vaccines : - MDX 1379 : 2 gp100 melanoma Ags.

-SGP March 29/01, INCY (Oct 18/01)

MIPI IPO Molecular Insight, priced Feb 2/07 - Onalta, edotreotide, radiolabeled somatostatin, ph II, lic from Novartis

MITI C V M K

MicroMet was CancerVax ( CNVX) From John Wayne Cancer Institute (Santa Monica) ????? Files for IPO Aug 15/03 (Lehman) : 72m trading since Oct 30/03 Jan 9/06 to merge w Micromet AG (closed May 3/06) : - MT 201 fully Hu Mab anti Ep CAM expressed by cancer stem cells (adecatumumab epithelial cell adhesion molecule), partnered w/Serono Dec 7/07. Ph II Prostate, mBK (w/Taxotere). Fails Dec 4/06 but endpoint too tough (good dose response)

- Canvaxin (3 allogenic whole cell lines vaccines), ph III melanoma ( N = 1100 stage III, 660 stage IV), New enrol on hold (characterization of product) May 2/02. Reinit April 15/03 (feb 04 enrol 870 stage III, 349 stage IV). Enrol stage III, N = 1118 completed Sept 20/04, survival interim 1Q05delayed (Jan 05) to 3Q (all data delayed from end 05 to mid 06) for st III, 06 for st IV (April 6/05 stage IV discont). Oct 4/05 st III discont Dec 9/02 Melanoma stage III 5 year data (N = 2600) survival w/vaccine 56.4 m, versus 31.9 (p = 0.0001) Fast track. Safety Committee OK on interim March 1/04 Colon to start - March 14/04 : T-oligos lic from Semaco, telomere homologue oligos, K - Monoclonals : from Cellmatrix, D93 (anti cleaved collagen, antiangiogenic) - EGF vaccine lic from Cuba. ASCO 04. After 1st line in NSCLC, rand to BSC or vaccine. Survival (p < 0.05) 17.33 m / 10.27 m. Co dev w/YM Bioscience - MT 203, anti GM-CSF for RA, w/Nycomed. Ti init clin 2008

Partnered w/Serono Dec 16/04 50/50 US, exclusive ROW Trial stopped Oct 04


- 101 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MLNM

M K

MILLENIUM (MLNM). N = 2150, Dec 02 Staff ↘ June 6/03 : to cut 600 Dec 5/02 : changes in senior execs; Merge w/CORR Feb 12/02 Until 2006 EPS to be disappointing because of genomic revenues ↘ " Indicated ( May 03) for MM pts who have received at least 2 prior therapies, with disease progression" March 05 approved 2nd line Myeloma 15000 new/y US, 11000 deaths ww Prevalence 80,000 Price $ 20,000/year Manuf. cost ??? Sales init May 20/03: 2Q : $ 7.9m, 3Q 23 ; FY 59.6; 1Q04 29.6, 1Q05 45, FY 06 220?5 (+ 15%), 2Q07 62.6 ASCO 03 > 20 abstracts Onco sales force : 75 Research : melanocortin COR THERAPEUTICS (CORR) (but the acq was in convertible notes to be redeemed April 29/03 → $ 637m cash, could be delayed 1 year) . NO, paid April 29/03 CV Sales force : 100 July 1/03 : EU Velcade to JNJ (just after they received the CPMP questions). Low upfront shows concern, CPMP could wait for ph III results for milestones. Upfront 15m + 40% of joint dev costs (to 2005, could be $ 500m), milestones $ 500 (125 Myeloma, 330 other K, 65 if EU sales reach a certain level), R 20 to 25%. June 23/04, forEU, switches Integrelin to GSK. July 25/05 US rights to SGP

Genomics -obesity, diabetes II, -Cancer, -Atherosclerosis, -CNS,, -Inflam.resp.dis. -Fungal infect, -Bacterial infec, -Inflammation- Thrombospondin mutations™coronary dis.™™™ Humanized MAbs from LeukoSite (merger oct 14/00) : -Campath(anti CD52)→CLL),EU OK march 29/01 "under exceptional circumstances, after failure of other agents". FDA ditto (May 01). Sales 3Q01 : $11m --LDP-01(antiintegrin)→stroke, �hi, w/Xoma, terminated Oct 10/03 -LDP-02(to a4b7 integrin r)→ulcerative col, ph II, w/XOMA/DNA - MLN 591 *Mab to PSMA, ph I, prostate K, MLN 2704 w/maytansinoid DM1 selected by CDER March 04 for MAP2, term Jan 26/06 Other small molecules : -LDP-519(proteasome inhib)→stroke, I -Velcade LDP(PS)-341 Bortezomib dipeptide boronic acid analog (proteasome inhib), I.V.→refractory myeloma, ph II enrol compl(N=75 expanded to 200). CLL ph II, NHL,pancreas (w/gemzar) colon (w/5FU or irinotecan, halted Jan 04)ph I , Breast (w/Taxotere)ph I,carcinoids ph II, ovary,NSCLC ph II 2nd line ASCO 04, RCC ph II.Neuropathy gr III : 3% -LDP-977(small mol. inhib of Leukotrienes)→asthma,ph I,oral, lic to Taisho (on hold, liver tox) -Molecules from LeukoSite/Morphosys partnership -anti CCR3, asthma, pre, w/Roche -anti CCR 1,inflam, pre, w/Aventis - MLNM 4760, MCR 4 antag, carboxypeptidase inh ph I, obesity - XR 11612, oral dual topoisomerase inhib, pre, K, from Xenova Dec 01 -Integrilin/eptifibatide(antigpIIb/IIIa) : now leader in Rx growth ,overtaking Aggrastat & ReoPro .Lowering of death post stenting 35% (p<0.001). 2001 : $ 231 m. 2002 : $ 303, 1Q03 89 2Q 92(50 to MLNM, 1Q04 48) . Could benefit from low price in post stenting package. CABG trial (Cabernet) to start 2Q03; STEMI (w/PTCA init Nov 02) -Cromafiban (oral) : �hi Could be $B MKT. On hold -Oral Xa inhib, pre⇑DVT, ph I init Dec 23/02 - CT 53518 (MLN 518) small molecule FLT3 receptor TK antag, AML, ph I started June 02 (in vitro active on cells with FLT3 mutation). Fast track June 5/02. ∏ ASH 03??; competition CEPH 701, NOV PKC 412, SU 5614 (PHA/PFE) -MLN0415 (w/ Sanofi ), oral, IKK inhibitor, decreases NF kappa B activation

$ 245m/01, $ 193/02. Decreasing Roche;ABT (term Aug 15/03)w Meridia from BASF LLY LLY AHP (K channel protein) AZN PFE WYE Bayer (expired Oct 03 ) AVE (term at 3 years April 22/03) →lic to Schering AG(Berlex), & JV LeukoSite/ILXO sold back to ILXO (Oct 29/01), royalties from 05, fees before 9/16/02 primary end point NS (activity index), but remission signif; DDW 03 remission rate ↗ Oct 8/03 : not to move forward →Genentech, BZL Biologics for DM1 (ph I) w/Paion GmBh (March 15/02) Proteasomes activate bcl-2, NFκB, CDKs → ASH 01(myeloma CREST). ASCO 02.only 78 pts presented, prot M ¬ >90% in 20% pts .Ph III( APEX) init June 12/02 N=700 (95 sites), refractory, open label comp Dexa, 9 months enrol (fully enrol Oct 03), powered for 30% ↗, TTP. Dec 15/03 control arm stopped because of success at interim Fast track granted (June 5/02).DATA ASCO 04. May 18/04 Apex survival signif. ASH 02 complete ph II SUMMIT : 202 pts single arm), : M prot ↘ 50% 27%pts, ↘ 100% 10%; M survival 16.4 m (hist 6m)ph II filed Jan 22/03; PDUFA July 22/03 Approved May 13, 03, filed EU Feb 4/03. Medicare OK Sept 26/03; EMEA OK JAN 22/04. VISTA 1st line MM w/ M & P, N = 682. High signif OS, PFS. Data ASH 07 SGP (50/50 profit sharing), 160 coprom revenue 2002 CRUSADE : N=60000 high risk heart patnts, until 2004, compares assoc Lovenox to w/high mol weight heparins. But (March 18/02) AHA/ACC new guidelines recommends mainly anti gp2b/3a in UA w/PTCA, rather than UA alone.A. Heart Nov 17/20 02 (data on first 25, 000)


- 102 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MNKD MANNKIND (MNKD) inhaled dry powder Insulin, ph III

MNTA MOMENTA - Generic M Enoxaparin, a NDA filed Aug 05. Review will exceed 24 months; rejected BY fda Nov 6/07 : risk of immunogenicity - M118 next generation heparin, ph II

MOGN K GUILFORD PHARMACEUTICALS Merger aborted GLIA (aug 28/00) US Gliadel sales force 45 Acq (July 21/05) by MGI Pharma : $ 177 m

Gliadel : BCNU wafer→recurrent glioblast.,MKT (00 : $ 16m, 01 : $ 14m, 03 : 19). ODAC Dec 4/01 OK(8/5) for first line, but chairman says placebo!Non Approvable March 20/02; Sept 20/02 some new data filed. FDA OK Feb 26/03 -Paclimer :taxol wafer→ovary K, IND ph I/II -NIL-A,Neuroimmunophilin ligand (oral) : Park, ph I→II (Aug 8). July 26/01 : NS !! - Aquavan (propofol prodrug) : (anesthetic), NDA to be filed YE 07 - Naaladase inhib, ph II : diabetic neuropathy - Dipeptidase inhib w/PFE, pre, May 8/03

reacq. (oct 24/00) from Aventis for equity.w/Orion Amgen discont. (Sept 19/01)

MOGN

MGI PHARMA (MOGN) Dec 2/02 : PIPE $ 21m Sept 1/04 acq Zycos & Aesgen

-Palonosetron, ALOXI CT antiemetic, NDA filed Nov02 Approved July 25/03. Sales 2004 : $ 159.3, 1Q06 63,

3Q07 111 -Salagen tablets for chronic dry mouth after H&N radiation-DIDRONEL, MKT, -Irofulven, ph III, liver & pancreatic cancer, term April 17/02 (< 5FU), ph II ongoing NSCLC, ovary - MG 98 antisense to DNA methyltransferase, ph II, H&N and renal, AML ph I - Dacogen lic from SUPG Sept 1/04, approvable Sept 5/05. EMEA filing withdrawn Nov 15/05. FDA OK May 3/06, lic to JNJ July 6/06 ex US - ZYC 101a vaccine for cervical intraepithelial neoplasma, better than tTransgene (Eurogyn 2006, April 25/06) - Saforis, acq w/Aesgen, for oral mucositis : "approvable" Oct 13/06 - AKR 501 thrombopoietin mimetic (c-Mpl agonist), ph II, oral (GSK has Promacta in ph III.

ASCO 03 . N = 1800/palonosetron success 81% / ondansetron 68.6%.. But Generics & new Merck drug. parner : MethylGene discontinues Dec 15/06


- 103 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MORP

M

MORPHOSYS (NM, 663200) Jürgen Drews on the Board Value ++ if they become a drug Company They have synthesized the key genes of Abs, keep them in phages, and can express them in E. coli : time to production faster than for transgenic mice Planning US listing. Dec 01 : Schering acq 10% Dec 3/07 big expansion of Novartis agreement, for 10 years, potential $ 1B

Technology platform for 2nd generation MAbs that can be produced in E. coli : -HuCAL : user friendly human combinatorial antibody library, with 2X 109 Ab variable domain genes,phage display (non exclusive licence from Dyax),patent litigation with CAT : Aug 20 preliminary ruling in favour of MOR. Ongoing litigation on Winter II - CysDisplay : improves screening (Abs are recovered from phages by chemical cleavage rather than elution) -TRIM : triage techn. excl. lic. Johns Hopkins -scFv : non exclus lic from SCA ventures (Enzon) - F(ab) : lic from Biosite - MOR 101 (anti ICAM1/CD54) for burns, pre - MOR 102, PSO, pre - MOR 201, blood borne K, pre

PHA 97→99 (dis) B. Mannheim 95→97 (dis) DuPont :98 CHIR : 98 LeukoSite (MLNM,10 targets) :98 Genome Pharma Corp AG : 99 Bayer (10 Targets) : 99 B.I. expanded Nov 13/06 Roche (MAb for Alzheimer), MLNM, GPC Biotech, EOS, ProChon Biotech(Israel):MAb to HGFr™K oct 00 : alliance w/IMGN :hu MAbs for K dec 00 : BGEN: MAbs against EST proteins jan 01 : Centocor/JNJ partnership (30 targets) 2003 PFE until 2008, expanded Dec 20/06 until

2011

MDH MEDICURE (CND) - MC 1,, cardioprotective for CABG - Aggrastat : for ACS

MRK ROSETTA Inpharmatics (RSTA) acq by MRK (May 11/01)

Bioinformatics and Yeast models IMNX

MRVT MIRAVANT (MRVT) SnET2 photodynamic therapy ph III , ARMD, term Jan 15/02

PHA

MS BIOMS (TSX : MS.CN) MBP 8298, synthetic myelin basic peptide (17 aa)molecular replicate of the site of attack, ph II/III SPMS (secondary progressive MS, and not RRMS) Maestro 01, Ph II/III CND/EU, DB, TTP, 24 m trial. 2nd interim 2008, full anal 2009. US ph III N = 500 init June 07, completion expected 2010Also a trial in RRMS in EU

MSHL K Marshall Edwards Inc (MSHL) subs of Australia Novogen IPO Dec 18/03, trading since Dec 18/03)

- Phenoxodiol (lic from Novogen, Australia), oral, ph III init Aug 07, 2nd line squamous cell K cervix/vagina; small isoflavone, blocks sphingosine kinase & AKT (prevents phosphorylation of XIAP) - Phenoxodiol IV ph II, leukaemia Also in ovary K


- 104 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS MVIR MEDIVIR (Sweden) - Lipsovir, ph III, herpes

- Hep C protease inhib ph II w/Tibotec - Valomaciclovir, ph III - Cathepsin K, osteoarthritis

MYG K MethylGene (MYG : TO) Don Corcoran

-MG 98, w/British Biotech & MGI Pharma, ph I, DNA methyltransferase inhib

-MGCD 0103, orally active histone deacetylase enzyme, ph I.>? Partn. w/Pharmion Jan 31/06

-Small molecule inhibitors of VEGF R family and also c-Met, Tie-2, Ron- kinases - Sirtuin antagonists (histone deacylase inhibs), pre, w/PHRM

lic to Taih o, Oct 21/03 ASH 05

MYGN K MYRIAD (MYGN) 65 reps selling to oncologists of predictive tests BRCA, Colaris, Melaris (for melanoma) since Sept 27/01

Genomic by population studies (Utah, Quebec) : BRCA 1 & 2 CHD1 (coronary heart disease) Gene predisposing to Diabetes I MMAC1 (glioma gene) MMSC1 (prostate K gene) -MPC7869 Flurizan(flurbiprofene stereoisomer !), prostate K,ph II, acq. from Encore, ph II/III init Dec 01 (to last 2y)JAN 8/07 fails; also in Alzheimer , called SALA selective amyloid beta lowering agent (lowers amyloid beta). 2 Ph III.US fully enrolled (N = 1687) top line YE 07, 18 m Tmt; global to complete enrol 1H08 Slight efficacy, side-effects -MPC 1203, antithrombotic protein, pre. - MPC 0920 oral antithrombin, precl - MPI 176716, pre, apoptosis activator, prostate K, NHL - MPC 2130 apoptosis inducer, ph I to init 1H07 - MPC 6827 Azixa, from Epicept who got from Maxim, anti tubulin polymerizing agent, "vascular disrupting" ph II init March 8/07 ,glioblastoma w/oxaliplat vs oxaliplat alone. AACR 07 data in vitro induce surge !! Aug 16 init 3rd ph III in brain metas of NSCLC, w/temozolamide

NABI V

NABI (NABI) Nov 4/04 filing Phoslo EU (Mut Recog) (with also CARE study)

-StaphVAX (types 5 & 8, 85% of cases), ph III: sept 18/03 fails to meet 12 month endpoint, but signif at 10 months (40%). 2nd ph III fully enrolled Aug 17/04 in ESRD N = 3600, enrol. in less than 1 year. Data

Supplies plasma to Baxter ICAAC 05


- 105 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS AB

Dec 20/05 closes EU operations (primary endpoint 8 m) Oct/Nov 05. Fails Nov 1/05 Filed EU Dec 21/04 (w/1st ph III). Withdrawn Nov 1/05 Could be due to contract manufacturer (changed to Cambrex, add Ags 336 & PS-1; will reinitiate (March 22/06) Jan 5/05 : init of study in prophylaxis of orthopaedic surgery infections. N = 120, Data 3Q05. End point Ab levels, BLA filing 4Q05, Oct 3/05 95% pts reach good Ab level. Other target : cardiac valve protheses. - next generation staphvax ( 5, 8 & 336) -Human extractive immunoglobulins : -NABI-HB, MKT →prevents Hep B -WinRho SDF (anti D)→ITP -Autoplex T→anti inhibitor for Hemophilia A - Altastaph Ph II failure Nov 7/04. Stopped Nov 1/05 - Civacir : hu polyclonal Ab for Hep C in liver transplants acq Phoslo (Ca acetate) : DB > Renagel Nov 03, Kidney Internat May 04 > Renagel (CARE) June 04 init Phoslo + Lipitor to prevent calcify in ESRD. Data end 05. - Antithymoglobulin, acq from Fresenius April 4/06

NBIX

NEUROCRINE BIOSCIENCES (NBIX) -Shelf filing (Nov 29/01) - Secondary Nov 01 : $ 163M Indiplon lic to PFE Dec 19/02, upfront $ 100m, milestones → $ 300m (clin trial success, filing & approvals). Dev funding; $ 175 m credit line post launch; PFE will develop NBIX sales force (200) for Indiplon + Zoloft IR : capsules MR : tablets April 11/05 : Sanofi extended release Ambien "approvable". June 25/06 PFE terminates

-CRFr antag 30775→anxiodepression, ph II -CRF antag NBI34041,,anxiety/depression & Irr BS (July

24/01) -NBI5788APL (peptide from MBP) →MS, ph II (APL = altered peptide ligand) terminated March 8/06 -NBI 3001(IL4 fusion toxin)→glioma, ph II data Dec26/02, N = 32, survival ↗ -NBI 6024(APL)→Diabetes I, ph II, w/Taisho -MCR4 agonist™™™™™™ -Indiplon NBI 34060 Indiplon,hypnotic,8ph III init Nov 16/01(non BZD GABA agon). 2 formulations (bed-time MR & middle of night IR but out of the system by morning; filing 1Q04 a bit delayed N=2200. Launch 1H05. Ph III MR 15 mg, N = 229. Data released Sept 9/04. Filed IR Oct 19/ 04, MR filed Nov 22/04 Dec 21/04 : FDA refuse IR (navigation issue) Jan 11/05 will also resubmit MR : IR end of 1Q/2Q, MR 2Q? IR capsules refiled April 14/05. MR Tablets refilled

J & J discont (liver enz ∨) lic to GSK Oct 29/01; $15m milestone 4Q01 Novartis But (Oct 14/02) Taisho abandons all but Japan acq Northwest Neurol., MCR specialist. Lic from AHP 98 (Ambien patent 2005) then from DOVP, latest patent∏ 2020 ! Permanent news flow : 1st ph III data Nov 14/02 on IR : p < 0.0001. 2nd IR ph III + April 22/03 (3 IR ph III to come, & 3 MR; middle ?) June 23/04 Sanofi files Ambien CR (patent 2007), and SEPR has refiled June 16/04 -> PDUFA Dec 15/04. approved Jan 12/05, but mkt delays due to schedule IV issues. Sept 6/05 Sanofi Ambien CR approved


- 106 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS May 30/05. PDUFAs capsule May 15/06, tablets March 27/06. ADV COM May 15/06 for both : IR approvable, MR not approvable : 2 years delay for MR ? - Oral GnRH antag, ph I

Others : LLY, AHP, Taisho

NBY IPO NovaBay antibiotics NEOL M

K

NEOPHARM (NEOL) June 04 Chairman & CEO resign Sept 6/04 : Kapoor (largest shareholder files to fire the Board) March 16/05 CEO (Greg Young ) resigns Nov 1/05 new CEO G. Herrera forecasted price of Cintredekin : $40,000

-Technologies licensed out : LEP(liposomal cardiolipine encapsulated paclitaxel), ph

II/III LED(lipos. encaps. doxorubicine), Ph II/III -Developments : LE-AON antisense to c-raf in lip., ph I/II IL 13 ( only K cells have IL 13 receptors) chimeric (pseomonas toxin) prot.cintredekin besudotox→glioma 2nd line, ph I/II (MD Anderson + CBER) median survival 52w. Follow-up Eur Ass Neurooncol Sept 18/06 : best results in patients with optimaly placed catheters. Ph III March 8/04 against Gliadel (PRECISE) , continuous intratumoral infusion. Orphan. To last 18m.N = 300; Prim endpoint 50% > Gliadel (historic = 28 w), interim at 100 deaths (reached Nov 21/05, end Dec, review com recom continue). Interim 160 deaths 2Q06Filing end 06 ? or earlier : enrol 250 Sept 27/05. Enrol compl April 06. Could fail (June 22 : cath positioning). Dec 11/06 fails; survival 36.4 m vs 35.3. March 29/07 FDA requires new trial June 11/07 to init nebulized in pulmonary fibrosis - TR 38 : targets EGFR + pseudomonas, tox, ph I Mesothelin scFv MAb(+ PE38 toxin)→mesothelioma,

H&N ph I/II Liposomal SN 38, (active metab of Campto whose

patent expires 2007,$800m/y), ph I/II. Failure CRC April 2/07

→PHA, fails, NEOL could reinitiate →PHA, fails ; NEOL sues PHA (formulation!) April 21/02; SEC investigation May 11/04, not relevant May 04 Amer Ass Neurol surgeons : side effects, long term depends on cath position. 5 ongoing trials CMA Continuous marketing application Pilot 2 program by Div of Oncology April 8/04 manuf by Akzo Nobel AACR April 03 ASCO 03

NEUSF NEUROSEARCH (DK) Nov 16/06 expands GSK alliance

- ACR 16, end of ph II, Huntington - NS 2359 depression ph II GSK - NS 2359 ADHD ph II GSK - Tesofensine obesity ph IIb, March 7/07 partner delayed (is it like Nomifensine hepatotox ??). Data Sept 17/07 dose dependent signif weight loss

NEXL V NEXELL (NEXL), was VIMRx -Cell therapy equipment Baxter owns 20 %


- 107 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS C K

-acq K Ags from EPMN(march 01) for dendritic cell vaccination

-Bought CellPro in 98

NFLD NORTHFIELD LABS (NFLD) Feb 7/05 Secondary ( $ 67 m) to build plant.

Polyheme : pyridoxylated outdated Hb shelflife 12 m, ph III; Have infused up to 20 Units per patient ! In trauma 75% survival rate ( historical comparator 20%). BLA filed Aug 29/01. Nov 19/01 : FDA issues "refusal to file letter". New ph III (endpoint 30 d survival) authorized March 6/03. N = 720 tmt starts at site of injury. July 04 gets continue nod from monitoring committee. April 12/04 ditto. 3rd interim (250 enrolled). Next at 500. Enrol to be compl end 05. Dec 20/06 fails. May 23/07 FAILS

Oct 01 : Amer Coll Surg

NGEN NANOGEN (NGEN) Genetic testing with nanochips Becton Dickinson, Elan, Aventis,Hitachi NGPI NEOGENESIS (NGPI)

IPO filed Nov 19/01, withdrawn Feb 11/02

NGSX IPO NeurogesX MS, Pacific Growth, Lazard Traded since end April 07

- Transacin (NGX 4010),, capsaicin patch ( 1 application gives 3 months efficacy). 3 ph III (1 fails, 2 good), post herpes neuralgia, to file EU 2007, US 2008. Int congr neuropathic pain June 8/07. Reduct in pain 29% vs 20% p = 0.091.signif data herpetic neuralgie (but takes 2 h to apply) Also liquid formulation precl

see ANSV

NKTR

Jan 03 : NEKTAR (NKTR), was Inhale (INHL) Jan 07 new CEO from RNAI ∗PROPRIETARY DRY POWDERS : - PulmoSol : big molecules - PulmoSphere : small molecules ∗MULTIPLE DEVICES : - "Inhance" : for insulin - "Solo" disposable - MDI : for PulmoSphere ∗ACQUISITIONS / - Bid for Quadrant ($60m) overtaken by ELN in Oct 00. July 21/01 : loses infringement case for trehalose stabilisation against Quadrant) -Bid (dec 21, 00; $200m, compl. feb 01) for Bradford Particle Design (supercritical fluid

- Hu rHuInsulin (Exubera), ph III (since Aug 99), diab I & II. Already 48 months efficacy and safety(FEV1 & DLCO). In type II Hb A1c 9.7%™7.4%, 90 % patients want to stay on "inhaled " rather than return to oral. Filing ww 1H03, later, launch 1H04 ( 05….) open label 1000 ptnt safety trial started May 02 (for 2/3 years) 1 case of fibrosis in 1000 pts is not a concern. According to Pr Attali (Aug 30/01) who coordinates French trials & has seen the data, this 1 case could be eventually related, but 3 others have other causes. He compares activity to that of Humalog (LLY) Filed EMEA March 04, CHMP OK Oct 14/05, FDA accepted for filing March 2/05. Could reach mkt 2006 EU, 2007 US. FDA panel OK Sept 9/05 (7/2). PDUFA late Oct., delayed to 1Q06. FDA OK JAN 06 (launch mid 06). On MKT May 06. GP launch delayed until Jan

™PFE ( production of insulin by AVE), end 05 Aventis sells to PFE

copromotion PFE/AVE(3/7 sales share,INHL 20%R) May : ATS : less LRTI than in controls ! June 01 : ADA better HbA1c with bedtime Ultralente than 2 regular insulins/24h, but more Abs June 02 ADA 28% pts have Abs (4% with sub cut), signif decrease in DL/CO PFE dec 18/01 analyst meeting : FEV1 ¬ 1%. July

25/02 seems ditto in injectable ADA June 07 : 3 years trial "small lung function

median decline, reverts on cessation"


- 108 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS technology ensures longer shelf life). Partners : AZN,BMY, GSK, LLY, PFE ∗Key People : J. Patton, R. Platz , world experts in respiratory protein delivery. VP regulatory spent 15 years at FDA. ∗May 22/01 : acq Shearwater (operates roughly at breakeven), will split royalties on CDP 870 w/ENZN June 18 /02 Aventis R/D day too enthusiastic→short Dec 17/02 : staff ↘ 10%

07. SALES ?? PFE analyst conf end Nov 06 : working on new generation device; Exubera terminated Oct 18/07 -INF β, ph I , MS, suspended Jan 24/02 -AAT, ph I aerosol, cong. emphysema,completed April/01; ph III delayed. Launch 05 -Forteo (PTH), ph I , osteoporosis - Calcitonin (salmon), ph I, osteoporosis - Tobramycin, ph I, DPI (lung delivery x 3.5, speed X 10), w/CHIR - Amikacin, w/Bayer , Aug 6/07 ph II -Albuterol, pre, asthma. SHEARWATER : #technology for Pegasys,milestones +R #role in manuf of PegIntron, R #PEG-hGHr antag (Somavert)for acromegaly, w/PHA/PFE, BLA OK March 25/03, also lowers ILGF, milestones + R # AMGN's Neulasta , milestones + R # New mol w/JNJ oct 10/01, milestones +R

Biogen AVE-Behring. Competition : Bayer (IV,MKT) and PPL/Bayer (ph II) LLY (discont Oct 24/01)


Manufacturing : final steps at INHL

NMPS MATRITECH (NMPS) Nuclear matrix prot test : better than PAP NOVC K NOVACEA (NOVC)

IPO filed Feb 13/06 listed May 10/06 Lead Bear Stearns & Credit Suisse, also Pacific Growth CMO & VP Dev were at Genentech

- DN 101, Asentar, ph III, oral calcitriol formulation, HRPC, + Taxotere QW (ph II N = 250, had shown 49% improvement OS vs Taxotere Q3W alone, p < 0.04), N = 900, init April 14/06, endpoint OS. May 30/07 lic to SGP $ 440m; Nov 5/07 HALTED! Oct 11/07 Pancreas + Gemzar +/- Tarceva - Oral Vinorelbine ph III to init late 06 (Breast, NSCLC), lic for US from P. Fabre, - AQ4N, banoxantrone topoisomerase II inhib prodrug, lic from Kudos Ltd, to init ph I/II 2H/06 glioblastoma

qw could improve safety of Taxotere

NPRO NAPRO BIOTHERAPEUTICS (NPRO) specialized in extraction of paclitaxel bulk from yew trees -sells to Faulding -since July 99, contract with ABT -complex affair with IVAX

NPSP NPS Pharmaceuticals (NPSP) April 21/04 for EU : Nycomed files EMEA March 05,


- 109 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS merged w/Allelix (dec 99) Oct 25/02 shelf raises $ 95.8m, MS, ML, SSB Jan 20/02 to merge w/ENZN (MS, SGC). Closing June 03, stock exchange (26% premium to ENZN shares) : NPS will own 53%. Term June 6/03 Sept 22/03 bad data on assoc w/Fosamax

-recombinant hPTH( 84aa) Preos SC daily→ osteoporosis, ph III(N = 2600), 12m interim 2Q03, dosing to last 18 m (conclusion Sept 03);. Aug 19/02 12m data in rats no sarcoma (but 24 m study). NIH trial compares to Fosamax. To file 2H 04??? Delayed (feb 8/05) to 1H05, ACR Oct22/04 ph III 21% hypercalcemias > 107. March 10/06, FDA "approvable" (hypercalcemia). Feb 06 CHMP says OK ! May 3/06 FDA requests new trial (June 12/06 53% staff reduction) Oct 21/02 : commercial lots will be manuf by BI. Bulk by Synco, F & F by Vetter - ALX 0600, Gattex, teduglutide (GLP2 analogue) ph II,

lic to Nycomed, short bowel sd., April 6/04 ph III init; Oct 11/07 misses primary

-AMG 073 Cinacalcet, w/AMGN , calcimimetic, but (A. Soc N Oct 01) vomiting, resp infect, pain, 10% royalty -NMDA antag from spider venom (NPS 1506) →stroke, ph I →head trauma, pre -Metabotropic glutamate rec. program w/AZN (03/01)

OK Feb 06 →AZN discontinued (LLY's Forteo is 34aa fragment (e. coli)of PTH,SC daily, $ 7,300/y; induces osteosarcoma in rats at 15 m (black box), FDA approv. Nov 02, CPMP OK Dec 02; launched , sales $ 25m/03, 1Q06 87m.. OK for spine, but radial demineralistion. April 03 Public Citizen warns against Forteo.11% hypercalcemias AMGN filed Sept 9/03, approved March 04

NRGN NEUROGEN (NRGN) March 20/04 $ 100m PIPE Oct 3/02 staff ¬ 10%

-NGD91 3(GABA modul)→anxiolytic, ph I -NGD97 1(GABA modul)→alzheimer, ph II -NGD96 3(GABA modul)→insomnia,ph I March 11/02 -Melanocortin recept antag→obesity, ph I Nov 13/06 -NGD98 1(CRFr blocker)→depression, pre, w/AVE (Dec

20/01), returned Sept 16/04 - NGD 2000-1 : C5a receptor antag, ph II. RA primary

endpoint CRP (fails June 16/04); asthma.(fails Jan 04)

- NG2-73 insomnia, ph II, Aug 2/07 confusing data - NGD-8243 ph II Lic to MRK, vanilloid receptor antag for

pain - Aplindore, ph II to start. Park. DA partial agonist (D2)

PFE (disappointing, Dec 20/01), will drop PFE, failure Nov 12/02, will drop PFE PFE

NRGX Neurologix (OTCBB : NRGX) - XIAP (X linked inhibitor of apoptosis) in AAV, active in animal model of Huntington (Nov 18/05)

- Gene therapy w/GAD (glutamic acid decarboxylase) AAV, ph I published June 22/07, N = 12; Good. PARKINSON

NRLS Neuralstem, OTCBB


- 110 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS NRM NEUROCHEM (TSE:NRM,

NRMX Nasdaq Bellini was Chairman US IPO Aug 20/03 w/UBS (NRMX)

- Alzhemed, ph III, 3 amino 1 propane sulfonic acid, fails Aug 27/07

- Alzheimer vaccine - Alzheimer dg , w/Nycomed Amersham - Fibrillex, Kiacta ( 1-3 propane disulfonate) ph II/III ( n = 183) to end Dec 04, Orphan, “ amyloidosis, lic to Centocor Dec 22/04. Certainly the most clear cut possibility for a success. April 19/05 misses endpoint (kidney function p + 0.06 and death). Aug 22/05 rolling filing initiated, completed April 18/06, PDUFA Aug 13/06 : "approvable" request more efficacy data and manuf. New filing , PDUFA July 16/07 "approvable" again

Lundbeck discont Oct 12/01

NSTK NASTECH (NSTK) Nov 8/06 lic from City of Hope rights to "Dicer substrate RNA interfrence IP and technology" 5 rights exclusive.

- calcitonin nasal spray , aNDA "not approvable" July 06 - morphine nasal ph II - PTH ( 1 – 34)nasal ph II; ph III to init 06 N = 600 – 800, vs LLy Forteo (non-inferiority) on bone mineral density on a single bone site. Lic to PG Feb 1/06. Terminated Nov 7/07 - Peptide PYY ph I, nasal, anti hunger, obesity. March 2/06 : MRK drops. - siRNA anti TNF from Alnylam , pre - siRNA anti H5N1 : G 00101, pre

NTEC NEOSE (NTEC) Incorporated 1990 Public 1996

∗Therapeutics ("GlycoTherapeutics"), w/ BioGenerics AG GlycoPeg / NE 180 EPO in baculo, IND 3Q04, on hold FDA July 05, ph II Jan 07 Switzerland GlycoPeg/G-CSF in baculo IND 3Q04, delayed, partnered w/ Biogenerix AG (Ratiopharm) GlycoPeg VII, VIII, IX w/NN; precl -Carbohydrate identical to cell mb site for H. pylori : discont in ph II, 1997 -Carbohydrate NE 1530 for otitis media : discont in ph II, 1997 -Collab w/Bracco for imaging : discont -Collab w/Neuronyx since June 00 on glycolipids for Park. (res) -Collab w/Novazyme for lysosomal storage disease, restructured in March 01 (NTEC is no longer in JV) -Manuf GMK ganglioside conjugate vaccine for BMY. BMY terminated May 15/01 & reassigned to Progenics. ECOG stopped but Ph III ongoing w/EORTC (too many

-partners : LLY, BGEN, WYE (Dec 01) for rPSGL-Ig


- 111 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS centers, still recruiting, 7 years follow up) ∗Neutraceuticals ("GlycoActives") Carbohydrate bulking agents for McNeil (JNJ) & Wyeth (AHP) infant feed formulas. Construction of pilot plant is slow. ∗Enzymatic carbohydrate modifications ("GlycoAdvance") acquired in 99 from Cytel : technology to remove Galactose, & to increase sialylation. Not impressive, could at best generate low contractual revenues. Could apply to plant MAbs & EPO. Applied to TP 10 from Avant

(P selectin glycoprot ligand, linked to Fc), ph II, coronary reperfusion sd : terminated May 10/02, failure ph II§

NTGC NETGENICS (NTGC) IPO filed 3/13/00 (CHQ)

bioinformatics

NTI Neurobiological Technologies Arvin, ph III, stroke

NTMD NITROMED (NTMD) April 13/05 Frank Douglas appointed to Board Jan 6/06 Manuel Worcel leaves March 21/06 : CEO & CFO resign

BiDil filed Dec 23/04, PDUFA June 23/05 ADV COM JUNE 16 OK 8/8 (but lupus side effects) FDA OK June 23/05 : heart failure in blacks. Launch July 15/05. Weekly Rx Aug 12 : 250; sales 3Q05 : $ 1.1m

NUVO NUVELO (NUVO) traded since March 3/04 R & R 05 : presented by CFO who says "anticoagulants" for "thrombolytics".

- Alfimeprase (w/AMGN, who opts not to continue on Nov 1/04) ph II for acute periph arterial occlusion & catheter occlusion. Ph III PAO (NAPA II)init April 18/05, N = 700, endpoint : avoidance of surgery in patients slated for surgery. NAPA III SPA n = 300 identical structure, Sept 05 init ph III central venous cath. occlusion. Jan 31/06 lic to Bayer ($ 385 m). Dec 11/06, fails. June 27/07 Bayer terminates - r NAPc2, ph II, DVT, acq from DNDN, and ph II a for acute coronary sd , ANTHEM, reinitiated May 04 (TIMI 32), data 1H 05. Jan 5/07, 2nd line m CRC, ph II. March 27/07 1st line CRC w/Folfox Avastin - ARC 183 aptamer direct thrombin inhibitor, ph I, for CABg, t ½ 2 min (no reversal agent needed). Terminated Sept 22/05 - NU 206 (R Spondin, Wnt agonist), w/Kirin, for gut epithelium regeneration

recombinant fibrolase (from Southern Copperhead Snake venom) , direct fibrin lytic enzyme, not a Plasminogen activator Lic to Bayer Jan 5/06 ($ 385m) & 40% of dev costs

NVAX NOVAVAX (NVAX) -cream transdermal deliver. Estros(phIII) & Andros(phI) -anti HPV vaccine (with rVLP)


- 112 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS (VLP=Virus like particles) - anti avian flu vaccine, pre, VLP

NVLT K NOVELOS (OTC BB NVLT) NOV 002, ph III, NSCLC, w/chemotherapy, oxidized glutathione based chemoprotectant (MKT in Russia) US ph III w/Taxol & Carbo 1st line NSCLC init June 06, N = 850

NVS V K

CHIRON (CHIR) NVS owns 42%. Nov to acq (Sept 1/05 , $ 4.5 B Oct 31 /05 $ 5.1B, closed April 19/06 Jan 8/02 : acq MATX (for Tezacitabine) $ 61m Oct 3/03 : acq Cubicin for ex-US Acq. (Aug 15/00)PGNS for $700m Sold Gene therapy manuf facility to CEGE Acq Powderject May 19/03 $ 880m, which has contract with UK for Bavarian Nordic small pox vaccine

- Pulminiq (inhaled ciclosporin) for lung transplant. Ph III N = 26, primary endpoint survival NS; FDA questions blinding ! Adv Com June 6/05 : 8/8 -Vaccines : $344 m/00, 357/02, 687/03. Fluvirin UK ban Oct 6/04 -Betaseron : $99 m direct + royalties. May 5/01 Amer Acad Neurol 12 months MRI for new lesions : Betaseron 15%, Avonex 30% -Proleukin : $112 m, 03 : 115, 2004 129m -TFPI / Tifacogin→sepsis, ph III, N = 2000, Nov 21/01 fail to reduce 28 day mortality( but the 225 subset with CAP & not receiving Heparin benefited); Xigris reduces from 31% to 25%. 18 May 04 reinitiates ph III in severe CAP, N = 2100, primary endpoint 28d mortality :Captivate; data 4Q06. Dec 19/05 Indep. Com says "continue". -FGF2 (antiapoptosis)→coronary dis.,ph II ACC : fails to meet end-point -VIII gene ther.,ph I, retro, IV -antiangiogenic ribozyme (Angiozyme)→K :I/II - TOBI, patented formulation for nebulizer Tobramycin: $90m/01, 147/02, 172/03, 2Q04 : 51 marketed in US & UK(EU mut. rec Aug 7/00). -PA-824, resistant TB, ph I lic to TB Alliance (Feb 02) - Tezacitabine (fluorodeoxycytidine), K, ph II, was HMR, failure oesophageal K March 20/04 - HBV-MF 59, hep B, ph II, halted Oct 02 - Melanocortin 4 R, res, lic to GSK (Jan 8/03), obesity. - CHIR 258, ph I, pan anti kinases VEGF, PDGF, c-Kit, Flt3 - CHIR 265 RAF kinase inhib, melanoma, ph I (init April 11/06)

(have divested Dg to Bayer Sept 98) →incredible $100m shipping to UK!(one time event) Schering AG/Berlex Searle Proleukin competition : human expressed IL2, pre, Apollo Life Sciences, Australia →→→ presented ACC 1H00, is bovine,hu rFGF was lic by Scios in late 99…… RZYM

NWBT V C

Northwest Biotherapeutics (OTC BB NWBT) IPO filed Aug 14/01(Unterberg,Tobin) Traded since Dec 17/01

- Dendritic cell vaccine (auto + BCG)to PSMA (DCVax prostate), ph I/II (AACR 02 : N=33, 1 a month x 4 ∏ 55% ORR; ph III started (N=495) filing 2004…enrol suspended Oct 12/02 (financial reasons). Restarting Feb 05.


- 113 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS K - DC Vax Brain ph II in US since Dec 06, to conclude end

08. ATU in Switzerland - Dendritic cell approach to lung (IND), renal, - Immature dendritic cell (+ auto tumoral peptides)for glioma (DCVaxBrain) ph I (AACR 02 : 30% progression rate at 1 year, hist Comp 85%),ph II to start N= 90 - HuRx Prostate : fully Hu Mab to prostate, ph II - DC-Vax direct : autologous dendritic cells, pre - patent on CXCR4 gene (activated by Hypoxia ) in K cells, that migrate looking for ligand (CXCL12 (especially secreted in bone & lung) precl (Feb 06) lung metas reduced 75%

w/Medarex

NWRN IPO NEWRON ( SWX) Chairman Rolf Stahel Lehman/MS Traded Dec 11/06 Park :>1 M US patients

- Safinamide (lic to Serono/Merck), Park, , DA uptake inhib, Na channel blocker, MAO-A inhib 1st ph III good data June 19/06, 2nd ph III init Nov 27/06. Data 3Q/07 : Aug 22/07 efficacy endpoint not met - Ralfinamide, pain, ph II. Neuropathic pain vs placebo. July 2/07 NS reduct in severity of pain; retinal anomalies in animal tox

MKT leader Mirapex (DA agonist) $ 300 m/year Teva/Lundbeck MAO inhib to reach 140 m In 2010. Many generics

NXXI AMBI (AMBI) change to NUTRITION 21 (NXXI)

Nutrition products (Lite Bites)

OGXI IPO K

ONCOGENEX filed Dec 13/06, withdrawn March 7/07 RBC

antisense - OGX-011 antisurvivin / clusterin w/ISIS, 5 ph II

ongoing; prostate, NSCLC, Breast - OGX 427 anti HSP 27, IND for 2007 - OGX 225 decreases product of ILGF binding proteins,

pre

OMRI IPO OMRIX priced April 21/06

Human plama derived Thrombin Evithron; approved Aug 28/07

ONC Oncolytics (CND) Reolysin : squamous cell skin K, ph I/II intratumoral + RT : PR, Oct 1/07

ONCOB OncoMethylome Sciences (Belgium) - PCR technol to measure DNA methylation - Urine based prostate cancer test

competition Epigenomics

ONTY V K

ONCOTHYREON was BIOMIRA (BIOM) May 4/01 : partnership w/Merck KGaA worth $ 150m for Theratope & BLP25 (except in Israel:Megapharm). Discont. Staff ¬ Oct 02

-Theratope(STn-KLH) :vaccine for Breast K,PhIII, fast track design. by FDA on May 8; CA 125¬ (enrollment 900 pts ended April 2/01). Interim anal 2H01(might miss endpoint)delayed (oct 22/01)to 3Q02 TTP (Sept 02) misses endpoint,; final report mid-03on survival: misses, Dec 8/03 subset misses TTP - Theratope meta colorectal ph II enrol compl Oct 9 02, N

w/Merck KGaA (returned)


- 114 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Henney CEO since Aug 06. Oct 30/06 acq ProIX

= 20. Data mid 03. -anti NHL vaccine -Stimuvax, BLP25 vacc (25 aa of Muc1 in lip.)ph II→ prost., NSCLC rand. open 2nd line, stage IIIb/IV, N = 171. Median survival treated 17.7m > control 13.3. IIIb subgroup median survival > 23m (Dec 3/04) But ASCO 05 p = 0. 09; May 1/06, anal IIb OS 30.6m vs 13.3. Jan 2/07 new ph III in stage III stable after at least 2 cycles of Pt/Rx + Best standard of care. Wrap up YE 08. PLacebo control, endpoint survival. N = 1300 (w/Merck AG Jan 06) - PX12, Ph II, thioreduxin inhib (refract pancreas K) - PX 478 Hif 1 α inhib, pre - PX 866 PI-3 kinase inhib, pre - PX 316 AKT inhib, pre

™Biovector SA :Terminated by BIOM April 2/01 W/Merck KGaA

ONXX K

ONYX (ONXX) oct 12 : pricing of secondary $15 Aug 14/00 : Leonard Post becomes CSO Oct 30/01 : staff cut 30% Feb 28/02 : resources reallocated to BAY 429006 July 14/03 secondary $ 80m Feb 3/04 shelf (filed Dec 13) raises 156 Price could be $ 25,000/year Sales 3Q06 $ 45m, FY 06 153.8, 3Q07 104 PFE SU 11248, Sutent ph III, halted for efficacy Feb 05, success in GIST, PDUFA Feb 06. Ph III RCC data end 07

-Onyx 015,modif. Adeno kills p53 deleted K cells, ph III H & N initiated June 6 to be manuf by XOMA (delays ++) ph II→50% shrinkage liver metastases : ph I/II low dose : 155d survival, high dose 342 days (ASCO/01) pancreatic K : ph II. All terminated Jan 27/03 -Sorafenib, Nexavar, Raf kinase inhib & VEGFR2 & PDGFRβ (BAY 439006, Nexavar, ORAL bis aryl urea), ph II, hepatocarcinoma, colon, melanoma .RCC pivotal ph III 2nd line with SPA init Oct 27/03.( Ph II interim had 44% ORR). 100 sites (US, CND, France), N = 900, survival, fully enrolled end 04, 12 m follow up. Only ECOG 0 & 1. March 22/05 interim : longer PFS, filed July 11/05 for advanced RCC, PDUFA JAN 11/06, approved Dec 20/05, PRICE $ 4,333/month, but ph III will continue until survival endpoint, but unblinded May 05 & all pts crossed to drug. ASCO May 16/05 PFS 24w/12w, PR 2% (Sutent 40%). ECCO Nov 3/05 : interim anal at 220 deaths. p = 0.018 which is NS.: anal is planned at 540 deaths and requires p < 0.0005 EU filing Sept 12/05, CHMP OK April 28/06, EU ph III 2nd line RCC to init. RCC 1st line w/IFN ph III data YE 05 NS -NSCLC : EORTC Nov 17/05 serious side effects Ph III w Carbo/Taxol init Feb 16/06, N = 900 (squamous & adeno). Data 2008

milestone from WLA/PFE (May 23/00) Aug 7/01 : reacq H & N rights from PFE. Sept 16/02 PFE terminates. Dec 18/03 lic to Sangamo Aug 2: res agreement w/EPTTCO Ltd, a prodrug specialist (015 could be prodrug vehicle) Bayer 50/50 (but Bayer responsible for clin dev) ASCO 03 : very preliminary N = 118. See AACR Oct 02 (in patients T cells, decreases ERK phosphorylation). Might file ph II end 04 ?????NO (Oct 26/04) Ph II ESMO Nov 04, N = 502, 202 w/RCC, 65 stabilized by BAY, rand to placebo/verum : better absence of progression w/Verum. Sutent (PFE) filed Aug 10 for 2nd line GIST and RCC. EU filing 3Q05. US OK Jan 27/06, CHMP OK April 28/06, July 27 "conditional approval". Full approval Jan 8/07. Feb 8/07 approved 1st line Others : PFE Axitinib (ph II ASCO 07), GSK Pazopanib (ASCO 07) PR 27% in RCC


- 115 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS HCC : 19,000 new cases/Y US, 32,000 EU

. HCC .Advanced hepatocarcinoma 1st line, ph III init March 8/05, enrol compl June 06, survival; April 18/06 EMEA grants Orphan designation. Data YE 07, Feb 11/07 stopped at interim N = 602 (in ph II OS was 9.2m). ASCO 07 10.7m vs 7.9 p = 0.0006. Filing being prepared. .Melanoma ph III init (?)end March 05, N = 800, 1st line, w/ carbo-Taxol, stages III/IV, powered for 30% survival increase (9m to 12 m). May 13/05 init ph III 2nd line w/ carboTaxol, N = 270, PFS NS Dec 4/06. Dec 2/06 fails; ongoing with DTIC -Agent killing Rb deficient cells, pre, IND 4Q01? - Small molecule inhib of cell cycle kinase enzyme, w/PFE

OPHM ORAPHARMA (OPHM) Mynocyclin in proprietary periodontal biodegradable microspheres delivery system, ph III

OPTR IPO macrocyclic AB PHARMACEUTICALS filed Nov 11/06. Traded Feb 9/07 Piper Jaffray, R & R PIPE Oct 25/07 $ 35.9M

- Difimicin, OPT 80 (RNA polymerase inhib) oral, 2 ph III (init March 24 & May 1/07, N = 664 x 2) Clostridium difficile associated diarrhea (reacq 1Q07 from Par Pharma PAR 101)..Remarkable in vitro data. Clin data 1H/08, Filing 2H 08. Ph II usually no or low systemic absorption. - Plurifloxacin, ph III, traveller's diarrhea

Competition : oral Vanco (Viropharma), Genz, Oscient (ramoplanin), Replidyne (precl), Targanta (oritavancin)

ORCH ORCHID BIOSC. (ORCH) IPO, traded since May 5

SNP scoring : Genetic Bit Analysis -creating portfolios of "medically interesting SNPs" -screening populations receiving best selling drugs - RxScreen mouth swab to detect genetic risk of sensitivity

to drug Also Agro mkt correlating crop growth & SNPs, hence hybridization rather than GMO

Bayer, MLNM, PEB, BMY, LLY, AZN

OREX IPO OREXIGEN IPO filed Dec 20/06 ML Traded end April 07

- Contrave, to init ph III (Naltrexone + Zyban), N = 1500, filing 2009

- Excalia, NDA expected 2010 : Zyban + Zonisamide, which already has 2 deaths by Stevens Johnson

ORG C

ORGANOGENESYS (ORG) Apligraf(grown from foreskins), MKT in US for wound healing; FDA june approval for diabetic foot ulcers

→AVENTIS

ORPH Orphan Medical (ORPH) Xyrem (oxybate;gamma hydroxybutirate "date-rape drug"), ph II, narcolepsy/cataplexy; Adv Com cancelled (march 4/01). July 3/01 approvable letter w/safety concerns


- 116 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ORTC ORTEC (ORTC) Wound dressing with bovine collagen OSCI AB OSCIENT (OSCI) , was GENOME

THERAPEUTICS CORP (GENE) March 7/02 : sale of $ 15 m convertibles to accelerate Ramoplanin. Sept 26/02 : staff cut 17% Nov 18/03 : to merge w/Genesoft (with FDA approved Factive, Gemifloxacin) Feb 9/04 Follow on 88m

-microbial & fungal genomics(PathoGenome database) -Asthma genomics -Osteoporosis genomics -Gastrointest. genomics -Ion channel genomics - Ramoplanin; ph III, sachet oral prevention of VRE sepsis. 33% of 950 pts enrolled. Filing 2004 : delayed (slow enrol.). July 04 : enrol closed at N = 650 Capsules bioequiv Dec 10/02; Feb 20/03, init ph II C. versus Vanco, difficile diarrhea, N = 87, data Aug 11/04 : response 71%, Vanco 78% Fast track Feb 18/04; was supposed to file 2005…….. - Factive approved ( Sept 9/04)for CAP & Acute exacerbations of chronic bronchitis caused bt S. pneumoniae, H. Influenza, H. para, Moraxella

Aventis, Bayer, SGP∏ ICAAC ? SGP AHP AZN ICAgen Lic (oct 01) from Biosearch Italia after failure of IBPI. ICAAC 01 : 1 in vitro poster

OSIP K OSI (OSIP), was Oncogene Science Sir M. Richmond, GLX, elected to Board Bob Ingram (ex GSK) chairman Jan 7/03 Issue of $ 200 m convertibles (Jan 29/02), $ 40 m repurchased Aug 29/02 Sept 3/03 issued $ 135m convertibles AZN filed (Dec 28/01) a ph II on refractory NSCLC, with IRESSA gefitinib, transformed into rolling. Reviewed at Sept 24/02 ODAC : - 11/3 "a 10% response rate is reasonable to predict clin. benefit" - 9/5 "symptom improvement cannot be adequately evaluated without a control arm".(there was no control group & end points are T. response and symptoms). Also too many adenocar. Eligibility ? 25% rashes. PDUFA : Feb 5/03 delayed (Jan 9/03) to May 5/03 : approved ($1,872 /m; 22,000/y) for advanced or metastatic NSCLC resistant to Pt or taxotere (non controlled ORR trial Ideal 1 & 2), survival trial ongoing (data

CCP 754(H ras farnesylation inhib)→bladder K,ph I/II CP 663427 (ras farnesyl inhib) K, pre CCP 547632, anti VEGFr(Flk1 TK),ph I CP-724714, oral anti HER2 tyr kinase inhib , ph I, w/PFE OSI 774 (erlotinib),Tarceva oral EGFR inhib & decreases N of EGFRvIII that dimerize. Ph II alone in refractory NSCLC(C+PR 24%) -ph III refractory (2nd & 3rd line)BR21 , 150 mg/d controlled (against "best supportive care", survival endpoint (Iressa refractory had median survival 6 m), ↗ from 330 to 731 pts (Sept 25/02, now powered for 33% difference rather than 50%) →enrol init Oct 2001 & compl Jan 30/ 03 data 2Q/04, approval 2H04? (fast track Sept 24/02). Rolling filing init Jan 21/04 (clin data April 26/04, > BSC for survival, TTP, ORR, but BSC is < Taxotere !!; data at ASCO, 6.7m/4.7, p < 0.001 NDA completed Aug 2nd, PDUFA Jan 30, 2005.FDA OKNov 18/04 $ 2,026 "locally advanced or metastatic NSCLC after failure of at least one prior CT. But only 10% of patients have reduction of tumor size (BWFW Dec 27/04) Sales 4Q04 : $ 13.3. 1Q05 47.6, 2Q 70.2, 3Q 73.2, 4Q 84, FY 05 275, 1Q06 93, 2Q 103, 3Q 100, 4Q 109, 1Q07 102 (US) 91 (ROW); 2Q07 ww 212; 3Q Roche 126.9 US 101 Aug 26/04 : filing in refractory to EU. June 27/05 CHMP OK "when prescribing Tarceva factors associated with prolonged survival should be taken into account. EU OK Sept 21/05. EPAR Nov 3/05 - New ph II dose escalation refractory NSCLC init Nov 10/03 - New ph II init March 19/04, 1st line, open, rand, versus carbo/taxol, N = 102, poor performance score - Sept 13/04 init open label expanded access to BR21

acq. certain assets from Cadus, hence links with Solvay PFE(returned)→ AACR (April 6-10/02). Term Dec 12/02 PFE →DNA/Roche; PFE(term. because of FTC :WLA), in US will share commercial costs & profit w/DNA. In EU royalties low 20ies.

ASCO 03 : -glioblastoma ph I +/- temozolomide (Iressa also in glioma) w/ABC2 clinical network : ph II init Aug 9/03 (Iressa Jan 8/04 glioblastoma fails) - bronchioalveolar K ph II - Tarceva + Avastin NSCLC - Metastatic colorectal ph II

Needs lower dose than Iressa Carbo/pacli mean survival alone 9.5 m Gemzar/cisplat alone mean surv 8.7

April 10/03 : for Tribute, Tarceva to be discont in case of "progression". Could be


- 117 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS 2005), acne : 25% Iressa has no dose effect (500mg<250 in ph II), ph III is less powered than Tarceva (3 arms), which has much better bioavailability. GILD oncol acq ($ 130 m cash + 40 in stock), dec 01 CLPA Feb 10/02 : to acq. OK JUne 11/03 March 12/03 acq from SRA US/K Novantrone for $ 55m (sales US 02 $ 80m, 55 in K) Dec 21/04 class action suit on misleading survival statements (BWT Dec 21/04) Aug 22/05 : to merge w/EYET. Closed Nov 4/05 $ 935m

-NSCLC naïve 150mg/placebo endpoint survival (bar at 33% >) : US(TRIBUTE) ph III init Jul 01 enrol compl Aug 02(N=1000, + carboplat & paclitaxel)fast track May 15/02 results Oct 1/03(TTP ↗), EU(TALENT) ph III init Nov 20/01enrol compl Sept 02 N = 1200(+gemcitabin e/cisplat) ;completion end 02, results Oct1/03, →failure to meet 25% ↗ survival pancreas first line ph III init Oct 01,enrol compl Jan 28/03 (N=800,w/gemzar, downsized to569)data Sept 20/04, end point survival 6.4m/5.9 p = 0.025, filed April 2005. No difference in ORR, 1 year survival 24% vs 17%. Filed May 2/05, ODAC Sept 13 reviewer critical but OK 10/3, PDUFA Nov 2 : approved Nov 2/05, JULY 30/06 CHMP NO - ovary (PR 10%), - H&N→ASCO 01, 6%PR, 80% rashes. -NX-211, acq from GILD (Nov 01)who acq from GSK, ph II, liposomal lurtotecan (topoisomerase I inhib), SCLC, ovary (N = 80, comp to Topotecan).Data 2H03 - OSI 7904 L (liposomal thymidylate synthase inhib, was GW 1843) ph I -OSI 7836, Gemzar like, ph I, nucleoside analogue (in vitro > Gemzar). - Gelclair : oral gel for mucositis (from CELG) - OSI 906 ph I, oral inhibitor of ILGF1-R pathway - PSN 9301 DPP inhib , ph I, diabetes Oct 2/07 partnershi w/Aveo for EMT (c-MET ?°

linked to Taxotere subst to Taxol increasing lung risk

Pancreas Gemzar alone mean survival 23w → ASCO 02 (ovary K) : nl efficacy & tox More Iressa(filed CPMP Feb 11/03) :approval ?? interst. Pneumonia Japan (125 cases, 39 deaths) -ESMO Oct 02 : Intact 1 (non US, N = 1093, gemcitabine + cisplat, no diff survival 250/500/CT alone); Intact 2 ( US, N = 1023, carboplat + paclitaxel). Feb 10/03 AZN files EU same data as FDA (IDEAL 1 & 2). 2002 sales japan $ 62m ISEL data Dec 17/ 04 failure, N = 1692, vs placebo. But (Dec 27/04), BWFW, Rick Pazdur suggests exploratory trial in mutated patients. Jan 3/05 strong OSIP insider sales announced, Jan 4/05 AZN withdraws EU filing. ODAC March 4/05 to discuss. march 07 : 100 tissue samles to ViroLogic for mutation search. Data June 05. April 19/05 NCI halts an Iressa trial "consolidation in stage III NSCLC after 1st line chemo/Rx" June 17/05 Iressa label change

OSIP Eyetech ( EYET) Filed for IPO Sept 15/03 (EYET), ML, MSDW. Jan 30/04 : $ 136m.

Macugen intraocular (Pegaptanib Na),aptamer lic. from Gilead ($ 32m, April 2000); anti VEGF, ph III, ARMD intravitreal every 6 weeks Nov 03 Amer Acad Opht : fails to show > Visudyne Nov 8/05 : Lucentis (DNA) > Visudyne

PFE Dec 18/02, upfront 100m, 195 m milestones on submissions & approval, 450 m milestones upon reaching certain sales levels. Pfe funds Dev. Filing June 17/04, Adv Com August 27. Sept 20/04 update provided to FDA; PDUFA DEC 17 OK Dec 20/04 EU approval slated Jan 06

OSIP CELL PATHWAYS (CLPA) Being acquired (Feb 10/03) $ 32m by OSIP (share exchange, 58% premium)

-Aptosyn/exisulind (oral cGMP PDinhib):famil. polyps:NDA filed Aug 99⇑ rejected sept 25/01 _assoc w/Gemzar _assoc w/Xeloda _assoc w/Taxotere,NSCLC N = 600,ph III init 03/01& suspended Oct 5/01, resuming Nov enrol compl March 6/03; endpoint is survival ↗;prostate ph II - CP 461(2nd generation Aptosyn), ph II, CLL, RCC -Apoptosis inducers -Nilandron(acq from AVE july 5), MKT ($14m/Y)

-lawsuit against CLPA (March 13/01) for false statements -LLY -Roche -Aventis


- 118 - printed : 03/07/10 (d/m/y) 08:07


OSIR C OSIRIS * files for IPO May 12/06 traded since Aug 06

July 26/07 partnership w/GENZ for Acute radiation sd". To focus first on Prochymal

Adult banked allo mesenchymal stem cells (from Bone Marrow) for IV : - Prochymal, ph III, GVHD, Crohn - Provacel (IV) ph I, Myocard Infarct w/ Boston Scientific, completed N = 53, April 5/06, data ACC March 07 - Chondrogen (adult mesenchymal stem cells), ph II init April 2/05 for meniscus repair; Feb 13/07 no efficacy. Nov 27/07 : 1 year data, vs hyaluronic acid, knee, signif. - Osteocal, bone matrix for grafts, MKT since July 05 - Trial for Crohn

verum placebo p arrythmia 9% 37% 0.025 overall improval 6 months

42% 11% 0.027

eject fr improval

25% no

FEV1 17 points 6 points < 0.05

OSTE C OSTEOTECH (OSTE) World's largest processor of allograft bone tissue : 500 recipients every day :

Grafton, MKT in US as gel and plasticine for surgeons

acq. 90% of OST Developpement (Clermont Ferrand) 30/9/02 : voluntary retrieval of some tissues.

OSTX OSTEX (OSTX) Urine test for bone resorption (cross-linked telopeptides) OXB K OXFORD BIOMEDICA TROVAX poxvirus (MVA) delivers gene for 5T4 (highly

expressed in RCC) ph III TRIST init (Jan 10/07). ASCO 07 N = 48/53. Alone or wIL2 or w/IFN : 2CR, 3PR, 19SD lic to Sanofi $ 690 m, CRC ph III to initiate

w/Sanofi

OXGN K OXIGENE (OXGN) JV w/PPHM (what happened to CEO ?), ARCUS, for vascular targeting agents June 10/03 : PIPE $ 15m Jan 14/04 PIPE (R & R) 22.3m

-Combretastatin(slightly modified Distilbene, which is mkt since 1945 (antiangiogenic)™K,phI/II (3 trials, all with severe neurol side-effects-ataxia-and one with 3 responses/14pts); AACR posters only in vitro. Dec 5/05 ph Ib w/Avastin to initiate. Ovary ph II. mNSCLC to start (Dec 05) in UK w/rx + CT -Sensamide (metoclopropamide/Primperan)ADPRT inhib, radiosensitizer, ph II glioma∏disappointing - Combretastatin A4 prodrug ph II thyroid K w/doxo cisplat Rx. Fast track, orphan. Disrupts tubulin of endothelial cells (like ZD 6126). To enter I/II in combi for H& N, Lung, prostate, ARMD -Neusensamide (new formulation) ph II/III NSCLC ∏disppointing (1998) -Declopramide (new name for Sensamide), NFκB inhib, ph II ongoing - Cordycepine, ALL, halted in 99 for toxicity.

BMY(dec 99). Terminated Oct 25/01 BMY terminated Oct 01 (cardiac tox ??)


- 119 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS OXIS OXIS (OXIS), Nasdaq & LNM -Dg Kits for Free Radicals

-Glutathion peroxydase mimetic→Ulc.Colitis,ph II

PANC

PANACOS (PANC) PA 457 , bevirimat, AIDS, Ph II once a day pill (not formulated yet), IIb to init 2Q06 HIV maturation inhib (blocks conversion of capsid precursor p 25 to p 24. Dec 20/06 poor bioavailability

PARD M K

PONIARD was NeoRx Corp (NERX) Jerry McMahon, PhD, CEO, key to discovery of Sutent when at Sugen SCLC is 20% of lung cancers

-STR →myeloma, phIII suspended nov 7: TTP/HUS (STR=skeletal targeted radiotherapy, with Holmium), hold lifted April 24/03, to reinit 1Q04 at lower doses.. Term May 9/05 -Pretarget™(avidin conj MAb then Y/Biotin NHL, ph I Lung,prostate? - NX 473/ AMD 473/ Picoplatin IV, acq from Anormed (had been returned by AZN) April 04, Ph II init 05 SCLC vs Topotecan, N = 75 (2/1), 2nd line. Trial to last 12 to 18months. April 25/06 expanded. Nov 06 median survival 26.7 w (historical 13-14, GSK; 16-20 NCCN) SPA Jan 3/07, ph III, 2nd line N = 400 vs BSC, primary OS, filing 09, lic to Pharmion. Init May 1/07 *HRPC, ph I *CRC ph I ASCO 07, FOLPI : much less neurotoxic - Kinase inhibitors (w/Scripps Florida)

PCOP PHARMACOPEIA (PCOP) The leading profitable technology platform company Merger w/EOS term Jan 17/02

-Combinatorial chemistry, with proprietary bar code -Modeling, simulation, rational drug design, lead

optimization -In vitro pharmacology - In house molecules : - DARA dual acting angiotensin & endothelin receptor

antag, precl anti JAK 3 immunosuppressant, res, lic to WYE Jan

4/07 anti integrin ARMD, res adenosine A2a receptor modulator (Parkinson ), res CCR1 receptor modulator (MS, RA) anti CXCR2 COPD, ph I anti p 38, RA, Ph I, w/BMY

JAK 3 competition : PFE CP-690,550 RA ph II

PCYC

PHARMACYCLICS (PCYC) Cost per pt. : $ 10,000; US : 170 000 brain meta cases/y

uses texaphyrins + Me for photodynamic therapy : -Xcytrin(Gadolinium texaph.)→brain metas, ph III non blinded(N= 428, but 28 open) (fully enrolled 03/ 01,Dec 13/01 : fails to meet primary

ASTRO. Nov 7/01 : protocol shown. ASTRO 02 : Oct 6-9/02: 12m data on NSCLC meta :


- 120 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Competition : - Dusa's Levulan - Miravent's Purlytin - QLT's Photofrin

endpoints.Jan 8/02 improves time to neurol progression in pts w/NSCLC metas; all groups 3.8m/4.3m (p = 0.018); NSCLC 3.7m/5.5m (p = 0.025). FDA April 02 meeting : requested to conduct new specific ph III (init Jan 7/03) SPA (special protocol assessment) SMART N=550, time to neurol progression (powered for 1 m improvement). Filing 2005/6. Enrol compl March 14/05, Dec 19/05 : fails. FILED DEC 22/06. Feb 21/07 "refusal-to-file" letter. April 4/07 "filing over protest" →Glioma ph II enrol compl Aug 2/ 01 → NSCLC ph I (w/Taxotere)ph II init Sept 05, 2nd line, RECIST NHL w/Rituxan + Zevalin init Nov 03 trials started w/Taxotere, doxo, & H & N(5FU/cis), also RCC - single agent (no Rx) CLL, Int conf hematol malignancies March 11/04, interim, partial efficacy. -Lutrin(Lutetium texaph.)→breast K, ph II;rights returned

from Nycomed (May 01) -Optrin→ARMD, ph II -Antrin→PAD, ph II, coronary ph I Transcath Conf Sept 02 From Celera (April 06) - HDAC inhib, ph I, K - HDAC 8 selective inhibitor, K, precl - PCI 24781 HDAC inhib & downregulates RAD 51 (like SUPG MP-470) - VIIa inhib, pre

TT neurol P 7.4m/not reached (p = 0.048); CNS death ¬ 51.5%/32.5% (p = 0.02° ⇑ASCO 01 : ph II glioma median survival 17.3m ASH 04 : poster N = 13, 3 might respond ?? Alcon Labs (returned Oct 17/01) nov 8/04 precin stabilisation of plaques

PDGM PARADIGM (PDGM) IPO may 5

Agro functional genomics PHA (from Monsanto), Bayer(herbicides)

PDLI M

PROTEIN DESIGN LABS (PDLI) FOR SALE Oct 2/07 Aug 29/07 : rebecoming develop stage company -All revenues are from licenses & interest -Clever business model leveraging patents through licenses & services. Manufacturing : commercial facility being built. Clin. trial facility exists in Minnessota.

CDR grafting , better known as "humanization", is the I.P. of PDL (Queen patent, 1996). Agreement on Queen/Cabilly Sept 98- Sept 03 : renewed -Zenapax/daclizumab (anti CD25) once a month for PSO (maintenance of remission,ph II endpoint is time to recurrence), ulcerative colitis (ph II data 1Q04), MS w BIIB (I/II), Diabetes( I/II), RA,asthma(II)data 1Q04 , long term safety since years -M 195,Zamyl (hz anti CD 33)→AML, ph III (N=193) ORR 43% (> Mylotarg). Lic (March 18/03 to Actinium for Act 225 & Bi 213 in AML (ph II MSKCC, 30 already on Bi) Nov 1/05 subcut w/Roche for graft maintenance March 12/07 MS ph II OK w/BIIB

→hence royalties 3% (1 quarter late)worth 6-12$/share from Zenapax (Roche 10.5%),Herceptin (DNA), Synagis (MEDI/ABT), Mylotarg, Xolair, Xanelim, MDX 210, Humicade, Avastin, LUCENTIS, anti IL5 GSK, 870, LDP 02, Antegren, Medi 507, 5G1.1 March 20/02 discont. for PSO maintenance. For non graft indics PDL got 60% on sales & free goods. Sept 30/03 PDLI acquires all rights for non graft. Sept 16/04 new Roche deal Asthma. Stop Aug 31/06. Nov 24/06 Roche terminates all Zenapax Nice study in ulcerative colitis, N=10, but ph II N =


- 121 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ROYALTIES growth (18 m delays on prior forecasts, but great safety) : 03 :with launch of Xolair 04 : w/Antegren(++), Avastin ., Xanelim (4Q03) May 2/02 : Korn ↗ Chairman, Levitt (Head R/D) resigns. New CEO Mark McDade (worked w/Max Link at BM, cofounder Corixa, to become Chairman. To resign end 07 Jan 03 : acq EOS July 8/03 : to offer up to $ 200m in convertibles due 2023 in PIPE (already has $ 150m convert. due Feb 07) Aug 15/03 : DNA claims "Queen " does not apply to Xolair. June 30/04 : Max Link elected Chairman Jan 25/05 acq ESP Pharma $ 475 m : hospital branded generics, IV Nifedipine, busulfex, acebutolol

-hz anti IL4 pascalizumab (SB240683)asthma, ph I/II™march 01 AAAA:+ data; ph II init Oct 9/01 DB R on FEV1, pts without steroids or long acting β+). Failure May 7/03. Term. -1D10, Remitogen, hz anti HLA-DR, NHL, ph II Korn, April 18/02 : "we may not continue in NHL, but perhaps in another

K". Term Jan 7/03 -hz anti L selectin,Trauma, ph II, w/Scil, Ib PSO -hz antiγ IFNfontolizumab, HuZaf, Crohn, ph I/II, PSO (init June 02) -Nuvion (visilizumab), hz anti CD3, ster resistant GVHD, ph IIb N=80 ∏ % 180d survivors (open) since March 02, PSO(discont June21/01), Infl BD Perhaps also for diabetes (then Zenapax) Nuvion discont Aug 30/07 -Hz anti IL12∏autoimmune disease (MS), ph I (Nl volunteers) init June

26/02, back to precl Jan 8/03 - M 200 volociximab w/BIIB, ch, : anti-α 5 β 1integrin (antiangiogenesis), K, ph I, 66% SD but neutralizing Abs & humanization could decrease specificity. Ph II RCC init Jan 12/05, melanoma, pancreas. Data 2Q06 -Ostavir →Hep B "fully human", ph II - Ularitide (from ESP), natriuretic peptide (like Natrecor see Scios/JNJ £ 375 m in 2004, but creat increase at all doses in March 05 metaanal of 1269 pts) Ph II SIRIUS EU, PCWP improved , but failure ph II in tmt of acute renal failure. For sale Aug 30/07 - Terlipressin (synthetic ADH w/ triglycyl Lys) for esophageal varices & hepatorenal sd

159 DB fails May 17/04 ( b ut Simulect works ?); Asthma AAAAI March 19/04 : OK ASH 01, does not meet endpoint(CR at 70d).Filing 2H03 or before, no liver tox (> Mylotarg, N=104, 0RR 31%) ∏ ASCO 02(May 20, Failure : TERMINATED) lic from GSK, AAAAI, 03/03 ASH 01: ph I, 4 PR/7pts. Ph II ongoing (1PR on 25 first pts, angioedema,) Dig Dis Week May 21/02 (but in prior data low dose is < placebo) again placebo works as well, or nearly DDW again 2004, March 23/04 : fails again in Crohn Should work (cf Ortho ) Ulc. Colitis ph I DDW May 03; but → lymphopenia w TH2 cytokine switch (IL6, INF α, INF γ), could file on ph II 2004, w/ph III starting late 04 & ongoing until 2005. DDW May 15-20/04 on 27 pts open ph I, "provocative results" interim Sept 28/04 N = 30, 3 doses, not very clear.. Aug 04 : 2 cases w/DLTCompetition Sangstat/PG, Otzuka (OPC 6535), remicade (N E J Med Dec 05)

PDLI M

EOS (private) Was to merge w/PCOP, term Jan 02, acq by PDLI Jan 03

Repository of Hu cancer samples (genomic screening w/AFFX), seeking targets for MAbs

MEDX, MOR, BGEN, AVE

PEB P E BIOSYSTEMS (PEB) THEY MAKE EQUIPMENT FOR ALL THE GENOMIC COMPANIES

PEB has 4 operating units : -Applied Biosystems :material for genomics -Perseptive Biosystems : cosumables for mol. �hi�. -PE informatics : software -Tropix : chemoluminescence

The PE corp. has 2 operating groups PEB & CRA PEB sales : $1.2 B. INVESTING IN PEB IS LIKE INVESTING INTO A GENOMIC FUND !

PERL PERLEGEN (PERL) IPO filed April 06 (Lehman, Deutsche Bank) Chairman is CEO of Affymetrix Fruchart on Board

"analyze millions of unique genetic variations in clinical trial participants"

PFE, MRK, GSK, AZN, JNJ


- 122 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS PFE

AB VICURON (MICU) was VERSICOR (VERS) SAB from BMY/LLY/MRK PIPE April 12/02 $ 44.9m July 30/02 : acq Biosearch Italia March 18/03 N= 600 oesophageal candidiasis, IV anidulafungin efficacy= oral diflucan, but 14 d relapse rate 3 times higher July 12/03 : secondary $ 23 m Feb 13/04 $ 200 m shelf June 16/05 to be acq by PFE

Antibiotics and antifungals : -V-echinocandin/anidulafungin, IV antifungal, phIII (in vitro > Cancidas/ caspofungin ( also an echinocandin)/MRK approv. Jan 01 sales 2004 $ 430m:. Filing April 29/03 ( oesophageal candidiasis 50mg), launch 2-3 Q04? NO, Jan 26/04 FDA requests 90 d more (to May 25/04). May 24 : approvable. Feb 7/04 : sepsis, DB, N = 256 100 mg/d IV vs 400mg fluconazole (Diflucan PFE). Response rate at end of tmt 75.6%/60.2%; 6 w follow-up demonstrates non-inferiority 55.9/44.1% -2nd generation oxazolidine VEC3583, PRE∏phI, lic to PHA (who has Linezolid/ZYVOX MKT april 00) -Antibacterial Deformylase & MUR pathway inhibitor, PRE, lic to Novartis -V-glycopeptide BI 397(dalbavancin), Vancomycin like, akin to Teicoplanin. Once a week IV, ph II SSTIcompl. May 21/02(ph III init Dec 16/02, SSTI : 2 X N = 550, comp to Zyvox/Cephalexin , enrol compl May 11/04). Aug 12/04 Conf Call : 3 SSTI ph III, endpoints clin resp. N = 565 versus Cefazolin 89.1/89.1% N = 854, complicated, vs Zyvox, 88.9/91.2 N = 156, MRSA, vs Vanco 89.9/86.7. Will file. Bacteremia init March 10/02 N=180, open, catheter infections, QD/QW. Completion 1Q03. Data Jan 12/04 : 21 days after end of tmt response rate (clin & bact) 87% for Dalba, 50% for Vanco. Filing Dec 21/04 SSTI. Priority review ? 6 m to PDUFA. May 11/05 PDUFA delayed to Sept 21/05

Competition: Micafungin Fujisawa (filed April 30/02, delayed 18 m after meeting w/FDA approved March 17/05 for Oesophageal AND prophylaxis during HSCT)also echinocandin, filed > Diflucan ( oral fluconazole PFE, 2002 $ 1.1B). Diflucan has HSCT indication, but not Cancidas New strategy Sept 21/04 : for esophageal will complete 100 mg ongoing pivotal and file 2Q05; for sepsis will file 3Q05 PHA/PFE; competition AZN 2563, ph I lic to Novartis, ™ ICAAC 02 lic. from Biosearch Italia (NO US comp of matter IP) ICAAC 02 for ph II late breaker Sept 13; N = 62, open clinical success 94% (standard tmt 72%) & bact 72% (standard 64%). Full data ECMID Prague, May 1-4 2004 Filed EU Dec 03

PGNX M V K

PROGENICS (PGNX) -Cancer : ganglioside conjugate vaccines GMK (GM2 Ag + Immunogenic protein KLH)→melanoma, ph III. - Methylnatrexone IV, SCph II for post –op ileus: active Jan 05 -AIDS PRO 542 (fusion protein IgG2/CD4, anti CD 4, ph I/II, synergistic w/T20 (Trimeris) -Pro 140, anti CCR5 MAb ,hz, AIDS, pre, high activity in mice, ph I -Fully Hu MAb anti PSMA, JV w/CYTO (who regains rights April 25/06), collab w/ABGX, ph I

BMY (terminated May 15/01) interim anal (may 26/00):placebo>verum ROCHE


- 123 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS PHRM

K PHARMION (PHRM) Price Vidaza $ 32,000 per patient Cancer Consultants survey March 1/05 preferred frontline :

Vidaza 49% Thalomid 16% Revlimid 12% Dacogen 5%

Also Zanestra / tipifanib (JNJ) PDUFA 2H05 Nov 19/07 CELG to acq $ 2.9B

- Thalidomide in Europe, withdrawn May 04, resubmitted to EMEA 2005. Seeking Compassionate 1Q04 : 12.6m, 3Q 17.8, FY 06 77 (under review, May 07) - Vidaza , azacytidine (acq from PHA) , demethylating agent for MDS.23% patients CR or PR NDA filed Dec 29/03, accepted Feb 23/04, priority : 2 ph II BSC +/- Vidaza. FDA OK May 20/04 .Sales 3Q04 20.4, 3Q06 36m; FY 06 142, 2Q07 32.5, 3Q 33.3 CHMP filed Sept 04, withdrawn Nov 17/05. To refile late 07. Ph III vs BSC OS 24.4 m/ 15 m (OS for Dacogen will be mid 08) - Amrubicin, acq from Cabrellas who got from Sumitomo) lack of cumulative tox. Ph II SCLC, ph III init Oct 17/07 2nd line w/topotecan, NSCLC, Breast , filing 2010 ( - Satraplatin for EU : lic from GPC Biotech, Dec 20/05, filed EU June 26/07 . But OS ?? - MGLD 0103 HDAC inhib ph I/II, w/Methylgene

ASH 04 poster on induction in AML HDAC competition : MRK Zolinza (SAHA) approved Oct 06 for CTCL.

POTP K Point Therapeutics (POTP) March 13/07 Nasdaq delisting risk Oct 10/07 merges w/Dara

-Talabostat, oral, inhibits FAP (fibroblast activating protein), a tumor stroma member of the DPP (dipeptidyl peptidase) family of serine threonine kinases NSCLC IIIb/IV ph II durable CRs; PFS 2nd line 4.9m, 3rd line 2.7m. Ph III 2nd & 3rd line x2 one w/Taxotere vs Tax alone, other w/Alimta vs Alim alone. Endpoint PFS ( N = 800) data 4Q07 but w/Taxotere behind schedule (because Alimta/Tarceva is gaining mkt share, 2nd line; also melanoma, refractory CLL (w/Rituxan), pancreas (w/Gemzar) data 2nd line : Jan 12/07 N = 60, interim 21 : 48% survival > 6m (primary endpoint). Final data mid 07. Why did'nt they wait for ASCO-GI ? why did a Board member resign ? March 1/07 : 51 evaluable, endpoint not reached. May 21/07 trial halted CLL ph II ASH 05 2nd/3rd line 21% PR, 50% SD melanoma ph II - PT 630 diabetes type 2

ASCO 06 : CLL, CRC, melanoma

POZN POZEN (POZN) traded since oct 11/01

Treatments of migraine : -MT 100, oral metoclopropamide + naproxen, ph III, Jan 26/01 : FDA asks for carcinotox (rats expected 2003, p53 knock out mice OK now). Could file UK (Mut Recog) 4Q03. NDA filed Dec 17/02. June 2/04 Non approvable -MT 300, injectable DHE, 2 ph III, 1st one meets endpoint (July 22/02), 2nd meets primary Oct 4/02 (sustained relief 24h)


- 124 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - Trexima MT 400 (triptan + NSAI), acute tmt; ph II signif, lic to GSKfor US $ 160m deal June 03. April 21/05 ph III OK, to file, seeks EU partner. June 10/06 "approvable", need for more trials PN 400, combi esomeprazole/naproxen, NDA planned 2009- MT 500, 5HT antag,prevention, ph I

PHST PHARSIGHT (PHST) Computer assisted trial designs AZN, SBH, JNJ, LLY

PPDI PHARMACEUT. PROD. DEV. (PPDI) CRO also in PHARMACOGENOMICS : -Genomic Banking -Genotyping -Polymorphism discovery - Oral Dipeptidyl-peptidase IV inhibitors (ph I & II), lic to

Takeda July 14/05

PPHM M K

PEREGRINE (PPHM) was TECHNICLONE (TCLN) to rename : Peregrine Jan 12/01 : CEO takes leave of absence

-Oncolym, LYM, (m I*anti HLA-Dr10β)→NHL,ph II/III -Cotara(*I ch MAb anti necrotic core of tumors)→glioma,

ph II, fast track granted Oct 10/01, ph III planned for IQ02, OK for FDA Feb 4/03. Waits for partner

- bavituximab (antiphospholipid)Tarvacin, ph I K, HCV

lic to Schering AG,retuned June 11/01 JV Oxigene ("Arcus") ended March 4/02 partn w/Scotia

PRTG PROTARGA (PRTG) IPO filed (UBSW) Dec 12/01, Pulled Oct 3/02 Files for Bankruptcy 2003. Assets disseminated

Targaceuticals (drug + docosahexaenoic acid release in target) : - Taxapresin : paclitaxel + docosa, metastatic melanoma, ph III to start 1H03

PRW K PRO-PHARMACEUTICALS (PRW) Davanat, polysaccharide derived from galactomannan, ph II, 3rd 4th line CRC, bile duct carcinoma ph II

ASCO

PTCT K PTC Therapeutics * 10% of the 30,000 US people w/CF have non-sense mutations IPO filed April 3/06 (PTCT) M. Stanley, Pacific Growth Postponed April 20/07 Jan 8/07 partnership w/PFE 141 M (probably PTC 299) Sept 13/07 CELG invests $ 20M into K

molecules for exon skipping - PTC 124 oral, Feb 22/05, funds from CF Foundation To init ph II Duchenne & CF YE 05. ph II initiated Dec 23/04 for Duchenne & CF (with nonsense mutations 15%, 10% of cases). April 4/06 improves nasal transepithelial potendial difference. Nov 6/06: Confirmation Oct 23/06 increases dystrophin in muscle biopsies. Nov 5/06 normalizes blood neutrophil count - other drugs for hemophilia, neurofibromatosis, retinitis pigmentosa, LSD. - PTC 199, antiangiogenic, precl, lic to Bausch & Lomb


- 125 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS targets - March 06 lic small molecules candidate inhibiting Her C

IRES to SGP $ 200m : deal - PTC 299 K, ph Ia, init March 12/06, oral, anti VEGF production; successful, ph I/II to init (4Q07) in Breast - June 7/06 Spinal Muscular Atrophy research

PTIE PAIN THERAPEUTICS (PTIE) investors : Bill Gates, Mr Robertson (from R. Stephens)

Develop associations of opiates & antagonists to enhance safety Oxydrex ph III fails Nov 22/05 - PTI 901, ph III, IBS, fails Dec 12/05

PTD PEPTECH (Australia) earned 30% of Domantis sale to GSK

- PMX 53 : anti C5a receptor for ARMD (ph I completed) Royalties for antiTNF until 2010

PTIL Protherix (LSE) Polyclonal anti TNF for sepsis, w/AZN. Nov 06 FDA & EMEA request 2nd ph IIb

PTN PALATIN (PTN) PIPE $ 11.5m Nov 02 PIPE $ 19 m, April 03

- Peptidomimetic small molecules, melanocortin agon. -NeutroSpec (was LeuTech), Tc tagged Mab anti CD 15 : radiodg of leukocyte collections, manuf data requested (sept 29/00) by FDA before approval for "equivocal appendicitis, osteomyelitis". FDA approved July 6/04. Sales halted Dec 19/05 : 2 deaths - LeuTech for anthrax detection : trial with US army (Nov 01) - Melanocortin obesity program lic to AZN Jan 31/07 $ 310m -Bremelanotide, PT141,7aa analog of α MSH, MED, ph II, intranasal, melanocortin MR3 & 4 agon., ph III to init 1Q07. Aug 3/06 arousal post menop doubled March 05 synergy w/Viagra Feb 8/05 ph II data in women. Ph III was to init end 06, but Flushing & nausea (mild). Delayed (Aug 30/07) by FDA. Sept 10/07 King terminates

Aug 12/04 lic to King (being acq by Mylan , $ 250 m

(upfront 20)

QLTI K

QLT PHOTOTHERAPEUTICS (QLTI)

Visudyne launch April 14/00.

QLTI becomes profitable ! Nov 23/02 : staff ¬ 18% June 14/04 to merge w/Atrix (Eligard for Prostate K, $ 89m for 2005)

∗Photodynamic therapies : -Photofrin QLT→K(NSCLC , esophagus), $10 mWW,to

be sold ww to Axcan (May 00) SASY sell in US Beaufour Ibsen terminated June 99∏ Axcan -Visudyne IV (verteporfin) →ARMD, revenues for QLT $

129m/01, 1Q03 USD 83 m., 1Q05 $ 125, 2005 : 485

CPMP approval April 12/00, FDA April 14/00, Feb 6/01 FDA expands indication (pathologic myopia),

SASY COHR & Zeiss are the key laser sellers : used in 1500

centres Competition : Alcon (Anecortave, steroid, head to

head 2 year trial since Jan 02), Eyetech, anti VEGF (DNA)

Novartis Ophtalmics 50/50 JV(total sales 01 US $


- 126 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS CPMP approves "occult" AMD

∗Signal transduct inhibs : acq of Kinetek, June11/01 ∗XR 9576(tariquidar, sort of MDR inhib), lic in from Xenova (Aug 14/01),ph II, NSCLC, breast (MD Anderson). 2 phase III init June 27/02 NSCLC US (w/Paclitaxel) EU (w/Vinorelbine). Feb 21/03 enrol suspended 3 m for safety evaluation. Pivotal halted May 13/03. Chemorefractory breast MD Anderson continues * Synthetic retinoid for Leber, pre, lic from Retinagenix (April 5/06) upfront $ 1.5 m Deal

223m; 02 : 275 to 300)) ASCO 03 : Breast (Hortobagyi)

QSC QUESTCOR PHARM (QSC) -Ethanol→sclerosis of oesophageal varices, MKT -Inuline→renal tests, MKT -Migrasta(propranolol nasal spray), in dev -Ceresine→TBI, ph I/II

merger of Ribogene & Cypros

QURK IPO Quark Biotech Filed 03/07 JP Morgan, CIBC

siRNA - RTP 801i-14, for AMD, inhibits RTP 801, ph I, lic to

nPFE - AKI i-5, inhibits p 53, ph I, for systemic delivery to

prevent acute renal failure

RDYN REPLIDYNE REP 3123, precl, inhic C. difficile - Faropenem, ph III, bronchitis - REP 8839 SSTI, MRSA ph I


- 127 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS REGN M

K

REGENERON (REGN) PG now (aug 3) owns 18% Aventis deal Sept 8/03 : upfront $ 80m + 45 stock. Early milestone 25. Other milestones on "approvals" for 8 indications US & EU : 360. Ave funds dev (if profitable, REGN will refund 50%). Ave will build manuf facility, will share 50/50 promotion & profits Feb 16/06 Acomplia not approvable for smoking, and "approvable" for obesity Feb 5/07 : Ab platform lic to AZN Nov 29/07 Sanofi deal $ 1B (from 4 to 19% ownership) : - Ab to IL6R, ph I, RA : but Actemra BLA filed by Roche Nov 25/07, and Notch very hypothetical - anti DLL4 (delta like ligand) to start clinicals 2008

-Axokine(2nd gener CNTF)→ALS reduces appetite, seems to activate HSV (cold sores), ph II + in obesity, but effect maintained after arrest. PhIII (injectable once a day)enrolled (Jan 02)4 other phase III ongoing (N = 4000). Side-effect Guillain Barré, Bell. BLA filing 2H04. Launch ?? 2H05 -Axokine oral →obesity -Axokine Pegylated, w/Shearwater INHL, ph I -BDNF→ALS 1st subcut trial failed 2nd underway intrathecal 18 months DB random, enrol.ended Nov 99 - IL1 trap ribonacept : ph II ongoing RA (data 3Q03). Sept 05 discont in RA, continued in periodic dis. Blocks IL1 on cell surface. W/NVS (April 2/03) : upfront $ 21 m cash + 48 equity; 275 m milestones if product approved. Ph III costs shared. Pre ph III paid. Oct 7/03 : ACR20 ph II target not reached June 10/05 : ph I/II active in CIAS1 (cold induced autoinflammatory sd 1) periodic sd . Top line YE 06 : Oct 30 good ph III data , rol. filing completed June 8/0707; PDUFA Nov 07 delayed (Nov 3/07) until Feb 29/08 - IL4/13 trap, asthma, ph I - VEGF trap , aflibercept (extracell domain of VEGFR 1 & 2 fused to Fc of IgG1) SC/ IV ph I, solid K & NHL, - some good data in NSCLC. NCI, lic to AVENTIS Sept 8/03. Jan 10/06 Sanofi confirms license.; - Ph I/II w/ FOLFOX init May 13/06; - Dec 05 : more than 16 studies, & ovary, malignant ascites- ph II : ovary (interim ph II N = 200 ASCO 07, 3rd or more line, 8% PR, 77% SD, CA-125 reduct > 50% in 13% pts. Avastin trial ASCO 07 gave 16% PR, but bowel perforations), malignant peritoneal ascites, adeno NSCLC 2ND/3rd line (ph II ASCO 07, adenoK resistant to Pt & erlotinib); ph II breast suspended Nov 9/07 To init 5 ph III early 07 (Sanofi presentation Feb 13/07)- 1st line HRPC + Taxotere : init Aug 23/07, N = 1200, primary : OS - 1st line Pancreas + Gemzar; N = 650 to init YE 07 - 1st line gastric + Taxotere - 2nd line NSCLC + Taxotere: init Aug 23/07 ; see Sept

PG discont Gives cough & nausea Data April 03 on 2500 pts : neutralizing Abs in 70%

pts (less efficacy). Weight loss signif, but small.

Price $ 3000/year →with EMISPHERE →Amgen intrathecal has been halted by FDA ASCO 2006 : ph I, N = 27, ovary, CRC, kidney Dec 22/05 deal extends to Japan. SASY funds dev. Sanofi guidance (Feb 23/06) : filing 2007/2008


- 128 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS R/D day: N = 900, should have init late Sept 07 - 2nd line CRC + Folfiri; N = 1,200, to init YE 07. Ph II suspended Nov 30/07 1st filing 2008 on mkt 2009 - ARMD ph I not w/SASY Good data ARVO May 1/06, 8 abstracts, systemic; local init 3Q06 phase III ARMD to init 2H07 (vs lucentis, to try to show same efficacy q3m than q1m), final ph II data early 07 Lic to Bayer Oct 18/06, upfront 75 m, cost sharing, milestones 245m. March 27/07 good ph II interim on "retinal thickness". Ph III vs Lucentis int Aug 3/07, N = 1200. Primary endpoint 1 year Lucentis q/4w vs Trap q/4w, vs Trap q/8w Targeted genomics, functionomics & designer protein

therapeutics →partnership with MEDAREX (MAb), 13march

00 REX K VIREX (REX), was Altarex Ovarex (oregovomab), murine mAb, ph III, ovary K;

failure Nov 5/07

RGEN M REPLIGEN (RGEN) - Protein A (for protein purification) -rPF4 seems to have been discarded -Secretin (synthetic : Secreflo)→autism, in ph II (daughter of CEO is autistic). Ph III init Feb 15/02. Data 1Q03 April4/01: 136 pts, DB, did not meet primary endpoint, but did statistically improve signs -CTLA4-Ig→BMT from mismatches, ph II (BMY is in ph

III with another CTLA4-Ig in RA; patents issues) -TAU (triacetyluridine)ph I, tmt of mitochondrial acidosis

patent issued Feb 00; BMY data at ACR Oct 04 Abatacept Orencia(T cell costimulation modulator). Patients refractory to anti-TNF, vs placebo, 6 m, N = 258

ACR20 ACR 50 ACR 70 CTLA4-Ig 50.4% 20.3% 10.2% placebo 19.5 3.8 1.5 p < 0.001 <0.001 <0.03 Orencia sold since Feb 06. 1H06 $ 23m

RIGL K RIGEL (RIGL)

filed(w/MSDW) 9/18/00 Trading since Nov 28/00 secondary Feb 20/04 : $ 57m

Post-genomic combinatorial chemistry - R 112Small molecule IgE receptor inhib (blocks Syk kinase), asthma, ph II. Dec 1/05 fails - R 406 oral : mastocyte IgG receptor inhib, ph I, RA.. - Drugs active on Ubiquitin ligases : K (lic to MRK Nov 15/04) - R 763 : oral & IV aurora kinase inhib,. Oct 25/05 lic to Serono $ 125m Ph I init July 12/07 - R 788, syk kinase inhib, ph II initiated Sept 06, RA - JAK 2 inhib, pre

CEGE, JNJ, NOV, PFE, NBIX AAAAI, March 05 see also VRTX, Supergen, SNSS, AZN, BI, PFE, Cyclacel, Entremed


- 129 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - JAK 3 kinase inhib, R 348, pre, RA - Polo like kinase inhib, pre - AXL kinase inhib, pre

RNAI SIRNA Therapeutics ( RNAI) April 17,03 was RIBOZYME PHARM. (RZYM) Oct 30/06 MRK to acq $ 1.1B Aug 11/02 : staff ¬ 25% CEO Howard Robin (was Christophersen). J Curnock Cook chairman. Feb 17/02 : $ 48 m PIPE (Sprout, Venrock, Oxford Bioscience) for siRNA ( 50 patents, 30 issued) April 3/06 US patent on nucleic acids targeting IKK (NFKB) Sept 29/05 $ 250m deal w/Allergan for ophtalmics (upfront 5m, milestones 245, res funding) DEAL April 3/06 $ 700m w GSK respiratory DEAL

-Angiozyme(anti VEGF R1),ph I/II∏phII fails (April 29/02) in Breast (Mono), ongoing ph II colorectal ( Saltz irinotecan + 5FU + leucovorine). Data June 10/02 first 40 pts at 12w, only 12.5% have disease progression (historical. comp 25%) -Heptazyme(anti Hep C virus), ph I completed sept 12, . Term April 29/02 (animals go blind) -Herzyme(anti EGFR)→breast K, ph I, Aug 30/01 - HepBzyme (anti hep B), pre. Term Aug 16/02 - Telomerase inhib GRN 163 (w Geron) - siRNA s for Huntington : res, w/Targeted (Jan 05) - siRNA-027 w/ALLERGAN, targets VEGF R1 for

ARMD, ph I , data Aug 10/06 not bad - siRNA HCV, IND to file Q406 - siRNA for permanent hair removal (knocks out the

"hairless" transcription factor

CHIR ASCO 03 OCT 30/06 MRK to acq : $ 1.1B ELN (term) -acq Innovir (that had been acq by Vimrx, now

Nexell,for oligos anti Hep B and APL) -Functional genomics with Roche & Schering AG

RNA RIBAPHARM (RNA) IPO filed 6/15/01 (UBS), priced April 12/02 Spin off from ICN Considerable Ribavirin patent litigation issues.

- Ribavirin, MKT by SGP, hep C ; royalties 155/00, 139/01 ¬ - Levovirin, ph I, lic to Roche, - Viramidine ph I - IL 12, anti K, colon

Competition : - a form of ribavirin developed by Roche (Copegus) - US Ribavirin generics : Teva, Geneva.

RNVS RENOVIS (RNVS) Cerovive, ph III efficacy in stroke, p = 0.038, filing 2007 after 2nd ph III, delayed, hemorrhage : failure March 14/06 small molecule inhib. of vanilloid receptor VR1 for pain (Sept 05 $ 187 m research deal w/PFE)

lic to AZN

ROSG IPO Rosetta Informatics micro RNA

RPRX V REPROS Therapeutics, was ZONAGEN (ZONA) Oct 31/02 : merging w US subsidiary of Lavipharm (large Greek profitable pharma)

-VASOMAX (oral phentolamine), NDA filed Clinical hold by FDA (new 2 year rat data filed 04/01,

brown fat prolif in mice)) - Contraceptive vaccines suspended Sept 26/01 - Praellex : antiprogesterone ph II fibroids, endometriosis - Androxol : pituitary androgen agonist

SGP, could get UK approval in 02 : CSM says no, application withdrawn (April 29/02)


- 130 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS RTIX REGENERATION TECHNOL. (RTIX) Allografts from cadaveric donors (BioCleanse system)

RXIP IPO RXi Pharmaceuticals, filed Oct 30/07 siRNA spin off CytRx

RXHN REXAHN (RXHN) - RX- 0201, Akt inhibitor, ph I, antisense - RX 0047, HIF inhibitor, pre

SANTARIS A/S micro RNA

SBIO SYNBIOTICS (SBIO) Veterinary diagnostics

SCLN K SCICLONE (SCLN) Zadaxin : thymosine™hep B & C, MKT in 3rd world ph III fails dec 14/05 Dec 22/06 w/SigmaTau, w/DTIC – IFN, N = 386, ph II,

Melanoma. Longer median survival. 5 arms + DTIC : 10.2 m vs 6.6m + DTIC + IFN 19.9m

SEPR SEPRACOR (SEPR) July 30/02 : VP/RD resigns The stereoisomer company March 25/04 expanding sales force from 450 to 1250 The future rested on Soltara, but Hismanal had serious QT issues : are they absent with Soltara ??? : answer Nov 16-21 ACAAI: no QTc > 500 ms, and CPMP limits to 450! Also AUC up w/Erythromycine Nov 7/01 : PP of $ 400 m convertible subordinates How will they survive Claritin generics( Dec 02) ? Nov 02 : class action suit on Soltara Cash 2Q07 : 861

-levocetirizine (for Zyrtec), ph III, approv. in Germany (jan 16, 01) & 4 other EU countries -R-fluoxetine (for Prozac), ph II ? -norcisaprid (for Propulsid), ph II ? -norastemizole/Soltara/Tecastemizole (for Hismanal), filed, discont Dec 03 -descarbloratadine Clarinex (for Claritin),MKT -Xopenex, levalbuterol, MKT,approved 2002; 2004 sales $ 320m. March 14/05 metered dose inhaler approved, 2Q07 $ 105 -Allegra (for Seldane), MKT -R-formoterol (for Foradil Novartis), ph III, -S-oxybutinin SR(for Ditropan AZA),ph III,; 2nd ph III to start 2H04, ? -S-Zopiclone(Lunesta, Estorra), for insomnia, ph III,, but t1/2 = 5-7 h. Bad taste. Filed Jan 03, PDUFA Nov 30/03 , 2006 $ 566.8 M2Q07 $ 143. EU filed 3Q07, lic to GSK Sept 11/07 March 1/04 : approvable letter - S-Amlodipine, ph II (less edema) ?

UCB (for Europe) LLY(term oct19/00), JNJ(term April 23/01) NDA filed march 12/01;Not approvable March

7/02. QT∨, phospholipidosis, cardiomyopathy

SGP3% royalty (CPMP OK, sept 21, 00)FDA OK(Dec 20/01). No interaction with macrolides. ABT Aventis (3% royalties), Albany Molecular Liquid form & tablet will be filed N=436, DB, Placebo, filing Feb 2 Q03., approvable March 1/04 Resubmitted June 16. Class II (6m)PDUFA Dec15/04 FDA OK Dec 15/04 : 6 m efficacy/safety. Delay on availability due to schedule IV issues. Available April 7/05 for long term tmt (under schedule IV)

SFPH-OTC

Sheffield Pharmaceuticals merging (Nov 06) w/ Pipex

- Coprexa (tetrathiomolybdate), ph II, Wilson


- 131 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SGEN M

K

SEATTLE GENETICS (SGEN) EPS not positive until 2007 IPO filed nov 20 ( JPM),priced $7:DNA acq $2m, MEDX acq $2m in PIPE Non-exclusive single chain licenses from ENZN & Creative Biomolecules (CRIS) Created by ex BMY employees, with license from BMY to the BR96 Abs (anti Lewis y, also present in gut) improved by AMEV. Competition Hz anti Lewiw lic by PDLI to Igeneon AG 'Austria) July 2/03 : PIPE $ 41m

- SGN 10, BR96 scFv, pseudomonas toxin linked, ovary K,with Taxotere, ph I;ASCO 01:problems of vascular leakage. Term Nov 7/02. - SGN 15, BR96 ch, doxo linked, ph II, with Taxotere, breast(term Nov 7/02)/prostate/colon K/NSCLC. ASCO 01 : serious digestive side-effects; ovary w/Gemzar init Aug 02

- SGN 14 , naked anti CD40 (competition IDPH, AMEV), pre -SGN 30 (anti CD30, activated T cells), ph I init March 21/02, Hodgkin & NHL; ph II CTCL - SGN 17/19 ADEPT (antibody directed enzyme prodrug therapy): sFv against p97(melanoma Ag), fused to β lactamase, then pt receives cephalosporin derivative of Melphalan - SGN 40 : Hz anti CD 40, lic to DNA Jan 7/07, 800m (upfront 60m); see Idec 131 & AMEV/LLY ph I & II MM, NHL, CLL; ASH 06 good ph I data NHL - Auristatin, proprietary cytotoxic that can be linked to Abs.

w/Aventis w/Aventis, w/ICOS ASCO 03 : HRPC w/ or wo/ Taxotere, NSCLC : progression free survival 15.3w (taxotere alone group 7.5w), without GI side effects → August 03 World conf on lung cancer : survival Tax alone 5.1m, assoc 11.4 m DNA discont Oct 9/02 → ASH 03 June 01:lic toxins & linkers to EOS f hu partnership w/Medarex (feb 7/01)

SGMO SANGAMO (SGMO) Engineered zinc finger (ZF) transcription factors : nucleases (cut DNA where you wish)

-Aug 17 :method to improve expression of EPO -Method to overexpress GPCR - Z F + gene for X-SCID, res - Z.F. to disrupt CCR 5 R, to init 2006 - VEGF / Z.F. disrupted gene acq from Edwards

Lifesciences, ph II, gene therapy peripheral neuropathy and ischemia

AZN, Bayer, DuPont,, DNA, GENSET, GLX, Roche IMNX, JNJ, MLNM, Merck KGaA, PFE, PNU, PNG,

Schering AG, SKB, WL w/MDRX : MAbs to GPCRs

SGXP K SGX (SGXP) was Structural Genomix IPO Traded Feb 1/06 Good team

Cytidine analogue, ph II/III, 3rd line AML fails Aug 29/06 - SGX 393, bcr/abl inhib w/Novartis, IND 1H08 - SGX 523, anti c-MET, to file IND 1Q08 - JAK 2 inhib, res, polycythemia - Ras inhib, res

SHM SHEFFIELD MEDICAL TECHNOL (SHM) re-fillable MDI (lic from Siemens) Dev & Mkt agreement w/Zambon


- 132 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SHP SHIRE

TRANSKARYOTIC THERAPIES (TKTX) Really human (glycosylation pattern !!!)EPO Gene activation patent is licensed from CEGE CFO tells me (Nov 01) : Replagal is manufactured by a bunch of contract manufacturers Adv Com Sept 27/02 POSTPONED→Jan 13/14-03 : 15/0 failure to provide evidence of efficacy March 19/03 : staff↘ 25% April 4/03 : CFO Dan Geffkin resigns Hunter : 2000 pts WW - Since Dec 03, President of Dr Reddy US on Board. -Renovating Alewife manuf facility in US (to restart 2H04 for I2S & GCB) April 25/05 to be acq by Shire, OK July 27/05 Hunter : around 2000 pts ww

-GA-EPO (Dynepo), human cell line, filed FDA/CPMP Aug 3/00, additional process validation requested from AVE by FDA (nov 24/00). Dec 12/01 : OK CPMP. AMGN EU patents expire 04 Aug 3/04 : manuf by Lonza -Replagal agalsidase α,Fabry (TKTX says 5000 pts ww),BLA (human cell line∏better glycosylation) filed June 19/00,CPMP+ march01,giving slightly better labelling than to Fabrazyme, EU approval Aug 01 efficacy (p< 0.0001)Jan4/01:FDA requests more data (did TKTX answer ?? : NO, Dan Geffken, CFO Oct 15/01) May 01 (int congr hum genetics) : signif reduct cardiac mass; 100% clearance of GL3, infusion 40 min (0.2 mg/kg) June 5/01 : signif reduct in pain, (uninterpretable methodol. says FDA Sep 26/02)& improvement in EKG & GFR. Dec 2/02 : no statistical ∨ GFR Sept 25/01 : signif improvement in cerebral blood flow -ex vivo Gene therapy VIII, ph I (transfected auto-fibroblasts). June 01 : NEJM -GA II, ph I, returned by AVE dec 8/00 - Iduronate sulfatase Elaprase I2S, Elarsulfatase ; Hunter sd (MPS II) , ph I/II, ph III, 12m , N = 96, init Sept 19/03,completed April 3/04, filing FDA Nov 23/05 , PDUFA May 25/06, extended on May 16 to Aug 25 , approved July 25/06; EMEA Dec 1/05, approval Jan 11/07 Top line ph III June 05 : June 20/05 top line data p = 0.005 (composite forced vital capacity + 6 min walk) - GA-GCB : Gaucher, ph I/II fully enrolled April 20/05.

Data 2H05, on mkt in 2008 - LSD-CNS : Hunter & San Filippo (MPSIII) - GAL-6S : Morquio, res - GA-CSF, ph I (terminated by Aventis) seeking partner - GA- FSH, pre, seeking partner - Juvista (lic from Renovo June 20/07), r TGF beta 3, ph II,

to improve/prevent scarring

Aventis patent litig AMGN (May 7/02 complex hearing,US decision expected 2H03) & UK, no launch before completion ;costs assumed by AVE. Reacq by TKTx 1Q04;Sept 14/04 Aventis licenses to TKT onco data available 1H05, if US patent litigation completed Oct 18/04 : TKT loses in US, Oct 21 UK court revokes AMGN patent ! Shire to launch EU 1H06 -Sumitomo, waiting for approval 2H04 Price 0.2 mg Replagal = 1mg Fabrazyme = $ 165,000 /patient/year Registry : 150 treated EU pts Selling l EU 02 : $ 47.5; 1Q03 12, 2Q 14.4, 3Q 15.2, 4Q 15.2. 2004 : $ 77m (4Q 22.5). New manuf process to be approved in EU -G.I. (AHP).June 5/01:signif increase 4/6pts W/GENZ in Japan (30% royalty)


- 133 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SHR COLLATERAL THERAPEUTICS (CLTX)

Being acq by Schering AG (March 20/02)

AdFGF4(Genvascor)→PAD, phI -AdFGF4 (Generx)→ischemic heart, ph II/III ™™→→→ -FGF/VEGF gene (GeneCor), PRE, w/CEGE - Adenyl cyclase gene (Corgenic),PRE, CHF,w/TGEN

Partn. with Schering AG(who is decreasing support) ™present. A.Coll Card march 20/01, improvement in treadmill but not signif. But at 8 weeks perfusion defect reduced versus placebo.

SIGA SIGA web site not updated Lead investor (Eliot Rose Asset Management (Providence) sold 71% of his holdings oct 31/06

small pox therapy SIGA-246, oral cysteine proteinase inhibitor. Ph I safey OK. POC monkeys before or 12 days after inoculation Oct 18/ 06 March 19/07 child with eczema vaccinatorum improved

competitor Chimerix is in ph I since June 28/06 : CMX 001)

SIBI K SiBiono * CHINA

Gendicine, adeno p 53 for H & N K. Approved, commercialized since 2004. See "Human Gene Therapy" Sept 05

SIRT IPO SIRTRIS Pharma calorie restriction diets activate SIR-1 (increases NAD synthesis)

SRT 501 : resveratrol, ph Ib, appetite control - Activation of SIRT1 : protects animals against

neurodegenerative disease (June 26/07) - New product tested on ageing mice (CRADA) Sept 6/07

SLN K SILENCE THERAPEUTICS (LSE) was SR Pharma that merged w/Atugen AG (antisense)

siRNAs - for respiratory, lic to AZN, July 6/07, $ 400 - for eye, lic to PFE, ph I - cancer, precl : pancreas & NSCLC to init 2008

SLXP SALIX (SLXP) gastrointestinal diseases

SMDX IPO K

SALMEDIX (SMDX), filed Sept 15/04 Pacific Growth

- SDX 105, Bendamustine : Treanda marketed in Germany; ROW Ph II NHL

- SDX 101 R-etodolac, CLL ph I - SDX 102,n L Alanosine, Ph II, NSCLC

SNAP SYNAPTIC PHARM CORP (SNAP) Being acq (Nov 12/02) by Lundbeck $ 121 m cash

- melanocortin receptors - strong IP in GPCR (165 issued patents -alpha 1antag→BPH, ph II -serotonin compounds→depression, ph I

MRK terminated 2 March 00 LLY

SNMX SENOMYX (SNMX) filed (DB) Feb 21/01


- 134 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SNSS IPO

K

SUNESIS (SNSS), filed Dec 23/04 (Lehman, SG Cowen), refiled Dec 23/04 Lehman, Needham traded since SEpt 27/05

cdk inhibs in K - SNS 595 (lic from Dainippon) naphtyridine analog, IV : cell cycle modulator inhibits CDK 2,3 & 9; ph II, SCLC (ECCO 07), AML (but mucositis, ASH); ph II NSCLC 2nd line init Jan 4/06 terminated May 07. Ovary 2nd line AACR Oct 07 - Raf kinase inhib (w/BIIB), pre - SNS 032 cdk 2/7/9 inhib (lic from BMY) ph I/II 4Q05,

ph I to repeat 1Q07 B cell malignancies - SN 314, aurora kinase inhib, ph I Sept 07

BIIB (kinase program for K), JNJ, MRK (Alzheimer) ASH 06

SNTA IPO K

Synta Pharmaceuticals since inception raised $ 200m Lazard, Lehman Bear Team from MLNM, VRTX, BIIB Pipeline acquired from Pricipia/Shionogi Postponed Jan 05, refiled Nov 22/06 PRICED Feb 6/07 mMelanoma OS : 6-9 m Oct 10/07 w/GSK $ 1.1B

- STA 4783 (bis thiobenzoyl hydrazide induces HSP 70 expression on K cells and activates NK), ph IIb meta melanoma, DB +/- TaXol PFS 3.68m vs 1.84 (N = 81, p = 0.03) ORR 15% vs 3.6% ph III init Nov 12/2007, Taxol + STA vs Taxol, endpoint PFS. Results 2H08. Catalysts EORTC Oct 22-26, Nov 1-4 Int Melanoma Conf New York - STA 9090 : HSP 90 inhib, pre - oral inhib of IL12/IL23 Apilimod (chemically different from imiquimod), ph II, RA

competition for Apilimod anti IL12 / IL 23 Mabs : CNTO-1275 ph III pso (NEJM Feb 8/07), ABT 874 (Pso, MS, Crohn)

SNTS SANTARUS ZEGERID, MTT, omeprazole + bicar in capsules or powder. Indications : - short term tmt of active duod ulcer - short term tmt of active gastric ulcer - GERD - erosive esophagitis claim to be superior to Nexium or Protonix for "nocturnal acid breakthrough".

SNUS K SONUS PHARMACEUTICALS ( SNUS) acquiring Synt:em Nov 5/04, $ 30m

-EchoGen, ultrasound contrast agent, approved Europe, FDA filing withdrawn (oct 13/00) -QW 4737, to assess myocardial perfusion, ph I -QW 8184, paclitaxel emulsion formulation oil in water w/Vit E, Tocosol, ph II init, April 5/02., fast track bladder (Oct 03), lic to Schering AG Oct 18/05. Ph III metastatic breast init July 8/06, weekly, compared to Taxol, but Abraxane's response rate is double of Taxol.Enrol compl Nov 16/06Data 1H07. Filing 2H07 ? Failure Sept 24/07

sold to Nycomed Amersham (Aug 6/01)

SNVT SAVIENT (SNVT) was Bio-Technology General Corp (BTGC) Class action suit 2002

-Oxandrin (anabol. steroid) : $25m (Mkt w/ABT-Ross) -Bio Tropin (HGH) : $17m -OxSodrol (r hu SOD) →ARDS, in dev -r hu anti Xa, PRE

Contract fees from Teva decreased in 99 March 23/05 divests to Ferring its Israel manufacturing facilities


- 135 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Changes (June 23/03) to SAVIENT ( SNVT)

- Prosapeptide analgesic ph II, terminated March 05 - Nuflexa : hyaluronic acid for joints (Ferring to MKT in EU) - Uricase ph III

SP Specialty Labs (NYSE : SP) Founded 1975 IPO filed 9/12 (ML), trading since dec 8

3000 different "esoteric " diagnostics performed.

SPA SR Pharma (SPA/LES)/ Atugen ATUGEN AG * Potential IPO -CEO Rudi Neirinckz -VP Bus Dev : Zisi Fotev

- SRL 172 (M.Vaccae) : NSCLC, ph III, fails; booster of Hep B vaccine to start

-BCG immunotherapies - PVAC, partnered w/CRXA Antisense, lic to Genta (jan 01):GeneBloc molecules for

"knock-down" drug discovery

w/G.O.T. Therapeutics GmbH for lipid delivery Roche, Bayer, BI, AZN

SPPI K K

SPECTRUM Therapeutics (SPPI) was NEOTHERAPEUTICS (NEOT) June 18/02 could be delisted Aug 23/02 restructuring

Hypoxanthine analogues : -AIT 082(Neotrofin)→Alzheimer, ph IIb,halted, but PET promising ™higher dose ?,III init feb 01 at high dose alone (april10), �hi�lment 6 months completed March 15/02, April 29/02 fails to meet 12w endpoint ∏Spinal cord injury, �hi - Parkinson : interim ph II (May 30/02)efficacy 500mg<250 ∏ Halted - elsamitrucin, topoisomerase I & II inhib, ph II -AIT 034→Dementia, IND filed Sept 26/01 - AIT 202, obesity, pre. - Satraplatin,oral , lic from BMY, prostate K; July 02 pre ph III meeting w/FDA postponed, init Sept 29/03. Ph III 2nd line HRPC expanded to EU. Licence fee $ 22m. ASCO 03 1st line TTP 5.2 m/2.5 Fully enrol Dec 05 (N = 912). Interim efficacy end 06. Rolling filing FDA by GPC Dec 15/05 5CPC) NSCLC + taxol, 1st line, ph III init Dec 9/05 - RenaZorb, lic in from Altair (Jan 31/05), close to Renagel- SPI 153 ozarelix w/Aeterna for EU, ph II, HRPC, LHRH antag - Lucanthone, ph II, K , radiation sensitizer - Eoquin, apaziquone, ph II, intravesical, K, bladder; frontline w/transurethral resection 2 ph III (March 07) to

Lic to GPC Biotech, Oct 1/02


- 136 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS init. Data 2009/2010

SQNM M

SEQUENOM (SQNM) acq GMNI (May 29/01, completed Sept 20/01 The leading provider of instrumentation for SNP genotyping 2 landmark patents receive notice of allowance Jan 10

"MassArray", industrial scale SNP analysis : collab w/FDA & Aventis for quality control of live vaccines and RNA viruses (Oct 25/01)

Only 400 of the 40000 genes are involved in "very frequent diseases" : this is what SQNM is looking for Gemini : Population (and twin) genomics -Patent for dg of HBP predisposition -exploring genes of depression & anxiety

-Clients : Genzyme, NIH, NCI,GSK, AHP, GNSC, GSK

-Partners : Gemini genomics plc (population genomics database) Incyte, Methexis Genomics (Belgium)

Hitachi, GSK (diabetes II) Gemini : -sept 6/00 : patent genes for "poor responders" CYP 2D6 & CYP 2C19 (hyperactive cyt P 450), but AFFX is marketing a chip for this ? -sept 14 : w/LSBC isolate 70 proteins concerned with osteoporosis, OA, diab, cardio-vasc. -GenMab

SSB STRESSGEN (TSE : SSB) Hsp 7, ph II, respiratory papillomatosis, recomb vaccine, Ph II in children; endpoint is "intervals between surgery", phII/ III to init, delayed (April 20/06); ph I/II high grade cervical dysplasia to init 2Q06

STEM C

STEM CELLS (STEM) was Cytotherapeutics Sept 24/02 staff ¬ 25% July 05 lic in c-myc ERTAM adult human stem cell immortalization technology from ReNeuron, with "removable trigger" (Myc is a transcription factor)

now focusing on stem cells -use of PBSC as hepatocytes (nov 1) -use of human fetal cells to differentiate into neurons (repopulation of mouse brain OK), liver, pancreas, delayed Sept 25/02 - July 29/04 : neural stem cells surviving in brain of immunosuppressed stroke rats. - HuCNS-SC (human neural stem cells), ph I to init (March 9/06) in Batten (neuronal ceroid lipofuscinosis)

-lic its device to Neurotech S.A -2 key patents issued (june 01) on harvest of neuronal stem cells, & separation of hepatic & pancreatic stem cells.. Strong adult neurol stem cell patent estate (stroke, Huntington, Parkinson). ReNeuron's cells can differentiate into Tyr-hydroxylase expressing neurons.

STEM UK C

Stem Cell Sciences plc (STEM : AIM) Established in Melbourne, headquartered in Edinburgh, with Japanese subsidiary (SCD KK, which is a JV with Sosei). Expanding operations to US and Cambridge UK

Nov 15/05 : license hMADS technology (human multipotent adipose derived cells) from Inserm Nice Sophia Antipolis (Dani & Ailhaud), for :

- Duchenne - Cardiac preclinical to initiate 2006


- 137 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SUPG M

SUPERGEN (SUPG) *others are injectable : Campto (AVE, PHA), Hycamtin (SBH) April 25/03 class action suit on misleading MitoExtra statements June 25/03 : PIPE $ 21.25 in convertibles PIPE March 5/04 : $ 34m

-Nipent→hairy cell L, MKT, sold to Mayne Ltd June 22/06 $ 34m (sales 05 : $ 15m)

-ExtraMItomycin : branded generic, FDA OK Nov 18/02 -Rubitecan orathecin (campto derived oral* topoisomerase I inhib)→pancreas K, ph III(June 12/01, 1st line, N = 1000/gemzar, too many crossovers , Filed 2 other ph III (409, 400 pts) in Refractory. In one survival not hit, but TTP & ORR OK : Rol. NDA init Dec 30/02 CMC, precl Feb 7/03), completed Jan 27/04. FDA action Nov 04, PDUFA extended (Nov 29) to Feb 26/05. EMEA filed July 1/04. Jan 4/05 FDA says does not support, SUPG withdraws. Jan 20/06 withdraws EMEA Ph II + Gemzar 1st line pancreas fails April 26/05 Sept 18 : good efficacy in CML - MP 470, c-MET and Rad 51 inhibitor, pre : the only

one in this category, could potentiate chemotherapy & Radiotherapy

-Decitabine, DACOGEN IV (DNAmethyl transferase inhib),myelodysplasia ph III versus BSC, May 12/03 fast track. CEO says survival benefit (PHRM Vidaza does not) Feb 13/04 interim : time to death or transformation to AML improved. reanalysis April 1/04 logrank p = 0.198, Wilcoxon p = 0.042. Rolling filing init May 31/04 (CMC) Completed Nov 2/04 (will get milestone from MOGN) ph II init + Gleevec June 14/03 CML ph I/II init JUne 30/03 w Carboplat, K Sept 5/05 : FDA approvable, additional anal of transfusion data. OK May 3/06 N = 170, ORR 17% vs 9% p < 0.001. Royalties from MOGN 20% up to sales $ 50m, then + 2.5% per 50m. Peak 30% DEAL -Water soluble Taxol→→→→→→→→→→→→precl -MAb for vascular targeting→K, pre -AVICINE (from AVI) hcG vaccine ph II, ph III soon - aurora kinase drugs pre, from MONTIGEN -VEGF targeting (w/PPHM)

ABT expressed concerns in Aug 00 on trial

management ABT terminates March 02 →ASCO 03 (ph III data) primary endpoint (survival) not met patent issued 3 feb 00 lic from PP → ASH 03 →ASH 03 lic to MOGN Sept 1/04 Oct 1/04 filed EU by EuroGen , SUPG's EU subsidiary


- 138 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS SYBB

SYNSORB BIOTECH (SYBB) Dec 12/01 : staff trimmed 50% Complex litigation/merger with Scout Capital (May 02)

-Synsorb Pk : carbohydrate to inactivate and treat E coli O 157:H7 toxiinfect; ph III (fast track) given within 2 days, decreases HUS 59%, comp. to plac., discont dec 14/00 Synsorb Cd( Clostridium difficile)→pseudomembranous colitis, ph II.: Recurrence rates : -placebo : 41.7%;-verum 21.9%. Terminated Dec 12/01

Takeda for Japan May 25/01 provides CND govmt with emergency

supplies

TARG IPO TARGANTA filed May 07 Traded Oct 10/07

Oritavancin, lic Dec 05 from ITMN who had licensed from LLY Sept 01. Phlebitis at injection sites. To file NDA 1Q08, seeks non inferiority delta ph III 15% (FDA usually requires 10%)

TBIO TRANSGENOMIC (TBIO) -WAVE system for SNP scoring -automated systems for nucleic acid analysis

MRK, GSK, LLY, NIH, CNRS, GeneOdyssée SA

TELK K TELIK (TELK) CEO Wick, ex Lederle, Dana Farber CMO Gail Brown, oncologisy from Harvard was "Terrapin" Secondary filed Sept 12/02 ∏ $ 74.4 Sept 30/02. Secondary filed Nov 03 raises $ 130 m (UBS, Lehman, Bear Stern, Needham, Lazard, Fortis). Jan 28/05 secondary $ 91.6 m

-TLK 286 Telcyta,nitrogen mustard Canfosfamide, (might be activated by non K cells) K prodrug, ph II,activated by GST P1-1 (Glutathion transferase). Jan 02 : enrol compl in CRC N = 73 (CEA ↘), breast init.April 02 , NSCLC N = 51, ovary K N = 36. mNSCLC 1st line ph IIb (AACR 07) N = 129. First patients receive Carbo Taxol & Telcyta. 77% have objective response or stable. Half go on with Telcyta, half do not. w/Telcyta OS 14.2m, without 8.4m, p = 0.0003. But overall OS median 9.6 m. This only demonstrates that maintenance treatment can be useful. ASSIST I Ovary ph III init March 27/03, 3rd line, N = 440, random , fast track, vs Doxil or Hycamtin. Accrual 15m, endpoint survival. Dec 30/04 fully accrued; powered to detect 28.6% delta. ASCO 03 ORR 18% bur only N = 11 (DOXIL FDA ORR 13.8%, Hycamtin 21%) . Data 4Q05/1Q06 : Dec 26/06 FAILURE. ASCO 07 OS 8.5m vs control 13.6 ASSIST II FDA OK Sept 26/02 for ph III for NSCLC, Fast track granted Dec 2/03, 2nd /3rd line, N = 520, to be compl. end 1Q05, vs Iressa, endpoint survival. Data 4Q05/1Q06 ASCO 05 : interim data ph I/II 1st line w/cisplat : 36% ORR; also Telcyta/carbo/taxol 62% ORR ASSIST III, 3nd line ovary w/carbo, vs Doxil alone, init

ASCO 02 : refractory ovary ph II ORR 15%; refractory NSCLC no ORR Microscopic hematuria 10% of pts AACR Nov 19-22/02 in irinotecan failures TTP 2.9m, Oxaliplat 1.6m, 5FU/LV 2.7m ASCO 03 refractory NSCLC, ovary, breast ASCO 05 : frontline data ASSIST II March 13/06 : ODAC rejects Gemzar/carbo in 2nd line ovary on PFS


- 139 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Dec 29/04, N = 244, endpoint ORR ( ph II ASCO 04 ORR 63% , & Doxil ORR 2/3rd line FDA 19.7%). Data release end 05 ? NO : data 1Q06 : but ORR is worse than PFS , and data could be read Carbo > Doxil !! June 07 FDA on hold, Oct 15/07 hold removed -TLK 199, Telintra, myelostimulant, I/II, MDS, init April 23/02. ASH 06 -Insulin receptor kinase modulator, TLK16998,pre, oral →ADA (June 01)

TEVA SICOR (SCRI) was Gensia Sicor Acq Biotechnica, Vilnius (Lithuania) July 01. FDA inspected. Acq by TEVA

Generics for hospitals (injectable) : and IFN α2b (Reaferon) registered in 16 countries

TGEN TARGETED GENETICS (TGEN) Aug 10/01 acquired Genovo (owned by BGEN). It's good to be near BGEN, but Genovo was involved in questioned gene therapy trials Staff ¬ 25% Aug 5/02 Staff ↘ 50% Dec 17/02 Class action suit Jan 27/03

-AAV-CFTR, ph I/II, ph II data June 5/03 : trend in FEV1 -AAV-E1A(anti her2/Neu)→K H&N, ph II (on hold until partner found) -AAV-VIII(B domain off), pre;clin for 2003, resp delivery ? -AAV-HIV, tg AAC 09 ph I (Bel, D, India), IM; Ph II S. Africa init Nov 05. N = 78 x 2 + 16 Zambia, data end 07. . But (ph I) is there an immune response in humans ?. -Emerald, collab for 2nd gener →→→→→→→→→→ -AAV-ad cyclase gene→CHF, pre→→→→→→→→ - AAV SERCA 2 alpha gene (Mydicar) coronary infusin

for heart failure, w/Celladon, ph I - AAV-IX, res - tg AAC 94, pre, AAV/TNFR-Fc, efficacy on RA in animals. Ph I, safe and effective (sustained improvement in 7/9 pts 8 w after tmt, ph I/II N = 40 data mid 06, amended March 16/06 to N = 120. Interim June 07 : 33% pts high dose get 2 points reduct in swelling at 12 w. 0 w/ placebo. Full data mid 08 - Jan 11/05 partnership w/RNAI (Sirna) on AAV delivery of silencing sRNAs for Huntington - AAV-ornithine transcarbamylase July 29 patient dies liver failure (should not have been enrolled) - AAV + RPE 65 gene ph I/II intra-ocular

Celltech (term Dec 2/02), discont March 16/05 ASCO 02 ovary 6/7 pts have reduct of CA 125 ™WYE (NOV 9/00). Term Dec 17/02 International AIDS vaccine initiative; WW around 30

preventive vaccines in trials Elan Collateral Therap Others Huntington : Trophos (Marseille) : ALS,

Spinal Muscular Atrophy


- 140 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS THLD K THRESHOLD (THLD)

filed April 2004 CIBC, traded March 05

- Glufosfamide (ifosfamide + glucose), ph III, 2nd line pancreatic K w/Gemzar, fails July 17/06; anal Feb 27/07 fails again on OS; BUT Sept 27/07 in diabetics taking sulfonylureas OS 13.7 m vs 2.4 m Jan 31/07 init ph II Pt resistant ovary K, SCLC (halted Oct 11/07 April 9/07 soft tissue sarcoma - TH 070, ph III, BPH, N = 500, results early 4Q06; liver tox May 12/06 - 2 deoxyglucose, ph I, solid K

ASCO 06 ??

THRX AB

THERAVANCE (THRX), was "Advanced Medicine" files for IPO June 14/04, traded since Oct 04 20% owned by GSK; had a call to acq 50%, did not (July 2/07) (Lehman, ML, Perseus) Significant side –effects : QT, hypoK, nausea, insomnia

-Telavancin,IV, glycopeptide ph II : efficacy ++ (ACCMID, Prague, May 11/04). Lic to Astellas (Tokyo)Nov 8/05 ($ 221m) - ATTAIN : Hosp acq pneumonia staph/pneumo vs vanco, ph III, last patient enrolled June 21/07 - SSTI, ph III, N + 1867. Aug 23/06 : non inf to Vanco (microbial eradication 89.9 vs 85.4 p = 0.053). Filed Dec 9/06, but is "non inferiority "sufficient"? FDA action YE 07, PDUFA Oct 20/07; APPROVABLE Ph II data July 10/07 clinically slightly > to Vanco Filed EMEA April 07 - Long acting beta agonist (1Q05 lic by GSK), ph II good data June 27/05 - Long acting muscarinic antag (lic by GSK 1Q05) . Competitor of Atrovent BI, Spiriva PFE/BI) TD 5742, GSK 656 398, ph I June 13/05 - TD 1792, AB, Astellas opts out Sept 7/07

GSK has option to lic. all their products competitors : PFE , Zeven (dalbavancin) from Vicuron/ Biosearch Italia/ versicor : "approvable" July 20/06, still under FDA review (Jan 4/07). Basilea /JNJ has a nice molecule (ceftobiprole) filed 2007.

TLCR IPO TALECRIS filed (MS) July 30/07

- Gamunex (IVIG) : $ 162m 1Q07, for ITP, CLL, BMT (but CSL Behring will launch IVIG in US 1Q08 - alpha 1 AT - Albumin - VII + X

TLN K Thallion, was Ecopia Biosciences (TSE/EIA) Jan 5/07 to merge w/Caprion

Microbial genomics initially - ECO 4601, ph I/II, anti MAP kinase (RAS pathway), crosses BBB, completed Aug 22/09 - CAP-232, ph II melanoma, acts on glycolytic pathways.

June 6/07 partnet w/ ABT Ab targets in lung cancer

Caprion Pharmaceuticals* (CND) Cell organelle proteomics, dg products for CJD (MAbs from IDXX)


- 141 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Topo K A/S

April 11/07 acq Apoxis : - APO 866 , inhib of nicotinamide psosphoribosyltransferase, ph II melanoma & CTCL - APO 010, recombinant modified fas ligand, ph I

- Savene Totect , MKT, topo II inhib for extravasation. To launch US 2H 07. Approved Sept 7/07Sales 1H07 DKK 8.3M - PDX 101, belinostat, HDAC inhib, oral & IV , 18 trials ongoing, ph II, CRC, CTCL, peripheral T cell lymphoma, MM 2nd 3rd line w/Velcade after Velcade alone N = 35, data YE 07; w Curagen. ASCO 07 ph I/II in advanced K : very safe, and HCC 1st line ph I/II. Ph III to init 2008. AML ph I/II init Aug 28/07. Oct 07 Curagen increases expenditure. Oct 25/07 AACR positive data ph II ovary alone or w/carbo-taxol - Avugane, HDAC inhib, ph II, acne - Baseca, HDAC inhib, ph II, basal cell carcinoma, lic to LEO, PSO - Topotect to protect from side effects of Topo II inhibs - Zemab, anti Her 2 with Pseudomonas toxin, ph I - Oct 4/07 w/Lundbeck : siramesine (sigma 2 receptor ligand) , caspase independent apoptosis inducer, to go into ph II (ph I anxiety, safe)

the 1st HDAC inhib (MRK SAHA, Vorinostat, Zolinza) was approved for CTCL Oct 6/06

PDX 101 time to response 1 m vs Zolinza 2 m Competition : MRK on MKT, Bayer MS 275 ph II, Methylgene/Pharmion MGCD 103 ph II, LBH 589 Novartis

TPPH K TAPESTRY (TPPH), was napro Biotherapeutics

- TPI 287, 3rd generation taxane, ph I. 2 posters ASCO 07. Poor efficacy, no neutropenia - Quassinoids, precl

TRBN K TRUBION traded Oct 18/06 (TRBN), Morgan Stanley, Pacific Growth, Lazard

Monoclonal like molecules with only F(ab) and Fc : - TRU 015 anti CD20, ph II, RA data 2H07 (enrol compl Jan 17/07, so end of trial July 17/07, data Sept 12/07 24 w ACR 20/50/70 : 61%, 13%, 4% vs placebo 33/9/2). Single dose ) B cell depletion similar & efficacy similar to Rituxan, perhaps less activation of C' (less intolerance ?), SLE - TRU 016 anti CD 37, pre, NHL, CLL

anti CD 20 lic to WYe Jan 3/06 $ 800m, upfront 40m DEAL

oct 5/06 partenr w/DYAX

TRCA TERCICA (TRCA) US MKT 30,000 prevalence of short stature w Nl or high HGH (6,000 have low ILGF) Competitor Insmed : March 7/07 wins patent fight vs Insmed

Increlex (r Hu ILGF1) filed Feb 28/05 for children resistant to HGH. Priority review, PDUFA Aug 3/05. To file in EU. Approved Aug 31/05 Ph III in severe IGF1 deficiency showed statistical efficacy on 8 years. Phase IIIb ongoing in less severe cases. Also hopes for obesity, osteoporosis

licensed from DNA


- 142 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS TRGA TREGA BIOSCIENCES (TRGA)

Acquired by Lion Biosciences AG. on March 12/01

-Combinatorial chemistry(iDEA, ADME simulation in-silico) -Melanocortin receptors: MC-4r (obesity, diabetes)→→→→→→→ MC-1r (pain, asthma)→→→→→→→→→ -HP228→pain, ph II

Chugaï, IMNX, ONO, ROCHE Novartis ONO

TRGNY K TRANSGENE (TRGNY/Nasdaq;LNM 6274) Founded in 1979. Since then has burnt more than € 200m Transgene has less partnerships and more employees (197) than any other gene therapy company Dec 20/00 : BioMerieux merges w/P.Fabre. BMPF has 70% of T., Mr A Merieux & Mr P Fabre jointly own 52.8% of T. Demerger June 02, TRGNY stays w/BioMerieux. New CEO : Gilles Bélanger (all his career w/Merieux). Then (July 02) JF Carmier New issue offering for €80m : April 23/01, raise 63m (May 25/01) from Merieux, PF, AFM. CV to belicensed out, using HGSI genes : CTFG2 for ischemia & TIMP4 for restenosis.

-Ad-CFTR, ph I. Terminated -Vero-IL2→melanoma, ph II, cellular vector will be

replaced by adeno -Ad-IL2→K, ph I -pox vector,Muc1 vaccine→breast K, ph II. N=31, 2 pts

have tumor reduct > 50% - MVA (modified virus Ankara) + Muc 1 + IL2, to start ph II : Breast, prostate, NSCLC ,w cisplat & Navelbine -plasmid with minidystrophin (™Duchenne), ph I initiated

sept 00 - TG 4001, therapeutic HPV vaccine for highgrade

intraepithelial neoplasia : clears HPV 16 (Nov 13/06). Ph III to init Q3 07, now (April 07) YE 07 or 08, lic to Roche € 218m

- TG 4040 (MVA + HCV) therapeutic vaccine for HCV, ph I/II init Jan 13/07

- TG 4010, IIb, NSCLC, MVA MUC1 – IL12 - TG 1042 : CTCL, ph II, adeno IFN gamma

BioMerieux Alliance is the holding company of TRGNY & BioMerieux (which sells reagents for in vitro dg)

Partnership with SGP (who has lic-in TRGNY's Ad for its p53)

HGS has 10% (giving TRGNY access to data base & right to 10 genes)

Partnership w/ Mirus Corp for IV musculotrope delivery of minidystrophin ( but Univ of Pittsburg (PNAS nov 28/00) has AAV + dystrophin, active in animals)

TRGT IPO TARGACEPT (TRGT), filed Feb 4/05 Pacific Growth posponed Feb 28/05, refiled March 11/06 TRADED APRIL 12/06

Neuropharmacology - Inversine (mecamylamine), MKT, HBP - Isopronicline, ph II, Alzheimer (targets NNRs, neuronal

nicotinic receptors) - TC 2696, Pain, ph II

TRIBY TRINITY BIOTECH (TRIBY) -gold particle tagged MAb for invitro dg : Hep B, H. pylori, Chlamydia, HIV -Saliva test for HIV antibodies


- 143 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS TRMS TRIMERIS (TRMS)

PIPE completed May 15/01 PIPE for $ 41m filed Jan 26/02 Secondary $ 111m, Aug 26/02, netted $ 102 (Sept 26/02) for dev & commercialization costs of Fuzeon EPS + in 03 : 50% of operating profit in N.America (will Roche do all the MKT ? not clear in 10K: TRMS will pay $ 25m in 2003), 10-12% royalty in Europe Peak sales $ 800 m at 10, 000/Pt with 25% penetration of those who failed 2 combis. Could be much more.Dec 02 : price raised to $ 16,500→20000 (Feb 25/03) BUT : July 2/02 at Seville resistance workshop Visible Genetics detects mutations linked to T20 intense selection pressure. This could compromise use in non NRTI resistant patients. March 20/03 : will be distributed in US by Chronimed (CHMD) who provide no guidance (April 22/03) even for 2004 ! Mid 05 the super protease from Boehringer Tipranavir could be approved, and it's association w/Fuzeon could be excellent (CROI, Feb 05)

Peptides that inhibit(bind gp 41) viral fusion to cells. -T20 Fuzeon(36aa) enfuvirtide→AIDS subcut 90mg BID or minipump ph II viral load ¬69-97% in non-responders to other drugs. 2 unblinded ph III (TORO 1US,2 EU)in association with optimal (genotyping + phenotyping) antiviral CT, fully enrol. Aug 6/01, last patient to reach 6 m. endpoint March 02. Launch 03. Fast track. Early Access program opens Aug 19/02 : is it 1st step to rationing ? TORO 1 (N=491) viral load ¬ 1.7 log (control O.763 log, p<0.0001) a bit different from retrovirus conf TORO 2 (N=504) data 17 May 02: viral load 24w ¬ 1.65log (1.43 at Barcelona), control ¬ 0.65 (p< 0.0001). 48 w data 4Q02 Filed FDA Sept 16/02 priority review granted (OK March 14/ 03)., CPMP filed Sept 20/02, OK March 20/03 2Q/03 US $ 4.3m, ex US 0.87, 3Q 13.1 (US 10.7) , 2003 $ 35m, 2004 $ 135 COULD SUPPLY EXCEED DEMAND ?? - end 05 sNDA planned for needle free Bioject delivery -T1249→AIDS, subcut, ph I/II, can be given once a day.

On hold Jan 6/04. Halted - June 14/05 TRMS alliance with Chembridge for "new

peptide". -RSV -Influenza

ROCHE; FDA fast track, manuf of commercial

supplies initiated (Boulder, Co),validation end 02/1Q03, to produce 3-5 tons/year. But 106 stages. Roche PR Aug 2/02 : cannot exceed present capacity in the short term.

KEY AIDS DATES : - ICAAC01 : ph I/II pediatrics efficacy + safety - Retrovirus conf : Feb 24-28/ 02 : viral load reduct –

2.62 logs/background alone – 1.87) Results : World Aids conf July12 02 ICAAC : full data Toro 2

In the western world 500,000 pts are treated for AIDS. 80,000 could be treated by TRMS, 25,000 were forecasted for year end 2003, now only 12,500 ??, perhaps only 7,500 ( Dec 19/02, guidance May 12/03 : 8 to 10,000); could be enough for 37000 pts in 2004 (→ 2005). July 15/03 Roche analyst meeting : manuf facility to be expanded (WHEN??) for Fuzeon & 1249

COGS around 33%

TRPS TRIPOS (TRPS) Leading provider of Biotech software Lion, NN, Arena, BMY, Merck KGaA

TTP M C

TITAN (TTP) -Zomaril(iloperidone)→schizo, ph III;filing delayed (July 01)→ end 02, approval ?? 04. July 22/02 Novartis compares to Geodon : QT↗. Dec 05 NVS licenses to Vanda -Spheramine→Park, ph I, encaps. hu DA retinal cells -CeaVac-(antiidiotype MAb)→K colorect, ph II→phIII (June 19/01)Dec 11/02 endpoint missed, NSCLC (+ TriAb) - TriGem (antiidiotype vaccine), seems very effective in neuroblastoma (ASCO 01), ditto melanoma

Novartis, lic from Aventis in 97 Schering AG


- 144 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS -Rb gene therapy, pre - Pivanex, ph II, NSCLC, histone deacetylase inhib.

TWTI THIRD WAVE TECHNOLOGY (TWTI) IPO filed 7/31 (LB), traded since Feb 12/01

SNP scoring with "Invader"

UBDE C US Biodefense (OTC BB : UBDE) forms subsidiary "Stem cell research institute of california"

- liver cell progenitors - human neural crest stem cells - drug resistant hemopoietic stem cells - human oral keratinocytes (for hemophilia, diabetes) - non marrow stem cells for cardiac regeneration

UCB M

Celltech Chiroscience/Medeva (CCH/LSE;CLL/Nasdaq)

acq by UCB

UCOR UROCOR (UCOR) Services for urologists (dg, trials, specimen banking) UGNE UNIGENE (UGNE,OTCBB) Oral PTH, pre, osteoporosis Lic to GSK (April 15/02)

Competition LLY Forteo (ph III) NPS ph III EMIS oral, pre.

URGP URIGEN was VALENTIS (VLTS) Oct 9/06 to merge w/Urigen Aug 17/01 : w/Flemington, sublingual insulin spray (res). Jan 17/02 : closing the GeneMedicine facilities Staff ¬ Oct 9/02 July 10/06 : to sell ?

PLASMIDS IN LIPIDS -CFTR, ph II -IL12→H & N K, ph I/II -BRCA 1→ovary K,pre -IL2 IV, NSCLC, ph I - IL2 local H&N, w/Roche, Terminated dec 3/01 - VEGF 165, CAD, PAD ph II (Finland) - Del 1(development regulated endothelial locus 1), ph I/II : PAD, ischemic heart. Sept 29/04 misses endpoint - VLTS 934 : non ionic poloxamer (anti-inflammatory) ph IIb. Jan 11/06, N = 148 vs placebo. Important improvement in exercise tolerance, fails July 10/06

merger of Megabios & GeneMedicine (03/99) GLX Roche LLY competitor : Cilostazol (Pletal)

UTHR M K

UNITED THERAPEUTICS (UTHR) Price for Remodulin $ 50,000/year

-Beraprost ,oral prostacyclin derivative→PVD, PHT 2nd ph IIIenrol.compl feb 26/01 (there had been a first

one by Aventis….)but is Aventis still interested) CLAIMED THEY Would GET EUROPEAN APPROVAL

IN Q1/00 !!!!!!

-Toray, Japan Oct 15/01 : ph III PVD failure


- 145 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Total Remodulin pts in US around 700 Feb 23/05 patent extension until 2014 June 6/05 : sildenafil approved (Revatio) 20 mg tid June 13/06 lic oral formulation of Remodulin from Supernus Sept 4/07 deal w/ARDM : WHY ?? Viveta troo bulky ???? (Jan 9/07 Actelion acq Cotherix for Ventavis)

-UT-15 (Uniprost/Remodulin, treprostinil), subcut prostacyclin analogue for PHT ,that could be the successor of Flolan IV(epoprostenol). –EU filing through France (feb 5/01). Rejected by AFSSAPS SEpt 23/03. Approved France March 8/05 -Aug 14/00: incomplete filing to FDA,oct 16 complete Told by FDA "no need for Adv. Com on feb 9" ??. April 11/01 FDA adds 3 months delay Adv Com Aug 9/01 : OK6/3. FDA OK May 22/02 sales 03 $ 49, 1Q04 12.6; 2Q 16.2, 3Q 18.4, 2Q05 28.5; 1Q07 38.2; 2Q 49.4; 3Q 57 - Feb 2/04 files for IV with only Bioequivalence data (PDUFA Nov 30) FDA could want to see data from ongoing open label, UTHR could file it Oct . FDA OK IV Nov 24/04 "for those not able to tolerate a subcut"- Inhalable Remodulin (VIVETA) initiated (but CoTherix ?? Ventavis (Iloprost from Shering AG, approved in EU, and US DEC 29/04, but UTHR inhaler very bulky. However VIVETA trial TRIUMPH positive data Nov 1/07

- Ovarex orgovomab IV murine anti CA 125 (ascites), ph III, lic from AltaRex for US (April 22/02). Oct 15/04 AltaRexx acq by ViRexx.. 2nd ph III enrol compl June 20/06. N = 177, data Nov 5/ 2007: FAILURE. Prior trial not positive

Amer Heart ( McLaughlin) Approvable letter Feb 11/02 Improves dyspnea, but not distance in 6 min walk (Tracleer does). Approved class II to IV May 24/02 (Flolan & Tracleer are III & IV). Ph IV requested to show that Flolan patients can be switched. Aug 21/03 :ph IV timeline increased

VBI K VIVENTIA (VBI TSX) - Proxinium, ph II, cytotoxic Mab to EpCAM, H & N K - Vicinium

VGIN VISIBLE GENETICS (VGIN) Being acq by Bayer ($ 61.4 m cash) July 24/02

Leader in HIV genotyping, using DNA sequencing, rather than probes such as those of Affymetrix, Nanogen or Innogenetics

GLX

VGNX VARIAGENICS (VGNX) Nov 11/02 : merging w/Hyseq

Pharmacogenomics : streamlining development by eliminating (with SNPs & haplotypes) non responders.

Covance, Quintiles

VIAC C

ViaCell (VIAC) IPO filed Jan 30/02 (UBS, CSFB), pulled Jan 5/04, refiled April 04, traded Jan 23/05

-Umbilical cord stem cells : system to collect and preserve baby's cord blood stem cells (Viacord). ACC March 06 : dose dependent response in animal myocardial I nfarction. June 13/06 lic to JNJ/Centocor

Aug 30/05 publication on human umbilical cord stem cells, piglets improve ejection fraction after infarction


- 146 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS equity held by AMGN, GENZ, GSK Goal "true off the shelf stem cell product"

- CB 001, ph I, cord blood technology w/AMGN, data end 06, K - SCF, Flt3 ligand, non exclusive ww license from AMGN for ex-vivo cell therapy ( Jan 2/04) - Viacyte : system to preserve and store human eggs - w/GENZ, partnership to create an islet stem cell transplant product for diabetes

VIAP VIA was CORAUTUS (VEGF) was GENSTAR (GNT), was Urogene(UROG) April 3/03, Staff ↘ (Bob Sobol) merged w/Vascular Genetics → AUTUS → CORAUTUS Feb 6/03 Feb 8/07 merger w/ VIA (oral leukotriene synthesis inhib for carotid endarterectomy)

- Gutted adenos, w/Centocor (May 8/02) -Maximum : VIII in adenovirus derived vector : ph I (June 18/01), suspended for coag & hepatic issues. Restarted Sept 25/01; 8 months after the patient still has 1% VIII - MAX AD Prostate (IL3) - Lentivirus as vectors for HIV genes - VEGF 2 from Vascular Genetics : IIb init 2H03. Catheter delivery of VEGF for severe angina; ph II suspended March 14/06 (pericardial effusion) - VIA 2291 (from ABT) 5 lipox inhib; carotid endarterectomy, ACS. - Library of PDE inhibs from Neuro3d (Strasbourg)

BAXTER

VICL K VICAL (VICL) "GENES IN A BOTTLE" CEO quits (April 00)

- HGS (hepatic growth factor) w/plasmid lic to AnGes MG Inc (Osaka) who partnered w/Daichi, ph III (cf VICL web site)peripheral heart dis & ischemic heart . June 18/07 strong data ph III PAD. Preparing to file in Japan

-Allovectin(HLA-B7), ph III→melanoma, completed June

02, data 2H02. Term Sept 19/02 for low dose. Now high dose ph II → ASCO 04

SPA (Feb 10/05) for high dose vs dacarbazine or temozolomide, ph III, N = 375, end point ORR at 24 weeks. To init 1Q07 w/AnGes

→H & N,ph II (august 01 H&N conf only 10% of patients show response)

-Leuvectin(IL2),ph II,Terminated (april 01) renal K failure. Ph I direct intratumor, then poration

Nked DNA vaccines→→→→→→→→→→→→→ - Anthrax effective pre - Flu vaccine very positive data H5N1 in mice & ferrets,

May 2/06

strategic alliance HGS (feb 23/00),and Vascular Genetics (private, owned by HGS),on VEGF2

MRK (influenza, HBV, HCV, HIV init Jan 7/00); Aug 21/03 influenza, HPV & HSV returned. MRK gets 3 new K vaccines. Aventis (PMSV) JNJ (Centocor) for K


- 147 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS VION K VION PHARMACEUTICALS (VION)

CSO Terrena Doyle was in charge of Taxol 10 years June 2/02 staff cut from 50 to 35 Feb 10/04 PIPE R & Renshaw Claim they have the rights on 3TC.

Interference case with Biochem Pharma since Nov 29/99

-Promycin (alkylating)→K, ph III, fails interim anal. -Triapine (aminopyridine carboxyaldehyde thiosemicarbazone, an iron chelator), K, (inhibitor of ribonucleotide reductase) + Gemzar, AACR Nov 02 → Synergy, ph II init May 03 pancreas , NSCLC : Sept 04 not > to Gemzar alone Feb 6/04 trial in prostate & H&N w/Triapine alone terminated. -TAPET : use of genetically engineered Salmonella to deliver CT or * to K,ph I - VNP 40101M (cloretazine, sulfonylhydrazine) ph II, glioma Fast track 2nd line elderley AML, ph III(SPA OK Feb 10/05) initiated March 28/05 : Ara C +/- cloretazine, N =420, accrual 30m. Endpoint CR & CRp (powered for 50% delta), interim at 210 pts; data bof Oct 26/06. AML terminated May 23/07

Boehringer Ingelheim other RR inhibs are Hydroxyurea, fludarabine,

gemcitabine ASCO 04 ? With Sloan Kettering for metastasis imaging ph I/II Int symp and expert workshop on leukaemia & lymphoma, Amsterdam, 16-19 March 05 :<30% ORR elderly AML ASH 05

VIR K VIRexx Ovarex, lic to UTHR

VLGC VIROLOGIC (VLGC) Pipe Nov 02 $ 7m PFE acq (Nov 02) 5% Staff Nov 02 ¬ ; N = 40 June 2/04 : to merge w/Aclara

- PhenoSense HIV,MKT, to measure clinically signif drug resitance (adapted to fusion inhibitors) - March 05 : w/ AZN and w/DNA tests for mutations in tumor and skin (dimerization of receptors)

VPHM VIROPHARMA (VPHM) De Rosen CEO (Aug 22/01)

-PLECONARIL (antipicornavirus) .viral meningitis, filing 2Q00™™™™™™™™™ .common cold: VRI (viral respiratory infection) 2096 pts, 65% had picornavirus. Duration of running nose 6.2 days/7.7 (p<0.001).Filed Aug 1/01 Negative view in Barron's (May 01).Not approvable letter June 5/02. Lic to SGP Aug 04 -Hep C VP50406 : ph II. Terminated -VP 14637⇑RSV, ph I (oct 10) discont. Sept 24/01

(animal CNS tox) - Maribavir, ph II, CMV in allo BMT. Data end 1Q06 - HCV 796 for hep C, ph Ib. Safety : discont Aug 12/07 - Vancocin (oral vanco not reabsorbed) lic from LLY (Oct

22/04; $ 116m), for Clostridium difficile diarrhea (LLY sales 2003 : $ 28). Will price 20 x 250 mg

SASY for Europe (renegotiated), lic to AVE (Sept 01) Term Aug 2/02

results +, but not remarkable (April11/01) Cholesterol increase ?? Adv Com March 19/02 15/0 against(menstrual

anomalies, arrythmias) w/AHP


- 148 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS capsules at $ 446. Sales for 9m 05 : $ 92m. March 17/06 generic threat

- Feb 27/06 lic in non toxicogenic strains of c. difficile, to treat and prevent CDAD

VQPH VioQuest (VQPH OB) merging with Greenwich May 05 Meichel Weiser, from Paramount, on Board

-VOD 002 API- 2, tricyclic nucleoside inhibitor of Akt (and test for Akt), ph I/II at Moffit & MD Anderson -VOD 001, Na Stibogluconate (was for leishmaniosis), tyrosine phosphatase inhib, ph II (Taussig)

VRA VIRAGEN (VRA) IFN α natural human leukocyte derived : high dose (9 MIU/d) provide esperimental protection for SARS

VRML VERMILION was CIPHERGEN (CIPH)

Chips for proteomics (SELDI) : surface enhanced laser desorption/ionization chips Biosepra (Cergy Pontoise) sorbents for high scale separation of proteins

ALKS/AMGN/AZN/BI/CAT/CNTBY/CBMI/GENE/GLX/NN/WLA/AVE/SGP/SBH/Roche

VRTX K

VERTEX (VRTX) Staff 980 , then 848. June 11/03 ↘ 10% Aurora acq (July 01) Secondary June 05 : $ 153m Aventis R/D day June 18/02 too enthusiastic on 740 Schering AG NVS IMPD : inosine monophosphate dehydrogenase Hep C : 10,000 deaths /year in US (33% of all liver transplants). INF α + ribavirin gives 38% sustained viral response . aasld Nov 2-6/07

-Agenerase (amprenavir)protease inhib, mkt - Lexiva fos-amprenavis, VX175 (908), less pills,filing US/EU Dec 02 → FDA OK Oct 20/03. July 27/03 GSK trial misses endpoint (non inferior to Kaletra). EU OK March 23/04 - VX-385, , anti HIV protease, ph II, w/GSK

-VX 740 Pralnacasan, oral, IL18 & ICE inhib (IL1 conv enz)→RA, ph II April 25/02 : ACR 20/12w p=0.07. - VX 765 proprietary ICE inhib ph I to initiate 2Q03 -Oral IMPD inhib like Ribavirin : -Hep C, merimepodip VX 497, ph II -PSO, ph II, VX 148, ph II -Timcodar (neurophilin),diab neuropath, ph II -VX 710, MDR & MRP antag, ph II -Kinase inhibs→→→→→→ - VX 950, telaprevir Protease inhib Hep C, oral liquid, to become tablet, ph Ib init 2H03, June 14/04, lic Asia to Mitsubishi. May 10/05 : 14 d reduct in viral (HCV genotype 1, 70 to 75% of US pts) load 4 logs (IFN α leads to 1-2 log decrease) (see also Avalon AVN-944, ph I, Sept 05).Ib combi to init YE 05 Ph II 2006, ph

GSK (CPMP OK june 30/00). Royalties negligible: $ 17m 2004

July 7/02 AIDS meeting : 2 ph III data NDA & CPMP

filed Dec 23/02 AVE upfront $ 20m. Full dev funding. Milestones $ 62m RA, others for OA; launch 2006,ACR Oct 25-29/02 : subgroup anal signif at high dose (1200 mg/d ; ACR 20 @ 6m = 44%, but Enbrel 65%!). OA ph II init Jan 03. Nov 11/03 AVE halts (animal liver tox) , waits for 12 m tox (in > 12m) COMPETITION : ITMN is only preclinical, Idenix is ph I/II (April 12/07 53% naïve pts reach 48 weeks undetectable)., also SGP protease inhib SCH 7, Anadys, GILD, Roche 1626 (bone marrow tox), Wyeth HCV 796, Coley Actilon, HGSI Albuferon, Pharmasset (VRUS)


- 149 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS III 1H08 (filing 2010/11). 28d trial init w/ IFN & RibavirinDec 5/05. Feb 6.06 drops to undetectable ! July 10/06 lic ex US to JNJ. Oct 27/06 : active on Hep C wild and resistant Jan 07 init of PROVE III in hep C refractory to IFN -VX745,oral p38 MAP kinase inhib→RA, ph II, terminated, CNS animal tox - VX 702, 2nd generation oral P 38 MAPKinase inhib ph I init June 12/02, RA ph II init June 10/05; March 9/06 : 12w ACR 20 40% (placebo 30%). Ph II in acute coronary. - VX 409 Na channel modulator, pre, lic to GSK Dec 13/05 $ 405m (upfront 20) - VX 322 w/NVA, anti Flt3 & cKIT - VX-680 (MK 0457), small molecule inhib of Aurora kinase 2, FLT3, JAK2 , BCR-ABL (active on T3151mutation). K,. Interferes w/cell cycle (centrosome); competition see Rigel), lic to MRK. Ph I good. Dec 7/05 3 phase II ongoing. Pivotal ph II init Dec 21/06in CML & ALL w T3151 mutation (MRK could file on this). N =270. Recruit suspended Nov 20/07 (QT elongation) - May24/ 04 : discovery of small molecules active on CFTR, see CFF conf June 5/04

w/Roche Nov 2-6/07 two large ph II : PROVE I (US) & II (EU) AASLD : SVR (sutained virological response) low 60% for Prove I, but Prove 2 79% undetectable at 12 w, 70% in P. I. Side effects rash (54% vs 31% IFN Riba ), nausea (50% vs 31%) in PROVE II at AASLD Nov 07. Discont rate Prove I 18% verum vs 3% control Aurora competition : Rigel, Merck Serono, MLNM, Cyclacel, Sunesis VX 680, lic to MRK June 22/04 ($ 350m)

VRTX AURORA BIOSCIENCES (ABSC) Acqcq by VRTX (July 01)

Ultra High Throughput Screening GenomeScreen (but a collaborator left on March 4

AHP, Becton Dickinson,, BMY, LLY, Roche, DNA, GSK, MRK, PFE, PNU, WLA,Organon

VSGN VASOGEN (VSV, now VSGN) PIPE July 1/03 : $ 37.5m

- Celacade : to init ph III 3Q/03 "stress a sample of patients blood 20 min, reinject → IL10 ↗, cardiovasc antiinflam../ CHF, PAD. Device , patient's blood is treated in VSGN unit, then reinjected IM. Aug 30/05 Safety Comm; closes trial in PAD. March 13/06 endpoint missed - VP 025 , pre, neuroinflammation

Lic to Ferrer for EU. To launch 2H07 as a device.

VVUS VIVUS (VVUS) - MUSE , local PDE5 inhib, MKT - Topical Alprostadil, ph III, female sexual arousal (ph II success p < 0.02) - Testosterone spray , ph II, N = 261 - Evamist , ph III init Dec 04, low dose estrogen spray, HRT


- 150 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS VXGN

V

VAXGEN (VXGN) CEO resigned Dec 00 Short 11% of float JV w/South Korean partners in Incheon : Celltrion Inc. To manuf for BMS abatacept & belatacept

-anti HIVpreventive vaccine in phase III:r gp 120 from HIV 1MN & HIV 1 GNE8. Safe after 23000 injections, efficacy (interim, final nov 02)could be reviewed Nov 01→ inconclusive?? (contains SQ 21). Feb 27/02, NIH decides not to test w/Aventis vaccine (because AVE data bad). Feb 25/03 failure to reduce infection , but effective in black subset. Failed 2003 in Thailand - Dec 16/02 smallpox vaccine from Kaketsuken (LC-16, mkt in Japan). IND filing early 03, grown in rabbit kidney cells) - Anthrax vaccine (rPA 102), Nov 5/04, $ 878m BioShield contract for 75 m doses (BioPort to provide 5 m !!). Nov 5/06 probl w FDA. Gov contract canceled Sept 14/07

spinoff from Genentech

VYSI VYSIS (VYSI) First profitable quarter Being acq by ABT (tender Oct 24/01) CEO: John Bishop

Genetic diagnostic products : Her2/neu test (ODAC + Dec 5/01) & many mutation dg kits

"Genomic Disease Management company"

part w/ABT (April 5/01)

WL6 GR

K WILEX BIOTECHNOLOGY, German

-WX-G 250 Rencarex anti CAIX (carbonic anhydrase IX) Ag, non labelled, ph I (Mayo Clinic), since ASCO 01; RCC ph III ongoing 2007 in non-metastatic pts, after total or partial nephrectomy, enrol 420/856 April 3/07. Data 2H08

-*I chimeric WX-G 250, ph II, ⇑renal K, at Ludwig Institute (New York);orphan drug (June 01)

- WX-UKI, ph I, K, small molecule active on urokinase activator system

exclusive lic.from Centocor April 8/02 CPMP orphan drug designation for both Nov 14/07 Int Sympo on CA-IX

XGEN XENOGEN (XGEN) Initial funding from SR-One, Pictet, etc..

Luciferase tool-box for biologics & genomics Proprietary in-vivo biphotonic imaging (from glowing

fungi to light producing mice)

XNPT XENOPORT (XNPT)

- XPI 3512, Gabapentin prodrug, ph II, diab neuropathy, restles leggs. Lic Feb 8/07 to GSK (XNPT could copromote Requip); lic to Astellas for Asia Dec 05. April 25/07 improvement vs placebo, but no data vs Requip –GSK, patent expires Dec 07) or Mirapex (B.I.) - XPI 986 generic bacofen (Gaba agonist) for gastric reflux

XNVA K XENOVA (XNVA) merged with Cantab

-XR 5000(topoisomerase I & II inhib),side-effects in phII -XR 9576 :MDR inhib, ph II, ph III to start 4Q if partner

found : QLT (AUG 14/01)

June 1: colorectal discont, breast& ovary ongoing, results for 4Q


- 151 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS XOMA M

K

XOMA (XOMA) -The BIG Neuprex failure→→→→→→→ … Crohn ph II init July 27/01 - Xanelim anti CD 11 MAb→PSO, ph III (25% of US operating profit, in EU mid single digit royalties). April 13/03, 90 days after approval will have to repay DNA's loan of around $ 60m (offset against royalties). Must also share mkt costs in US. RA trial terminated May 12/03 -to manufacture ONYX 015 : suspended - w/MLNM : LDP 01 - W/MLNM CAB 2, recomb anti C4 fusion prot for reperfusion injury - Aug 17/04 : fails Ph III BPI in acne - HCD 122, fully human anti CD 40 myeloma ph I w/CHIR Novartis (see also IDPH, AMEV, SGEN), CLL, MM

→lic to BAXTER (24 JAN/00). XOMA regains July 8/03

→w/DNA: 6 months delay annonced Oct 5/01, more

delays announced April 8/02 on manuf diff w/DNA

XZL C

SELECT THERAPEUTICS (XZL)

- Cytomatrix : technology for expansion of stem cells without cytokines. Ph I/II BMT to start Dana Farber mid 01 for auto & cord

- In Researsh ditto : pancreas, liver, brain - Activation of Ag presentation to dendritic cells by

linkage to verotoxin

-Part. w/ Haemonetics (HAE) - JV w/ Cytomatrix LLC : Cell Science Therapeutics

(CST) -w/Crucell (June 26/01), PERC6 ,who will manufacture gene therapy product.

YMI K YM Biosciences (CND) TSX/AIM : YMB, AMEX YMI IPO filed March 02. Trading since June 12/02 Raised $ 9.7m Monoclonal manufactured in Cuba by CIM (cannot be sold in US) CSO left Nov 02 Atlas could merge it ? (but that was Novus…CTIC) April 14/06, acq Eximias : - Thymitaq, thymidilate synthase inhib (from Agouron), failed in HCC - Orataq, oral formulation No intention to develop, bought for cash and US site

- Tesmilifene (DPPE diethylphenylmethylphenoxyethanamine, tamoxifene derivative), ph III, histamine antag, chemotherapy potentiator for K, prostate ph II w/doxo, breast meta 1st line ph III w/BMY (term. 99) w/doxo <vs doxo alone OS signif, but TTP NS ASCO 05 doxo + tesmilifene survival 29.7m / 12.2 in unplanned subgroup anal Temilifene + Taxotere N = 39 w/Sanofi, data end 07 . To reinitiate (FDA OK March 03) w/epi + cyclo (SPA, special protocol assessment) Breast Meta. Terminated Jan 30/07 - Theracim hR3, nimotuzumab (anti extracellular epitope, like all the others !), EGFR hz MAb, ph II( CND, Cuba), H&N. NSCLC (UK, CND) ph II enroled. Glioma ph II 35% ORR, partner Oncoscience (Germany) EU ph III underway April 06 pontine + Rx, ph I/II init March 23/06. Lic to Sankyo for Japan -*Y Theracin in Italy, ph I/II, glioma

Partner : CIM (Centro de Immunologia, Cuba) had something with PHA, but PFE ???


- 152 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - anti EGFR vaccine, ph II, NSCLC, see CNVX, Returned

to CIM Oct 8/02 - Norelin (GnRH vaccine), ph I/II, prostate K, reduces

testosterone.a YRK YORK (YRK, London)

ZGEN ZYMOGENETICS (ZGEN) Established 1981. Was NN until Nov 00, then 62%. Now NN has 32.7% (2006 Proxy) CATALYSTS for 1H07 : - EU partner for rHu Thrombin - 2H07 : clear evidence of efficacy of Atacicept .

- Discoverer of. Novolin and. Novoseven (which is fully retained by NN, no royalties) -IL 20 (inflam), pre - IL 21 (K), ph I/II, melanoma, RCC,NHL, CLL lic to NN; studies planned 07 w/Rituxan, Sutent, Nexavar - Il 28, 29, 31, res - Atacicept (TACI-Ig) fusion prot linking extracellular part of TACI to Fc of Ig to BLISS & APRIL, lic to Serono/Merck (2001). CLL ongoing RA ph Ib TNF refractory enrol complete RA Ph II init Dec 20/06 rand, biw. Primary : ACR 20 at 26 w. SLE ph II/III to init mid 07 (direct HGSI competitor). Oct 4/07 FDA SPA OK, N = 200 lupus nephritis, will do 2nd study in SLE per se - rHu XIII,pre (but Behring & SASY/IDM), ph I (Feb 4/03), lic from Aventis/Behring - PDGF lic to JNJ (Regranex) & to BioMimetic (for periodontal disease, May 29/02) pivotal ongoing - rHu Thrombin (manuf by ABT), ph II, surgical bleeding (liver resection, spine surgery). Ph III (compared to bovine IIa from King, sales $ 240m in 2004) init Oct 27/05, N = 417, filed Dec 18/ 06 (10 m review : PDUFA Oct 18 Aug 28/07 extended to Jan 17); ph III data Sept5/ 06 : hemostasis identical, Antibodies 1.5% vs 22%, p < 0.0001. Spray formulation, FDA says (March 7/07) no need for additional trial. June 19/07 lic to Bayer ex US, and B. will help US marketing & sales for 3 years Nov 2/07 King files "citizen petition against ZGEN !! - Pegylated IFN lambda (IL 29): to init ph I, 1H07 (more tolerable than IFN alpha)

Oct 00 w/Medarex Sept 01 w/Serono, for 2 preclinical candidates. Competition BIIb & DNA have a BAFF-Ig fusion

protein competition : plasma derived human thrombin Omrix OMRI lic to Ehicon (JNJ), ph III equiv activity to bovine, BLA filed Nov 6/06, approved Aug 28/07 Thermogenesis device (trial) to produce thrombin from patient blood samples.


- 153 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ZIOP K ZIOPHARM (OTC BB : ZIOP) - ZIO-101, ph II, organic As for advanced Myeloma, MDS,

HCC - ZIO-201, I/II, isophosphoramide mustard lysine :

sarcoma (combined formulation of ifosfamide & cyclophosphamide)

- ZIO-301, indibulin (binds tubulin), ph I

ZZZZ ACUITY* siRNA - Cand5, anti VEGF, ph I ARMD, ph II diabetic macular edema, full enrol May 1/06 - N-chlorotaurine, lic April 06 , anti-infective - anti Syk kinase, from Zabecor, for ocular inflammation (May 06)

ZZZZ K ADHEREX ADH-1 limb infusion for N-cadherin positive melanoma ZZZZ K AEGERA* (CND) AEG 35169 antisense to XIAP (x linked inhibitor of

apoptosis protein) ph I AEG 35156, 2nd generation anti XIAP, ph II, AML w/ AraC & Idarubicin; Also ph I/II NSCLC, Pancreac, BC

other XIAP : TetraLogic, AVII, DNA, NRGX

ZZZZ AEOLUS * AEOL 101150 for ALS ph I ZZZZ K AFFYMAX * - Hematide : peptide EPO mimetic, ph II

- G-CSF agonist peptide - TRAIL-R2 against K

Lic to Takeda for Japan (Feb 13/06)

ZZZZ K AGENDIA BV marker test for resistance to Herceptin ZZZZ K ALETHIA (CND) anti – clusterin Mabs, interact with EMt (c-MET) ZZZZ K AMBIT KINOME SCAN screens activity on over 300 kinases

- AC 220, FLT3 inhib, w/ Cephalon. FLT 3 competition MLN 518, relatively specific but not that potent; PKC 412 Novartis hits a lot of other kinases

ZZZZ K ANGIOGENICS, Public but not traded developed around Id genes & proteins that halt K neoangiogenesis : control dev of VEGF receptors

ZZZZ K ANTISENSE PHARMA GmbH - AP 12000 (antisense to TGF beta 2), glioma IIb (ASCO 07 > temozolomide), CRC I/II, Melanoma I/II

ZZZZ ARCHEMIX anti von Willebrand ph I ACS, ph IIa init Nov 13/07; N = 300, compared to ReoPro

ZZZZ ARGENES (Tokyo) ARG 198 anti Fas IgM Mab (Fas = CD 95), RA ZZZZ c ARTERIOCYTE * - Adult BM stem cells, auto, ischemia : PAD ph I

- Allo BM stem cells, precl

ZZZZ ARTISAN ART-123, recombinant trombomodulin (lic from ASAHI) for DIC in sepsis

ZZZZ K ASTEX* - AT7519 cell cycle inhib, ph I, w Novartis


- 154 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS - AKT inhib, res w AZN

ZZZZ K AUREON Techniques to identify patients who could benefit from Iressa w/AZN ZZZZ K AVEO pharmaceuticals

Oct 2/07 partnership w/OSIP

- AV 412 (from Mitsubichi), ph I, oral anti RTK EGFR & Her2 - AV 951 ph I anti VEGFR - AV 299, pre, anti HGF (hepatocyte growth factor)/c-Met pathway, lic to SGP April 4/07 $ 477m

competition Tykerb

ZZZZ K BIPAR* BSI201, ph 1, PARP (poly adenylribose polymerase) inhib. ZZZZ K BIOTICA - anti HSP 90 : lead optimization

- mTOR inhib, precl, lic to Wyeth $ 195 m DEAL Upfront, milestones, res support, royalties. The companies willw ork together on a discovery program. Wyeth will handle dev & commercialization of selected candidates

MTOR competition : Isotechnika, Ariad

ZZZZ K BIOVAX * oncolytic virus, ph II ZZZZ BIOXELL (Italy)

funded by Roche, BB Biotech, etc ph II non bacterial prostatitis ph II (BXL 628, vitamin D 3 analogue) in BPH

ZZZZ CALANDO* key investor : ARWR

siRNA delivery systems based on cyclodextrins

ZZZZ CELLADON * Kris Zsebo

Mydicar enhances SERCA2a, which regulates myocardial contractility. Percut AAV delivery to heart

Partnership w/Targeted

ZZZZ C

CELLERANT* Allo progenitor hematopoietic stem cells that do not need to be matched

ZZZZ CELLOMICS IPO filed 3/3 (PVS) posponed dec 21,withdrawn Oct 31/01 CFO comes from Oncormed

The neologism after "Proteomics" : virtual cell concept - Carl Zeiss - Aclara

ZZZZ CEREGENE* CEO Jeff Ostrove SAB Fred Gage, Inder Verma

gene therapy AAV for Alzheimer (NGF, ph I), ALS, Park (GDNF & Neurturin) - CERE 120, AAV Neurturin (boosts Levodopa transformation into DA, more for late stage PARK than the Avigen product which is for late stage), Park, ph II, N = 51 follow up 12 m April 07 : Reduct of Park symptoms in 36% of Pts (p < 0.001). April 07 init comparartive ph II vs placebo. June 21/07 : lic ex US to GENZ

ZZZZ COMBIMATRIX IPO filed nov 22/00 (SSB), pulled

going into siRNAs


- 155 - printed : 03/07/10 (d/m/y) 08:07


ZZZZ COPERNICUS* Non viral inhaled gene transfer : - CF : pre - IX : pre

ZZZZ CORUS (CSHP) filed Oct 19/04( ML, Pacific Growth) PULLED

Corus 1030 asthma : inhaled lidocaine, lic from mayo Clinic, ph II Corus 1020 inhaled Aztreonam for Cystic Fibrosis, ph II (could be restricted to associations, e;g; Tobi)

April 12/06 GILD invests $ 25M

ZZZZ C Cryocell Internat.* Umbilical cord stem cells

ZZZZ DICERNA siRNA company (26 to 30 bp). Alnylam & Sirna only protected to 25

ZZZZ Drug Abuse Science withdrawn oct 15/01

ZZZZ DNA Sciences (DNAS) IPO filed (jan 8/01) by LB Withdrawn 21/7/01

Genomic drug & dg discovery part w/Amersham Pharm. Biotech

ZZZZ EDISON pharma Mitochondria : Leber, Friedreich ZZZZ ELITRA (ELIT)*

Intend to mkt their drugs, in the US at least. IPO filed 9/5 (CHQ),withdrawn (nov 21/00) Harry Hixson chairman June 26/03

-Bacterial genomic drug targets, novel ABs & antifungals - Purchased the PathoSeq business from Incyte Looking for genes common to many bacteria, and absent from humans

-oct 12/00, acq Mycota (CND) : candida genomics -partner : LG Chem (Korea) - partn w/DCGN July 2/02 - Oct 26/01 : will provide AB targets to MRK

ZZZZ ExSar EXR 101 ph I, Tay Sachs ZZZZ FAUST pharmaceuticals SA, Stasbourg

Board Gilly CEO ex CEO Guilford Investors Sofinnova, Auriga, etc

FP 001 ALS, Ph II, antiglutamatergic

ZZZZ K FeRx * Experienced management

MTC (magnetic targeted carriers). Proprietary magnetic field applicator. - MTC Dox, ph II/III, primary hepatoma, intraarterial (ph II was in China). AACR Nov 02 21 lesions , 1CR, 2PR - MTC + Mitomycin intraarterial refractory NSCLC, init Jan 04

Orphan drug, fast track (Aug 27/02), regained rights from ELN Sept 27/02


- 156 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ZZZZ FIBROGEN* - FG 2216 oral prolyl hydroxylase inhib, degrades HIF,

activates EPO production, May 1/06, Astellas 765 m deal

ZZZZ K FivePrime Therapeutics Gail Maderis

- FTP 039, modified growth factor receptor that targets a protein overexpressed in K, pre - FTP 038, diabetes II, pre - RA, w/BI

ZZZZ FoldRx * Protein mis folding company - Parkinson : alpha synuclein program to prevent misfolding - FAC (familial amyloid cardiomyopathy) mutations induce heart failure in afro-americans above 60; Fx-1006 stabilizes transerythrin (TTR) to prevent it from misfolding

ZZZZ Gentra Systems* Founded in 1988 sales 2000 : $ 5.2m 67 employees 16 patent applications expected sales 2005 : $ 135m

nucleic acid purification technology Specialists of automation. Claim to have the world's first fully automated system.

ZZZZ HYPERION urea cycle disorders ZZZZ K ILYPSA* - ILY 101 phosphate binder, lic to Astellas, ph I

- ILY 102, Na binder - ILY 103, C. difficile toxin binder - ILY 105, K binder

ZZZZ K INTARCIA files Feb 7/04? pulled CSFB, Lazard, Pac. Growth

- Omega IFN in Alza Duros (3 – 6 months) : Hep C ph II - Atamestane , aromatase inhib , 2 ph III + Toremifene vs Letrozole (but on TTP, and mainly eastern Europe)

ZZZZ K INTRACEL Oncovax, autologous colon K vaccine, approved in Holland & Switzerland, ph III

ZZZZ K INTRADIGM siRNA for systemic. In nanoparticles w ligand , and nucleic acid carrier.

- ICS 283 K pre

ZZZZ KEMIA

p38 MAP kinase inhib, allosteric, ph I, RA, Aug 06


- 157 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ZZZZ K METASTATIX CXCR4 inhibitors in K and AIDS

ZZZZ MIRUS CORP * non-viral DNA delivery systems (novel cationic polymer). Claim to be able to reach muscle delivery by IV route (but use tourniquet)

⇑ TRGNY, for Duchenne

ZZZZ

MITOKOR*(MITO) Very strong management team. (Alta, Domain, SR-One) IPO filed (RBC) March 12/02, withdrawn March 25/03 25 issued patents

The Mitochondrion company

-Res in Alzheimer, Parkinson, osteoarthritis, Diabetes II (mutations in mitochondrial ATP synthase & tRNA lysine genes - MITO 4509, ph I, non feminizing E2, Park - non feminizing E2, ph III, w/WYE, Alzheimer - Neurostat (E2), stroke, pre, mitochondrial stabilizer - MITO 3108, obesity, pre

Partners : PFE, WYE, CHIR

ZZZZ MOMENTA M118, anticoagulant, ph II, IV ZZZZ C Nereus* - NPI 2358, pre vascular disrupting agent

- NPI 0052, pre, proteasome inhibitor - NFKB modulator

ZZZZ C Neurotech* (USA) NT 501, cell therapy for retinitis pigmentosa ZZZZ NeuTec (AIM, UK) AuroGraf,,recopmbinant anti staph antibody acq by Novartis, June 7/06 ZZZZ K NOVELIS anti MDM 2 ZZZZ OCTAGEN Corp * Second generation F VIII for hemophilia ZZZZ K Oncolytics Biotech

(ONC/TSE;ONCY/Nasdaq) Reolysin , oncolytic reovirus, because K cells with activated ras pathway are incapable of blocking reoviruses; prosta ph I init April 02, glioma ph I/II init July 02. June 20/06 intratumoral + RT

ZZZZ OPTHERION recombinant Complement factor H (mutated in 50% AMD patients) , also CV disease & RA

ZZZZ K PEPLIN Ltd (Australia) PEP 005, topical , basal cell carcinoma gel. 2 applications clear 71% of tumors

ZZZZ C PharmaStem * (was Biocyte) Umbilical cord stem cells

ZZZZ K Plexxikon - PLX 4032 IND filed Oct 1/06 melanoma DEAL Roche : upfront 40, 6 m research 2 y, 660 m milestones . Small molecule anti B-raf V600E - Servier $ 100 m collab Sept 30/06 to discover non-peptidic renin inhibitor.


- 158 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ZZZZ PHYTON * long acting GH antagonist

ZZZZ PROTALIS Glucocerebrosidase, Gaucher, from plant cell cultures, ph III

ZZZZ K RECEPTOR BIOLOGIX * CEO Michael Shepard, co-discoverer of Herceptin

Dimercept, pre, Mab to the 4 HER receptors

ZZZZ REGADO Biosciences RB 006 aptamer anti IX, good anticoagulant

ZZZZ RENAMED Device for acute renal failure ph II 67% survival at day 28 vs 39 conventional dialysis, ph III to init mid 07

ZZZZ Santhera AG SNT – MC17, Idebenone, ph III Friedreich ataxia (20,000 patients US & EU). Also in Duchenne & Leber

ZZZZ Senesco * Inhibitor of eucaryotic init. factor 5 A, for sepsis

ZZZZ K SENETEK Plc siRNA to Tenascin C Glioblastoma

ZZZZ SR Pharma Plc ATU 027 reconstituted lyophilized si RNA

ZZZZ Symphogen A/S r Hu polyclonal antibodies

ZZZZ Targegen * - TG 100115, ph I/II, anti P13 kinase, Myocardial infarction - TG 100801, pre, multitarget kinase inhibitor. Would act on VEGF mechanism for AMD. Non-invasive : eye-drops

ZZZZ Therapeutic Human Polyclonals acq by ROCHE April 2/07 $ 56 m

Hz recombinant rabbit polyclonals. Developing humanized Thymoglobulin

Competition : Symphogen A/S, Kirin (by acq of Humatech in 2005, cow based humanized polyclonals)

ZZZZ THERION, * H&Q, Pacific Horizon, Sofinov Funding difficulties for sla June 06

Pox virus based vaccines -Alvac CEA/B7.1, colorectal K gene therapy vaccine �hi -Gene Therap. vaccine for melanoma & NSCLC - Panvac-VF (anti CEA & MUC 1 w immunostimulants B7.1, ICAM 1, LFA3) metastatic pancreas 2nd line init 3Q04, 2nd line; survival vs/BSC; N = 250, + GM-CSF.

™Aventis-Pasteur


- 159 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS Fails June 28/06. Median survival 2nd line is 3 months, whatever the drug used - Prostvac VF, Ph II

ZZZZ K TRACON TRC 102, anti DNA repair , ph I w/Temodar

ZZZZ TRANSXENOGEN (Cambridge, Mass) to produce Insulin in eggs of genetically modified chicken

ZZZZ TROPHOS ( Marseille) TRO 19622, Spinal Muscular Atrophy, ph Ib Oct 07

ZZZZ K VasGene * - Veglin (VEGF antisense, to A, C & D), ph II, no sign of hypertension. RCC, CRC, NSCLC. - Mab to Eph B4 TK receptor, and to Ephrin B4 ligand, pre, w/MEDI

ZZZZ VasoGenix * Calcitonin Gene Related Peptide for cardiology

ZZZZ VASTOX plc small molecule to up-regulate utrophin (similar to dystrophine), res, Duchenne

ZZZZ XENCOR * Engineers Fc fragment domains of Mabs (Medarex also)

ZZZZ XENON GENETICS* (CND) "Extreme Genetics"

ZZZZ ZELOS * CND PTH analogue


- 160 - printed : 03/07/10 (d/m/y) 08:07

FIRM (TICKER)/ Specific comments ACTIVITIES PARTNERS/UPCOMING NEWS ZZZZ ZYSTOR * attach peptide tag to LSD enzymes, targeting receptors on

cell surface, avoiding M6P pathway (PNAS March 04). Technique lic from Symbiontics

POMPE

april 07 us compendium

Documents